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ABSTRACT		
The	 aim	of	my	PhD	project	was	 the	design,	 optimization,	 characterisation	 and	
performance	of	nanocarriers	for	brain	delivery	loaded	with	natural	compounds.	
Blood	brain	barrier	(BBB)	represents	an	important	physio-chemical	obstacle	for	
the	 delivery	 of	 therapeutics	 into	 the	 brain	 and	 the	 limitations	 of	 conventional	
therapies	 increase	 the	 interest	 regard	 the	 use	 of	 nanotechnologies	 for	
neurodegenerative	treatments.		
Several	 natural	 products	 have	 been	 studied	 for	 the	 prevention	 and	 the	
treatment	of	brain	diseases,	frequently,	with	very	interesting	therapeutic	effects	
but	their	poor	solubility,	bioavailability	and	BBB	permeability	have	limited	their	
use.	 To	 overcome	 these	 problematical	 aspects,	 different	 NPs	 that	 target	 and	
reach	brain	tissues	were	formulated	and	examined	during	this	PhD	thesis.	
My	 investigation	 started	 from	 the	 analysis	 of	 BBB	 in	 order	 to	 establish	
formulative	 strategies.	 Two	 different	 endogenous	 mechanisms	 of	 transport	
across	the	BBB,	and	deliver	therapeutics	into	the	brain,	were	selected:	receptor	
mediated	endocytosis	by	Apo-lipoprotein	E	(Apo-E)	and	adsorptive	transcytosis	
by	plasmatic	proteins.	
One	 synthetic	unit,	 ethyl-cyanoacrylate,	 and	a	protein,	 human	 serum	albumin,	
were	 selected	as	materials	 for	 the	design	of	brain	delivery	 systems.	 In	 case	of	
albumin	nanoparticle,	two	distinctive	method	of	preparations	were	investigated	
in	 order	 to	 reduce	 the	 use	 of	 toxic	 agents	 in	 the	 formulation,	 according	with	
green	chemistry	criteria.	
Nanocarriers	were	developed	and	fully	characterized	in	term	of	size,	superficial	
charge,	 encapsulation	 efficiency,	 loading	 capacity	 and	 morphology,	 using	
Dynamic	Light	Scattering	(DLS)	and	Transmission	Electron	Microscopy	(TEM).	
The	brain	uptake	of	fluorescent	NPs,	their	biodistribution	and	cellular-functional	
effects	were	evaluated	in	vivo	in	healthy	rats,	after	intracerebral	injection,	while	
the	 ability	 of	 developed	 nanocarriers	 to	 cross	 BBB,	 after	 intraperitoneal	 and	
intravenous	administration,	were	assessed.	Behavioural	studies	were	performed	
for	the	investigation	of	safety	profile.	After	the	results	obtained	from	the	in	vivo	
examinations,	Salvianolic	acid	B	(SalB)	isolated	from	Salvia	miltiorrhiza	Bge.	and	
Andrographolide	(AG)	from	Andrographis	paniculata’s	 leaves	were	selected,	for	
their	pharmacological	profile,	to	be	loaded	in	developed	NPs	for	the	treatment	
of	neurodegenerative	disease.		
		
XX	
The	 permeability	 across	 the	 BBB	 of	 AG	 in	 the	 free	 form	 and	 loaded	 in	
nanocarriers	was	evaluated	using	a	well	established	in	vitro	BBB	model	based	on	
monolayers	 of	 human	 immortalized	 endothelial	 cells	 hCMEC	 /	 D3,	 that	
expresses	the	receptors	for	Apo-E	(LRP-1expression).	
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1.1 BIOLOGICAL	 ASPECTS	 IN	 CENTRAL	 NERVOUS	 SYSTEM	 (CNS)	 DRUG	
DELIVERY		
 
The	brain	 is	a	unique	organ	highly	protected	 from	the	periphery	by	 two	major	
barriers	(Figure	1),	the	BBB	whit	the	largest	surface	area	(approximately	20	m2)	
and	 the	 blood–cerebrospinal	 fluid	 barrier	 (BCSFB).	 The	 first	 represents	 a	wide	
permeability	 range,	 highly	 regulates	 intracellular	 and	 intercellular	 signalling	
pathways	and	maintains	CNS	homeostasis	[1].	
 
	
FIGURE	1:	THE	TWO	MAIN	BARRIERS	IN	THE	CNS:	BBB	AND	BCSF	[36] 
Several	 neuropathological	 conditions	 such	 as	 stroke,	 trauma,	 bacterial	 or	 viral	
infection,	 multiple	 sclerosis,	 Alzheimer's	 disease,	 Parkinson's	 disease,	 epilepsy	
and	brain	tumours	can	compromise	the	integrity	of	the	BBB	and	as	a	result	CNS	
permeability	can	be	significantly	altered	[2]	
Main	 drugs	 and	 large	 molecular	 weight	 particulate	 agents	 as	 recombinant	
proteins,	 peptides,	 monoclonal	 antibodies,	 small-interfering	 RNA	 (siRNA)	 and	
gene	therapeutics	do	not	readily	permeate	into	brain	parenchyma,	so	one	of	the	
most	 significant	 challenges	 facing	 CNS	 drug	 development,	 is	 the	 availability	 of	
effective	brain	drug	targeting	technology[3].	
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1.1.1 BLOOD-BRAIN	BARRIER	(BBB)	
The	BBB,	was	described	for	the	first	time	by	Paul	Ehrlich	in	1885,	it	 is	primarily	
composed	of	 not	 fenestrated	 brain	microvessel	 endothelial	 cells	 characterized	
by	the	presence	of	tight	junctions	which	form	a	continuous	almost	impermeable	
cellular	 barrier	 that	 dramatically	 limits	 and	 regulates	 the	 traffic	 of	 immune	
surveillance	 cells	 (macrophages),	 xenobiotics	 and	 endogenous	 compounds.	 In	
particular,	tight	junction	proteins	(i.e.,	claudins,	occludin)	and	adherent	junction	
proteins	 (i.e.,	 junctional	 adhesion	molecule	 1	 )	 expressed	 in	 brain	microvessel	
cells	are	responsible	for	the	high	transendothelial	electrical	resistance	(1500	to	
2000	ohm	cm2)	that	restricts	the	paracellular	entry	of	water	and	solutes	[4].	The	
functional	 unit	 of	 the	 BBB	 includes	 more	 than	 just	 capillary	 endothelial	 cells.	
Several	other	cell	 types,	as	pericytes	and	perivascular	astrocytes	are	 in	contact	
with	the	endothelium	and	maintenance	of	the	brain	capillary	phenotype	seems	
to	 be	 critically	 dependent	 on	 interactions	 with	 these	 other	 cells	 [5–7].	 In	
addition,	 is	 present	 also	 a	 selective	 metabolism-driven	 barrier	 that	 largely	
reflects	 expression	 and	 function	 of	 several	 receptors,	 ion	 channels	 and	
influx/efflux	transport	proteins	expressed	prominently	at	the	BBB.	In	particular,	
ATP-binding	 cassette	 (ABC)	 membrane	 associated	 transporters	 such	 as	 P-
glycoprotein	(P-gp),	Multidrug	Resistance-associated	Proteins	(MRPs)	and	Breast	
Cancer	 Resistance	 Protein	 (BCRP)	 play	 a	 significant	 role	 in	 restricting	 the	
permeability	 of	 several	 pharmacological	 agents	 including	 anti-cancer	 and	 anti-
HIV	agents	[8–12].	The	most	extensively	characterized	transporter	protein	at	the	
BBB	 is	 P-gp	expressed	 at	 the	 luminal	membrane	of	 the	brain	 capillary,	 it	 is	 an	
efflux	 pumps	 to	 extrude	 xenobiotics	 from	 the	 brain	 tissue	 back	 into	 the	
circulation	 [5].	 Influx	 transporters	 such	 as	 members	 of	 the	 organic	 anion	
transporting	polypeptide	 family	 (OATPs)	and	organic	anion	transporters	 (OATs)	
can	 facilitate	 both:	 substrate	 delivery	 into	 the	 brain	 as	 well	 as	 efflux	 [13].	 In	
addition	 to	 transporters,	 the	 BBB	 also	 displays	 a	 metabolic	 barrier	 which	
together	 with	 influx	 and	 efflux	 transporter	 proteins	 can	 regulate	 the	 overall	
pharmacokinetic	and	pharmacodynamic	profile	of	xenobiotics	in	the	brain	[14].	
1.1.2 BLOOD-CEREBROSPINAL	FLUID	BARRIER	
The	 BCSFB	 is	 composed	 by	 choroid	 plexus	 epithelial	 cells	 with	 much	 smaller	
surface	 area	 then	 BBB.	 The	 choroid	 plexus	 is	 a	 highly	 vascularized	 branched	
structure	 with	 numerous	 villi	 that	 project	 into	 all	 four	 cerebral	 ventricles	
[15].The	 capillaries	 are	 fenestrated	 and	 provide	 little	 resistance	 to	 the	
movement	of	water	and	solutes,	a	barrier	is	formed	by	a	monolayer	of	polarized	
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epithelial	 cells	 surrounding	 the	 fenestrated	 capillaries	 that	 are	 joined	 together	
by	 tight	 junctional	proteins	 that	 restricts	 the	movement	of	molecules	and	 ions	
[16,17]	 .The	choroid	plexus	epithelial	maintain	the	homeostatic	composition	of	
the	cerebrospinal	fluid	(CSF),	that	fills	the	ventricles	of	the	brain,	the	spinal	canal	
and	subarachnoid	space	and	provides	a	drainage	system	for	the	brain	known	as	
the	sink	effect	into	which	products	of	metabolism	and	molecules	are	diluted	and	
subsequently	removed.	The	sink	effect	is	greater	for	large	molecular	weight	and	
hydrophilic	 compounds.	 In	 humans,	 the	 total	 volume	 of	 CSF	 is	 approximately	
140	ml	and	it	is	replaced	four	to	five	times	daily	[18–20].	Polarized	expression	of	
numerous	 receptors,	 ion	 channels	 and	 transporters	 has	 been	 reported	 at	 the	
level	of	epithelial	cells	[15,21–23].		
1.2 DRUG	TRANSPORT	ACROSS	THE	BBB	
The	schematic	endogenous	transport	mechanisms	by	which	solutes	move	across	
membranes	in	and	out	of	the	brain,	across	the	BBB,	are	shown	in	Figure	2.		
 
	
FIGURE	2:	POTENTIAL	TRANSPORT	MECHANISM	ACROSS	BBB[24] 
Firstly,	the	transport	may	occur	due	to	diffusion,	or	simply	diffusion	or	facilitated	
transport	 across	 aqueous	 channels.	 The	 primary	 bioenergy	 comes	 from	 a	
concentration	gradient	across	the	membranes,	between	cells	(i.e.,	paracellular)	
or	across	cells	(i.e.,	transcellular).	This	passive	diffusion	depending	from	size	and	
lipophilicity	of	 the	substances.	Secondly,	active	movement	may	be	caused	due	
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to	 the	 molecular	 affinity,	 fluid	 streams	 or	 magnetic	 fields.	 Carrier	 mediated	
transport	 (CMT)	 can	 be	 passive	 or	 active	 and	 include	 the	 unidirectional	
transport	 of	 drugs	 from	 the	 blood	 to	 the	 brain.	 It	 is	 mainly	 involved	 in	 the	
transport	of	many	essential	polar	molecules,	with	the	help	of	carrier	systems	or	
transporters,	 as	 glucose	 (GLUT1	 glucose	 transporter),	 amino	 acids	 (the	 LAT1	
large	neutral	amino	acid	transporter,	the	CAT1	cationic	amino	acid	transporter),	
carboxylic	 acids	 (the	 MCT1	 monocarboxylic	 acid	 transporter)	 and	 nucleosides	
(the	CNT2	nucleoside	transporter)	into	the	brain.	This	type	of	transport	involves	
extrusion	of	drugs	from	the	brain	in	the	presence	of	efflux	transporters	such	as	
P-gp,	 MRPs,	 BCRP	 and	 other	 transporters,	 while	 the	 active	 efflux	 transport	
causes	 the	 active	 efflux	 of	 drugs	 from	 brain	 back	 to	 blood.	 It	 acts	 as	 a	major	
obstacle	in	pharmacological	drug	delivery	to	the	CNS.	
Receptor	 mediated	 transport	 is	 primarily	 employed	 in	 the	 transport	 of	
macromolecules	 like	 peptides	 and	 proteins	 across	 the	 BBB	 by	 conjugating	 the	
substance	with	ligands	such	as	lactoferrin,	transferrin	and	insulin.	
Adsorptive	mediated	transport	is	a	type	of	endocytosis	induced	by	electrostatic	
interaction	with	the	anionic	sites	present	on	the	membrane.	
Finally,	 tight	 junction	 (TJ)	modulation	 is	 caused	 by	 the	 relaxation	 of	 junctions,	
which	facilitates	selective	aqueous	diffusion	across	paracellular	junctions	in	the	
BBB	[24].	
In	our	rational	in	the	design	of	NPs	for	brain	delivery,	optimized	during	my	PhD,	
two	different	endogenous	transport	mechanism	across	the	BBB	were	evaluated:	
• Receptor	 mediated	 endocytosis	 (RME), is	 a	 highly	 specific	 and	 energy	
mediated	 transport	 allowing	 eukaryotic	 cells	 to	 selective	 uptake	
macromolecules	 as	 specific	 cargo.	 For	 the	 BBB	 receptor-specific	 ligands	
have	 also	 been	 shown	 to	 be	 very	 effective	 to	 transport	 endogenous	
peptides	 like	 insulin	 and	 transferrin,	 albumin,	 and	 opioid	 peptides	 e.g.	
deltorphins,	 [D-penicillamine	 2,5]	 encephalin	 and	 deltorphin	 II.	 Receptor-	
mediated	drug	delivery,	is	a	promising	Trojan	horse	approach	for	the	release	
of	therapeutics	into	neuronal	cells,	and	tissues.	Nanocarriers	conjugated	to	
different	 types	 of	 ligands	 of	 cell	 surface	 receptors	 expressed	 on	 brain	
endothelial	cells,	can	accumulate	and	eventually	be	internalized	by	cells	on	
the	vascular	side	of	the	brain	through	the	mechanism	of	receptor-mediated	
endocytosis.	 According	 with	 one	 possible	 fate	 of	 targeted	 receptors,	 the	
ligand	 conjugated	 nanocarrier	 gets	 collected	 in	 specialized	 areas	 of	 the	
plasma	 membrane	 known	 as	 coated	 pits.	 These	 clathrin	 coated	 pits	
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invaginate	 to	 form	 coated	 vesicles,	 upon	 endosomal	 processing	 of	 the	
vesicle,	 clathrin	 and	 associated	 proteins	 dissociate	 from	 the	 vesicle	
membrane	 (early	 endosome),	 to	 form	new	 coated	pits	 at	 the	 cell	 surface.	
The	receptor	dissociates	from	the	ligand	conjugated	nanocarrier	due	to	the	
acidification	 of	 the	 vesicle	 in	 the	 late	 endosome,	 and	 the	 nanocarrier	
complex	 degrades,	 hence	 releasing	 the	 drug	 to	 the	 cell.	 In	 addition,	
apolipoproteins	 B	 and	 E	 may	 be	 chiefly	 involved	 in	 the	 transport	 of	 NP-
bound	 drugs	 into	 the	 brain.	 They	 concluded	 that	 by	 coating	 the	NPs	with	
polysorbate	80	(TW80),	apolipoproteins	B	and	E	get	adsorbed	onto	the	NP	
surface	 from	the	blood	after	 injection	and	 thus	 seem	to	mimic	 lipoprotein	
particles	 that	 could	be	 taken	up	by	 the	brain	 capillary	endothelial	 cells	 via	
receptor-mediated	 endocytosis.	 After	 endocytosis,	 drugs	may	 be	 released	
within	 the	 endothelium	 cells	 and	 undergo	 further	 transportation	 into	 the	
brain	by	diffusion	or	through	transcytosis	[24].	
	
• Adsorptive-mediated	 endocytosis	 (AME)	 is	 based	 on	 the	 electrostatic	
interaction	 between	 a	 positively	 charged	 substance	 and	 the	 negatively	
charged	 sites	 on	 the	 brain	 endothelial	 cell	 surface	 (e.g.	 glycoprotein).	 The	
concept	 of	 AME	 through	 the	 BBB	 originated	 from	 the	 observation	 that	
polycationic	 proteins	 such	 as	 protamine	 could	 not	 only	 bind	 to	 the	
endothelial	cell	surface	but	could	also	penetrate	the	BBB.	Moreover,	mixing	
protamine,	 poly-L-lysine	 or	 other	 cationic	 molecules	 with	 proteins	 (e.g.	
albumin)	 or	 enzymeas	 (e.g.	 horseradish	 peroxidase)	 greatly	 increased	 the	
permeability	 of	 these	 proteins	 across	 cerebral	 microvessels,	 probably	 for	
their	binding	affinity	for	polycations.	In	a	similar	manner,	cationized	proteins	
can	 be	 transported	 through	 the	 BBB.	 These	 findings	 were	 explained	 by	
adsorptive-mediated	 endocytosis	 triggered	 by	 electrostatic	 interactions	
between	 the	 positively	 charged	 moieties	 of	 the	 proteins	 and	 negatively	
charged	membrane	surface	regions	on	the	brain	endothelial	cells	(ECs).	As	a	
consequence,	 the	 cationic	 net	 charge	 of	 a	 peptide/protein	 has	 gradually	
become	 recognized	 as	 an	 important	 determinant	 in	 the	 brain	 capillary	
uptake	of	these	molecules.	BBB	is	readily	equipped	for	the	AMT	process:	 it	
provides	both	the	potential	for	binding	of	cationic	molecules	to	the	luminal	
surface	of	endothelial	cells,	and	then	for	exocytosis	at	the	abluminal	surface;	
the	 transcytotic	 pathways	 present	 at	 the	 BBB	 and	 its	 morphological	 and	
enzymatic	 properties,	 as	 well	 as	 the	 high	 content	 of	 mitochondria	 in	
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cerebral	ECs	provide	the	means	for	movement	of	the	molecules	through	the	
endothelial	cytoplasm	[24]. 
1.3 NEURODEGENERATIVE	DISEASE		
Neurodegenerative	 diseases	 are	 some	 of	 the	 most	 debilitating	 disorders,	
affecting	 thinking,	 skilled	 movements,	 feelings,	 cognitive	 and	 memory.	 Today	
are	 the	 fourth	 leading	 cause	 of	 death	 in	 the	 developed	 world	 after	 heart	
diseases,	 cancer	 and	 stroke.	 Globally,	 each	 year,	 over	 10	million	 people	 have	
neurodegenerative	 diseases.	 This	 figure	 is	 expected	 to	 grow	 by	 20%	 over	 the	
next	decade	as	the	aging	population	increases	and	lives	longer.	Many	similarities	
appear	that	relate	these	diseases	to	each	other	on	a	sub-cellular	and	molecular	
levels.	These	disorders	have	a	high	prevalence	as	well	 as	 short-	and	 long-term	
impairments	 and	disabilities.	 They	 include	 serious	disorders	 such	 as	Alzheimer	
Disease	 (AD),	 Parkinson	 Disease	 (PD),	 Lewy	 body	 dementia	 (LBD),	
Frontotemporal	 dementia	 (FTD),	 Vascular	 dementia	 (VD)	 and	 some	 rare	
disorders	 such	as	amyotrophic	 lateral	 sclerosis	 (ALS),	Huntington	disease	 (HD),	
spinocerebellar	 ataxia	 and	 prion	 diseases.	 There	 are	 important	 differences	 in	
clinical	manifestation	but	neurodegenerative	disorders	share	common	features:	
their	 appearance	 late	 in	 life,	 the	 extensive	 neuronal	 loss	 and	 synaptic	
abnormalities,	 and	 the	 presence	 of	 cerebral	 deposits	 of	 misfolded	 proteins	
aggregates.	 Approximately	 24	million	people	worldwide	 suffer	 from	dementia,	
60%	of	cases	being	due	to	AD,	which	occurs	in	1%	of	 individuals	aged	50	to	70	
and	dramatically	 increases	 to	50%	for	 those	over	70	years.	Dramatically,	 these	
numbers	are	estimated	to	increase	to	15	million	in	the	next	40	years	[25].		
AD	is	a	chronic	and	progressive	neurodegenerative	disorder	and	the	most	cause	
of	 dementia.	 It	 is	 typified	 clinically	 by	 learning	 and	 memory	 impairment	 and	
pathologically	 by	 cerebral	 atrophy,	 indicative	 of	 neuronal	 loss,	with	 numerous	
extracellular	 neuritic	 amyloid	 plaques	 and	 intracellular	 neurofibrillary	 tangles	
found	 predominantly	 in	 the	 frontal	 and	 temporal	 lobes,	 including	 the	
hippocampus.	Although	the	mechanisms	underlying	AD	are	not	completely	clear	
yet	 several	 approaches	aimed	at	 inhibiting	disease	progression	have	advanced	
to	 clinical	 trials.	 AD	 in	 characterized	 by	 amyloid	 plaques	 extracellularly	 in	 the	
brain	 parenchyma	 and	 around	 the	 cerebral	 vessels	 walls	 and	 their	 main	
component	is	a	1-40	and	1-42	residues	peptide	termed	beta-amyloid	protein.	It	
is	 well	 established	 that	 innocuous	 monomers	 of	 amyloid	 beta	 become	
neurotoxic	 upon	 aggregation	 and	 the	 toxicity	 of	 amyloid	 beta	 involved	 self	
aggregation	 of	monomers	 into	 oligomers	 and	 higher	 aggregated	 forms.	 In	 the	
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last	 studies,	 a	 variety	 of	 post-transcriptionally	 modified	 variants	 have	 been	
identified	but	the	predominant	accumulation	and	initial	peptide	deposited	in	the	
brain	parenchyma	is	a	fibrillogenic	amyloid-beta	1-42.	Targeting	amyloid-beta	1-
42	in	all	its	aggregation	forms	has	been	suggested	for	therapeutic	and	diagnostic	
purposes.	Recently	has	been	demonstrated	 that	brain	and	blood	amyloid-beta	
are	 in	equilibrium	 through	 the	BBB,	 and	 sequestration	of	 amyloid-	beta	 in	 the	
blood	may	shift	this	equilibrium,	drawing	out	the	excess	from	the	brain[26–29].		
PD	 is	 also	 a	 chronic	 disorder	 that	 involves	 the	 malfunction	 of	 dopaminergic	
neurons.	 The	 symptoms	 of	 the	 disease	 include	 tremors,	 stiffness	 and	 slow	 or	
hesitant	speech	and	it	is	characterized	by	massive	depletion	of	striatal	dopamine	
as	a	result	of	degeneration	of	dopaminergic	neurons	in	the	substantia	nigra	pars	
compacta.	 Besides	 the	 lack	 of	 dopamine	 at	 the	 cellular	 level	 may	 appear	 the	
formation	 of	 Lewy	 bodies	 in	 the	 substantia	 nigra,	 which	 are	 cytoplasmic	
inclusions	 composed	 of	 fibrils,	 ubiquitin	 and	 alpha-synuclein.	 There	 are	 an	
estimated	 7-10	 million	 people	 living	 with	 PD	 in	 the	 world;	 1.2	 million	 people	
suffering	from	PD	in	Europe	and	over	1	million	in	US,	however,	medication	only	
provides	patients	with	 temporary	 symptomatic	 relief,	while	access	 to	care	and	
treatment	differs	widely	depending	on	where	patients	live	[30–32].	
LBD	is	the	second	most	common	type	of	progressive	dementia	after	AD,	causes	
a	 progressive	 decline	 in	 mental	 abilities;	 is	 characterized	 by	 fluctuations	 in	
cognition	 with	 variations	 in	 attention	 and	 alertness,	 recurrent	 formed	 visual	
hallucinations,	 visual	 spatial	 dysfunction	 and,	 like	 PD,	 LBD	 can	 result	 in	 rigid	
muscles,	 slowed	movement	 and	 tremors.	 Variation	 in	 the	distribution	of	 Lewy	
body	pathology	is	present	in	LBD,	with	more	neocortical	and	limbic	system	Lewy	
bodies	 in	 both.	 The	 loss	 of	 cholinergic	 neurons	 originates	 the	 degradation	 of	
cognitive	 functioning,	 while	 the	 loss	 of	 dopaminergic	 neurons	 is	 thought	 to	
account	 for	 the	 degradation	 of	 motor	 control,	 as	 in	 PD:	 the	 overlap	 of	
neuropathologies	 and	 presenting	 symptoms	 (cognitive,	 emotional,	 and	motor)	
can	make	an	accurate	differential	diagnosis	difficult.	Current	estimates	are	that	
about	60	to	75%	of	diagnosed	dementias	are	of	the	AD	and	10	to	15%	are	LBD	
[33–36].	
FTD	is	a	clinical	syndrome	associated	with	reduction	of	the	frontal	and	temporal	
anterior	 lobes	 of	 the	 brain.	 The	 current	 designation	 of	 the	 syndrome	 groups	
together	Pick’s	disease,	primary	progressive	aphasia,	and	semantic	dementia	as	
FTD,	 in	 fact	 the	 symptoms	 of	 FTD	 are	 based	 in	 change	 in	 behaviour	 and	
problems	with	 language.	 FTD	affects	parts	of	 the	brain	 containing	microscopic	
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Pick	bodies;	abnormal	protein-filled	structures	that	develop	within	neurons.	The	
histological	 features	 of	 FTD	 are	 the	 presence	 of	 neurofibrillary	 tangles	 of	
phosphor-Tau	 in	 the	 brain,	 a	 variety	 of	 mutations	 on	 several	 different	 genes	
such	as	MAPT,	PGRN,	FUS	or	VCP	are	involved	and	there	isn’t	familiarity	in	more	
than	half	the	people	who	develop	FTD	[37–39].			
VD	is	widely	considered	the	second	most	common	and	distinct	type	of	dementia	
and	 these	 alterations	 occur	 in	 an	 already	 aged	 brain.	 VD	 develops	 when	
compromised	blood	flow	to	parts	of	the	brain	deprives	cells	of	food	and	oxygen.	
The	diagnosis	may	be	clearest	when	symptoms	appear	soon	after	a	single	major	
stroke	blocks	a	large	blood	vessel	and	disrupts	the	blood	supply	to	a	significant	
portion	 of	 the	 brain.	 This	 situation	 is	 sometimes	 called	 post-stroke	 dementia.	
Symptoms	 of	 VD	 can	 vary,	 depending	 on	 the	 specific	 brain	 areas	 deprived	 of	
blood.	 Impairment	 may	 occur	 in	 steps	 and	 memory	 problems	 may	 not	 be	 a	
prominent	symptom,	depending	on	whether	brain	regions	important	in	memory	
are	affected	[40].	
Other	rare	neurodegenerative	diseases	are:	
• ALS	 is	 a	 form	 of	 motor	 neuron	 disease	 caused	 by	 the	 degeneration	 of	
neurons	 located	 in	 the	 ventral	 horn	 of	 the	 spinal	 cord	 and	 the	 cortical	
neurons	 that	provide	 their	afferent	 input.	This	disorder	 is	characterized	by	
rapidly	 progressive	 weakness,	 muscle	 atrophy	 and	 fasciculation,	 pasticity	
and	respiratory	compromise	[41].	
• HD	is	a	rare	fatal	brain	disorder	caused	by	inherited	changes	in	a	single	gene	
called	huntingtin.	The	either	of	an	 individual's	 two	copies	of	 the	gene.	 It	 is	
the	 most	 common	 genetic	 cause	 of	 abnormal	 involuntary	 writhing	
movements	called	chorea.	These	changes	lead	to	destruction	of	neurons	in	
certain	brain	regions	[25].	
• Spinocerebellar	 ataxia	 is	 a	 congenital	 disorder	 characterized	 by	 problems	
with	coordination	that	often	disturb	legs,	hands	and	speech.	There	are	more	
than	20	types	of	spinocerebellar	ataxia	that	have	been	described.	All	 types	
of	 spinocerebellar	ataxia	are	 characterized	by	a	progressive	 incoordination	
of	walking.	In	addition,	they	are	often	associated	with	poor	coordination	of	
hand	 movements,	 eye	 movements,	 and	 speech.	 The	 symptoms	 usually	
occur	 after	 the	 age	of	 18	but	 condition	 gradually	worsen	over	 a	period	of	
years.	Some	types	of	spinocerebellar	ataxia	can	progress	more	rapidly	than	
others.	 Brain	 scans	 such	 as	 magnetic	 resonance	 imaging	 (MRI)	 and	
computerized	tomography	(CT)	of	affected	persons	often	show	reduction	or	
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atrophy	 of	 the	 cerebellum	 that	 becomes	 more	 noticeable	 as	 the	 disease	
progresses	[42,43].	
• Prion	 diseases	 are	 conformational	 neurodegenerative	 disorders	
characterized	 by	 the	 structural	 modification	 of	 the	 normal	 cellular	 prion	
protein	 into	 a	 pathological	 conformer;	 can	 be	 inherited,	 infectious	 or	
sporadic.	The	transmissible	pathogen	for	 these	diseases	 is	a	proteinaceous	
infectious	particle	 (hence	the	term	 ‘prion’).	These	disorders	 in	humans	are	
very	rare,	affecting	only	about	one	person	per	million	worldwide	each	year	
but,	 transmissible	 prion	 proteins	 can	 reach	 epidemic	 proportions,	 as	 was	
seen	in	the	UK.	At	this	moment,	there	isn’t	effective	therapy	for	this	group	
of	diseases	[20,44].		
1.4 NANOTECHNOLOGY	FOR	BRAIN	DELIVERY		
Nanotechnology,	 in	 the	context	of	medicine,	 is	defined	as	 the	technologies	 for	
making	 nanocarriers	 of	 therapeutics	 and	 imaging	 agents,	 nanoelectronic	
biosensors,	 nanodevices,	 and	 microdevices	 containing	 nanostructures.	 Unlike	
the	definition	in	core	nanotechnology	field,	which	restricts	the	“nano”	to	at	least	
1–100	 nm	 in	 one	 dimension,	 nanocarriers	 in	 the	 biomedical	 field	 are	 often	
referred	 to	 as	 particles	 with	 a	 dimension	 a	 few	 nanometers	 to	 1000	 nm;	 so,	
nanotechnology,	 when	 applied	 to	 biomedical	 and	 clinical	 applications,	 has	 a	
broader	definition.	Nanomedicine	and	nanotechnology	share	a	common	ground	
of	basic	 science	and	 technologies.	Many	 techniques	 for	making	nanomaterials,	
especially	 those	 bottom-up	 techniques	 such	 as	 chemical	 synthesis,	 self-
assembly,	 and	positional	 assembly	methods,	 are	 used	 to	 prepare	 nanocarriers	
for	 delivering	 therapeutics	 and	 imaging	 agents.	 Nanomedicine	 is	 generally	
defined	as	the	application	of	nanotechnology	in	the	clinical	field.	There	are	two	
main	 medical	 applications	 of	 nanotechnology:	 medical	 imaging/diagnosis	 and	
therapeutic	 delivery.	 In	 order	 to	 have	 the	maximum	 therapeutic	 benefits,	 the	
carriers	must	be	designed	to	delivery	at	 target	sites	at	 the	 right	 time	the	 right	
dose	 with	 the	 appropriate	 release	 kinetics.	 As	 discussed	 in	 this	 PhD	 thesis,	
multiple	 physiological,	 pathological	 and	 cellular	 barriers	 must	 be	 overcome	
before	an	adequate	drug	dose	can	reach	the	site	of	action[45].		
1.4.1 DEFINITION	OF	NANOPARTICLES		
According	 with	 the	 classical	 definition	 of	 NPs	 in	 the	 Encyclopedia	 of	
Pharmaceutical	 Technology	 and	 in	 the	 Encyclopedia	 of	 Nanoscience	 and	
Nanotechnology	 formulated	 already	 40	 years	 ago:	 “NPs	 for	 pharmaceutical	
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purposes	are	solid	colloidal	particles	ranging	 in	size	 from	1	to	1000	nm	(1	μm)	
consisting	 of	 macromolecular	 materials	 in	 which	 the	 active	 principle	 (drug	 or	
biologically	active	material)	is	dissolved,	entrapped,	or	encapsulated,	or	to	which	
the	active	principle	is	adsorbed	or	attached”	[46].	
This	definition	diverges	 from	the	definition	of	physicists	and	material	scientists	
who	 limit	 the	 upper	 size	 of	 NPs	 to	 100	 nm.	 However,	 up	 to	 1000	 nm	 size	
appears	 to	 be	 of	 no	 important	 influence	 concerning	 uptake	 into	 cells	 of	 the	
reticuloendothelial	 system	 (RES),	 i.e.	 macrophages	 and	 endothelial	 cells,	 and	
also	most	other	parts	of	the	body	[46].	
Schäfer	et	al.	[47]	demonstrated	 in	vitro	using	electron	microscopy	that	human	
macrophages	 endocytose	 NPs	 independent	 of	 size,	 while	 Gao	 and	 Jiang	 [48]	
reported	small,	i.e.	20%,	increase	in	methotrexate	delivery	to	the	brain	using	70	
nm	 sized	methotrexate	 loaded	 poly(butyl	 cyanoacrylate)	 NPs	 overcoated	 with	
TW80	after	intravenous	injection.		
No	differences	in	methotrexate	brain	delivery	occurred	between	170,	220,	and	
345	nm	sized	particles.	This	insignificant	particle	size	influence	can	be	attributed	
to	the	mechanism	of	NPs	uptake	and	of	bound	drugs	into	the	brain	but	the	drug	
payload	decreases	with	a	reduced	particles	size.	From	other	side,	with	sizes	over	
1000	nm	the	danger	of	embolization	of	the	lung	capillaries	is	increasing	in	size-	
and	dose-dependent	manner	[46].	
1.4.2 TYPES	OF	NANOPARTICLE	POLYMERS	
The	main	 prerequisite	 for	 nanoparticulate	 brain	 delivery	 systems	must	 be	 the	
biodegradability	 and	 the	 biocompatibility.	 In	 fact,	 non-degradable	 particles	 as	
fullerenes,	metal	particles	or	toxic	systems	such	as	quantumdots,	or	potentially	
risky	 needle-shaped	 delivery	 systems	 as	 carbon	 nanotubes,	 which	 may	 have	
dangerous	effects	similar	 to	asbestos,	 therefore,	are	not	useful.	Similarly,	silica	
particles	 also	 appear	 to	 be	 not	 suitable	 as	 they	 would	 import	 a	 very	 foreign	
material	 into	the	brain.	Fumed	silica	has	been	used	as	an	auxiliary	material	 for	
oral	 application	 but	 appears	 to	 be	 not	 absorbed	 into	 the	 body	 in	 significant	
amounts.	Silica	NPs	also	are	not	a	good	model	system	as	their	body	distribution	
is	totally	different	from	carbon	chemistry-derived	materials	[46].		
In	 this	 moment	 only	 three	 types	 of	 materials	 appear	 to	 be	 suitable	 for	 the	
formulation	 of	 nanocarriers:	 (poly(alky	 cyanoacrylates)	 as	 poly(butyl	
cyanoacrylate)	 PBCA,	 poly(lactic	 acid)	 (PLA)	 or	 its	 copolymer	 (lactide-co-
glycolide)	(PLGA),	and	human	serum	albumin	(HSA)	[46].	
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Numerous	 studies	 show	 that	 PBCA	 is	 the	 fastest	 biodegrading	 material.	 This	
rapid	 elimination,	 probably,	 depends	 to	 the	 low	 molecular	 weights	 of	 the	
poly(alkyl	 cyanoacrylates)	 in	 nanoparticulate	 form	 of	 around	 2000–3000	 Da	
while	 a	 minimal	 portion	 of	 higher	 molecular	 weight	 compounds	 also	 may	 be	
present	 in	 the	 particles.	 Degradation	 of	 the	 polymer	 occurs	 by	 enzymatic	
cleavage	of	the	ester	bond	of	the	alkyl	side	chain	of	the	polymer	resulting	in	the	
formation	 of	 the	 low-toxic	 water-soluble	 products—poly(cyanoacrylate)	 acid	
and	 appropriate	 alcohol	 by	 esterases.	 Consequently,	 the	molecular	weights	 of	
the	poly(alkyl	 cyanoacrylate)	esters	 increase	with	 increasing	molecular	weights	
whereas	 their	 degradation	 rate	 decreases.	 This	 reduced	 degradation	
significantly	 decreases	 their	 toxicity	 [46].	 For	 all	 these	 reasons,	 poly(isohexyl	
cyanoacrylate)	was	chosen	for	clinical	trials	and	is	now	in	clinical	phase	III	[49].	
Biodegradation	 of	 the	 PLGA	 NPs	 also	 depends	 by	 enzymatic	 degradation	 by	
lipases	 due	 to	 their	 small	 size	which	 is	 in	 contrast	 to	 larger	 PLA	 particles	 and	
materials	where	hydrolytic	degradation	is	the	prevailing	degradation	mechanism	
[50].	
The	 degradation	 rate	 of	 HSA	 NPs	 also	 is	 quite	 rapid:	 if	 prepared	 by	 heat	
denaturation	 they	were	 totally	degraded	within	3	days	 in	macrophages,	 and	 if	
they	 are	 made	 by	 chemical-	 crosslinking,	 a	 rapid	 degradation	 also	 can	 be	
estimated,	 and	 the	 observed	 toxicity	 of	 the	 latter	 particles	was	 extremely	 low	
[51].	
In	 addition	 to	 the	 above	 materials,	 chitosan	 can	 be	 another	 advantageous	
polymer,	 because	 chitosan	 NPs	 also	 are	 biodegradable	 and	 biocompatible,	
possess	good	stability,	low	toxicity	and	can	be	manufactured	by	simple	and	mild	
preparation	methods	[52].		
1.4.3 METHODS	OF	PREPARATION	OF	NANOPARTICLE		
Some	of	the	most	commonly	method	of	preparation	of	NPs	are	discussed	below,	
as	described	by	Goyal	and	co-workers	[53]:	
Nano-precipitation	Method	
The	 polymer	 is	 first	 dissolved	 in	 a	 water	 miscible	 solvent	 as	 acetone,	
tetrahydrofuran,	methanol,	ethanol,	acetonitrile,	DMF	etc.,	 then	 it	 is	dispersed	
in	the	aqueous	phase	under	constant	stirring.	The	aqueous	phase	may	contain	
surfactant.	The	organic	phase	will	be	removed	to	obtain	the	NPs	in	the	aqueous	
phase.	 NPs	 quickly	 precipitate	 because	 the	 organic	 solvent	 is	 diffused	 in	 the	
aqueous	 phase.	 As	 the	 solvent	 diffuses	 from	 organic	 phase	 to	 the	 aqueous	
phase,	 it	 carries	with	 it	 some	polymeric	 chains,	which	 aggregate	 to	 form	NPs.	
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The	 size	 of	NPs	 are	 affected	by	 the	 concentration	 of	 polymer	 and	 the	 solvent	
system	used.		
	
Solvent	Evaporation	
This	method	 is	 similar	 to	 nano-precipitation,	 the	 difference	 lies	 in	 the	 organic	
solvent	in	fact,	in	nano-precipitation	is	miscible	with	water,	while	in	the	solvent	
evaporation	method	is	immiscible.	
The	organic	phase	is	dispersed	in	the	aqueous	phase	and	it	forms	an	oil-in-water	
emulsion.	 The	 emulsion	 is	 stabilized	by	using	 surfactants	 like	 TW80,	 poly	 vinyl	
alcohol,	 poloxamer-188,	 etc.	 and	 after	 the	 stabilization,	 the	 organic	 phase	 is	
evaporated	under	constant	stirring.		
	
Salting	Out	
In	 this	 process	 the	 polymer	 is	 slowly	 dissolved	 in	 a	 water	 miscible	 organic	
solvent.	The	aqueous	phase	contains	high	concentration	of	salt	and	emulsifiers	
due	 to	 which	 the	 mixing	 of	 organic	 phase	 and	 the	 aqueous	 phase	 is	 slowed	
down.	These	separate	phases	are	emulsified	by	stirring.	NPs	are	formed	adding	
water	 rapidly	 to	 reduce	 the	 ionic	 strength.	 The	 excess	 salt	 must	 be	 removed	
before	 using	 it	 for	 therapeutic	 use.	 Sometimes	 the	 washing	 steps	 to	 remove	
excess	salts	and	stabilizing	agents	became	very	extensive.	
	
Emulsion	Diffusion	
The	polymer	is	dissolved	in	an	organic	solvent,	partially	miscible	with	water	(e.g.	
ethylacetate,	 polyprolylene	 carbonate,	 etc.).	 Aqueous	 phase	 containing	
stabilizer	 is	 added	 to	 this	 system.	 The	 mixture	 is	 constantly	 stirred	 with	
simultaneous	 addition	 of	water.	 Copious	 quantity	 of	water	 is	 added,	 until	 the	
formation	of	 oil-in-water	 emulsion.	 The	organic	 phase	 is	 removed	by	 constant	
stirring,	 which	 results	 in	 the	 formation	 of	 NPs.	 This	 process	 has	 high	
reproducibility	thanks	the	stabilizers	that	reduce	the	surface	tension	and	makes	
the	particle	size	smaller.	
	
Emulsion	Evaporation	
An	 oil-in-water	 emulsion	 is	 done	 by	 dispersing	 the	 organic	 solvent	 containing	
polymer	in	the	aqueous	phase	with	stabilizers.	A	strong	shear	stress	is	applied	to	
the	emulsion	droplets,	which	further	breaks	down	the	droplets	into	smaller	size,	
then	 the	organic	phase	 is	 evaporated	 and	polymer	 is	 precipitated	 to	 form	 the	
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NPs.	 Apply	 high	 shear	 stress	 is	 important	 to	 stop	 the	 migration	 of	 emulsion	
droplets	towards	each	other	and	prevent	their	aggregation.	
1.4.4 BRAIN	DELIVERY	SYSTEMS		
In	 the	 last	 35	 years,	 with	 the	 advent	 of	 nanomedicine,	 different	 formulations	
have	been	proposed	to	enhance	the	delivery	of	 therapeutics	 into	the	brain,	as	
showed	in	the	following	highlights	(Figure	3)	and	described	below	[53].	
 
	
FIGURE	3:	HIGHLIGHTS	OF	THE	MAJOR	DEVELOPMENT	IN	BRAIN	DELIVERY	SINCE	1980	
[91] 
Micelles	
They	 are	 basically	 made	 of	 block	 copolymers,	 which	 self-assemble	 to	 from	 a	
dense	hydrophobic	core,	which	 is	surrounded	by	a	hydrophilic	brush	 like	 layer.	
The	brush	 like	outer	structure	prevents	 the	micelles	 from	adhering	to	proteins	
and	cells,	prevents	opsonization	and	hence	gives	the	micelles	the	advantage	of	
having	 long	circulation	 time	 in	 the	body.	Additional	advantages	of	micelles	are	
controlled	drug	release	and	good	tissue	penetrating	ability.	Various	hydrophobic	
core	 are	 used	 in	 micelle	 formation,	 like	 poly(propylene	 oxide),	 PLA,	 poly(ε	 -
caprolactone),	 poly(l-aspartate)	 and	 poloxamers	 and	 provide	 an	 excellent	
environment	 for	 the	 encapsulation	 of	 hydrophobic	 drugs.	 There	 are	 different	
disadvantages	associated	with	micelles	such	as	limited	stability,	difficult	polymer	
synthesis,	 immature	 drug	 encapsulation	 technology,	 limitation	 to	 hydrophobic	
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drugs,	 slow	 extravasation	 and	 possible	 chronic	 liver	 toxicity	 due	 to	 slow	
metabolic	processing.	
 
	
FIGURE	4:	MORPHOLOGY	OF	POLYMERIC	MICELLE	[91] 
Nanospheres 
They	 are	 solid	 particle	 formed	 by	 polymeric	 matrix	 in	 which	 drugs	 can	 be	
dissolved,	 encapsulated	 or	 entrapped.	 The	 drugs	 can	 also	 be	 attached	 to	 the	
polymeric	matrix	by	adsorption	or	 chemical	bonding.	 The	hydrophobic	 surface	
of	 the	 nanospheres	 is	 susceptible	 to	 opsonization	 and	hence	 it	 does	 not	 have	
long	circulation	time.	
 
	
FIGURE	5:	NANOSPHERES	[91] 
Nanocapsules	
They	 have	 nanoscale	 vesicular	 structures,	 so	 are	 made	 up	 of	 polymeric	
membrane,	 which	 encapsulates	 the	 inner	 core.	 Concerning	 the	 size	 of	
nanocapsules,	they	are	generally	ranges	from	10-1000	nm,	as	nanospheres	too.	
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The	 drug	 is	 loaded	 into	 the	 inner	 core	 and	 should	 be	 both	 lipophilic	 and	
hydrophilic	depending	on	the	method	of	preparation	of	the	nanocapsules.	
 
	
FIGURE	6:	NANOCAPSULES	[91] 
Polymersomes	
With	 a	 vesicular	 structure,	 they	 are	 composed	 by	 aqueous	 internal	 core	
surrounded	by	a	polymeric	membrane.	The	polymeric	membrane	can	be	viewed	
as	 a	 hydrophobic	 layer	 sandwiched	 between	 hydrophilic	 polymeric	 brushes.	
Thanks	their	thicker	outer	membranes,	they	are	considered	more	stable	vesicles	
if	compared	with	the	lipid	based	vesicles.	The	size	are	comprised	between	5	nm	
and	5	μm.	
The	advantage	of	using	the	polymeric	drug	delivery	system	are	related	with	their	
robustness	 and	 stability,	with	 a	high	drug	 loading	 capacity	 and	an	opportunity	
with	the	possibility	to	control	the	drug	release	kinetics	of	the	system.	
	
FIGURE	7:	CROSS	-SECTIONAL	VIEW	OF	A	POLYMERSOME	[91] 
Liposomes	
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The	main	advantage	of	this	nanocarrier	is	the	structure	similar	to	cells	with	lipid	
bilayer.	 The	 vesicle	has	 a	hydrophilic	 core	 surrounded	by	a	hydrophobic	 layer,	
decorated	with	hydrophilic	groups	on	the	outer	surface.	The	bilayer	is	generally	
composed	of	the	phospholipids.	Liposomes	can	successfully	act	as	nanocarriers	
to	deliver	drugs	across	the	BBB.	Liposomes	were	developed	and	conjugated	with	
antibodies	 to	 work	 as	 immunoliposomes	 in	 the	 treatment	 of	 Alzheimer’s	
disease,	 in	 this	 study,	 the	 antibodies	 against	 the	 transferrin	 receptor	 were	
conjugated	onto	the	surface	of	the	liposomes	to	cross	the	BBB.	
Higher	 bioavailability,	 low	 cost,	 simplicity	 of	 preparation	 and	 the	 capability	 of	
transporting	 both	 hydrophobic	 and	 hydrophilic	 drugs	 makes	 liposomes	 an	
attractive	nanocarrier	 for	CNS	drug	delivery.	 The	disadvantages	 are	 associated	
with	the	higher	size.	
 
	
FIGURE	8:	CROSS-SECTION	OF	LIPOSOME	AND	SINGLE	UNIT	OF	PHOSPHOLIPIDS	[91]	
Microemulsions	
These	emulsions	have	droplet	size	at	least	100	times	less	than	the	conventional	
emulsion	 system,	 they	 are	 thermodynamically	 stable	 blends	 of	 oil,	 water,	 and	
surfactant,	 and	 widely	 used	 for	 enhancing	 the	 bioavailability	 of	 the	 poorly	
soluble	drugs.	The	small	droplet	size	and	low	surface	tension	of	microemulsions	
leads	to	higher	absorption	and	permeation	across	the	BBB.	
Microemulsions	 are	 thermodynamically	 more	 stable	 and,	 therefore	 easy	 to	
store.	 They	 have	 higher	 skin	 penetration	 and	 diffusion	 rate	 but	 use	 of	 large	
amounts	of	surfactants	to	stabilize	microemulsions	is	still	a	major	concern.	
	
Solid	Lipid	Nanoparticles	(SLNPs)	
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They	 are	 nanoparticulate	 system	with	 a	 solid	 core,	 synthesized	 from	 the	 solid	
lipids	at	room	temperature.	The	main	advantage	of	SLNPs	is	their	very	high	drug	
loading	capacities.		
The	 surface	 of	 SLNPs	 loaded	 with	 carmustine	 was	 modified	 with	 monoclonal	
antibody	 to	 enhance	 the	drug	delivery	 across	 the	BBB.	 This	 research	provided	
promising	 breakthrough	 to	 the	 use	 of	 SLNPs	 for	 CNS	 drug	 delivery	 The	
nanocarrier	is	really	advantageous	for	their	control	the	drug	release	and	for	the	
incorporation	of	both	hydrophilic	and	lipophilic	drugs.	Is	very	important	consider	
that	using	the	physiological	lipids	in	the	synthesis	process,	is	possible	reduce	the	
risk	of	toxicity.	
	
Nanogels	
They	are	hydrogels	with	crosslinks	of	nanoscale	size.	The	crosslinking	is	between	
hydrophilic	 or	 amphiphilic	 polymeric	 chains.	 The	 nanogel	 made	 from	
polyethyleneimine	 and	 polyethylene	 glycol	 (PEG)	 swells	 by	 making	 crosslinks	
when	 dispersed	 in	 a	 solution.	 As	 the	 drug	 binds	 to	 it	 through	 electrostatic	
interaction,	 the	 nanogel	 collapses.	 PEG	 plays	 a	 major	 role	 in	 stabilizing	 the	
structure	and	nanogels	 form	a	 stabilized	dispersion.	Nanogels	are	prepared	by	
the	 ionic	 gelation	 method	 using	 sodium	 tripolyphosphate	 and	 chitosan.	 If	
nanogels	are	modified	with	polysorbate	80,	the	drug	loaded	cross	BBB	[54].	
In	 a	 recent	 study,	 it	 was	 shown	 that	 5’-triphosphates	 of	 Nucleoside	 reverse	
transcriptase	 inhibitors	 encapsulated	 in	 cationized	 nanogels	 were	 more	
successful	in	suppressing	the	HIV-1	activity	in	CNS	than	NRTIs.	The	cationic	drug-
loaded	nanogels	exhibited	less	toxicity	to	the	mitochondria	[55].	
	
Implants	
They	are	the	device	used	to	replace	a	structure,	support	a	damaged	structure,	
or	supplement	an	existing	structure	in	human	body.	The	implants	are	also	used	
for	 diagnostic	 and	 drug	 delivery	 applications.	 They	 are	 traditionally	 made	 by	
silicon	 and	 use	 for	 investigating	 the	 neuronal	 firing	 but	 severe	
neuroinflammation	 are	 caused	 by	 the	 implant.	 It	 is	 hypothesized	 that	 the	
mechanical	incompatibility	between	the	rigid	implant	and	soft	brain	tissue	is	the	
significant	 reason	 for	neuroinflammation.	 In	 case	of	 intracortical	 implants,	 it	 is	
seen	 that	 the	 implant	 caused	 tissue	 reactivity,	 which	 is	 probably	 for	 the	
oxidative	stress	created	by	the	implant	as	well	as	its	inflexibility.	Its	rigidity	with	
respect	to	the	softness	brain	tissue	leads	to	the	failure	of	the	implant.	
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Recently,	a	group	developed	PVA	based	polymeric	implants.	These	implants	are	
mechanically	adaptive	and	flexible,	and	designed	to	release	curcumin.	The	two	
important	 parameters,	 which	 acted	 synergistically	 in	 vivo	 were:	 softening	 and	
flexibility	of	the	implant	and	presence	of	an	antioxidant	[56].	The	results	of	this	
investigation	 have	 opened	 up	 a	 new	 channel	 of	 flexible	 intracortical	 implants,	
where	 the	 neuroinflammation	 due	 to	 the	 rigidity	 of	 the	 implants	 has	 been	
minimized	remarkably.		
The	 implants	 are	 advantageous	 as	 they	 provide	 with	 maximum	 bioavailability	
but	 their	 implantation	 and	 removal	 requires	 surgical	 intervention,	 which	 is	
troublesome	for	the	patient.	
	
A	 considerable	number	of	drugs	have	been	already	 transported	 into	 the	brain	
across	 BBB	 using	 nanocarriers.	 These	 drugs	 include	 anticancer,	 analgesic,	
cardiovascular	 drugs,	 protease	 inhibitors,	 several	 macromolecules	 etc.	 The	
majority	of	this	drugs	are	listed	in	Table	1.	
	
TABLE	1:	DRUGS	LOADED		IN	NPS	FOR	BRAIN	DELIVERY	[46]	
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a	these	size	are	usually	small,*	PS	80	=	polysorbate	80,	**	PS	188	=	poloxamer	188,	***	P	407	=	poloxamer	407,	****	
n/r	=	not	reported	
	
The	next	table	reports	the	list	of	recent	patents	for	NPs	specifically	formulated	
for	the	brain. 
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TABLE	2:	PATENTS	OF	NANOCARRIERS	DEVELOPED	FOR	THE	BRAIN	[25]	
 
1.4.5 MECHANISM	OF	NANOPARTICLE-MEDIATED	UPTAKE	INTO	THE	BRAIN	
According	 with	 the	 last	 study	 of	 Kreuter	 [46],	 there	 are	 different	 proposed	
mechanisms	of	uptake	of	loaded	NPs	into	the	brain:	
1. An	 increased	 retention	 of	 the	 NPs	 in	 the	 brain	 blood	 capillaries	
combined	with	an	adsorption	to	the	capillary	walls.	This	could	create	a	
higher	concentration	gradient	that	would	increase	the	transport	across	
the	ECs	layer	and	as	a	result	enhance	the	delivery	to	the	brain.		
2. The	 TW80	 used	 as	 the	 coating	 agent	 could	 inhibit	 the	 efflux	 system,	
especially	Pgp.	
3. A	general	toxic	effect	on	the	brain	vasculature.	
4. A	general	surfactant	effect	characterised	by	the	solubilisation	of	the	EC	
membrane	 lipids	 that	would	 lead	 to	membrane	 fluidisation	 and	 to	 an	
enhanced	drug	permeability	across	the	BBB.	
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5. Opening	of	the	tight	junctions	between	the	brain	blood	vessel	ECs.	The	
drug	 could	 then	 permeate	 through	 the	 tight	 junctions	 in	 free	 form	 or	
together	with	the	NPs	in	bound	form.	
6. Endocytosis	by	the	ECs	followed	by	the	release	of	the	drugs	within	these	
cells	and	delivery	to	the	brain.	
7. Transcytosis	through	the	brain	ECs	layer.	
8. A	combination	of	the	above	effects.	
NPs	transport	across	the	BBB	seems	to	occur	by	endocytosis	of	the	particles	by	
the	brain	capillary	ECs	after	 intravenous	 injection	 followed	by	NPs	 transcytosis	
across	these	cells.	In	the	previous	reviews	[57–60]	was	evidenced	by	the	authors	
that	the	creation	of	high	drug	concentration	gradients	by	adherence	of	the	NPs	
to	 the	 inner	 surface	 of	 the	 blood	 capillary	walls	 (mechanism	 1)	would	 not	 be	
sufficient	for	an	effective	and	pharmacologically	relevant	drug	transport	across	
the	 ECs	 layer	 since	 the	 diffusing	 drug	 still	 would	 have	 been	 subjected	 to	 the	
highly	 efficient	 efflux	 transporters	 such	 as	 Pgp	 in	 the	 luminal	 membranes	 of	
these	cells.	These	efflux	transporters	also	cannot	be	blocked	by	the	presence	of	
the	 1%	 TW80	 in	 the	 injected	 NPs	 suspension	 because	 the	 pre-injection	 of	
polysorbate	 80-coated	 empty	 NPs	 5	 or	 30	 min	 before	 injection	 of	 a	 dalargin	
solution	 did	 not	 induce	 any	 pharmacological	 effects	 and	 this	 fact	 negates	 the	
permeabilisation	 of	 the	 BBB	 by	 toxic	 effects	 (mechanism	 3)	 or	 by	 membrane	
solubilisation	caused	by	 the	 surfactant	 (mechanism	4)	and	also	opening	of	 the	
tight	 junctions	 (mechanism	5).	This	conclusion	was	 further	verified	by	electron	
microscopic	 studies	 histological	 investigations	 and	 toxicological	 experiments	
[46].Moreover,	 a	 surfactant	 induced	permeability	 enhancement	 appears	 to	 be	
unlikely	 as	 no	 pharmacological	 responses	 were	 observed	 after	 injection	 of	
dalargin	 loaded	 in	NPs	 coated	with	other	 surfactants	 such	as	poloxamers	184,	
338,	 407,	 poloxamine	 908,	 Cremophor®	 EZ,	 Cremophor®	 RH	 40,	 and	
polyoxyethylene-(23)-laurylether	(Brij®	35).	Moreover,	the	electron	microscopic	
studies	by	Kreuter	et	al.	[61]	showed	that	the	tight	junctions	(mechanism	5)	did	
not	open	after	intravenous	administration	of	the	NPs.	Mechanisms	6	and	7	are	
the	 principal	 mechanisms	 for	 the	 transport	 of	 drugs	 across	 the	 BBB	 into	 the	
brain	[58].	
Different	 in	 vivo	 experiments	 were	 performed	 with	 different	 apolipoproteins	
adsorbed	 directly	 onto	 uncoated	 or	 polysorbate	 80-coated	 dalargin-loaded	
PBCA	 NPs	 prior	 to	 their	 intravenous	 injection,	 and	 the	 pharmacological	
responses	 (antinociceptive	 effects)	 were	 measured,	 demonstrating	 that,	
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especially	apo	E	and	B,	yielded	high	antinociceptive	effects.	Consequently,	it	was	
concluded	 that	 TW80	 and	 poloxamer	 188	 act	 as	 an	 anchor	 for	 the	
apolipoproteins	 and	 that	 these	 apolipoproteins	 then	 interact	 with	 lipoprotein	
receptors	on	the	brain	ECs	cells	 [57,58,60].	Apo	A-I	 is	able	to	 interact	with	the	
scavenger	receptor	class	B	type	I	and	apo	E	and	B	with	the	LDL	receptor	(LRP1),	
for	 this	 reason,	 interaction	with	 these	 receptors,	 followed	 by	 endocytosis	 and	
transcytosis	 across	 the	 brain	 capillary	 endothelial	 cells	 appears	 to	 be	 the	
principal	mechanism	for	the	drug	delivery	by	surfactant-coated	PBCA,	polylactic	
acid,	and	HSA	NPs	with	adsorbed	or	covalently	 linked	targeting	 ligands	such	as	
the	 apolipoproteins	 A-I,	 B,	 and	 E.	 Accordingly	 NPs	 would	 mimic	 lipoprotein	
particles	and	act	as	Trojan	horses.	 Zensi	et	al.	 [51]	 showed	 that	only	NPs	with	
covalently	bounded	apolipoprotein	A-I	or	apo	E	were	found	in	brain	capillary	ECs	
as	 well	 as	 in	 neurons.	 Reimold	 et	 al.	 [62]	 developed	 rhodamine-123-,	
fluorescein-isothiocyanate-dextran-,	or	doxorubicin-labelled	PBCA	NPs	and	after	
the	administration	of	TW80-coated	NPs	by	carotic	injection,	fluorescence	could	
first	 be	 detected	 in	 cryosections	 of	 the	 brain	 in	 capillary	 lumina	 with	 a	
progressive	 shift	 to	 capillary	 endothelial	 cells	 at	 30	 min	 followed	 by	 a	 rather	
evenly	spread	distribution	across	the	brain	tissue	at	60	min	after	administration.	
Sixty	 minutes	 after	 administration	 into	 the	 tail	 vein,	 the	 fluorescent	 particles	
could	be	assigned	to	ECs,	whereas	after	2	h	a	rather	evenly	spread	distribution	
across	the	he	brain	tissue	was	seen.	No	fluorescence	in	the	brain	was	detectable	
with	uncoated	NPs.	 It	 is	 very	 important	 to	note	 that	endocytotic	processes	by	
ECs	 including	 brain	 capillary	 ECs	 are	 quite	 rapid	 processes,	 in	 fact	 NPs	 are	
observable	in	these	cells	of	mice	and	rats	already	15	min	after	i.v.	injection	and	
at	the	same	time	significant	pharmacological	effects	are	observed	[46].		
The	transport	of	NPs	across	BBB	appears	to	be	also	circadian	phase-dependent	
in	 fact	 a	 circadian-time-dependent	 fluctuation	 in	 the	 permeability,	 or	 the	
transcytosis	capacity,	of	the	small	cerebral	vessels	was	observed	by	Ramge	et	al.	
[63].	
1.4.6 INFLUENCE	OF	SURFACE	PROPRIETIES		
The	surface	properties	of	the	NPs	were	found	to	be	the	key	factor	for	successful	
brain	delivery.	In	particular,	endocytosis	of	the	negatively	charged	200–300	nm	
PBCA	 NPs	 by	 brain	 capillary	 ECs	 was	 clearly	 enabled	 by	 TW80	 coating,	 which	
enhanced	the	adsorption	of	the	plasma	apolipoprotein	on	the	surface	of	these	
particles.	The	Apo	E	participates	 in	the	transport	of	 lipids	 into	the	brain	by	the	
low-density	 lipoprotein	 (LDL)	 receptors,	 which	 is	 essential	 for	 maintaining	
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cholesterol	homeostasis.	The	Apo	E	binds	to	a	number	of	receptors	on	the	BBB	
such	 as	 LDLR,	 LRP-1,	 very	 low	 density	 lipoprotein	 receptor	 (VLDLR),	
apolipoprotein	receptor-2	(Apo	ER-2)	and	megalin/gp330,	as	well	as	receptors	in	
other	parts	of	CNS.	Thus	 it	 is	probable	 that	 the	presence	of	Apo	E	on	 the	NPS	
surface	promoted	internalization	of	these	NPs	 in	the	brain	capillary	ECs	via	the	
LDL	receptors	expressed	by	these	cells.	As	described	previously,	polysorbate	80,	
and	 also	 20,	 40,	 60	 and	 poloxamer	 188	 were	 able	 to	 achieve	 antinociceptive	
effects	in	mice	after	binding	of	dalargin	following	intravenous	injection,	whereas	
other	 surfactants	 such	 as	 poloxamers	 184,	 338,	 407,	 poloxamine	 908,	
Cremophor®	EZ,	Cremophor®	RH	40,	and	polyoxyethylene-(23)-laurylether	(Brij®	
35)	did	not	yield	such	effects	[46].	
Calvo	 et	 al.	 [64]	 showed	 that	 in	 mice	 and	 rats	 after	 intravenous	 injection	 of	
PEGylated	 [14C]-poly[methoxy	 poly	 (ethylene	 glycol)	 cyanoacrylate-co-
hexadecyl	 cyanoacrylate]NPs	 ([14C]-PHDCA	NPs),	 the	 14C-concentrationin	was	
enhanced	considerably	in	different	brain	tissues.	If	NPs	are	PEGylated,	they	are	
called	 “stealth”	 and	 it	 means	 that	 they	 are	 characterized	 by	 a	 significant	
reduction	in	liver	uptake	and	increase	in	blood	circulation	time	and	distribution	
into	other	organs	and	tissues.	A	species-dependent	influence	of	the	surfactants	
on	the	brain	concentrations	was	observed:	 in	mice	the	brain	concentrations	of	
the	 [14C]-PHDCA	 NPs	 were	 higher	 after	 coating	 with	 TW80	 than	 with	
poloxamine	908	whereas	in	rats	this	order	was	reversed.	After	the	reduction	of	
the	 NPs	 dose,	 maintaining	 the	 same	 total	 polysorbate	 concentration,	 higher	
[14C]	 brain	 levels	 were	 observed	 with	 the	 TW80-coated	 NPs	 than	 with	 the	
PEGylated	 [14C]-PEG-PHDCA	 particles.	 In	 the	 studies	 of	 Brigger	 et	 al.	 [65]	 the	
tumour	 concentrations	 of	 the	 PEGylated	NPs	were	 about	 3	 times	 higher	 than	
with	the	normal	particles	and	about	5–6	times	higher	than	in	the	adjacent	brain	
areas;	in	the	tumour-bearing	rats,	the	brain	concentrations	in	the	areas	adjacent	
to	 the	 tumour	 as	 well	 as	 in	 the	 contralateral	 brain	 hemisphere	 also	 were	
increased	significantly	compared	to	normal	animals	without	tumour,	indicating	a	
generally	higher	permeability	 in	 the	diseased	animals.	 In	 this	context	Huang	et	
al.	 [66]	 found	 no	 difference	 in	 brain	 uptake	 between	 stealth	 and	 non-stealth	
[14C]-labelled	 polymethoxyethyleneglycol	 cyanoacrylate-co-n-hexadecyl	
cyanoacrylate	 (PEG-PHDCA)	 NPs	 in	 mice	 after	 intravenous	 injection,	 although	
the	 blood	 circulation	 time	 of	 the	 stealth	 particles	 again	 was	 significantly	
prolonged.	 Stealth	 properties	 alone,	 therefore,	 do	 not	 appear	 sufficient	 for	
enabling	a	NPs-mediated	transport	into	the	brain.	
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All	 these	 results	 underline	 the	 importance	 of	 the	 surface	 properties	 for	 brain	
drug	delivery	by	intravenous	injection.	
1.4.7 TOXICOLOGICAL	RESULTS	
In	 the	 literature	 several	 studied	 has	 been	 made	 in	 order	 to	 investigate	 the	
toxicity	of	developed	nanocarriers.		
The	 toxicity	 of	 empty	 and	 loaded	 with	 doxorubicin	 PBCA	 NPs	 and	 control	
solutions	of	doxorubicin	was	investigated	in	many	studies	in	normal	and	also	in	
glioma	101/8-bearing	rats.	Doses	up	to	400	mg/kg	of	empty	NPs	did	not	cause	
any	mortality	within	the	period	of	observation	(30	days)	nor	did	they	affect	body	
weight	 or	 weight	 of	 internal	 organs	 after	 intravenous	 injection.	 Higher	 doses	
cannot	 be	 administered	 intravenously	 by	 bolus	 injection	 because	 of	 biological	
and	 technical	 limitations.	 Single	 intravenous	 injections	 of	 doxorubicin	
formulations	 caused	 dose-dependent	mortality	 and	weight	 loss.	 No	 significant	
difference	in	toxicity	occurred	between	healthy	and	tumour-bearing	animals.	In	
addition,	multiple	intravenous	injections	(3	or	4	Å~	1.5	mg/kg)	were	performed	
to	 assess	 body	 and	 internal	 organ	 weight,	 hematological	 parameters,	 blood	
biochemical	 parameters,	 and	 urinalysis.	 Morphological	 evaluations	 including	
macroscopic	 and	 histological	 investigations	 of	 heart,	 lung,	 spleen,	 testes,	 and	
liver	 revealed	 a	 considerably	 decreased	 toxicity	 in	 heart	 and	 testes	 of	 the	
animals	 treated	with	 the	 doxorubicin	 bound	 to	 NPs	 compared	 to	 its	 solution.	
The	 lower	 toxicity	 of	 the	 nanoparticulate	 formulations	 of	 doxorubicin	 most	
probably	is	explained	by	the	altered	biodistribution	of	the	drug	mediated	by	the	
NPs.	The	reduced	cardiotoxicity	is	the	main	goal	because	represents	the	limiting	
factor	 in	 the	 tumour	 therapy	 with	 doxorubicin.	 Additionally,	 a	 lower	
hepatotoxicity	compared	to	the	solutions	occurred	with	the	NPs	although	higher	
liver	 concentrations	 were	 determined	 in	 pharmacokinetic	 studies.	 Probably	
binding	to	NPs	also	leads	to	a	different	distribution	of	the	doxorubicin	within	the	
liver	increasing	the	Kupffer	cell	uptake	thus	making	it	less	accessible	to	the	more	
sensitive	hepatocytes,	thereby	reducing	its	toxicity.	
After	autopsy,	healthy	animals	treated	with	doxorubicin	solution	showed	slight	
signs	of	lung	oedema	while	these	changes	were	not	observed	in	animals	treated	
with	doxorubicin	bound	to	the	NPs.	Indication	of	short-term	neurotoxicity,	such	
as	increased	apoptosis	in	areas	distant	from	the	tumour,	increased	expression	of	
GFAP	or	 ezrin	on	distant	 astrocytes	or	degenerative	morphological	 changes	of	
neurons,	were	 entirely	 absent	 in	 NPs	 treated	 animals	 on	 day	 12	 as	well	 as	 in	
long-term	 survivors.	 In	 addition,	 there	 was	 no	 indication	 of	 chronic	 glial	
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activation	 in	 areas	 distant	 from	 the	 tumour	 site	 in	 long-term	 surviving	 rats.	
Additionally,	 long-term	 survivors	 did	 not	 exhibit	 any	 obvious	 neurological	
symptoms	[46].	
1.5 MODELS	TO	PREDICT	BRAIN	PENETRATION		
Brain	 penetration	 of	 drugs	 has	 two	 important	mechanisms:	 rate	 (at	 the	 initial	
state)	 and	 extent	 (at	 steady	 state)	 (Figure	 9)	 The	 rate	 of	 brain	 penetration	
depends	 on	 the	 permeability	 of	 the	 compounds	 across	 the	 BBB	 (by	 passive	
diffusion,	 active	 uptake	 and/or	 efflux).	 The	 extent	 of	 brain	 penetration	 is	
determined	 by	 the	 distribution	 of	 the	 drug	 between	 brain	 and	 plasma,	 and	 is	
affected	 by	 multiple	 factors	 including	 metabolic	 clearance,	 plasma	 protein	
binding,	nonspecific	binding	 to	brain	 tissue,	 and	drug	 clearance	 from	brain	 ISF	
into	 CSF.	 Models	 to	 assess	 CNS	 penetration	 have	 typically	 been	 designed	 to	
measure	either	one	of	these	two	components	(rate	or	extent)	[67,68].	
	
	
FIGURE	9:CNS	PENETRATION	OF	A	DRUG	IS	IMPACTED	BY	THE	PERMEATION	ACROSS	THE	
BBB	AND	BY	THE	DISTRIBUTION	TO	AND	WITHIN	THE	BRAIN	[69] 
In	 the	 last	 years,	 a	wide	 spectrum	 of	 in	 silico,	 in	 vitro	 and	 in	 vivo	models	 has	
been	developed	and	employed	 in	academia	and	 industry,	primarily	dictated	by	
two	 factors:	 (1)	 the	 need	 to	 advance	 the	 understanding	 of	 the	 complex	
molecular	mechanisms	 regulating	 the	 brain	 environment	 and	 (2)	 facilitate	 the	
development	 of	 alternative	 and	 more	 effective	 pharmacological	 strategies	
aimed	to	CNS	targets	[70].	
1.5.1 IN	SILICO	MODELLING	AND	PREDICTION	
Recently	computational	models	to	predict	rate	and	extent	of	brain	penetration	
of	 drug	 molecules	 have	 become	 progressively	 popular.	 Methods	 based	 on	
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computer	simulation	are	gained	more	and	more	interest	in	the	research	field	as	
the	incredible	development	of	computer	technology	and	advance	algorithms	are	
becoming	 available.	 Brain	 penetration	 of	 a	 molecule	 is	 influenced	 by	 its	
physicochemical	 properties	 such	 as	 lipophilicity,	 polar	 surface	 area	 (PSA),	
molecular	weight	(MW),	hydrogen	bonding	and	ionization	state.	One	of	the	first	
set	of	rules	for	optimal	brain	penetration	was	 introduced	 in	1995	by	Pardridge	
[71]	since	he	specified	that	BBB	permeability	of	a	drug	is	possible	if	the	number	
of	total	H-bonds	is	<	8–10,	the	MW	<	400–600	Da,	and	if	the	compound	is	not	
an	acid	[71].	Others	studies	have	suggested	that	BBB	permeation	is	favorited	if	
the	sum	of	oxygen	and	nitrogen	is	≤	5,	the	PSA	<	60–70	Å2,	the	MW	<	450	Da,	
and	the	LogD	(at	pH	7.4)	between	1–3	[72–74].		
Use	of	physico-chemical	descriptors	determining	molecular	partition	 (Abraham	
solvation	equation)	has	proved	to	be	one	of	the	most	reliable	methods.	A	major	
problem	 has	 been	 the	 lack	 of	 biological	 experimental	 data,	 thus	 around	 20	
published	computational	modelling	approaches	have	used	variants	of	the	same	
log	BB	training	data	set,	or	pooled	data	from	different	sources.	There	are	even	
fewer	reliable	estimates	of	log	PS,	although	this	measure	is	expected	to	produce	
models	better	able	to	predict	BBB	permeability.	
Until	recently,	lack	of	detailed	knowledge	on	the	Structure	Activity	Relationship	
(SAR)	 of	 transporter	 proteins	 and	 enzymes	 has	 made	 it	 difficult	 to	 generate	
predictive	 models	 for	 the	 ‘transport’	 and	 ‘metabolic’	 barrier	 functions	 of	 the	
BBB.	 That	 is	 beginning	 to	 change,	 with	 the	 appearance	 of	 hybrid	 (in	 vitro/in	
silico)	 models	 capable	 of	 predicting	 both	 passive	 and	 transporter-mediated	
function,	and	software	tools	 for	screening	drugs	 for	chemical	 features	 likely	 to	
make	them	P-gp	substrates	[70].	
1.5.2 IN	VITRO	MODELS		
In	vitro	models	can	be	subdivided	into	physicochemical	methods	and	cell-based	
methods.	 The	 functional	 and	 structural	 requirements	 for	 an	 ideal	 in	 vitro	 BBB	
model	are	reported	in	the	subsequent	table:	
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TABLE	3:	REQUIREMENTS	FOR	AN	IDEAL	BBB	IN	VITRO	MODEL	[70]	
 
 
The	models	of	 the	BBB	 started	 to	emerge	 in	 the	early	1990s	as	potential	new	
research	 tools	 complementary	 to	 in	 vivo	 and	 human	 studies	 in	 basic,	
translational,	 and	 clinical/pharmaceutical	 research	 bearing	 a	 number	 of	
desirable	advantages:		
1. cost	 effective—they	 are	 relatively	 inexpensive	 when	 compared	 with	
animal	experimentation	with	a	significantly	higher	 throughput	 for	drug	
permeability	 testing	 (a	 quality	 most	 desirable	 in	 the	 pharmaceutical	
industry);		
2. simplified	working	environment—the	artificial	environment	provided	by	
these	in	vitro	models	allows	studying	and	manipulating	the	BBB	without	
the	 cumbersome	 number	 of	 additional	 variables	 to	 sort	 out	 when	
working	with	an	entire	organism;		
3. 	versatility—they	 provide	 highly	 controllable	 and	 in	 some	 case	 quasi-
physiological	environments	outside	of	a	living	organism	in	which	cells	or	
tissue	 can	 be	manipulated	 to	 study	 and	 dissect	 out	 the	 response	 of	 a	
specific	tissue/organ	to	a	broad	range	of	physiological	and	experimental	
stimuli	otherwise	difficult	to	reproduce		in	vivo	[70].		
1.5.2.1 Physicochemical	methods	
PAMPA-BBB		
Parallel	artificial	membrane	permeability	assays	(PAMPAs)	have	become	a	quite	
useful	and	versatile	in	vitro	tool	for	predicting	passive	transcellular	diffusion	of	a	
compound	across	the	BBB.	The	system	is	based	on	the	use	of	specially	designed	
artificial	lipid-impregnated	membrane	established	on	a	solid	filter	support	(e.g.,	
polycarbonate)	between	a	donor	and	an	acceptor	compartment.	In	this	system	a	
multiwell	plate	is	placed	at	the	bottom	for	the	donor	compartment,	whereas	the	
artificial	 lipid	 membrane/acceptor	 compartment	 is	 placed	 on	 top	 in	 a	
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“sandwich”	 like	 configuration.	 Initially,	 the	 test	 drug	 is	 added	 in	 the	 donor	
compartment	and	allowed	to	diffuse	across	the	membrane.	The	drug	diffused	in	
the	 acceptor	 compartment	 is	 then	 measured	 and	 quantified.	 PAMPAs	 have	
some	advantages	such	as:	a	high	degree	of	versatility,	automation	compatibility,	
and	assay	reproducibility.	The	system	can	be	modified	to	assess	the	effect	of	a	
wide	range	of	pH	on	the	permeability	of	the	test	drug	of	interest	(e.g.,	gastric	pH	
range	 1.0–2.5,	 intestine	 pH	 range	 6.6–7.0,	 etc.).	 The	 donor	 and/or	 acceptor	
compartments	 can	be	modified	 to	emulate	 in	 vivo	 conditions	by	 incorporating	
solubilizing	agents	or	additives	that	bind	the	compounds	as	they	diffuse	across	
the	 lipid	 membrane.	 PAMPAs	 are	 considered	 suitable	 early	 stage	 absorption	
screening	tool	alternatives	to	more	demanding	and	expensive	cell-based	assays.	
The	major	 limitation	of	PAMPA	systems	versus	cell-based	and	 in	vivo	studies	 is	
their	 inability	 to	 reproduce	 active	 transport	 mechanisms	 or	 metabolic	
transformations	that	a	compound	may	incur	during	transcellular	routing	across	
physiological	 membranes.	 This	 may	 significantly	 affect	 predictability	 of	
bioavailability	 of	 the	drug	on	 the	 targeted	 site	 and	 thus	 use	of	 PAMPAs	 alone	
would	be	 insufficient.	Their	combination	with	 in	silico	and	 the	development	of	
more	 complex	 algorithms	 that	 better	 reflect	 the	 behaviour	 of	 highly	 dynamic	
physiological	membranes	(e.g.,	BBB)	can	further	extend	the	use	of	this	broadly	
adopted	technology	beyond	an	early	stage	screening	tool	[70].	
	
Immobilized	artificial	membrane	(IAM)	chromatography	
This	method	mimic	 the	membrane	 lipid	environment	 found	 in	 living	 cells.	 This	
technology	 is	 more	 commonly	 used	 for	 purification	 of	 many	 biological	
substances	 but	 found	 other	 more	 specific	 applications	 in	 the	 study	 of	 drug–
membrane	 interactions	 and	 drug	 permeability	 across	 the	 BBB.	 Originally	
developed	 at	 Purdue	University	 by	 Charles	 Pidgeon,	 the	 IAM	 stationary	 phase	
consists	of	a	monolayer	of	carboxyl	phospholipids	that	bear	interfacial	functional	
groups	 identical	 to	 the	membrane	 phospholipids	 forming	 the	 cell	membranes	
(e.g.,	 phosphatidylcholine,	 phosphatidylglycerol,	 phosphatidic	 acid,	
phosphatidylethanolamine,	 and	 phosphatidylserine)	 covalently	 immobilized	 on	
an	 inert	 silica	 support.	 The	 resulting	 IAM	 surface	 is	 a	 chemically	 stable	
chromatographic	material,	which	mimics	the	lipid	outer	layer	of	a	biological	cell	
membrane.	 IAM	 chromatography	 can	 be	 used	 for	 the	 non-covalent	
immobilization	 as	well	 as	 analytical	 and	 preparative	 separation	 of	membrane-
associated	 proteins,	 it	 also	 a	 method	 to	 estimate	 membrane	 permeability	 of	
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small	drugs	and	to	measure	 their	 specific	phospholipophilicity.	However,	 there	
are	 different	 limitations	 of	 this	 technique	 as	 a	 method	 to	 assess	 drug	
permeability:	the	IAM	surface	has	limited	ability	to	reproduce	lateral	membrane	
diffusion,	 which	 occurs	 at	 the	 cellular	 level	 in	 vivo,	 the	 IAM	 surface	 is	 a	 lipid	
monolayer,	 thus	 using	 this	 model	 to	 extrapolate	 solute	 diffusion	 across	 a	
physiological	membrane	bilayer	is	extremely	difficult,	IAM	surface	cannot	mimic	
active	 efflux	 or	 drug	 metabolism,	 which	 normally	 occurs	 at	 the	 BBB	 level.	
Currently,	 IAM	 chromatography	 is	 primarily	 used	 as	 a	 single-step	 purification	
method	for	membrane	proteins	[70].		
	
Equilibrium	dialysis		
This	 method	 consents	 to	 obtain	 information	 on	 protein	 binding	 in	 brain	
homogenate	 and	 plasma	 and,	 consequently,	 on	 the	 free	 (unbound)	 drug	
fractions	 in	 both	 matrices.	 Information	 on	 free	 drug	 fractions	 in	 plasma	 is	
important	 as	 only	 unbound	molecules	 are	 available	 to	 cross	 the	 BBB.	 Thus,	 if	
plasma	 protein	 binding	 is	 too	 high,	 the	 extent	 of	 brain	 penetration	 may	 be	
insufficient	 [75].	However,	 attention	must	be	paid	when	using	 in	 vitro	 data	on	
plasma	 protein	 binding	 of	 compounds	 because	 that	 bound	 molecules	 within	
brain	capillaries	are	able	to	dissociate	more	readily	than	in	 in	vitro	models,	and	
thus	 the	 bioavailable	 fraction	 in	 vivo	 may	 be	 higher	 than	 expected	 [75].	
Unbound	drug	fractions	in	the	brain	can	be	used	for	the	calculation	of	unbound	
drug	concentrations	in	the	brain,	if	in	vivo	data	on	total	brain	levels	are	available	
[76].	Finally,	the	ratio	of	free	plasma	to	free	brain	fraction	has	been	suggested	as	
a	parameter	to	predict	the	in	vivo	extent	of	brain	distribution	[77].	
1.5.2.2 Cell-based	methods	
Isolated	brain	capillaries		
Brain	 microvessels	 from	 human	 or	 animal	 sources	 have	 been	 used	 in	 BBB	
research	 since	 their	 successful	 isolation	 more	 than	 three	 decades	 ago	 [78].	
However,	they	are	not	suitable	for	in	vitro	BBB	permeability	screenings	since	the	
luminal	side	(blood	side)	of	the	capillaries	is	hardly	accessible	[79].	
Cell	culture	models 
Cell-based	BBB	models	can	be	established	with	any	type	of	cell	source	(human,	
animal,	or	cell	line	derivative)	including	the	availability	of	BBB	ECs	and	astrocytes	
freshly	 isolated	 from	 human	 brain	 tissue	 (e.g.,	 from	 patients	 undergoing	
temporal	 lobectomies	 for	 drug	 refractory	 epilepsy,	 brain	 tumour	 resections,	
aneurisms,	 etc.).	 Is	 it	 important	 consider	 that	 cells	 cultured	 ex	 situ	 in	 an	
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artificially	environment	undergo	dedifferentiation	because	of	lack	of	exposure	to	
physiological	 aspects.	 This	 can	 affect	 the	 expression	 (deregulation)	 of	 relevant	
cell	 biological	 features	 (e.g.,	 transporters,	 ligands,	 enzymes,	 etc.),	 thus	
potentially	altering	the	BBB	physiology	in	vitro	as	well	as	its	response	to	stimuli.	
Therefore,	validation	of	 in	vitro	 findings	 in	 in	vivo	conditions	 is	often	necessary	
[70].		
Ø Static	models	of	BBB:	ECs	monocultures	
The	most	common	and	usually	utilized	BBB	model	 is	based	on	a	monolayer	of	
highly	specialized	brain	microvascular	ECs.	This	system,	known	as	the	Transwell	
apparatus	(e.g.,	Corning,	Lowell,	MA),	 is	a	vertical	side-by-side	diffusion	system	
across	 a	 microporous	 semipermeable	 membrane	 that	 separates	 the	 luminal	
(vascular)	 and	 the	 abluminal	 (parenchymal	 side)	 compartments.	 Brain	 vascular	
ECs	 (from	 various	 sources)	 are	 grown	 to	 confluence	 on	 the	 upper	 (luminal)	
surface	 of	 the	 membrane	 immersed	 in	 their	 specific	 growth	 media.	 The	
advantages	 of	 cultured	 endothelium	 include	 the	 potential	 for	 using	 pure	 cell	
populations	 as	 well	 as	 their	 relative	 capability.	 The	 microporous	 membrane	
interface	 allows	 for	 nutrient	 exchange	 and	 the	 passage	 of	 cell-derived	 and	
exogenous	 substances	 but	 does	 not	 allow	 for	 cell-movement	 across	 the	 two	
compartments.	Thanks	to	this	model	it	is	possible	to	test	the	drug	permeability	
and	 also	 the	 binding	 affinity	 (receptor–ligand).	 In	 particular,	 they	 are	 ideal	
systems	 to	 study	 Michaelis–Menten	 kinetics	 of	 transport	 because	 of	 fixed	
volumes	in	each	compartment.	Of	course	this	easy	reconstruction	of	BBB	lacks	a	
number	of	critical	 features	such	as	 the	absence	of	natural	physiological	stimuli	
as	 cell	 to	 cell	 interaction	 with	 perivascular	 astrocytes	 and	 other	 parenchymal	
cells	 (e.g.,	 neurons).	 This	 non-physiological	 culture	 condition	 may	 accelerate	
endothelial	 dedifferentiation	 and	 increase	 the	 loss	 of	 the	 BBB	 characteristics	
with	 serial	 cell.	 ECs	 grown	 in	 Transwell	 tend	 to	 have	 irregular	 patterns	 of	 cell	
adhesion,	 which	 prompt	 the	 so-called	 “edge	 effect.”	 This	 term	 refers	 to	 a	
condition	wherein	the	inability	to	form	proper	tight	junctions	between	adjacent	
cells	and	between	the	endothelium	beside	the	perimeter	of	the	membrane	and	
the	inner	wall	of	the	luminal	chamber	leads	to	artefactual	paracellular	diffusion,	
affecting	 the	 reliability	 of	 permeability	 measurements	 across	 the	 endothelial	
monolayer,	 especially	 for	 compounds	 that	 are	 highly	 hydrophilic	 and	 poorly	
cross	 the	 lipid	membrane	 bilayer	 of	 the	 cells	 [70].	 Thus,	 various	 immortalized	
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cell	lines	from	different	origin	have	been	used	to	model	the	BBB	in	vitro	(Tables	
4	and	5).		
TABLE	4:CURRENTLY	 AVAILABLE	 IMMORTALIZED	HUMAN	BRAIN	 CAPILLARY	 ENDOTHELIAL	
CELL	LINES	USED	FOR	THE	ESTABLISHMENT	OF		IN	VITRO	HUMAN	BBB	MODELS	[69]	
Brain	capillary	
endothelial	cell	line	
Transfection	method	
Year	
(first	
publication)	
Reference	
BB19	 E6E7	genes	of	HPV	 1996	
Prudhomme	et	al.	
[80]	
HBEC-5I	 SV40T	 1996	 Xiao	et	al.	[81]	
SV-HCEC	 SV40T	 1997	
Muruganandam	et	al.	
[82]	
hBMEC	 SV40T	 2001	 Stins	et	al.	[83]	
hTERT-HBEC	 hTERT	 2003	 Gu	et	al.	[84]	
hCMEC/D3	 hTERT	and	SV40T	 2005	 Weksler	et	al.	[4]	
NKIM-6	 E6E7	genes	of	HPV	type	16	 2007	
Ketabi-Kiyanvash	et	
al.	[85]	
TY08	
hTERT	and	temperature-
sensitive	SV40T	
2010	 Sano	et	al.	[86]	
TY09	
hTERT	and	temperature-
sensitive	SV40T	
2010	 Sano	et	al.	[86]	
HBMEC/ciβ	
hTERT	and	temperature-
sensitive	SV40T	
2012	 Kamiichi	et	al.	[87]	
TY10	
hTERT	and	temperature-
sensitive	SV40T	
2012	 Maeda	et	al.	[88]	
 
TABLE	5:IMMORTALIZED	ANIMAL	AND	NON-BRAIN	HUMAN	CELL	LINES	USED	FOR	BBB	 IN	
VITRO	MODELS	[69]	
Cell	line	 Description	 Origin	 Remarks	
Caco-2	
Human	epithelial	colon	
adenocarcinoma	cell	
line	
Human	
(colon)	
Limited	prediction	of	BBB	permeability	
(poor	correlation	of	in	vitro	Caco-2	and	in	
vivo	BBB	data)	[89]	
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ECV304	
Human	endothelial	
umbilical	vein	(HUVEC)	
cell	line	[90]	
Human	
(umbilical	
cord)	
Non-brain	origin,	but	cells	show	
endothelial	features,	barrier	tightness	
can	be	increased	(up	to	TEER1	of	200	
Ωcm2)		by	co-cultivation	with	
immortalized	rat	glioma	cells	(C6	cell	
line)	or	C6	conditioned	medium	[91,92]	
LLC-PK1	
Porcine	kidney	
epithelial	cell	line	[93]	
Pig	
(kidney)	
Relatively	tight	monolayers,	cell	line	can	
be	transfected	with	transporter	genes	
(e.g.	MDR1)	for	efflux	studies	
MDCK	
Madin	Darby	Canine	
Kidney	epithelial	cell	
line	[94]	
Dog	
(kidney)	
Tight	monolayers	(high	TEER1	values),	cell	
line	useful	for	determination	of	passive	
permeation	(due	to	low	expression	of	
transporters),	assay	straight	forward	(3–4	
days	of	culture)	[95,96]	
MDR1-
MDCK	(type	
I	or	II)	and	
BCRP-MDCK	
MDCK	transfected	with	
human	MDR1	gene	(P-
gp)	or	BCRP	
Dog	
(kidney)	
Tight	monolayers	(high	TEER1	values),	
polarized	expression	of	P-gp/BCRP,	
useful	for	P-gp/BCRP	efflux	studies	
(bidirectional	transport	assays)	[97]	
RBE4	
Rat	brain	capillary	
endothelial	cell	line	[98]	
Rat	(brain)	
Leaky	monolayers	(relatively	high	
permeability	to	small	molecules)	[98]	
cEND	
Murine	immortalized	
brain	(cerebral)	
capillary	endothelial	
cell	line	[99]	
Mouse	
(brain)	
Relatively	tight	monolayers	depending	on	
cultivation	protocol	(high	TEER1	values	
up	to	1000	Ωcm2)	[99]	
bEnd3	and	
bEnd5	
Mouse	brain	
microvascular	
endothelial	cell	lines	
[100,101]	
Mouse	
(brain)	
Leaky	monolayers	(relatively	low	TEER1	
values:	bEnd3	40–130	Ωcm2,	bEnd5	
around	120	Ωcm2)	[91,102]	
 
Immortalized	 cell	 lines,	 from	 human	 brains	 are	 of	 greatest	 interest	 but	 the		
available	 cell	 lines	 often	 show	 deficits	 (e.g.	 low	 transendothelial	 electrical	
resistance	 (TEER)	 values,	 relatively	 high	 paracellular	 permeation	 of	 negative	
control	 compounds,	 insufficient	expression	of	 key	 transporter	 systems).	Often,	
an	optimization	of	culture	conditions	and	a	validation	of	cell	 line-based	human	
in	 vitro	 BBB	models	 is	necessary.	 Significant	 advances	 in	modelling	 the	human	
BBB	in	vitro	have	been	achieved	recently	by	using	endothelial	cells	derived	from	
human	pluripotent	or	hematopoietic	stem	cells	[103,104].	As	stem	cells	offer	a	
high	 capacity	 of	 expansion	 by	 self-renewal	 while	 maintaining	 a	 homogenous	
genetic	 profile,	 stem	 cell-based	models	 are	 promising,	 but	 require	 systematic	
benchmarking	against	established	in	vitro	and	in	vivo	models	[105].	
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Ø Static	two-dimensional	models	of	the	BBB:	coculture	of	ECs	and	glia	
The	addition	of	abluminal	astrocytes	(Figure	10)	facilitate	the	formation	of	more	
stringent	 interendothelial	 tight	 junctions	 and	 the	 overall	 expression	 of	
proprietary	BBB	features,	that	more	closely	resemble	that	of	the	BBB	in	situ	[70].	
	
FIGURE	10:	SCHEMATIC	REPRESENTATION	OF		TRANSWELL	APPARATUS	[70] 
Different	 evidences	 indicate	 that	 astrocyte	 interaction	 with	 the	 cerebral	
endothelium	 helps	 determine	 BBB	 function,	 morphology	 (i.e.,	 tightness),	 and	
protein	 expression.	 Intercellular	 adhesion	 between	 astrocytes	 in	 the	 BBB	 has	
been	observed	 in	 the	 form	of	gap	and	adheres	 junctions.	The	presence	of	glia	
and	 the	 interactions	 glial–endothelial	 have	 been	 shown	 to	 increase	 the	
expression	 of	 transporters	 (e.g.,	 Glut-1	 and	 MRPs	 such	 as	 P-gp)	 and	 tight	
junctions,	 and	 have	 also	 helped	 mimic	 the	 in	 vivo	 condition.	 A	 limited	 cell	
polarity	is	inducible	in	ECs	when	co-cultured	with	glia	or	in	the	presence	of	glial-
conditioned	 medium.	 The	 exposure	 to	 glia	 promotes	 the	 expression	 of	 brain	
endothelial	 marker	 enzymes	 (e.g.,	 OX-26,	 alkaline	 phosphatase,	
acetylcholinesterase,	 Na+	 –K+	 -ATPase)	 as	 well	 as	 that	 of	 a	 number	 of	
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specialized	transport	and	efflux	systems	typically	observed	in	vivo.	TEER,	should	
be	higher	in	EC–glia	coculture	systems	than	EC	monocultures.	The	difference	in	
the	measurement	indicates	formation	of	a	more	stringent	and	selective	vascular	
bed	[70]. 
1.5.3 IN	VIVO	MODELS		
The	 last	 models	 provide	 some	 of	 the	 most	 reliable	 data	 to	 evaluate	 the	
permeability	 across	 the	 brain	 and	 the	 brain	 distribution	 [67].	 Of	 course,	 the	
methods	 are	 labour-intensive	 and	 low	 throughput	 and	 frequently	 are	 not	
applicable	to	humans.		
	
In	situ	brain	perfusion	
	Represent	a	 reliable	method	 to	determine	BBB	permeability	 of	 a	 drug	 [97].	A	
catheter	 is	 inserted	 into	 the	common	carotid	artery	of	an	anesthetized	animal	
(rat,	mouse,	guinea	pig,	rabbit)	and	a	solution	containing	the	test	drug	is	slowly	
perfused	through	the	brain	capillaries	[106].	Drug	concentrations	are	quantified	
in	 the	 perfused	 brain	 hemisphere	 of	 the	 sacrificed	 animals,	 and	 permeability	
surface	 area	 (PS)	 values,	 reflecting	 BBB	 permeability,	 are	 calculated	 [107].	
Limitations	 of	 the	 method	 are	 that	 it	 is	 costly,	 labour-intensive,	 and	 requires	
surgical	skills	and	expertise	[67].	
	
Total	brain-to-plasma	ratio	(Kp)	
Animals	are	dosed	with	a	test	drug,	then	they	are	sacrificed	at	designated	time-
point(s),	 and	 drug	 concentrations	 in	 brain	 homogenate	 and	 blood	 plasma	 are	
quantified.	Kp	values	are	calculated	based	on	the	respective	drug	concentrations	
or	 area	 under	 the	 curves	 (AUC)	 from	 both	 matrices	 (Kp	 =	 Cbrain/Cplasma	 or	
AUCbrain/AUCplasma).	 Kp	 values	 based	 on	 AUC	 need	 money,	 more	 labor	 and	
animals	but	may	is	more	useful	[108].	A	inconvenience	of	this	method	is	that	Kp	
values	 are	 firstly	 determined	 by	 non-specific	 binding	 of	 a	 substance	 to	 brain	
tissue	[109].		
	
Brain	microdialysis	
It	 is	 the	 best	method	 to	 determine	 the	 free	 concentration	 of	 a	 compound	 in	
brain	 interstitial	 fluid	 [76].	 A	 microdialysis	 probe	 with	 a	 semi-permeable	
membrane	is	implanted	into	a	specific	brain	region	of	an	animal	(rat	or	mouse).	
Unbound	molecules	 in	brain	 interstitial	 fluid	below	a	 certain	molecular	weight	
freely	 diffuse	 through	 the	membrane,	 and	 are	 captured	 in	 the	 fluid	 perfused	
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through	 the	 microdialysis	 probe	 [110].	 The	 unbound	 brain	 concentration	 can	
then	 be	 related	 to	 the	 unbound	 drug	 concentration	 in	 plasma,	 providing	 the	
parameter	Kp,uu	 (unbound	brain-to-plasma	ratio),	which	has	proved	to	be	more	
predictive	 than	 Kp	 values	 (total	 brain-to-plasma	 ratios)	 [111].	 This	 technique	
have	various	limitations:	firstly	the	invasiveness,	for	this	reason	it	is	not	suitable	
for	humans;	the	probe	used	for	the	dialysis	may	damage	locally	and	the	BBB	and	
lipophilic	compounds	should	adsorb	on	the	membrane	of	the	probe	[112].	
	
Cerebrospinal	fluid	(CSF)	sampling		
This	 in	vivo	methods	should	be	applicable	to	humans.	As	a	 lot	of	papers	show,	
CSF	 concentrations	 could	 be	 used	 to	 predict	 free	 drug	 concentration	 in	 brain	
interstitial	 fluid	 but	 data	 interpretation	 of	 CSF	 levels	 is	 not	 easy	 because	 the	
molecules	may	enter	the	CSF	compartment	via	the	Blood-CSF	barrier	[113].		So,	
if	 a	 drug	 is	 subject	 to	 active	 uptake	 or	 efflux	 at	 only	 one	 of	 the	 two	 barriers,	
concentrations	in	CSF	will	not	correctly	predict	free	drug	concentrations	in	brain	
interstitial	fluid.	There	are	others	limitations:	high	turnover	rate	of	CSF	(around	
6	 hours	 in	 humans),	which	 requires	 that	 CSF	 sampling	 is	 done	 at	 very	 specific	
time	 points,	 and	 that	 the	 CSF	 compartment	 is	 not	 well-mixed,	 resulting	 in	
varying	concentrations	depending	on	the	site	of	sample	collection	[108,114].	
1.6 BIOANALYSIS		
Bioanalysis	 is	 a	 section	 of	 analytical	 chemistry	 for	 the	 qualitative	 and	
quantitative	 analysis	 in	 biological	 matrices,	 like	 plasma,	 serum,	 urine,	 saliva,	
tissue	etc.	Development	and	validation	of	bioanalytical	method	 is	 important	to	
understand	the	pharmacokinetics	of	any	drug	and/or	its	metabolites.		
Bioanalytical	method	validation	includes	all	of	the	procedures	that	demonstrate	
that	 a	 particular	 method	 used	 for	 quantitative	 measurement	 of	 analytes	 in	 a	
given	 biological	matrix,	 such	 as	 blood,	 plasma,	 serum,	 or	 urine	 is	 reliable	 and	
reproducible	for	the	intended	use	[115].	
1.6.1 LIQUID	 CHROMATOGRAPHY	 COUPLED	 TO	 TRIPLE	 QUADRUPOLE	 MASS	
SPECTROMETERS	(LC-MS/MS)		
LC-MS/MS	 is	 a	 combination	 of	 two	 techniques:	 LC	 for	 the	 separation	 of	 a	
mixture	between	two	immiscible	phases	based	on	the	physical	properties	of	the	
constituents	 and	 triple	 quadrupole	MS	 for	 selective	 and	 sensitive	 detection	of	
analytes.	 Is	 possible	 choice	 between	 different	 LC	 system:	HPLC	 or	UHPLC	 (the	
acronym,	while	UPLC	is	used	only	for	Waters	Corp.	UHPLC	instruments	are	able	
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to	 operate	 at	 higher	 back-pressure	 than	 conventional	 HPLC	 systems,	 allowing	
the	use	of	shorter	columns	with	smaller	particles	as	stationary	phase	[116,117].		
LC	 system	 is	 principally	 coupled	 to	 the	 triple	 quadrupole	 detector	 via	
electrospray	ionization	(ESI)	or	atmospheric	pressure	chemical	ionization	(APCI)	
interfaces	[118].	ESI	and	APCI	are	both	soft	ionization	techniques,	by	which	the	
analytes	 eluting	 from	 the	 LC	 column	 are	 ionized	 to	 positively	 (M+H+)	 or	
negatively	(M-H-)	charged	ions	which	are	transferred	into	gas	phase,	and	finally	
introduced	into	the	MS	[119].	APCI	sources	are	more	suited	for	ionization	of	less	
polar	and	non-polar	compounds	[119]	while	ESI	sources	are	capable	of	ionizing	
almost	any	polar	molecule.	
Triple	quadrupole	mass	spectrometers	consist	of	three	quadrupoles	connected	
in	 series	 (Figure	 11)	 [120,121].	 A	 quadrupole	 typically	 consists	 of	 four	
molybdenum	 rods	 on	 which	 alternating	 DC	 (direct	 current)	 and	 RF	 (radio	
frequency)	voltages	are	applied	[121].	At	a	particular	DC/RF	ratio,	only	ions	with	
a	 certain	m/z	 value	 have	 a	 stable	 trajectory	 and	 are	 able	 to	 pass	 through	 the	
quadrupole	 [121].	 In	 quantitative	 bioanalysis,	 triple	 quadrupole	 detectors	 are	
primarily	 operated	 in	MRM	mode.	 In	 this	mode,	 the	 first	 (Q1)	 and	 third	 (Q3)	
quadrupole	 act	 as	 selective	 mass	 filters,	 while	 the	 second	 quadrupole	 (Q2),	
located	 between	 Q1	 and	 Q3,	 serves	 as	 collision	 cell	 (RF	 voltage	 applied	 only)	
(Figure	1)	[122].	Thus,	only	selected	precursor	ions	with	specific	m/z	values	are	
allowed	to	pass	through	Q1.	They	subsequently	collide	in	the	collision	cell	(Q2)	
with	 inert	 gas	 (argon	or	nitrogen)	 and	are	 fragmented	 into	numerous	product	
ions,	a	process	called	collision	induced	fragmentation	(CID)	[120].	Only	selected	
product	 ions	with	 certain	m/z	 values	 are	 allowed	 to	 pass	 through	Q3	 and	 are	
finally	detected	typically	by	some	type	of	electron	multiplier	(Figure	11)	[123].		
 
	
FIGURE	11:	SCHEMATIC	DIAGRAM	OF	A	TRIPLE	QUADRUPOLE	MASS	DETECTOR	[124]	
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1.6.1.1 Sample	preparation	for	LC-MS/MS	
The	 purpose	 of	 sample	 preparation	 is	 to	 clean	 up	 the	 sample	 before	 analysis	
and/or	to	concentrate	the	sample,	in	fact,	material	in	biological	samples	that	can	
interfere	 with	 analysis,	 the	 chromatographic	 column	 or	 the	 detector	 includes	
proteins,	salts,	endogenous	macromolecules,	small	molecules	and	metabolic	by-
products	 [115].	 A	 goal	 with	 the	 sample	 preparation	 is	 also	 to	 exchange	 the	
analyte	 from	 the	biological	matrix	 into	a	 solvent	 suitable	 for	 injection	 into	 the	
chromatographic	 system. If	 done	 efficiently,	 sample	 preparation	 enhances	
selectivity	 and	 sensitivity	 of	 the	 LC-MS/MS	 methods,	 leads	 to	 higher	
reproducibility	of	data,	and	increases	lifetime	of	column	and	instrumentation.	In	
addition	 to	 purification	 from	 interfering	 substances,	 main	 objectives	 of	 the	
clean-up	procedure	are	 the	concentration	of	 the	analyte	 to	 increase	detection	
limits,	 and	 dissolution	 of	 the	 analyte	 in	 a	 suitable	 solvent	 for	 instrumental	
analysis	[125,126].	The	most	common	preparation	procedures	will	be	described	
below:		
• Dilution	 is	 a	 rapid	 clean-up	procedure,	 in	which	biological	 samples	 are	
simply	 diluted	 with	 water	 or	 mobile	 phase	 solution	 prior	 to	 injection	
into	the	LC-MS.	This	type	of	procedure	is	simple	and	time-efficient,	but	
the	are	some	disadvantages,	such	as	the	fact	that	there	isn’t	the	step	of	
removing	 interfering	 compounds	 and	 the	 lack	 of	 an	 analyte	 pre-
concentration	 step,	 which	 may	 lead	 to	 insufficient	 selectivity	 and/or	
sensitivity	[127].		
• Protein	precipitation	(PP)	is	an	efficient	technique,	where	the	proteins	in	
the	 biological	 matrix	 are	 denatured	 by	 the	 use	 of	 a	 strong	 acid/base	
(resulting	 in	 a	 change	 of	 pH),	 by	 the	 application	 of	 heat,	 or	 by	 the	
addition	of	organic	solvents	such	as	methanol	or	acetonitrile	[128,129].	
During	 the	 denaturation	 process,	 proteins	 undergo	 a	 change	 in	 their	
tertiary	 and	 secondary	 structure,	 and	 analytes	 become	 thus	 freely	
soluble	 in	 the	 denaturing	 solvent.	 After	 centrifugation	 of	 samples,	 the	
denatured	proteins	 form	a	pellet	at	 the	bottom	of	 the	 tube,	while	 the	
analyte	 is	 dissolved	 in	 the	 supernatant.	 After	 evaporation	 of	 the	
supernatant	to	dryness,	and	subsequent	reconstitution	in	mobile	phase	
or	injection	solvent,	the	sample	is	ready	for	LC-MS/MS	analysis	[126].	PP	
is	simple,	fast,	and	inexpensive	[123].		
• Liquid-liquid	 extraction	 (LLE)	 is	 based	 on	 the	 different	 solubility	 and	
equilibrium	 of	 partition	 between	 an	 aqueous	 and	 an	 organic	 phase.	
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Analytes	 are	 extracted	 from	 the	 original	 sample	 in	 into	 organic	 phase	
which	is	immiscible	with	the	water	phase	[20].	The	LLE	technique	has	a	
number	 of	 disadvantages:	 the	 extraction	 of	 hydrophilic	 analytes	 is	
limited,	 recoveries	 may	 be	 variable,	 and	 relatively	 large	 biological	
sample	volumes	are	needed	[128].		
• Solid-phase	 extraction	 (SPE)	 is	 a	 selective	 method	 for	 sample	
preparation	 where	 the	 analyte	 is	 bound	 onto	 a	 solid	 support,	
interferences	are	washed	off	and	the	analyte	 is	 selectively	eluted.	Due	
to	many	different	choices	of	sorbents,	SPE	is	a	very	powerful	technique.	
SPE	 consists	 of	 four	 steps;	 conditioning,	 sample	 loading,	 washing	 and	
elution.	In	solid-phase	extraction	(SPE),	analytes	are	separated	from	the	
biological	matrix	by	means	of	a	solid	(stationary)	phase.	[115]	
• Supported-liquid	extraction	(SLE)	is	performed	using	commercial	96-well	
plates	(e.g.	Isolute®	SLE+	from	Biotage)	[130].	Each	well	is	packed	with	a	
modified	form	of	diatomaceous	earth	with	a	high	capacity	for	retaining	
aqueous	samples	[129].	The	biological	samples	are	loaded	onto	the	well,	
then	 the	 aqueous	 portion	 of	 the	 sample	 adsorbs	 to	 the	 hydrophilic	
surface	of	the	packing	material	and	analytes	can	successively	be	eluted	
applying	 appropriate	 eluent	 [130].	 SLE	 offers	 high	 recovery	 and	
reproducibility,	but	is	more	expensive	than	PP	and	LLE	[130].		
1.6.2 DEVELOPMENT	AND	VALIDATION	OF	LC-MS/MS	METHOD	
Develop	 LC-MS/MS	method	means	 take	 in	 consideration	 different	 phase	 that	
requires	 time	 and	 funds,	 but	 contributes	 considerably	 to	 a	 successful	method	
validation.		
First	 of	 all	 is	 important	 investigate	 the	 physicochemical	 properties	 of	 the	
analyte,	such	as	solubility,	lipophilicity,	thermal	and	light	stability	and	molecular	
structure,	then	must	be	selected	the	solvents	for	sample	processing.	
Then	 appear	 to	 be	 fundamental	 select	 the	 suitable	 internal	 standard	 (I.S.),	 a	
compound	at	known	concentration	to	add	at	every	quantification	sample,	 that	
can	 correct	 every	 variation	 in	 sample	 extraction,	 transfer/injection	 volumes,	
ionization	 efficiency,	 and	 detector	 response	 [131].	 Isotopic-labeled	 analytes	
should	 be	 selected	 as	 I.S.,	 when	 is	 possible,	 because	 it	 the	 same	 physico-
chemical	 characteristics	 of	 the	 analyte	 and,	 of	 course	 the	 equal	 behaviour	
during	 all	 phases	 of	 the	 analytical	 procedure.	 When	 is	 not	 possible	 use	 the	
isotopic-labelled	 analytes,	 for	 example,	 for	 natural	 compounds,	 structurally	
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similar	 compounds	 with	 small	 differences	 in	 functional	 groups	 and	 	 similar	
chromatographic	properties	may	be	employed	[132].		
After	 the	 selection	 of	 the	 I.S.,	 MS/MS	 parameters	 (MRM	 transitions,	 cone	
voltage,	collision	energy	etc.)	for	both	analyte	and	I.S.	are	tested	and	optimized,	
then	is	possible	to	start	with	the	development	of	a	chromatographic	method	for	
the	separation	of	the	analyte	from	other	compounds	in	the	sample.	So	different	
stationary	phases	(HPLC	columns)	and	mobile	phase	(eluents)	are	tested	and	the	
best	 gradient,	 flow,	 column	 temperature.	must	 be	 selected	Appear	 to	be	 very	
important,	 in	this	step	of	development,	that	the	retention	times	of	the	analyte	
and	 I.S.	 are	 relatively	 close,	 in	 order	 to	 compensate	 the	matrix	 effect.	 At	 this	
point	is	possible	select	the	suitable	technique	for	sample	preparation	to	extract	
the	compound(s)	of	interest	from	the	matrix.	The	traditional	approach	is	to	start	
with	 the	 simplest	 extraction	method	 such	 as	 PP	 or	 dilution	 [133],	 then	more	
sophisticated	extraction	methods	such	as	LLE,	SPE,	and	SLE	may	be	evaluated.		
The	concluding	steps	are	the	determination	of	the	quantification	range,	and	the	
estimation	of	the	carry-over	for	analyte	and	I.S.	The	quantification	range	should	
be	based	on	the	sample	concentrations	estimated	for	our	study.	The	lower	limits	
of	quantification	 (LLOQ;	 calibration	 standard	with	 the	 lowest	 concentration)	 in	
the	 pg/mL	 range	 can	 be	 done	 in	 LC-MS/MS,	 depending	 on	 the	 type	 of	 triple	
quadrupole	 detector,	 HPLC	 separation,	 and	 sample	 clean-up	 procedure.	 The	
carry-over	 should	be	evaluated	by	 injecting	a	blank	 sample	 (pure	matrix)	 after	
the	 upper	 limit	 of	 quantification	 (ULOQ;	 calibration	 standard	with	 the	 highest	
concentration).	According	to	EMA	guidelines,	carry-over	should	not	exceed	20%	
for	 the	 analyte	 and	 5%	 for	 the	 I.S.	 [134].	 If	 these	 acceptance	 criteria	 are	 not	
seen,	apposite	actions	should	be	taken	to	reduce	the	carry-over	(e.g.	change	of	
washing	 needle	 solution,	 injection	 of	 blank	 samples	 after	 each	 sample	
containing	analyte,	adaption	of	the	quantification	range	as	higher	LLOQ	or	lower	
ULOQ).	
At	 the	 end	 of	 the	 development	 of	 the	 LC-MS/MS	method,	 it	 can	 be	 validated	
according	 to	 good	 laboratory	 practice	 (GLP)	 guidelines	 defined	 by	 regulatory	
agencies.	 The	 European	 Medicines	 Agency	 (EMA)	 “Guideline	 on	 Bioanalytical	
Method	 Validation”	 	 (2009)	 and	 	 the	 US	 Food	 and	 Drug	 Administration	 (FDA)	
“Guidance	 for	 Industry,	 Bioanalytical	 Method	 Validation”	 (2001;	 new	 draft	 in	
2013)	 are	 the	 most	 used	 ones	 [134–137].	 A	 harmonized	 global	 guideline,	
however,	does	not	yet	exist	[138].		
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The	 EMA	 and	 FDA	 have	 different	 grades	 of	 bioanalytical	method	 validation	 in	
their	guidelines:	 full	validation,	partial	validation,	and	cross-validation.	The	first	
is	required	if	a	method	is	applied	for	the	first	time,	or	if	new	analytes	are	added	
to	an	already	existing	method.	Partial	validation	of	a	method	may	include	intra-
assay	 accuracy	 and	 precision	 determination.	 Cross-validation	 is	 required	 if	
samples	 from	one	 single	 study	are	analyzed	 in	 two	different	 laboratories,	or	 if	
two	 or	more	 different	 bioanalytical	 techniques	 (e.g.	 ELISA	 and	 LC-MS/MS)	 are	
employed	for	sample	analysis	[134,135].	
International	guidelines	describe	different	validation	parameters,	as	reported:	
	
• Calibration	 curve	 and	 LLOQ:	 A	 calibration	 curve	 should	 consist	 of	
calibration	 standards	 (calibrators)	 and	 quality	 controls	 (QCs)	 at	 a	
minimum	of	three	concentrations	levels	(low	=	QCL,	middle	=	QCM,	high	
=	 QCH)	 [134,135].	 QCL	 should	 be	 within	 3x	 of	 the	 lowest	 calibrator,	
QCM	 should	 be	 in	 the	 middle	 of	 the	 quantification	 range,	 and	 QCH	
should	be	approaching	the	high	end	of	the	range	[134,135].	Calibrators	
and	QCs	 should	 be	 prepared	 in	 the	 same	 biological	 fluid	 as	 the	 study	
samples	by	spiking	the	matrix	with	known	concentrations	of	the	analyte	
[135].	 The	 calibration	 curve	 should	 be	 recorded	 as	 follows:	 a	 blank	
sample,	a	zero	sample	(sample	processed	with	I.S.,	but	without	analyte),	
and	 six	 to	 eight	 calibrators	 covering	 the	 selected	 concentration	 range	
[135].	After	the	highest	calibrator	(upper	limit	of	quantification,	ULOQ),	
another	blank	sample	should	be	injected	for	carry-over	assessment.	The	
calibrator	 with	 the	 lowest	 concentration	 is	 defined	 as	 lowest	 limit	 of	
quantification	(LLOQ).	For	this,	the	following	conditions	need	to	be	met:	
the	analyte	response	of	the	LLOQ	should	be	at	least	5	times	higher	than	
the	analyte	response	in	the	blank	sample,	and	the	signal	to	noise	(S/N)	
ratio	should	be	>	10	[134,135,139].	Each	analytical	run	should	begin	and	
end	with	a	calibration	series	(bracketed	between	blank	samples)	which	
are	 injected	 in	 increasing	 concentration.	 Between	 the	 two	 sets	 of	
calibrators,	six	QCs	should	be	inserted	randomly	into	the	analytical	run.	
The	 simplest	 model	 that	 is	 able	 to	 appropriately	 describe	 the	
concentration	 versus	MS	 response	 curve	 should	 be	 applied	 [135].	 For	
75%	 of	 calibrators	 and	 67%	QCs	 (four	 out	 of	 six),	 the	 back-calculated	
concentrations	should	be	±	15%	nominal	values,	with	exception	of	 the	
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LLOQ,	 for	which	a	deviation	±	20%	 is	 allowed	 [135].	 The	 coefficient	of	
correlation	(R2)	should	furthermore	be	higher	than	0.96	[135].	
• Carry-over:	 Carry-over	 of	 analyte	 and	 I.S.	 should	 already	 be	 assessed	
during	 method	 development	 by	 injecting	 a	 blank	 sample	 after	 each	
ULOQ.	 If	 carry-over	 occurs,	 it	 should	be	minimized	 as	 best	 as	 possible	
[134,136].	 	 According	 to	 EMA	 guidelines,	 carry-over	 is	 not	 allowed	 to	
exceed	 20%	 for	 the	 analyte	 and	 5%	 for	 the	 I.S.	 [134].	 During	method	
validation	 and	 application,	 carry-over	 needs	 to	 be	 further	 monitored	
[134,136].		
• Selectivity	 and	 specificity:	 Selectivity	 is	 defined	 as	 the	 ability	 of	 an	
analytical	 method	 to	 differentiate	 and	 quantify	 the	 analyte	 in	 the	
presence	of	endogenous	matrix	components	or	other	compounds	in	the	
sample	 [135].	 It	 should	 be	 ensured	 at	 the	 LLOQ	 by	 using	 different	
batches	 of	 the	 same	 biological	 matrix	 [134,135].	 Specificity	 of	 the	
method	 should	 be	 proven	 by	 using	 independent	 sources	 of	 the	 same	
matrix	 [135].	 It	 should	 be	 noted	 that	 selectivity	 is	 not	 the	 same	 as	
specificity.	While	 selectivity	 can	 be	 graded,	 specificity	 cannot.	 It	 is	 an	
absolute	 characteristic	 that	 may	 be	 regarded	 as	 ultimate	 selectivity	
[140].	
	
• Matrix	effects:	In	LC-MS,	a	common	problem	is	the	occurrence	of	matrix	
effects.	 This	phenomenon	 is	 caused	by	molecules	originating	 from	 the	
biological	matrix	 that	co-elute	with	 the	analyte	and	may	 interfere	with	
the	 ionization	 process	 in	 the	 mass	 spectrometer	 (leading	 to	 ion	
suppression	 or	 enhancement)	 [141,142].	 Matrix	 effects	 can	 occur	 in	
diverse	 and	 unexpected	 forms	 and	 may	 have	 a	 negative	 impact	 on	
precision	 and	 accuracy	 of	 a	 bioanalytical	 method.	 Therefore,	 they	
should	 be	 carefully	 investigated	 in	 the	 course	 of	method	 validation	 to	
ensure	 that	 precision,	 selectivity,	 and	 sensitivity	 of	 the	 assay	 are	 not	
compromised	[134,135].	
	
• Accuracy	 and	 precision:	 Accuracy	 of	 a	 bioanalytical	 method	 describes	
the	 closeness	 of	 mean	 test	 results	 obtained	 by	 the	 method	 to	 the	
nominal	(true)	value	(concentration)	of	the	compound.	It	is	expressed	as	
relative	 error	 (RE%).	 Precision	 describes	 the	 closeness	 of	 repeated	
individual	measures,	and	is	expressed	as	coefficient	of	variation	(CV%).  
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 𝑅𝐸	 % = 	𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙	𝑐𝑜𝑛𝑐. −𝑁𝑜𝑚𝑖𝑛𝑎𝑙	𝑐𝑜𝑛𝑐.𝑁𝑜𝑚𝑖𝑛𝑎𝑙	𝑐𝑜𝑛𝑐. 	×100 
 𝐶𝑉	 % = 	𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑	𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛	(𝑆. 𝐷. )𝑀𝑒𝑎𝑛	𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙	𝑐𝑜𝑛𝑐. 	×100 
 
Accuracy	and	precision	of	a	method	can	be	 subdivided	 into	within-run	
and	 between-run	 accuracy	 and	 precision.	 The	 latter	 (between-run)	
reflects	 the	 reproducibility	 of	 a	 method	 [134,135].	 During	 method	
validation,	 both	 within-run	 and	 between-run	 accuracy	 and	 precision	
should	 be	 assessed	 by	 replicate	 analysis	 of	 samples	 (at	 least	 five)	 at	 a	
minimum	of	three	different	concentration	levels	[135].	Mean	values	and	
S.D.	 values	 should	 be	 calculated,	 from	 which	 RE%	 and	 CV%	 can	 be	
deduced.	RE%	 should	be	±	15%	 (±	20%	at	 the	 LLOQ),	 and	CV%	 should	
not	exceed	15%	(20%	at	the	LLOQ).	
	
• Recovery	(extraction	efficiency):	The	recovery	 is	a	ratio	of	the	detector	
response	 of	 an	 analyte	 from	 an	 extracted	 sample	 to	 the	 detector	
response	 of	 the	 analyte	 from	 an	 unextracted	 sample	 containing	 the	
same	amount	of	analyte	that	was	added	to	the	extracted	sample	[143].	
According	to	FDA	guidance,	recovery	does	not	need	to	be	100%,	but	 it	
should	be	consistent,	precise,	and	reproducible	[135].		
	
• Dilution	 integrity:	Study	samples	may	need	to	be	diluted	 if	they	have	a	
higher	 concentration	 than	 the	 ULOQ.	 However,	 dilution	 of	 samples	
should	 not	 have	 an	 impact	 on	 accuracy	 and	 precision	 of	 the	
bioanalytical	method.	Therefore,	representative	dilution	tests	should	be	
carried	 out	 during	 method	 validation	 in	 order	 to	 demonstrate	 that	
dilution	of	 study	 samples	 later	on	does	not	 interfere	with	 the	method	
[134,135].	
	
• Stability:	 During	 the	 entire	 bioanalysis	 chain	 (beginning	 with	 sample	
collection	 and	 ending	 with	 sample	 analysis	 after	 long	 and	 short-term	
storages),	 stability	of	 the	analyte	 in	 the	biofluid	should	be	guaranteed.	
Therefore,	 various	 stability	 tests	 should	 be	 carried	 out	 during	method	
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validation.	 According	 to	 FDA/EMA	 guideline,	 these	 include:	 freeze	 and	
thaw	(F/T)	stability,	benchtop	stability	(at	room	temperature),	long-term	
stability	 at	 planned	 storage	 conditions,	 post-preparative	 stability	
(autosampler	 stability),	 and	 stock	 solution	 stability	 [135].	 Importantly,	
conditions	used	 in	all	 these	stability	 tests	 should	 reflect	 the	conditions	
expected	to	be	encountered	during	real	sample	handling	and	analysis.		
1.7 NATURAL	COMPOUNDS	VS	NEURODEGENERATION		
1.7.1 SALVIANOLIC	ACID	B		
Salvia	miltiorrhiza	Bge	is	a	very	important	herbal	drug	(HD)	of	traditional	Chinese	
medicine.	 Bioactive	 constituents	 are	 represented	 by	 two	 main	 groups	 of	
secondary	metabolites,	the	lipophilic	diterpenic	quinones	known	as	tanshinones	
and	 the	 hydrophilic	 depsides	 known	 as	 salvianolic	 acids.	 The	 extracts	 of	 radix	
and	rhizome	and	single	constituents	have	been	shown	to	have	positive	effects	in	
CNS	 neuronal	 injury	 and	 degeneration	 in	 several	 animal	 models	 by	 various	
biological	 mechanisms.	 The	 models	 used	 are	 cerebral	 injury,	 streptozocin-
induced	 diabetes,	 hyperlipidemia,	 and	 an	 Alzheimerʼs	 model	 (Aβ	 peptide	
injection),	while	the	methods	of	evaluation	of	the	neurological	functions	include	
behavioral	 tests	 (Morris	 water	 maze,	 Y	 maze,	 and	 passive	 avoidance	 tests),	
neurological	 deficits	 score,	 and	 specific	 histological	 and	 biochemical	
investigations	such	as	measurement	of	the	brain	water	content,	 infarction	size,	
and	apoptotic	neurons,	BBB	disruption,	and	invasion	of	brain	tissues.	
In	 recent	 years,	 much	 attention	 has	 been	 directed	 to	 the	 water-soluble	
components	 that	 represent	 the	 major	 constituents	 of	 S.	 miltiorrhiza	 Bge	
decoction	used	in	traditional	medicine	[144].	
SalB	was	 selected	because	 is	 a	promising	molecule	 in	 the	 protection	 of	 neuro	
degeneration	 but	 its	 poor	 chemical	 stability	 and	 low	 bioavailability	 limits	 a	
clinical	application	for	CNS	neuronal	injury	and	degeneration,	for	this	reason	Sal	
B	was	loaded	into	NPs	(Figure	12).	
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FIGURE	12:	CHEMICAL	STUCTURE	OF	SALB 
Different	 papers	 report	 interesting	 results	 about	 the	 activity	 of	 Sal	 B.	 It	 was	
tested	 as	 a	 blocking	 agent	 of	 Aβ-induced	 Ca2+	intake	 in	 PC-12	 cells.	 This	 study	
showed	that	15	µM	Aβ25–35	caused	about	40%	additional	LDH	release	from	Aβ-
treated	 cells	 compared	 with	 normal	 cells,	 and	 the	 cotreatment	 with	 SalB	
inhibited	the	LDH	release	from	Aβ-treated	cells	[145].	
Lin	and	coworkers	[146]	investigated	the	neuroprotective	effects	of	SalB	on	the	
expression	of	BPRP.	Treatment	of	the	PC12	cells	with	SalB	significantly	(p	<	0.05)	
reversed	 the	 expression	 of	 BPRP	 and	 cell	 viability	 while	 it	 decreased	 ROS	
production	and	 intracellular	calcium.	 In	a	 further	study	of	 rats	pretreated	with	
10	 mg/kg	 SalB,	 the	 number	 of	 GFAP	 and	 OX-42	 positive	 cells	 were	 reduced.	
Subchronic	 SalB	 administration	 decreased	 iNOS	 and	 COX-2	 expression	 [147].	
Tian	 et	 al.	 [146]	 investigated	 the	 neuroprotective	 effects	 of	 SalB	 against	 6-
hydroxydopamine-induced	 cell	 death	 in	 human	 neuroblastoma	 SH-SY5Y	 cells.	
SalB	significantly	(p	<	0.05)	reduced	the	6-hydroxydopamine-induced	generation	
of	 ROS	 and	 prevented	 6-hydroxydopamine-induced	 increases	 in	 intracellular	
calcium.	 The	 data	 demonstrated	 that	 SalB	 reduced	 the	 6-hydroxydopamine-
induced	 increase	 of	 caspase-3	 activity,	 and	 cytochrome	 C	 translocation	 into	
cytosol	 from	 mitochondria.	 The	 protective	 effects	 of	 SalB	 in	 traumatic	 brain	
injury	 in	 mice	 was	 investigate	 by	 Chen	 et	 al.	 [148]	 and	 SalB	 treatment	
significantly	suppressed	the	expression	of	proinflammatory	cytokines	TNF-α	and	
IL-1β,	 and	 enhanced	 the	 expression	 of	 anti-inflammatory	 cytokines	 IL-10	 and	
TGF-β1	 after	 traumatic	 brain	 injury.	 Recently,	 Jiang	 and	 coworkers	 [149]	
examined	 the	 effects	 of	 SalB	 in	 a	 mouse	 model	 of	 cerebral	 ischemia	 and	
reperfusion	 injury	with	 sodium	nitroprusside.	Pretreatment	with	SalB	decrease	
the	MDA	content	and	NOS	activity,	and	increased	the	T-AOC	level	in	the	cortical	
area	 of	 I/R.	 SalB	 also	 improved	 pathological	 changes	 of	 hippocampal	 CA1	
neurons	 by	 preventing	 neuronal	 loss,	 increasing	 Bcl-2	 protein	 expression,	
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inhibiting	Bax	protein	expression,	and	enhancing	the	ratio	of	Bcl-2-IR	to	Bax-IR.	
Kim	 and	 coworkers,	 observed	 that	 SalB	 ameliorated	 the	memory	 impairments	
induced	by	scopolamine	or	the	Aβ25–35	peptide.	SalB	can	inhibit	GABA-induced	
Cl−	 currents	 in	 a	 single	 hippocampal	 neuron	 in	 a	 concentration-dependent	
manner.	 Therefore,	 the	 scopolamine-induced	 amnesic	 animal	model	might	 be	
the	 result	 of	 the	 inhibition	of	GABA	 signalling	 [150].	 Finally,	 itwas	demonstred	
that	 SalB	 inhibits	 fibril	 aggregation	 and	 destabilizes	 preformed	 Aβ	 fibril	 in	 a	
dose-	 and	 time-dependent	manner.	 SalB	might	 interact	 with	 the	 peptide	 side	
chain	to	inactivate	fibril	aggregation	[151].	
The	 biochemical	 mechanisms	 related	 to	 SalB	 are	 recently	 summarized	 by	
Bonaccini	et	al.	[144]	and	reported	below:	
• Antiapoptotic	mechanisms:	
↓	caspase-3	expression		
↓	cytochrome	c	translocation	into	cytosol	from	mitochondria		
↓	intracellular	calcium		
↑	Bcl-2	expression		
↓	Bax	expression		
↑	EPO	and	EPOR	expression		
↑	CD31	expression	via	the	JAK2/STAT3	and	VEGF/Flk-1	pathways		
• Anti-oxidant	mechanisms:	
↓	ROS	production		
↓	level	of	MDA		
↓	T‑AOC	
• Anti-inflammatory	mechanisms	
↓	GFAP	and	OX-42		
↓	iNOS	and	COX-2	expression		
↓	proinflammatory	cytokines	(TNF-α	and	IL-1)		
↑	anti-inflammatory	cytokines	(IL-10	and	TGF-β1)		
↓	NO	activity		
• Other	mechanisms:	
↓	BPRP	expression		
↓	release	of	LDH		
↑	cholineacetyltransferase	(ChAT)		
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↑	BDNF		
↓	GABA-induced	Cl	currents		
↓	fibril	aggregation	and	destabilize	preformed	Aβ	fibril		
1.7.2 ANDROGRAPHOLIDE	
Andrographis	paniculata	L.	is	a	native	plant	from	Southeast	Asian	countries.	For	
centuries,	this	plant	has	been	used	as	an	official	herbal	medicine	in	China	for	the	
treatment	 of	 various	 human	 illnesses,	 including	 acute	 hepatitis,	 meningitis,	
choriocarcinoma,	malaria,	 and	many	other	 acute	 inflammatory	 conditions	 that	
can	 be	 studied	 using	 different	 animal	 models	 [152].	 Earlier	 studies	 have	
indicated	 that	 AG,	 the	 main	 diterpene	 of	 the	 labdane	 family	 present	 in	 the	
leaves,	 is	 responsible	 for	 most	 of	 the	 biological	 effects	 of	 	 Andrographis	
paniculata	(Figure	13).			
 
	
FIGURE	13:	CHEMICAL	STRUCTURE	OF	AG 
Recent	studies	have	suggested	that	AG	might	exercise	neuroprotective	effects,	
i.e.,	against	damage	induced	by	dopamine	in	mesencephalic	neuronglial	cultures	
associated	 with	 a	 protective	 effect	 on	 inflammation-mediated	
neurodegeneration,	 oxidative	 stress	 induced	 by	 nicotine	 in	 the	 brain,	 and	
cerebral	 ischemia	 by	 inhibiting	 certain	 pathways	 related	 to	 inflammation	 and	
apoptosis,	 including	 Akt,	 NF-κB	 and	 MAPK	 signaling.	 AG	 could	 be	 efficient	
molecule	with	a	potential	property	for	various	CNS’s	treatments	[152].		
More	 recently,	 Serrano	 and	 co-authors	 have	 investigated	 the	 role	 of	 AG	 in	
neurodegeneration.	 They	 demonstrated	 that	 AG	 decreases	 Aβ	 depositions	 in	
young	 AβPPswe/PS-1mice	 while	 Tau	 phosphorylation	 decreased	 after	 AG	
treatment	 in	 both	 young	 and	 mature	 AβPPswe/PS-1	 mice.	 Additionally,	 AG	
recovered	 the	 synaptic	 functions	 in	 AβPPswe/PS1	 mice	 of	 different	 ages,	 the	
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spatial	memory	 in	AβPPswe/PS-1	double	 transgenic	mice	of	different	ages	and	
finally	inhibits	GSK-3β,	preventing	LTD	induction	[152].	
The	 interest	 regards	 the	 activity	 of	 this	 molecule	 increased	 in	 last	 years	 to	
understand	 the	 mechanism	 of	 action	 of	 AG.	 This	 year	 Tapia-Rojas	 and	 co-
workers	published	a	paper	[152]	in	which	they	evaluate	Wnt/β-catenin	signalling	
and	 the	 possible	 role	 of	 AG.	 Wnt/β-catenin	 is	 an	 important	 pathway	 that	
regulates	various	biological	processes,	including	cell	adhesion	and	determination	
of	cell	fate	during	animal	development;	in	the	adult	nervous	system	it	regulates	
the	 structure	 and	 function	 of	 synapses.	 Dysfunction	 of	 this	 signalling	 is	
associated	with	 several	 neurodegenerative	diseases	 such	as	 schizophrenia	 and	
AD.	 The	paper	 reports	 that	AG	 is	 a	potent	 activator	of	Wnt	 signaling,	 inducing	
the	transcription	of	Wnt	target	genes	by	a	mechanism	that	bypasses	Wnt	ligand	
binding	to	its	receptor.	In	vitro	AG	inhibits	glycogen	synthase	kinase	(GSK)-3β	by	
a	 non-ATP-competitive,	 substrate-competitive	 mode	 of	 action.	 In	 silico	 AG	
interacts	with	the	substrate-binding	site	of	GSK-3β,	while	in	vivo	is	observed	the	
increase	 in	 the	 levels	 of	 GSK-3β	 phosphorylated	 at	 Ser⁹	 as	 the	 result	 of	 an	
autoregulatory	 mechanism	 of	 the	 kinase,	 although	 not	 through	 activation	 of	
protein	phosphatase	type	1.	This	 last	study	suggest	that	AG	could	be	used	as	a	
potential	therapeutic	drug	for	neurodegenerative	diseases	[153].	
Nevertheless,	 AG	 is	 poorly	 soluble	 in	 water,	 stable	 under	 neutral	 and	 acidic	
conditions,	 but	 unstable	 under	 alkaline	 conditions.	 Moreover,	 it	 is	 rapidly	
metabolized	in	the	duodenum	and	jejunum	to	form	a	sulphate	conjugate	that	is	
hydrophilic	and	 likely	 to	be	 impermeable	 [154].	So,	all	 these	 factors	 led	 to	 the	
poor	oral	absorption	and	poor	bioavailability	of	the	drug.	
Till	now	there	aren’t	evidences	in	literature	that	AG	free	can	cross	BBB,	thus,	for	
all	this	reasons,	in	this	PhD	work,	AG	was	loaded	into	NPs.	
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2.1 ABSTRACT		
BBB	 hinders	 the	 passage	 of	 systemically	 delivered	 therapeutics	 and	 the	 brain	
extracellular	 matrix	 limits	 the	 distribution	 and	 durability	 of	 locally	 delivered	
agents.	 Drug-loaded	 nanocarriers	 represent	 a	 promising	 strategy	 to	 overcome	
these	barriers	and	address	specific	drug	delivery	challenges,	due	to	 their	 small	
size	and	versatile	design.	We	synthetized	fluorescent	poly	(ethyl-cyanoacrylate)	
nanoparticles	 (PECA-FITC-D-TW80	NPs)	 by	 emulsion	polymerization	method	 to	
target	and	reach	the	brain	after	intravenous	and	intraperitoneal	administration.	
NPs	 were	 characterized	 in	 terms	 of	 dimensional	 analysis,	 polydispersity	 (PDI)	
and	 Zeta	 Potential	 (ζ-potential);	 morphology,	 encapsulation	 efficacy	 (EE)	 and	
loading	capacity	(LC)	were	evaluated	too.	After	intracerebral	injection	in	healthy	
rats,	 NPs	 were	 distributed	 within	 the	 injected	 hemisphere	 and	 mainly	 they	
interacted	 with	 microglial	 cells,	 presumably	 involved	 in	 their	 clearance	 by	
phagocytosis.	 Furthermore,	 NPs	 were	 able	 to	 pass	 BBB	 after	 systemic	
administration	 in	 rats	 and	 the	 lack	 of	 toxicity	 in	 C57/B6	 mice	 chronically	
administered	 was	 highlighted.	 These	 evidences	 contribute	 to	 clarify	 NPs	
distribution,	 accumulation,	 fate	 and	 toxicity	 into	 the	 brain	 supporting	 the	
observation	 that	 the	 selected	 NPs	 may	 represent	 a	 biocompatible	 promising	
carrier	to	be	further	investigated	as	brain	delivery	systems.	SalB	from	the	Salvia	
miltiorrhiza	Bge,	 is	 a	promising	molecule	 in	 the	 protection	 of	 degeneration	 in	
several	 animal	models	 by	 various	biological	mechanisms	but	 its	 poor	 chemical	
stability	 and	 low	 bioavailability	 limits	 a	 clinical	 application	 for	 CNS	 neuronal	
injury	and	degeneration.	NPs	were	loaded	with	SalB	obtaining	an	EE%	and	LC%	
of	98.70	%	±	0.45	and	53.3%	±	0.24	respectively.	They	were	suitable	for	parental	
administration	because	 their	mean	diameter	was	 smaller	 than	300	nm,	with	a	
PDI	 of	 0.04	 ±	 0.03,	 and	 a	 ζ-potential	 of	 -8.38	 mV±	 3.87.	 The	 in	 vitro	 studies	
pointed	out	that	the	release	of	SalB	from	the	NPs	was	sustained	and	prolonged	
during	8	hours,	a	suitable	performance	for	a	promising	clinical	application.	
2.2 INTRODUCTION		
SalB	 (Figure	 12)	 represents	 the	most	 abundant	 constituent	 among	 the	water-
soluble	compounds	of	roots	and	rhizome	of	Danshen	(Salvia	miltiorrhiza	Bge.),	a	
medicinal	plant	widely	used	in	Asia	for	the	treatment	of	a	variety	of	diseases,	in	
particular	cardiovascular	diseases	such	as	angina	pectoris,	myocardial	infarction	
and	 stroke	 [1].	 Numerous	 studies	 have	 revealed	 multiple	 pharmacological	
actions	SalB	acting	with	various	molecular	targets	suggesting	an	important	role	
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in	the	different	CNS	pathologies,	both	the	acute	ones	such	as	cerebral	ischemia,	
traumatic	brain	 injury,	and	epilepsy,	but	also	chronic	diseases	such	as	multiple	
sclerosis,	AD,	Parkinsonʼs	disease,	schizophrenia.	
Besides	 the	 extensive	 studies	 reporting	 these	 mechanisms,	 pharmacokinetic	
studies	 are	 still	 very	 limited	 and	 not	 conclusive,	 reporting	 that	 oral	
administration	 give	 a	 rapid	 absorption,	 quick	 clearance,	 and	 poor	 absolute	
bioavailability;	 after	 i.v.	 administration,	 it	 is	 extensively	 metabolized	 and	
degraded	rapidly.	
A	 unique	 trial	 on	 humans,	 a	 randomized,	 open-label,	 single-dose	 study,	 was	
conducted	 in	 12	 healthy	 Chinese	 volunteers	 receiving	 a	 single	 intravenous	
infusion	 of	 a	 100-	 or	 200-mg	 of	 a	 mixture	 of	 depside	 salts	 (SalB	 ca.	 88%),	 a	
preparation	marketed	in	China	for	the	treatment	of	coronary	heart	disease,	and	
it	 disclosed	 that	 SalB	 is	 methylated	 rapidly	 in	 the	 liver	 and	 most	 of	 the	
metabolites	 (M1,	 M2,	 and	 M3	 detected	 in	 the	 plasma	 with	 very	 low	
concentrations	between	50	and	170	ng/	mL)	are	excreted	into	bile	and	faeces.	In	
a	 further	 study,	 SalB	 (50	 mg/kg	 BW)	 administrated	 intragastrically,	 was	 not	
detected	 in	blood	and	brain	microdialysates,	 collected	at	15-	 and	30-min	 time	
intervals	for	4	h,	respectively	[1].		
Aim	 of	 this	 study	 was	 to	 develop	 blood	 brain	 barrier	 (BBB)	 permeable	
nanocarriers	for	the	delivery	of	molecules	that	might	be	of	therapeutic	value	in	
the	 treatment	 of	 neurodegenerative	 and	 psychiatric	 disorders.	 Nanovectors	
(NVs)	can	cross	the	BBB	using	several	mechanisms	including	the	aperture	of	the	
tight	 junctions	 between	 endothelial	 cells,	 transcytosis	 and	 endocytosis,	
inhibition	of	 the	transmembrane	efflux	systems	(i.e.,	P-glycoprotein),	 induction	
of	local	toxic	effects	on	the	brain	vasculature	leading	to	a	limited	permeability	of	
the	brain	endothelial	cells	[2].	
Natural	 and	 synthetic	 polymers	 have	 been	 used	 to	 produce	 NPs,	 all	 these	
materials	 are	 very	 versatile	 for	 the	 transport	 of	 drugs,	 which	 may	 be	 bound	
either	 as	 a	 solid	 solution	 or	 as	 dispersion,	 can	 be	 adsorbed	 to	 the	 surface	 or	
chemically	attached.	Nanoparticulate	brain	delivery	systems	should	not	damage	
the	BBB	and	drug	delivery	should	be	targeted	to	 the	site	of	 intended	action	 in	
the	 brain.	 Moreover,	 the	 vectors	 should	 have	 an	 adequate	 shelf-life	 for	 a	
sustained	and	controlled	drug	delivery,	they	should	be	biodegradable	after	the	
drug	release,	not	toxic	and	antigenic	[3].	Poly	(alkyl	cyanoacrylates),	in	particular	
PBCA	and	poly(isohexyl	cyanoacrylate)	(PIHCA),	represent	suitable	polymers	for	
this	therapeutic	approach,	because	they	have	a	quite	rapid	elimination,	due	to	
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an	enzymatic	cleavage	of	the	ester	bond	of	the	alkyl	side	chain	of	the	polymer	
and	 resulting	 in	 the	 formation	 of	 the	 low-toxic	 water-soluble	 products-
poly(cyanoacrylate)	acid	and	appropriate	alcohol.	The	BBB	crossing	of	poly(alkyl	
cyanoacrylates)	NPs	is	acquired	by	overcoating	NPs	with	certain	surfactants	such	
as	TW80	or	poloxamer	188	(Pluronic®	F68)	[4].	Studies	with	PBCA	NPs	have	been	
assessed	that	doxorubicin	and	temozolomide	could	be	transport	across	only	 in	
rats	 treated	 with	 surfactant-coated	 NPs.	 These	 observations	 demonstrate	 the	
great	 potential	 of	 surface-coated	 PBCA	 NPs	 for	 the	 delivery	 of	 drugs	 to	 the	
central	 nervous	 system.	 This	delivery	 should	be	 achieved	by	 covalent	 coupling	
with	apolipoprotein	E,	A-I,	or	B-100,	followed	by	receptor-mediated	endocytosis	
of	 the	 NPs	 by	 the	 brain	 capillary	 endothelial	 cells	 [5,6]	 However,	 in	 vivo	 data	
concerning	 NPs	 uptake,	 distribution,	 time-dependent	 accumulation,	 tropism,	
fate	 and	 toxicity	 inside	 the	 brain	 is	 still	 almost	 unclarified.	 To	 the	 best	 of	 our	
knowledge,	 Fricker’s	 group	 has	 recently	 investigated	 the	 PBCA	 NPs’s	
biocompatibility	by	in	vitro	and	ex	vivo	studies.	No	cell	death	or	loss	of	metabolic	
activity	was	observed	 for	nanoparticle-concentrations	≤500	μg/ml	up	 to	3	h	of	
treatment.	 Metabolic	 activity	 was	 tested	 by	 the	 AlamarBlue®-assay	 and	 cell	
viability	by	 LDH-assay.	 Integrity	of	 the	BBB	was	analyzed	 in	 vitro	 by	measuring	
the	trans-endothelial	electrical	resistance	using	the	CellZscope®.	Additionally,	an	
in	vitro	 test	 (Multi-Analyte	ELISArray™	Kit	Human	 Inflammatory	Cytokines)	was	
used	to	evaluate	the	release	of	inflammatory	cytokines	in	human	blood	after	24	
h	 incubation	 of	 NPs.	 Only	 interleukin-8	 was	 released	 significantly.	 No	 severe	
inflammatory	processes	or	organ	damages	were	 identified	 in	 rats	 in	an	ex	vivo	
model	[7].	
In	the	present	work	we	developed	and	optimized	fluorescent-labeled	PECA	NPs	
to	 target	 and	 reach	brain	 tissues.	 This	 polymer	 is	 less	 investigated	 then	PBCA.	
NPs	 distribution	 and	 fate	 in	 the	 brain	 parenchyma	 were	 evaluated	 in	 healthy	
rats,	 after	 NPs	 intracerebral	 injection	 into	 the	 nucleus	 basalis	 magnocellularis	
(NBM)	of	the	basal	forebrain.	Furthermore,	we	report	the	ability	of	NPs	to	reach	
the	 brain	 after	 an	 acute	 systemic	 administration	 in	 rats	 and	 the	 lack	 of	 their	
toxicity	 in	 C57/B6	 mice	 NPs-administered	 for	 two	 weeks,	 supporting	 the	
observation	that	these	NPs	may	represent	a	promising	carrier	for	drug	delivery	
to	 the	 CNS.	 Hence,	 Sal	 B	 (88.2%),	 isolated	 from	 Danshen	 was	 loaded	 into	
optimized	PECA	NPs	and	their	performance	evaluated	in	vitro.		
2.3 RESULTS	
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2.3.1 DEVELOPMENT	AND	CHARACTERIZATION	OF	PECA	NPS		
PECA	 NPs	 were	 prepared	 and	 optimized	 by	 emulsion	 polymerization	method.	
The	 dimensional	 analysis,	 PDI	 and	 ζ-potential	 of	 PECA	 NPs,	 PECA	 NPs	 coated	
with	 Tween	 80	 (PECA-TW80	 NPs),	 PECA-FITC-D	 NPs,	 PECA-FITC-D-TW80	 and	
PECA	 NPs	 loaded	 with	 SalB,	 are	 reported	 in	 Table	 6.	 The	 mean	 diameter	 of	
PECA-TW80	 NPs	 was	 303±8	 nm,	 248±1	 nm	 for	 PECA-FITC-D-TW80	 and	 both	
resulted	suitable	for	the	systemic	administration.	The	dimensional	analysis	was	
not	affected	by	 the	coating.	The	mean	 ζ-potentials	of	PECA	NPs	coated	or	not	
with	1%	Tween	80	was	ca.	-4	mV	and	-3	mV,	respectively.	This	characteristic	was	
very	interesting	because	NPs	with	slightly	negative	surface	charge	encompasses	
reduced	plasma	protein	adsorption	and	 low	rate	of	nonspecific	cellular	uptake	
[8].	 The	 yields	 of	 preparative	 process	 for	 PECA-TW80	 and	 PECA-FITC-D-TW80	
NPs	were	very	high,	as	reported.		
TABLE	 6:	 CHARACTERIZATION	 OF	 PECA-BASED	 NPS	 IN	 TERMS	 OF	 MEAN	 DIAMETER,	
POLIDISPERSITY	 (PDI),	 ZETA-POTENTIAL,	 YIELD	 OF	 PREPARATIVE	 PROCESS,	
ENCAPSULATION	EFFICIENCY	AND	LOADING	CAPACITY	
PECA	NPs	 Size	(nm)	 PDI	 Z-Potential	(mV)	 Yield	%	 EE%	 LC%	
PECA	 288±	7	 0.19	±	0.01	 -2.85	±	1.18	 92±	9.51	 	 	
PECA-TW80	 303	±	8	 0.36	±	0.04	 -4.07	±	0.05	 -	 	 	
PECA-FITC-D	 247	±	2	 0.14	±0.04	 -2.83	±	0.55	 66±	0.01	 	 	
PECA-FITC-D-TW80	 248	±	1	 0.11	±0.07	 -3.38	±	0.55	 -	 	 	
PECA-	SalB	 205±2	 0.07±0.02	 -7.18±2.84	 59.73±7.00	 98.70±0.45	 53.3±0.24	
PECA-	SalB-TW80	 288±1	 0.04±0.03	 -8.38±3.87	 -	 -	 -	
	
TEM	analyses	provided	important	details	on	the	morphology	and	the	dimension	
of	 the	 NPs	 giving	 a	 different	 electronic	 cloud	 between	 the	 NPs	 core	 and	 the	
coating	 (Figure	 14).	 As	 showed	 in	 the	 Figure	 15,	 PECA-FITC-D-TW80	NPs	were	
sphere-shaped,	with	 a	 regular	 and	narrow	 size	distribution	 comparable	 to	DLS	
analysis.	 PECA-SalB	 NPs	 were	 obtained	 with	mean	 diameter	 smaller	 than	 300	
nm,	with	similar	results	to	empty	NPs,	so	the	selected	molecule	didn’t	impact	on	
the	 optimized	 formulation.	 The	 sample	 appears	 to	 be	 very	 homogenous,	with	
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very	low	PDI	and	the	yield	of	preparative	process	is	comparable	with	fluorescent	
NPs.		
	
FIGURE	14:	TEM	MICROGRAPH	OF	PECA-FITC-D-TW80	NPS	
	
FIGURE	15:	SEM	MICROGRAPH	OF	PECA-SAL	B	NPS	COATED	WITH	TWEEN	80	
2.3.2 IN	VIVO	EXPERIMENTS	
2.3.2.1 Fluorescein-labelled	PECA	NPs	injection	into	the	rat	NBM		
Firstly,	 1µl	 (8µg/µl)	 of	 PECA-FITC-D-TW80	 NPs	 was	 directly	 injected	 into	 the	
Nucleus	 Basalis	 Magnocellularis	 (NBM)	 of	 adult	 rats	 to	 follow	 the	 cellular	
distribution	of	NPs	within	 the	brain,	 the	occurrence	of	 general	 toxicity	 for	 the	
animals	as	well	as	NPs-induced	inflammatory	response	in	terms	of	glia	reaction.	
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Histochemical	analysis	revealed	at	the	injection	site	(asterisk),	a	large	amount	of	
fluorescent	NPs	(green)	at	one,	three	and	seven	days	after	 injection	(Figure	16	
b,d,g).	 The	 day	 after	 surgery	 some	NPs	were	 detected	 close	 to	 cellular	 nuclei	
(DAPI,	blue)	 in	 the	 injection	 site	 surroundings	 (Figure	16	c,	arrows).	Three	and	
seven	days	after	injection,	PECA-FITC-D-TW80	were	detected,	in	addition	to	the	
injection	site,	in	a	large	number	of	cells	with	glial	morphology	(Figure	16	e	and	h,	
arrows)	and	inside	blood	vessels	(inset	in	Figure	16	g)	in	the	ipsilateral	 injected	
hemisphere.	In	particular,	seven	days	after	injection	NPs	moved	and	distributed	
in	 the	 ipsilateral	 brain	 parenchyma	 in	 a	 roughly	 800µm	 distance	 from	 the	
injection	 site.	 Notably,	 fourteen	 days	 after	 injection	 PECA-FITC-D-TW80	
fluorescent	 staining	 was	 strongly	 reduced	 at	 the	 injection	 site	 (Figure	 16	 i,	
asterisk)	 and	 few	 cells	 with	 glial	 morphology	 were	 FITC-labeled	 (Figure	 16	 j,	
arrow).	 NPs	 uptake	 mediated	 by	 glial	 cells	 could,	 likely,	 result	 in	 the	
removal/phagocytosis	 of	 NPs	 from	 brain	 tissue,	 ensuring	 their	 clearance	 and	
biocompatibility.	 No	 PECA-FITC-D-TW80	 NPs	 were	 almost	 detected	 in	 the	
contralateral	un-injected	hemisphere	(Figure	16	a	and	f).	Immunohistochemical	
analysis	 did	 not	 reveal	 any	 astrocytosis	 either	 at	 the	 site	 of	 injection	 or	 in	 its	
vicinity,	 as	 shown	 by	 the	 resting	 morphology	 of	 GFAP-immunopositive	 cells	
(Figure	17,	 red)	 in	 PBS	 (Figure	17	 a)	 and	NPs	 injected	 groups	 (Figure	17	 c),	 as	
exemplified	 at	 seven	 days	 after	 injection.	 By	 contrast,	 microglial	 cells	 (red)	
increased	in	number	with	time	at	the	injection	site	and	in	its	proximity	1,	3	and	7	
days	 after	 surgery	 (as	 shown	 for	 the	 7	 day	 time-point	 in	 Figure	 17	 d)	 as	
compared	 to	 PBS-injected	 controls	 (Figure	 17	 b).	 Fluorescent	 NPs	 uptake	
mediated	 by	 microglial	 cells	 was	 revealed	 by	 the	 widespread	 colocalization	
(yellow)	between	FITC-labelled	NPs	(green)	and	Iba	1-immunopositive	cells	(red)	
(Figure	 17	 d,	 f).	 At	 14	 days	 after	 injection,	 the	 strong	 reduction	 in	 FITC	 NPs	
staining	 at	 the	 injection	 site,	 likely	 due	 to	microglia	 phagocytosis	 and	 removal	
from	 the	 brain,	 was	 accompanied	 by	 very	 few	 Iba-1	 immunopositive	 cells	 co-
stained	 with	 PECA-FITC-D-TW80	 NPs	 (Figure	 17	 e,	 arrows).	 In	 particular,	 the	
colocalization	 (yellow)	 between	 fluorescent	 NPs	 (green)	 and	 Iba	 1	 and	 OX6	
staining	 (red)	demonstrates	 that	 the	cellular	uptake	of	PECA-FITC-D-TW80	NPs	
was	 mainly	 mediated	 by	 activated	 microglial	 cells,	 that	 exhibit	 enlarged	 cell	
bodies,	 thickened	and	 retracted	processes	or	 losses	of	branches	 in	all	 injected	
groups,	 as	 shown	 for	 animals	 sacrificed	 7	 days	 after	 injection	 (Figure	 17	 f,	 g).	
PECA-FITC-D-TW80	 NPs	 partially	 interacted	 with	 GFAP-immunopositive	
astrocytes	(arrows),	as	shown	in	Fig.	4	for	the	7-day	time	point;	no	interactions	
CHAPTER	2	
	
72	
with	NeuN	positive	neurons	(red)	and	ChAT	positive	neurons	(red)	of	the	NBM	
(Figure	 17	 I,	 j)	 were	mostly	 detected.	 Overall,	 these	 data	 indicate	 that	 in	 situ	
administration	of	NPs	was	well	tolerated,	didn’t	induce	astrogliosis	and	favoured	
microglial	cells	migration	to	the	injection	site	for	phagocytosis	of	NPs,	ensuring	
their	elimination	from	brain	tissue	and	their	biocompatibility.	Consequently,	as	
clearly	shown	in	Figure	17,	microglial	cells	were	numerous	and	activated	7	days	
after	 NPs	 administration.	 In	 addition,	 a	 large	 amount	 of	 NPs	 co-localizes	 in	
microglial	cells,	 suggesting	an	early	 role	of	microglia	 in	removing	NPs	 from	the	
brain	parenchyma.	At	14	days	after	NPs	intracerebral	injection,	the	presence	of	
reactive	 microglia	 was	 much	 reduced	 in	 parallel	 with	 the	 reduction	 of	 NPs.	
These	data	indicate	an	important	role	of	microglia	in	the	immune	defence	of	the	
CNS.		
	
	
FIGURE	16:	INTRACEREBRAL	INJECTION	OF	PECA-FITC-D-TW80	NPS	IN	THE	RAT	NBM	
(B-E;	 G-J)	 TIME	 DEPENDENT	 NPS	 (GREEN)	 MOBILIZATION	 FROM	 THE	 INJECTION	 SITE	 (ASTERISK)	
ONE	 (B,C),	 THREE	 (D,E),	 SEVEN	 (G,H)	AND	 FOURTEEN	 (I,J)	DAYS	AFTER	 SURGERY.	THE	MAGNIFIED	
IMAGES	 (C,E,H,J)	 SHOW	 NPS	 UPTAKE	 BY	 CELLS	 WITH	 GLIAL	 MORPHOLOGY	 (INDICATED	 BY	 THE	
ARROWS,	 DAPI	 IN	 BLUE).	 THE	 INSET	 IN	 PANEL	 (G)	 SHOWS	 THE	 COLOCALIZATION	 (YELLOW)	
BETWEEN	 PECA-FITC-D-TW80	 NPS	 (GREEN)	 AND	 THE	 ENDOTHELIAL	 MARKER	 CD34	 (RED).	
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PECA-FITC-D-TW80	NPS	 LABELLING	 IS	 ABSENT	 IN	 THE	 UN-INJECTED	 HEMISPHERE	 (A,F).	 SCALE	
BARS:100	ΜM	APPLIED	TO	ALL	IMAGES	AND	10	ΜM	TO	THE	INSET	IN	PANEL	(G).	
	
FIGURE	17:	INTRACEREBRAL	INJECTED	PECA-FITC-D-TW80	NPS	INTERACTION	WITH	
GLIAL	CELLS	AND	NPS	BBB	CROSSING	AFTER	SYSTEMIC	ADMINISTRATION	
(C-J)	 DOUBLE	 LABELLING	 EXPERIMENTS	 BETWEEN	 PECAFITC-D-TW80	NPS	 (GREEN)	 AND	 GLIAL	
MARKERS	GFAP/IBA-1/OX6	 (RED,	 ARROWS)	OR	NEURONAL	NEUN/CHAT	ABS	 (RED)	 PLUS	DAPI	
(BLUE)	 IN	 INJECTED	RATS,	 SEVEN	 (C-D;	 F-J)	AND	FOURTEEN	 (E)	DAYS	AFTERSURGERY.	GFAP-	AND	
IBA	1-IMMUNOPOSITIVE	 CELLS	 (RED)	WITH	 RESTING	MORPHOLOGY	AND	NO	PECAFITC-D-TW80	
NPS	 (GREEN)	 SIGNAL	 WERE	 DETECTED	 IN	 PBS-INJECTED	 RATS	 (A,	 B).	 (K,L)	 THE	 LACK	 OF	
COLOCALIZATION	BETWEEN	PECA-FITC-D-TW80	NPS	(GREEN,	 INDICATED	BY	THE	ARROWS)	AND	
THE	 BRAIN	 VASCULAR	 ENDOTHELIUM	 MARKER	 CD34	 (RED)	 DEMONSTRATED	 THEIR	 ABILITY	 TO	
CROSS	THE	BBB	AFTER	AN	ACUTE	IV	(K)	AND	IP	(L)	ADMINISTRATION.	
2.3.2.2 Intravenous	and	intraperitoneal	administration	of	fluorescent	
PECA-FITC-D-TW80	NPs	in	rats		
The	 ability	 of	 fluorescent	 PECA-FITC-D-TW80	 NPs	 to	 cross	 the	 BBB	 was	
evaluated	in	rats	administered	acutely	with	100	mg/kg	iv	and	ip	of	FITC-labelled	
NPs.	Three	hours	after	administration	(Figure	17	k,	 l),	FITC-labelled	NPs	(green,	
arrows)	were	detected	in	the	brain	parenchyma	outside	the	vascular	bed	(CD34,	
red)	 indicating	 the	 ability	 of	 the	 developed	 nanoformulation	 to	 cross	 the	 BBB	
after	systemic	administration.		No	apparent	differences	were	evident	in	crossing	
BBB	with	the	two	routes	of	administration.	
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2.3.2.3 Systemic	 administration	 of	 fluorescent	 PECA-FITC-D-TW80	
NPs	in	mice	and	behavioral	test	
To	 exclude	 NPs	 toxicity	 and	 behavioural	 alterations,	 PECA-FITC-D-TW80	 NPs	
(200	mg/kg,	 ip)	were	daily	administered	to	C57/B6	mice	for	two	weeks.	During	
this	 period,	 the	 nanoformulation	 was	 well	 tolerated,	 no	 evident	 side	 effects	
were	 revealed,	 as	 also	 shown	 by	 the	 body	weight	 trend	 graph	 of	 NPs-treated	
mice	as	compared	to	controls	(Figure	18	a)	and	no	animals	died.	At	the	end	of	
the	treatment,	mice	were	behaviourally	evaluated	in	the	ORT	test,	to	check	for	
their	locomotor-exploratory	abilities	and	cognitive	functions.	As	shown	in	Figure	
18	 b,	 no	 locomotor	 (path	 length)	 nor	 cognitive	 impairments	 (discrimination	
score)	 were	 detected	 in	 NPs-treated	 mice	 as	 compared	 to	 controls	 (P>0.05).	
Overall	 these	 data	 provide	 an	 evidence	 on	 the	 biocompatibility	 and	 potential	
delivery	of	molecules	to	the	CNS	of	this	nanoformulation.		
 
	
FIGURE	18:	BODY	WEIGHT	AND	BEHAVIOURAL	EVALUATIONS	ON	MICE	CHRONICALLY	
ADMINISTERED	WITH	PECA-FITC-D-TW80	NPS	FOR	TWO	WEEKS	
(a-b)	PECA-FITC-D-TW80	NPs	did	not	affect	either	ponderal	(a)	or	ORT	(b)	
cognitive	and	locomotor	parameters.	
2.3.3 ISOLATION	OF	SALB		
The	method	of	extraction	and	isolation	of	SalB	was	rapid	and	easy	to	reproduce.	
The	dried	crude	extract	(2g)	of	the	roots	and	rhizome	of	Salvia	miltiorrhiza	Bge	
was	firstly	submitted	to	exclusion-size	chromatography	(Sephadex	LH-20)	using	
hydro-alcoholic	 solutions	 with	 descending	 polarity	 for	 a	 rapid	 separation	 and	
refinement	 of	 SalB	 thanks	 to	 the	 difference	 in	molecular	 size	 of	 the	 tetramer	
SalB	compared	to	other	monomers,	dimers	and	trimers	of	caffeic	acid	that	are	in	
the	extract.	Then,	to	have	pure	SalB,	liquid-liquid	extraction	and	acidification	at	
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pH=2	were	performed,	obtaining	829.7	mg	of	SalB	pure	at	88,2%.	The	presence	
of	 SalB	 in	 the	 extract	 was	 assessed	 by	 comparison	 of	 retention	 time	 and	 UV	
spectra	with	the	reference	standard	and	the	data	present	in	the	literature.		
TABLE	7:	FRACTIONS	OBTAINED	AFTER	EXCLUSION-SIZE	CHROMATOGRAPHY	(SEPHADEX	
LH-20)	AND	COMBINED	AFTER	MONITORING	BY	HPLC-DAD	
	
	
	
	
	
	
	
2.3.4 PREPARATION	AND	CHARACTERIZATION	OF	SALB	LOADED-PECA	NPS		
PECA-SalB	NPs	were	developed	dissolving	SalB	 in	the	0.1	N	HCl/dextran	70,000	
solution,	before	ECA	polymerization.	Coated	and	uncoated	PECA-SalB	NPs	were	
characterized	as	shown	in	Table	6.	A	slight	increment	of	ζ-potential,	from	-2	to	-
8	mV,	was	probably	related	to	the	interaction	of	SalB	with	the	superficial	charge	
and	 was	 useful	 to	 stabilize	 the	 formulation.	 After	 freeze-drying,	 NPs	 were	
suspended	with	PBS	at	concentration	of	20	mg	/	ml	with	vortex.	The	size	and	the	
PDI	didn’t	change.	The	value	obtained	in	term	of	EE%	was	too	high	(ca.	98%),	as	
show	in	the	Table	6,	and	the	LC	resulted	ca.	50	%.	
2.3.4.1 In	vitro	release	study	of	SalB	
The	test	provided	a	comprehension	of	 the	kinetics	of	 release	of	SalB	 loaded	 in	
uncoated	or	coated	with	Tween	80	PECA	NPs,	during	8	hours.		
To	calculate	the	%	of	SalB	released	in	the	medium	at	pH	7.4	at	each	point	time	
the	following	formula	was	used:	
%	SalB	releasedt	=	(mg	SalBt	x	100)	/	mg	SalBtot	
where:	
• mg	SalBt	=	mg	SalB	released	for	each	timepoint	t	
• mg	SalBtot	=	total	mg	of	SalB	loaded	in	NPs	(10.8mg)	
Fractions	 Solvent	 Constituent	
A	 EtOH	20%	 3,4-dihidrossi	acid	phenyl-lactic	
B	 EtOH	20%	 Mixture	of	phenolic	acids	
C	 EtOH	20%	 Lithospermic	acid	impure	
D	 EtOH	20%	 Lithospermic	acid	pure	
E	 EtOH	20%	 Lithospermic	acid	+		SalB	(salt)	
F	 EtOH	40%	 SalB	(salt)	
G	 EtOH	60%	 SalB	(salt)	+	Rosmarinic	acid	
H	 EtOH	60%	 Rosmarinic	acid	+	Sal	B	(neutral)	
I	 EtOH	80%	 Sal	B	(neutral)	
J	 MeOH	100%	 Sal	A	+	Salvianolic	Acid	A	
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NPs	were	 loaded	with	10.8	mg	of	 SalB.	 The	 release	profile	of	 the	drug-loaded	
PECA	NPs	is	shown	in	Figure	19.	A	typical	sustained	drug	release	was	found	and	
a	biphasic	release	profile	for	both	PECA	NPs	was	assessed.	The	initial	fast	release	
rate	may	be	due	to	smaller	particle	size	of	NPs	which	is	associated	with	smaller	
diffusion	path,	so	drug	accessible	to	the	solid/	dissolution	medium	interface	can	
diffuse	easily	to	the	surface.	Thereafter,	the	release	rate	decreased	that	reflects	
the	release	of	drug	entrapped	in	the	polymer.	In	the	second	phase,	the	release	
rate	is	assumed	to	be	controlled	by	diffusion	of	drug	across	the	polymer	matrix.	
These	 release	 studies	 fit	with	 others	 concerning	 Rivastigmine	NPs	 successfully	
developed	to	treat	Alzheimer’s	disease	[9,	10].	In	addition,	the	lower	release	of	
PECA-SalB-TW80	NPs	was	probably	due	to	the	presence	of	Tween	80,	which	can	
decrease	the	release	percentage	of	hydrophilic	drugs	from	NPs.		
	
	
FIGURE	19:	IN	VITRO	RELEASE	STUDIES	OF	SALB	FREE	AND	LOADED	IN	PECA	NPS	
UNCOATED	AND	COATED	WITH	TWEEN	80	AT	PH	7.4 
2.4 CONCLUSIONS	
Nanotechnology	is	an	emerging	field	that	can	offer	new	tools	and	opportunities	
to	provide	more	focused	and	fine-tuned	treatments	of	diseases,	enhancing	the	
therapeutic	 potential	 of	 drugs	 by	 altering	 their	 biodistribution.	 In	 the	 present	
study	we	develop	and	optimize	a	novel	250	nm	fluorescent-labelled	PECA	NPs	to	
!
% Sal B released  
PECA-SalB NPs 
Sal B free 
PECA-SalB-Tween80 NPs 
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target	the	CNS	crossing	the	BBB,	using	the	nonionic	surfactant	TW80	as	coating	
agent.	 A	 simple,	 relatively	 inexpensive,	 and	 highly	 reproducible	 method	 of	
preparation,	 with	 an	 ease	 scaling-up	 production	 was	 performed.	 The	 in	 vivo	
study	 demonstrated	 the	 biocompatibility	 and	 biodegradability	 of	 PECA-FITC-D-
TW80	 NPs.	 Chronic	 NPs	 administration	 in	 mice	 didn’t	 induce	 mortality,	 nor	
locomotor	activity	or	cognitive	dysfunctions.	The	decrease	of	FITC-labelled	NPs	
over	time	may	be	related	with	their	clearance	made	by	microglial	cells,	resident	
macrophages	 in	 the	 CNS,	 which,	 when	 activated,	 can	 migrate	 to	 the	 site	 of	
injury,	proliferate,	and	perform	phagocytosis.	Moreover,	the	presence	of	NPs	in	
the	 brain	 parenchyma	 didn’t	 induce	 astrocytosis.	 Among	 the	 various	 NPs,	
biocompatible	 and	 biodegradable	 polymeric	 NPs	 are	 the	 safest	 and	 most	
versatile	vehicles	for	drug	delivery	to	the	brain.	Our	studies	contribute	to	depict	
a	 clearer	 picture	of	 PECA	NPs	distribution,	 time-dependent	 accumulation,	 fate	
and	 toxicity	 inside	 the	 CNS.	 According	 to	 our	 findings,	 PECA-TW80	 NPs	 are	
useful	 to	 deliver	 a	 variety	 of	 therapeutics	 in	 the	 brain,	 achieving	 improved	
distribution,	 efficacy	 and	 sustained	 drug	 delivery	 to	 treat	 brain	 diseases	 and	
disorders.	In	this	investigation,	we	successfully	developed	PECA-SalB	NPs	coated	
with	 Tween	 80,	 suitable	 for	 parental	 administration,	 with	 high	 encapsulation	
efficiency	 and	a	 sustained	 release	behaviour,	which	 could	be	 valuable	 for	CNS	
clinical	 applications.	 These	 studies	 represent	 the	 starting	 point	 for	 future	
investigations	to	understand	the	potential	application	in	vivo	of	PECA-SalB	NPs	in	
the	treatment	of	neurodegenerative	disease.	
2.5 MATERIALS	AND	METHODS		
2.5.1 MATERIALS		
The	 monomer	 ethyl	 cyanoacrylate	 (ECA),	 dextran	 70,000	 (D),	 fluorescein	
isothiocyanate	 dextran	 70,000	 (FITC-D),	 D-(+)-glucose,	 TW80	 PBS	 (phosphate	
buffered	 saline)	 were	 purchased	 from	 Sigma-Aldrich,	 (Milan,	 Italy).	 S.	
miltiorrhiza	 Bge.	 (Lamiaceae)	 roots	 and	 rhizome	were	 purchased	 by	 Shenzhou	
Medical	Center,	Rome,	 Italy.	SalB	standard	CRS	was	kindly	provided	by	China’s	
National	 Institute	 for	 the	 Control	 of	 Pharmaceutical	 and	 Biological	 Products	
(NICPBP),	(C36H30O16;	MW	718.6;	purity	98.5%).		
All	other	materials	and	reagents	used	in	the	study	were	Analytical/HPLC	grade.	
Ethanol	was	analytical	reagent	grade	from	Riedel-de	Haen	(Seelze,	Germany).	All	
solvents	used	were	HPLC	grade;	CH3CN	and	MeOH	were	purchased	from	Merck	
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(Darmstadt,	Germany).	HCOOH	(85%)	was	provided	by	Carlo	Erba	(Milan,	Italy).	
Water	was	purified	by	a	Milli-Qplus	system	from	Millipore	(Milford,	MA,	USA).		
2.5.2 EXTRACTION	 AND	 ISOLATION	 OF	 SALB	 FROM	 SALVIA	 MILTIORRHIZA	
BGE.	
The	 isolation	 was	 carried	 out	 as	 previously	 reported	 [12].	 Briefly,	 powdered	
dried	 roots	 of	 S.	 miltiorrhiza	 Bge.	 were	 extracted	 with	 H2O:EtOH	 (4:1)	 and	
partitioned	with	n-hexane	and	dichloromethane,	acidified	to	pH=2	with	HCOOH,	
and	partitioned	with	ethyl	 acetate.	 The	 solvent	 soluble	 fraction	was	dried	and	
dissolved	 in	 20%	 EtOH.	 Then	 the	 solution	 was	 subjected	 to	 size-exclusion	
chromatography	 over	 Sephadex	 LH-20	 using	 hydroalcoholic	 mixtures	 of	
decreasing	 polarity	 (EtOH:H2O	 20:80,	 40:60,	 60:40,	 80:20)	 and	 MeOH	 100%.	
Pure	SalB	(829.7	mg)	was	obtained	after	liquid-liquid	extraction	of	the	acidified	
fractions.		
2.5.3 ANALYTICAL	HPLC-DAD	ANALYSIS	OF	SALB	
The	HPLC	 system	consists	 of	HP	1100	 L	 instrument	with	Diode	Array	Detector	
and	managed	by	HP900	workstation	(Agilent	Technologies,	Palo	Alto,	CA,	USA).	
The	analytical	method	was	previously	developed	and	validated	in	our	group,	as	
previously	 reported	 [12].	 	 For	 the	 quantification	 of	 SalB,	 internal	 standard	
method	 was	 applied.	 The	 HPLC-DAD	 method	 consented	 to	 monitor	 the	
fractionations	and	to	evaluate	 the	purity	of	SalB,	 to	calculate	 the	EE	and	LC	of	
SalB	 into	 NPs	 and	 the	 amount	 of	 compound	 released	 from	 the	 formulations	
during	the	time.	For	the	calibration	curve,	SalB	reference	standard	(CRS,	purity	
98%)	was	dissolved	in	MEOH	in	the	range	from	0.37	ng	to	1.11	μg;	the	linearity	
was	expressed	as	R2	=	0.999.	The	purity	was	88.2%.	
2.5.4 PRODUCTION	AND	COATING	OF	PECA	NPS		
PECA	 NPs	 were	 prepared	 by	 emulsion	 polymerization.	 Briefly,	 100	 µl	 of	 the	
monomer	ECA	were	added	drop	by	drop	under	magnetic	 stirring	 (500	 rpm)	 to	
10	ml	of	acidic	polymerization	medium	(0.1	N	HCl)	containing	100	mg	of	dextran	
70,000.	The	monomer	ECA	is	a	clear	 liquid,	which	undergoes	polymerization	 in	
contact	with	water.	The	mixture	was	stirred	magnetically	for	4	h	to	facilitate	NPs	
formation.	 The	 resulting	 suspension	 was	 neutralized	 with	 0.1	 N	 sodium	
hydroxide	solution	and	filtered	through	a	sintered	glass	filter	(pore	size	10	µm)	
to	 remove	 agglomerates.	 Anhydrous	 glucose	 (0.1%	 w/v)	 was	 added	 as	
cryoprotector	to	improve	redispersibility	of	the	NPs	after	lyophilisation.	The	NPs	
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suspension	was	then	lyophilized	using	a	freeze-drier	overnight.	Fluorescent	NPs	
were	 prepared	 as	 described	 above,	 using	 100	 mg	 FITC-D	 instead	 of	 un-
substituted	 dextran	 70,000.	 After	 lyophilisation,	 NPs	 dimensional	 analysis	 was	
optimised	 by	 applying	 20	 min	 of	 ultrasonication	 probe	 (cycles	 of	 5	 min,	
amplitude	 60%).	 PECA	NPs	were	 resuspended	 in	 PBS	 at	 a	 concentration	 of	 20	
mg/ml	under	constant	stirring	for	1	hour.	Then,	Tween	80	was	added	to	a	final	
concentration	 of	 1%,	 the	 mixture	 was	 incubated	 for	 30	 min	 at	 500	 rpm	 and	
finally	lyophilized.		
PECA-SalB	NPs	were	developed	dissolving	SalB	(drug:monomer	ratio	2:1)	 in	the	
0.1	N	HCl/dextran	70,000	solution,	before	ECA	polymerization.	The	process	yield	
of	PECA	NPs	was	determined	as	the	weight	percentage	of	the	final	product	after	
drying,	with	 respect	 to	 the	 initial	 total	amount	of	polymer	and	other	materials	
used	for	the	preparation.	
2.5.5 CHARACTERIZATION	 OF	 PECA	 NPS	 IN	 TERMS	 OF	 PARTICLE	 SIZE,	
POLYDISPERSITY	INDEX	AND	Ζ-	POTENTIAL		
Particle	size	of	the	developed	NPs	was	measured	by	a	Dynamic	Light	Scattering	
(DLS),	Zetasizer	Nano	series	ZS90	(Malvern	Instruments,	Malvern,	UK)	equipped	
with	 a	 JDS	 Uniphase	 22	 mW	 He–	 Ne	 laser	 operating	 at	 632.8	 nm,	 an	 optical	
fibre-based	 detector,	 a	 digital	 LV/LSE-5003	 correlator	 and	 a	 temperature	
controller	 (Julabo	 water-bath)	 set	 at	 25°C.	 Time	 correlation	 functions	 were	
analysed	 to	 obtain	 the	 hydrodynamic	 diameter	 of	 the	 particles	 (Zh)	 and	 the	
particle	 size	 distribution	 using	 the	 ALV-60X0	 software	 V.3.X	 provided	 by	
Malvern.	 Autocorrelation	 functions	 were	 analysed	 by	 Distribution,	 fitting	 a	
multiple	 exponential	 to	 the	 correlation	 function	 to	 obtain	 particle	 size	
distributions.	 In	 particular,	 PDI	 values	 were	 calculated	 for	 each	 peak	 as	 peak	
width/mean	 diameter.	 Scattering	 was	 measured	 in	 an	 optical	 quality	 4	 mL	
borosilicate	cell	at	a	90°	angle,	diluting	the	samples	30-folds	in	PBS.-potentials	of	
the	 NPs	 were	 measured	 using	 a	 Malvern	 Instruments	 Zetasizer	 Nano	 series	
ZS90.	For	all	samples,	an	average	of	three	measurements	at	stationary	level	was	
taken.	 The	 temperature	 was	 kept	 constant	 at	 25°C	 by	 a	 Haake	 temperature	
controller.	The	ζ-potential	was	calculated	from	the	electrophoretic	mobility,	µE,	
using	the	Henry	correction	to	Smoluchowski’s	equation.		
2.5.6 MORPHOLOGICAL	ANALYSIS	OF	PECA	NPS		
NPs	dispersions	were	analysed	 in	 terms	of	morphology	and	mean	diameter	by	
transmission	 electron	 microscope	 (TEM,	 Jeol	 Jem	 1010)	 and	 by	 scanning	
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electron	 microscope	 (SEM,	 Phenom	 G2	 ProX,	 Phenom-World,	 Alfatest,	 Italy).	
Ten	µL	of	NPs	dispersion	diluted	10-times	was	applied	to	a	carbon	film-covered	
copper	grid.	Most	of	the	dispersion	was	blotted	from	the	grid	with	filter	paper	to	
form	 a	 thin	 film	 specimen,	 which	 was	 stained	 with	 a	 phosphotungstic	 acid	
solution	 1%	w/v	 in	 sterile	water.	 The	 samples	were	 dried	 for	 3	min	 and	 then	
were	examined	under	a	JEOL	1010	electron	microscope	and	photographed	at	an	
accelerating	voltage	of	64	kV.		
2.5.7 PURIFICATION	OF	PECA-SALB	NPS		
NPs	were	purified	from	free	drug	by	ultracentrifugation	for	30,	60	and	90	min	at	
14000	 rpm,	 after	 resuspension	 at	 the	 concentration	 of	 20	mg/mL	 in	 PBS.	 The	
amount	 of	 SalB	 loaded	 into	 NPs	 was	 calculated	 using	 an	 indirect	 method,	
analysing,	by	HPLC-DAD,	the	supernatants	obtained	after	the	centrifugations.		
2.5.8 DETERMINATION	 OF	 ENCAPSULATION	 EFFICACY	 AND	 LOADING	
CAPACITY	OF	PECA-SALB	NPS	
After	 freeze-drying,	 NPs	 were	 resuspended	 in	 PBS	 at	 the	 concentration	 of	 20	
mg/ml,	 the	amount	of	SalB	 (Total	Drug)	 loaded	 in	1	ml	of	NPs	 (or	 in	20	mg	of	
NPs)	was	calculated	as	follow:	
[SalB	BL]:	[NPs	BL]=	[SalB	AL]:	[NPs	AL]	
where:	
• [SalB	BL]	is	the	amount	of	SalB	before	the	lyophilisation		
• [NPs	BL]	is	the	concentration	of	NPs	before	the	lyophilisation	
• [SalB	AL]	is	the	amount	of	SalB	after	the	lyophilisation	(Total	Drug)	
• [NPs	AL]	is	the	concentration	of	NPs	after	the	lyophilisation	
The	evaluation	of	 EE%	and	 LC%	were	performed	using	 an	 indirect	method,	by	
detracting	 the	mg	 total	of	 SalB	used	 in	 the	preparation	of	NPs	 (Total	Drug)	 to	
the	 amount	 of	 SalB	 free	 (Free	 drug)	 quantified	 in	 the	 supernatant	 after	
purification	of	the	NPs,	as	already	described.		
The	EE%	and	the	LC%	were	calculated	using	the	following	equations	[13]:	
	 𝐸𝐸% = 𝑇𝑜𝑡𝑎𝑙	𝑃𝑟𝑜𝑏𝑒 − 𝐹𝑟𝑒𝑒	𝑃𝑟𝑜𝑏𝑒𝑇𝑜𝑡𝑎𝑙	𝐷𝑟𝑢𝑔 ∙ 100 𝐿𝐶% = (𝑇𝑜𝑡𝑎𝑙	𝑃𝑟𝑜𝑏𝑒 − 𝐹𝑟𝑒𝑒	𝑃𝑟𝑜𝑏𝑒)𝑊𝑒𝑖𝑔ℎ𝑡	𝑜𝑓	𝑁𝑃𝑠 ∙ 100 
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2.5.9 IN	VITRO	RELEASE	STUDIES		
SalB	NPs	 loaded	with	 (drug:monomer	 ratio	2:1)	were	 subjected	 to	 the	 in	 vitro	
release	 studied,	 using	 the	 dialysis	 bag	method.	 The	 suspensions	 of	 NP	 coated	
and	uncoated	with	1%	of	Tween	80,	and	SalB	free	were	inserted	in	dialysis	bags	
and	 placed	 in	 PBS	 at	 pH	 7.4	 to	mime	 the	 sink-conditions.	 The	 volume	 of	 PBS	
(medium	 of	 release)	 was	 calculated	 according	 to	 [14].	 The	 bags	 were	 placed	
inside	a	thermostatic	bath	at	37	°C	±	0.5	°C,	under	magnetic	stirring	at	200	rpm,	
for8	hours.	The	release	was	monitored	at	15,	30,	45,	60,	90,120,180,	240,	360	
and	480	minutes;	aliquots	of	one	millilitre	were	withdraw	in	duplicate,	replaced	
with	fresh	PBS	maintained	at	37	°C,	and	analysed	by	HPLC	for	the	quantification	
of	released	drug.	
2.5.10 EVALUATION	OF	STABILITY	OF	PROBE	LINKED	TO	PECA	NPS		
The	 initial	 amount	 of	 fluorescent	 label	 present	 in	 NPs	 was	 determined	 by	
hydrolysis	 in	 4N	NaOH	 solution	 and	 the	 fluorophore	 released	was	 determined	
using	FITC-D	for	the	calibration	curve.	The	HPLC	system	consisted	of	a	HP	1200	L	
instrument	with	a	Diode	Array	Detector	and	fluorimetric	detector	and	managed	
by	a	HP	9000	workstation	(Agilent	Technologies,	Palo	Alto,	CA,	USA).	The	column	
was	 a	 Lycrosorb	 C18,	 (100	mm	 x	 4.6	mm)	 with	 a	 5	 µm	 particle	 size	 (Agilent)	
maintained	 at	 27	 °C.	 Eluents	 were	 H2O	 at	 pH	 3.2	 by	 formic	 acid	 (A)	 and	
acetonitrile	 (B)	at	a	 flow	 rate	of	0,8	ml/min.	The	gradient	condition	was:	0–10	
min,	87-85%	B;	10–23	min,	85–75%	B;	23–	28	min	75–5%	B;	28–31	min,	5–87%	
B,	with	a	10	min	equilibration	time.	 Injected	volume	of	the	samples	was	10	µl.	
The	 UV	 spectra	 were	 recorded	 between	 200	 and	 600	 nm.	 Chromatographic	
profile	of	fluorescein	was	registered	at	240	nm	and	λex=495	nm	and	λem=525	nm.	
For	 the	 stability	 studies,	 the	NPs	were	 incubated	 in	 PBS,	 pH	7.4,	 for	 7	days	 at	
room	 temperature	 under	 gentle	 mixing	 (100	 rpm).	 After	 this	 period,	 samples	
were	centrifuged	at	10.000	 rpm	 for	10	min,	and	 the	 supernatant	 (500	µl)	was	
transferred	 in	4	N	NaOH	solution	(100	µl)	 for	 the	determination	of	 fluorescent	
label	 released	 [15].	 In	 PECA-FITC-D	 NPs	 (λex=495	 nm	 and	 λem=525	 nm.;	 UV	
spectrum	at	240	nm;	FITC-D	186	µg/mg	NPs)	the	amount	of	probe	released	was	
13.8%±0.08,	n=3.		
2.5.11 IN	VIVO	EXPERIMENTS		
2.5.11.1 Animals		
Three-month-old,	230-250	grams,	Wistar	rats	(Harlan,	Milan,	 Italy)	 (n=3/group)	
and	 three-month-old,	 15-25	 grams,	 C57/B6	 mice	 (Harlan,	 Milan,	 Italy)	
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(n=8/group)	were	used	(male	and	female	were	equally	divided	within	treatment	
groups).	Animals	were	housed	in	macrolon	cages	with	ad	libitum	food	and	water	
and	maintained	on	a	12-hour	(h)	light/dark	cycle	at	23	°C.	All	experiments	were	
carried	 out	 according	 to	 the	 European	 Community	 Directive	 86/609/EEC	 for	
animal	 experiments	 and	 National	 guidelines	 for	 animal	 care	 (Permit	 Number:	
152/2014-B).	All	efforts	were	made	to	minimize	the	number	of	animals	used	and	
their	suffering.		
2.5.11.2 Brain	injections	of	fluorescent	PECA	NPs		
One-microliter	of	PECA-FITC-D-TW80	NPs	(8	mg/ml)	or	PBS	(control	group)	was	
injected	into	the	right	NBM	of	anesthetized	(chloral	hydrate,	400	mg/kg,	ip	plus	
Carprofen,	5	mg/kg,	sc)	rats,	at	the	following	stereotactic	coordinates:	AP=-0.2;	
L=-2.8	and	H=6.8	 from	Bregma	as	previously	described	 [16].	One,	 three,	 seven	
and	 fourteen	 days	 after	 injection,	 rats	 were	 deeply	 anesthetized	 with	 chloral	
hydrate	(400	mg/kg,	ip)	and	sacrificed	by	decapitation.		
2.5.11.3 Intravenous	and	intraperitoneal	administration	of	fluorescent	
PECA	NPs	
To	study	the	ability	of	NPs	to	cross	the	BBB	rats	were	acutely	dosed	with	PECA-
FITC-D-TW80	NPs	(100	mg/kg)	or	vehicle	(0.9%	NaCl)	by	i.v.	injection	by	the	tail	
vein	 and	 also	 by	 i.p.	 injection.	 Three	 hours	 after	 systemic	 administration	 rats	
were	perfused	 transcardially	with	 saline	 solution	 (0.9%)	and	 then	with	4%	 ice-
cold	 paraformaldehyde	 in	 0.1	M	PBS,	 pH	7.2,	 under	 deep	 anaesthesia	 (chloral	
hydrate,	400	mg/kg,	ip,	plus	Carprofen,	5	mg/kg,	s.c.).		
2.5.11.4 Animal	Tissue	Processing		
After	 sacrifice,	 brains	 were	 quickly	 extracted	 and	 fixed	 in	 phosphate-buffered	
4%	 paraformaldehyde	 (pH	 7.4)	 for	 48	 hs	 (after	 decapitation)	 or	 4	 hs	 (after	
transcardial	 perfusion)	 at	 4	 °C.	 Subsequently	 brains	 were	 rinsed	 with	 PBS,	
dehydrated	 using	 an	 automated	machine,	 and	 embedded	 in	 paraffin.	 Coronal	
sections	(5.0	µm)	were	cut	using	a	microtome	and	mounted	on	slides.		
2.5.11.5 Immunohistochemistry		
Sections	were	subjected	to	antigen	retrieval	by	microwave	incubation	in	10	mM	
Na-citrate	 buffer,	 pH	 6.0,	 and	 immunostained	 as	 previously	 described	 [17].	
Polyclonal	 ionized	 calcium	 binding	 adaptor	 molecule	 1	 (Iba1)	 (1:250	 dilution,	
Wako,	 Osaka,	 Japan),	 monoclonal	 anti-RT1B	 (anti-OX6,	 1:100	 dilution,	 BD	
Biosciences	Pharmingen,	Franklin	Lakes,	New	Jersey)	antibodies	(Abs)	were	used	
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to	detect	total	(resting	and	activated)	and	activated	microglia,	respectively	and	
anti	 glial	 fibrillary	 acid	 protein	 (GFAP)	 (1:1000	 dilution,	 Dako	 Cytomation,	
Glostrup	 Denmark)	 Ab	 was	 used	 to	 visualize	 astrocytes.	 Monoclonal	 anti-
neuronal	nuclei	(NeuN)	Ab	(1:100	dilution,	Millipore,	Billerica,	USA)	was	used	to	
detect	 neurons,	 polyclonal	 anti-choline	 acetyltransferase	 (ChAT)	 Ab	 (1:200	
dilution,	 Millipore,	 Billerica,	 USA)	 was	 used	 to	 stain	 cholinergic	 neurons	 and	
monoclonal	 anti	 CD34	 Class	 II	 Ab	 (1:200	 dilution,	 Dako	 Cytomation,	 Glostrup	
Denmark)	was	used	for	the	identification	of	vessels.	Co-localization	experiments	
were	performed	as	 previously	 reported	 [18],	 sections	were	 coverslipped	using	
ProLong	(Lyfe	Technologies,	New	York,	USA)	mounting	medium	with	or	without	
DAPI	 for	 nuclear	 staining.	 An	 Olympus	 BX63	microscope	 coupled	 to	 CellSense	
Dimension	Software	(Olympus,	Milan,	Italy)	was	used	to	acquire	representative	
images.	
2.5.11.6 PECA	NPs	toxicity	and	behavioural	studies	in	C57/B6	mice		
To	 reduce	 the	 amount	 of	 NPs	 to	 be	 employed,	 the	 in	 vivo	 toxicity	 was	
investigated	 in	 C57/B6	 mice	 daily	 dosed	 with	 either	 PECA-FITC-D	 -TW80	 NPs	
solution	(200	mg/kg,	ip)	or	vehicle	for	2	weeks.	The	animals	were	weighed	once	
a	day	and	the	body	weight	recorded.	At	the	end	of	the	sub-chronic	treatment,	
C57/B6	mice	treated	with	PECA-FITC-D-TW80	NPs	or	vehicle	were	behaviourally	
tested	 to	 evaluate	 their	 locomotor,	 explorative	 and	 cognitive	 functions	 by	 a	
widely	used	non	spatial	memory	task:	the	novel	object	recognition	test	(ORT)	as	
described	in	[19].	Briefly,	we	used	a	white	box	(60X50X25	cm)	with	a	grid	floor	
covered	by	white	filter	paper.	A	75-Watt	lamp	was	suspended	50	cm	above	the	
box.	The	day	before	testing,	mice	were	allowed	to	explore	the	box	for	5	min.	A	
session	of	two	trials	(T1	and	T2)	at	60	min	interval	was	given	on	the	test	day.	In	
T1,	the	time	spent	by	each	mouse	exploring	two	identical	8.0	cm	side	grey	cubes	
presented	for	10	min	 in	two	opposite	corners	of	the	box	was	recorded.	During	
T2,	one	of	the	cubes	was	replaced	by	a	8.0	cm	side	grey	cylinder,	and	the	mice	
were	left	in	the	box	for	5	min.	The	time	spent	for	the	exploration	of	the	familiar	
(F)	and	the	new	(N)	object	was	recorded	and	a	discrimination	score	(D	=	N/N+F)	
was	calculated.	A	discrimination	score	above	0.5	indicates	the	ability	of	mice	to	
discriminate	 between	 the	 familiar	 and	 novel	 objects	 while	 a	 score	 below	 or	
equal	to	0.5,	reflecting	a	novel	object	exploration	time	less	or	equal	to	the	half	
of	 the	 total	 [20,	 21]	 time	 spent	 between	 the	 two	 objects,	 indicates	 memory	
impairment	 in	 this	 task.	 Mouse	 behaviour	 was	 recorded	 by	 a	 video-
tracking/computer-digitizing	 system	 (HVS	 Image,	 UK)	 and	 the	 path	 length	
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crossed	 during	 T1	 exploration	 was	 recorded	 (HVS	 Image,	 Hampton,	 UK)	 and	
analysed	as	a	measure	of	locomotor	activity.		
2.5.11.7 Statistical	analysis		
Differences	 in	 the	 body	 weight	 between	 vehicle-and	 PECA-FITC-D-TW80	 NPs	
treated	 mice	 were	 analyzed	 by	 two-way	 ANOVA	 plus	 Bonferroni’s	 post	
comparison	 test.	 ORT	 data	 were	 evaluated	 by	 Student’s	 t	 test	 (two-tailed	
probability).	All	 calculations	were	performed	using	GraphPad	Prism	version	5.0	
for	 Windows,	 with	 statistical	 significance	 established	 at	 P<0.05.	 Data	 were	
expressed	as	mean	±	standard	error	of	the	mean	(S.E.M).		
  
CHAPTER	2	
	
85	
2.6 REFERENCES		
[1]	Bonaccini	L,	Karioti	A,	Bergonzi	MC,	Bilia	AR.	Effects	of	Salvia	miltiorrhiza	on	
CNS	Neuronal	Injury	and								Degeneration:	A	Plausible	Complementary	Role	of	
Tanshinones	and	Depsides.	Planta	Med	2015;	81:1003-1016.		
	
[2]	Barbu	E,	Molnar	E,	Tsibouklis	 J,	Gorecki	DC.	The	potential	 for	nanoparticle-
based	 drug	 delivery	 to	 the	 brain:	 overcoming	 the	 blood-brain	 barrier.	 Expert	
Opin	Drug	Deliv	2009;	6:553-565.	
	
[3]	Wohlfart	S,	Gelperina	S,	Kreuter	J.	Transport	of	drugs	across	the	blood-brain	
barrier	by	nanoparticles.	J	Control		Release	2012;	161:264-273.		
	
[4]	Kreuter	J,	Ramge	P,	Petrov	V,	Hamm	S,	Gelperina	SE,	Engelhardt	B,	Alyautdin	
R,	 von	 Briesen	 H,Begley	 DJ.	 Direct	 evidence	 that	 polysorbate-80-coated	
poly(butylcyanoacrylate)	 nanoparticles	 deliver	 drugs	 to	 the	 CNS	 via	 specific	
mechanisms	 requiring	 prior	 binding	 of	 drug	 to	 the	 nanoparticles.	 Pharm	 Res	
2003;	20:409-416.		
	
[5]	 Wohlfart	 S,	 Khalansky	 AS,	 Gelperina	 S,	 Begley	 D,	 Kreuter	 J.	 Kinetics	 of	
transport	of	doxorubicin	bound	to	nanoparticles	across	the	blood-brain	barrier.	J	
Control	Release	2011;	154:103-107.		
	
[6]	Tian	XH,	Lin	XN,	Wei	F,	Feng	W,	Huang	ZC,	Wang	P,	Ren	L,	Diao	Y.	Enhanced	
brain	 targeting	 of	 temozolomide	 in	 polysorbate-80	 coated	
polybutylcyanoacrylate	nanoparticles.	Int	J	Nanomedicine	2011;	6:445-452.		
	
[7]	 Kolter	 M,	 Ott	 M,	 Hauer	 C,	 Reimold	 I,	 Fricker	 G.	 	 Nanotoxicity	 of	 poly(n-
butylcyano-acrylate)	nanoparticles	 at	 the	blood–brain	barrier,	 in	human	whole	
blood	and	in	vivo.	J	Control	Rel	2015;	197:165-179.	
	
[8]	Alexis	F,	Pridgen	E,	Molnar	LK,	Farokhzad	OC.	Factors	affecting	the	clearance	
and	biodistribution	of	polymeric	nanoparticles.	Mol	Pharm	2008	;	5:	505-515.	
	
[9]	 Shrinidh	 AJ,	 Sandip	 SC,	 Krutika	 KS.	 Rivastigmine-loaded	 PLGA	 and	 PBCA	
nanoparticles:	 Preparation,	 optimization,	 characterization,	 in	 vitro	 and	
CHAPTER	2	
	
86	
pharmacodynamic	 studies.	 European	 Journal	 of	 Pharmaceutics	 and	
Biopharmaceutics	2010;	76:	189–199.	
	
[10]	Wilson	B,	Samanta	MK,	Santhi	K,	Kumar	KPS,	Paramakrishnan	N,	Suresh	B.	
Poly(n-butylcyanoacrylate)	 nanoparticles	 coated	 with	 polysorbate	 80	 for	 the	
targeted	 delivery	 of	 rivastigmine	 into	 the	 brain	 to	 treat	 Alzheimer's	 disease.	
Brain	Research	2008;	1200:	159-168.	
	
[12]	 Isacchi	 B,	 Fabbri	 V,	 Galeotti	 N,	 Bergonzi	 MC,	 Karioti	 A,	 Ghelardini	 C,	
Vannucchi	MG,	Bilia	AR.	 	Salvianolic	acid	B	and	its	 liposomal	formulations:	Anti-
hyperalgesic	 activityin	 the	 treatment	of	neuropathic	pain.	 European	 Journal	of	
Pharmaceutical	Sciences	2011;	44:		552–558.	
	
[13]	 Gulyaev	 AE,	 Gelperina	 SE,	 Skidan	 IN,	 Antropov	 AS,	 Kivman	 GY,	 Kreuter	 J.	
Significant	 transport	 of	 doxorubicin	 into	 the	 brain	with	 polysorbate	 80-coated	
nanoparticles.	Pharmaceutical	research	1999;16:	1564-1569.	
	
[14]	 Nimesh	 S,	 Manchanda	 R,	 Kumar	 R,	 Saxena	 A,	 Chaudhary	 A,	 Yadav	 V,	
Mozumdar	S,	Chandra	R.	Preparation,	characterization	and	in	vitro	drug	release	
studies	of	novel	polymeric	nanoparticles.	International	Journal	of	Pharmaceutics	
2006;	323:	146-152.	
	
[15]	 Costantino	 L,	 Gandolfi	 F,	 Tosi	 G,	 Rivasi	 F,	 Vandelli	 MA,	 Forni	 F.	 Peptide-
derivatized	biodegradable	nanoparticles	able	to	cross	the	blood-brain	barrier.	 J	
Control	Release	2005	;108:84-96.		
	
[16]	 Baglioni	 S,	 Casamenti	 F,	 Bucciantini	 M,	 Luheshi	 LM,	 Taddei	 N,	 Chiti	 F,	
Dobson	CM,	Stefani	M.	Prefibrillar	amyloid	aggregates	could	be	generic	toxins	in	
higher	organisms.	J	Neurosci	2006	;	26:8160-8167.		
	
[17]	Rosi	MC,	Luccarini	I,	Grossi	C,	Fiorentini	A,	Spillantini	MG,	Prisco	A,	Scali	C,	
Gianfriddo	M,	 Caricasole	 A,	 Terstappen	GC,	 Casamenti	 F	 Increased	 Dickkopf-1	
expression	 in	 transgenic	 mouse	 models	 of	 neurodegenerative	 disease.	 J	
Neurochem	2010;	112:1539-1551.		
	
CHAPTER	2	
	
87	
[18]	Fiorentini	A,	Rosi	MC,	Grossi	C,	Luccarini	 I,	Casamenti	F.	Lithium	 improves	
hippocampal	 neurogenesis,	 neuropathology	 and	 cognitive	 functions	 in	 APP	
mutant	mice.	PLoS	One	2010;	5:	e14382.		
	
[19]	Grossi	C,	Rigacci	S,	Ambrosini	S,	Ed	DT,	Luccarini	I,	Traini	C,	Failli	P,	Berti	A,	
Casamenti	F,	Stefani	M.	The	polyphenol	oleuropein	aglycone	protects	TgCRND8	
mice	against	Ass	plaque	pathology.	PLoS	One	2013;	8:e71702.		
	
[20]	Hammond	RS,	Tull	LE,	Stackman	RW.	On	the	delay-dependent	involvement	
of	the	hippocampus	in	object	recognition	memory.	Neurobiol	Learn	Mem	2004;	
82:26-34.		
	
[21]	Greco	 SJ,	 Bryan	 KJ,	 Sarkar	 S,	 Zhu	 X,	 Smith	MA,	Ashford	 JW,	 Johnston	 JM,	
Tezapsidis	N,	Casadesus	G.	Leptin	reduces	pathology	and	improves	memory	in	a	
transgenic	 mouse	 model	 of	 Alzheimer's	 disease.	 J	 Alzheimers	 Dis	 G	 2010;	
19:1155-1167.		

		
CHAPTER	3	
ALBUMIN-BASED	NANOPARTICLES	FOR	BRAIN	
DELIVERY:	A	COMPARISON	OF	CHEMICAL	VS	THERMAL	
PREPARATION	METHODS	AND	IN	VIVO	BEHAVIOUR	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
This	work	was	carried	out	in	collaboration	with	Maria	Camilla	Bergonzi1,	Cristina	Grossi2,	
Vieri	Piazzini1,	Andrea	Torracchi1,	Ilaria	Luccarini2,	Fiorella	Casamenti2,	Anna	Rita	Bilia1	
	
1	Department	of	Chemistry,	University	of	Florence,	Via	Ugo	Schiff	6,	50019	Sesto	Fiorentino,	Florence,	Italy	
	
2	Department	of	Neuroscience,	Psychology,	Drug	Research	and	Child	Health,	Division	of	Pharmacology	and	
Toxicology,	University	of	Florence,	50139	Florence,	Italy.	
	 	
CHAPTER	3	
	
90	
3.1 ABSTRACT	
	HSA	 NPs	 have	 gained	 considerable	 attention	 owing	 to	 their	 high	 loading	
capacity	 of	 various	 drugs	 and	 being	 well	 tolerated	 without	 any	 serious	 side	
effects.	The	aim	of	this	work	was	the	investigation	of	two	different	methods	of	
cross-linking	in	order	to	produce	HSA	NPs	without	using	unsafe	organic	solvents,	
obtaining	useful	drug	delivery	systems	to	cross	the	BBB.		NPs	were	obtained	by	
coacervation	 using	 both	 chemical	 (HSAC	NPs)	 and	 thermal	 cross-linking	 (HSAT	
NPs).	 NPs	 were	 developed	 and	 optimised	 to	 target	 brain	 tissues	 after	
intravenous	 and	 intraperitoneal	 administration	 in	 healthy	 rats.	 Furthermore,	
their	 distribution,	 cellular	 uptake	 and	 fate	 were	 investigated	 in	 vivo	 after	
intracerebral	 injection	 into	 the	 NBM	 of	 the	 basal	 forebrain	 of	 healthy	 rats.	 In	
addition,	 the	 toxicity	 of	 the	 developed	 carriers	 was	 estimated	 by	 behavioural	
test.	All	NPs	were	characterized	by	DLS,	TEM	and	HPLC-DAD-FLD	analyses.	HSAT	
NPs	were	superior	than	HSAC	NPs	in	terms	of	formulation	parameters,	while	the	
in	 vivo	 performance	was	very	 similar.	Distribution	and	 fate	of	NPs	 in	 the	brain	
were	evaluated	by	 fluorescent	microscope	 images.	NPs	were	able	 to	cross	 the	
BBB	 and	 reach	 brain	 tissue	 and	 did	 not	 induce	 inflammatory	 response.	
Behavioural	 test	 demonstrated	 no	 locomotor,	 explorative	 and	 cognitive	
functions	impairment	induced	by	NPs	in	rats.	
3.2 INTRODUCTION	
BBB	restricts	the	transport	from	the	blood	into	the	brain	of	many	therapeutically	
important	 drugs,	 including	 anticancer	 drugs,	 antibiotics	 and	 a	 wide	 variety	 of	
central	 nervous	 system	 (CNS)-active	 drugs,	 especially	macromolecules	 such	 as	
neuropeptides	 and	 proteins.	 The	 limitations	 imposed	 by	 BBB	 and	 the	 non-
selective	distribution	of	drugs	in	the	brain	have	hindered	the	effective	treatment	
of	brain	diseases	and	may	result	in	severe	side	effects	on	the	healthy	tissues	of	
brain.	 A	 number	 of	 different	 strategies	 have	 been	 devised	 to	 overcome	 this	
barrier	 and	 nanocarriers	 have	 emerged	 as	 versatile	 vectors	 for	 the	 specific	
delivery	of	drugs	to	brain	tissues	[1,2].	Various	macromolecular	substances	such	
as	 synthetic	 and	 natural	 polymers	 can	 be	 used	 for	 nanoparticle	 preparation	
[3,4].	Among	these,	HSA	is	a	promising	material	because	it	is	the	most	abundant	
plasma	 protein,	 has	 been	 shown	 to	 be	 non-toxic,	 non-immunogenic,	
biocompatible	 and	 biodegradable,	 it	 is	 extremely	 robust	 towards	 pH,	
temperature	 and	 organic	 solvents.	 These	 properties	 as	well	 as	 its	 preferential	
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uptake	in	tumour	and	inflamed	tissue,	its	ready	availability,	biodegradability	and	
lack	of	toxicity	make	it	an	ideal	candidate	for	drug	delivery	to	brain.		
Moreover,	 HSA	 NPs	 have	 gained	 considerable	 attention	 owing	 to	 their	 high	
binding	capacity	of	various	drugs	[5-6].	Albumin	nanoparticles	are	widely	used	as	
carriers	for	delivering	drugs	to	a	variety	of	organs	but	only	a	very	few	studies	are	
concerning	 in	 vivo	 brain	 delivery	 of	 albumin	 NPs	 without	 any	 surface	
modification.	 The	 endogenous	 transport	mechanisms	 to	 cross	 BBB	 are	diverse	
and	 include	 paracellular	 aqueous	 pathway,	 transcellular	 lipophilic	 pathway,	
proteins	transport	(carriers)-mediated,	RMT	and	AMT.	The	AMT	is	a	nonspecific	
process,	 which	 originated	 from	 the	 observation	 that	 policationic	 proteins,	 as	
protamine,	 can	 bind	 not	 only	 to	 the	 endothelial	 surface,	 but	 they	 can	 also	
penetrate	 the	BBB.	The	AMT	 is	 triggered	by	electrostatic	 interactions	between	
the	 positively	 charged	 parts	 of	 protein	 and	 the	 negatively	 charged	 brain	
membrane	 [7].	Nevertheless,	almost	all	 in	vivo	 studies	concerning	HSA	NPs	 for	
CNS	delivery	are	overcoated	nanoparticles	with	certain	surfactants	that	adsorb	
specific	apolipoproteins	 from	the	blood	after	 intravenous	 injection	or	with	 the	
covalent	attachment	of	 such	apolipoproteins,	or	 containing	 transferrin	or	anti-
transferrin-receptor	 monoclonal	 antibodies	 covalently	 coupled.	 These	 surface	
modifications	 or	 decorations	 enable	 the	 interaction	 of	 HAS	 NP	 with	 the	
respective	receptors	on	the	brain	capillary	endothelial	cells	to	cross	the	BBB	[3].		
The	aim	of	this	work	was	the	development	and	optimisation	of	HSA	NPs	as	drug	
delivery	 systems	 to	 cross	 BBB	 using	 two	 different	 cross-linking	 methods,	 the	
most	studied	chemical	cross-linking	and	the	lesser-known	thermal	cross-linking.	
All	 the	 preparation	 steps	 including	 extent	 of	 the	 polymerization	 process,	
concentration	 of	 reagents,	 time	 and	 temperature	 of	 cross-linking,	 NPs	
purification	 methods,	 type	 and	 concentration	 of	 cryoprotectants	 were	
optimised	 to	 obtain	 suitable	NPs	 for	 the	 parental	 administration.	 Additionally,	
NPs	 were	 loaded	 with	 fluorescein	 sodium	 salt	 (NAF)	 as	 a	 florescent	 probe	 to	
evaluated	 their	 in	 vivo	 performance.	 All	 NPs	 were	 characterized	 in	 terms	 of	
dimension,	 polydispersity	 and	 ζ-potential	 by	 DLS;	 their	 morphology	 was	
evaluated	 by	 TEM	while	 EE%,	 loading	 capacity	 LC%	 and	 the	 stability	 of	 probe	
were	measured	by	HPLC-DAD-FLD.		
HSA	NPs	 distribution,	 cellular	 uptake	 and	 fate	were	 studied	 in	 healthy	 rats	 by	
fluorescent	microscope	 images,	 after	NPs	 intracerebral	 injection	 into	 the	NBM	
of	 the	 basal	 forebrain.	 The	 occurrence	 of	 a	 potential	 general	 toxicity	 for	 the	
animals,	as	well	as	NPs-induced	inflammatory	response	in	terms	of	glia	reaction,	
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were	 deeply	 investigated.	 In	 addition,	 the	 ability	 of	 NPs	 to	 cross	 the	 BBB	was	
evaluated	 after	 intravenous	 and	 intraperitoneal	 administration	 in	 healthy	 rats	
and	 the	 potential	 toxicity	 of	 the	 carriers	was	 estimated	 by	 behavioural	 test	 in	
healthy	mice.	
3.3 MATERIALS	AND	METHODS	
3.3.1 MATERIALS	
HSA,	 glutaraldehyde	 25%,	 sodium	 chloride	 (NaCl),	 D-(+)-glucose	 anhydrous,	
sucrose,	NAF,	PBS	pH	7.4	were	purchased	from	Sigma-Aldrich	 (Milan,	 Italy).	All	
solvents	used	were	HPLC	grade:	CH3CN	and	MeOH	were	purchased	from	Merck	
(Darmstadt,	Germany).	EtOH	was	analytical	reagent	grade	from	Riedel-de	Haen	
(Seelze,	 Germany).	 HCOOH	 (85%)	 was	 provided	 by	 Carlo	 Erba	 (Milan,	 Italy).	
Phosphotungstic	 acid	 was	 obtained	 by	 Società	 Italiana	 Chimici	 (Rome,	 Italy).	
Water	was	purified	by	a	Milli-Qplus	system	from	Millipore	(Milford,	MA,	USA).	
3.3.2 HSAC	NPS	PREPARATION		
Empty	 HSAC	NPs	were	 prepared	modifying	 a	 previously	 proposed	 desolvation	
technique[7-9].	HSA	at	a	concentration	of	20	mg/ml	(2%	w/v)	was	dissolved	in	3	
ml	of	10	mM	NaCl	solution	under	magnetic	stirring	(500	rpm,	30	minutes).	NPs	
were	obtained	by	continuous	addition	of	6	ml	of	the	desolvating	agent	ethanol	
to	HSA	solution,	at	constant	rate	of	1	ml/min	(ratio	NaCl-ethanol	1:2	v/v)	under	
stirring	(500	rpm)	at	room	temperature.	After	the	desolvation	process,	60	µl	of	a	
solution	of	0.5	w/v	of	glutaraldehyde	in	ethanol	(5	µg/mg	protein)	were	added	
to	 induce	 particle	 crosslinking.	 The	 crosslinking	 process	 was	 performed	 under	
magnetic	 stirring	 for	 2	 hours	 at	 room	 temperature.	 The	 resulting	 NPs	 were	
purified	by	centrifugation	(4500	rpm,	30	min	x	3).	Then,	NPs	were	re-suspended	
in	 3	ml	 of	 10	mM	NaCl	 solution	 containing	 3%	w/v	 sucrose	 as	 cryoprotective	
agent	and	freeze-dried.	
3.3.3 FLUORESCENT	HSAC	NPS	PREPARATION		
HSAC	 NAF	 NPs	 were	 prepared	 using	 the	 same	 method	 optimized	 for	 non-
fluorescent	NPs,	 using	NAF	as	 fluorescent	probe	 (λ	 ex	=460	nm;	 λ	 em	=515	nm).	
NAF	(10	mg/ml,	1%	w/v)	was	incubated	with	3	ml	of	an	HSA	solution	(20	mg/ml,	
2%	w/v)	under	magnetic	 stirring	 (500	 rpm)	 for	2	h.	NPs	were	obtained	by	 the	
continuous	 addition	 of	 the	 ethanol	 at	 constant	 rate	 of	 1	 ml/min	 (ratio	 NaCl-
ethanol	1:2	v/v)	under	stirring	(500	rpm)	at	room	temperature.	Glutaraldehyde	
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(5	µg/mg	protein)	was	added	under	magnetic	stirring	at	room	temperature	for	2	
h	 to	 induce	 particle	 crosslinking.	 Fluorescent	 HSA	 NPs	 were	 purified	 by	
centrifugation	(4500	rpm,	30	min	x	3	times).	Then,	NPs	were	re-suspended	and	
dispersed	 in	 the	 original	 volume	 of	 10	 mM	 NaCl	 solution	 containing	 3%	 w/v	
sucrose	as	cryoprotective	agent,	then	the	samples	were	lyophilized.	
3.3.4 HSAT	NPS	PREPARATION		
Empty	 HSAT	 NPs	 were	 prepared	 modifying	 and	 optimizing	 a	 thermal	 cross-
linking	 method	 proposed	 by	 [10].	 Briefly,	 HSA	 at	 a	 concentration	 of	 5	 µg/ml	
(0.5%	 w/v)	 was	 dissolved	 in	 20	 ml	 of	 10	 mM	 NaCl	 solution	 under	 magnetic	
stirring	(700	rpm,	30	min).	Polymerization	process	was	performed	by	continuous	
addition	of	 20	ml	of	 the	ethanol	 at	 a	 rate	of	 1	ml/min	 (ratio	NaCl-ethanol	 1:1	
v/v)	under	stirring	(500	rpm)	at	room	temperature.	Magnetic	stirring	(500	rpm)	
was	continued	at	90°C	 for	1	hour	 to	yield	an	aqueous	suspension	of	 thermally	
cross-linked	HSA	NPs.	They	were	allowed	to	cool	at	room	temperature	and	then	
were	 purified	 by	 centrifugation	 (4500	 rpm,	 30	 min	 x	 3	 times).	 Pellets	 were	
suspended	in	the	10	ml	of	10	mM	NaCl	solution	containing	2%	w/v	anhydrous	D-
glucose	and	after	freeze-dried.	
3.3.5 FLUORESCENT	HSAT	NPS	PREPARATION		
Fluorescent	HSAT	NPs	were	prepared	by	 the	 same	method	optimized	 for	non-
fluorescent	NPs.	The	probe	(NAF)	(5	mg/ml,	0.5%	w/v)	was	incubated	with	3	ml	
of	HSA	solution	(5	mg/ml,	0.5%	w/v)	for	2	h	under	magnetic	stirring	at	500	rpm.	
Ethanol	 was	 added	 at	 constant	 rate	 of	 1	 ml/min	 (ratio	 NaCl-ethanol	 1:1	 v/v)	
under	 magnetic	 stirring	 (500	 rpm)	 at	 room	 temperature.	 The	 stirring	 was	
continued	at	90°C	for	1	h	to	obtained	an	aqueous	suspension	of	thermally	cross-
linked	 HSA	 NPs.	 NPs	 were	 allowed	 to	 cool	 at	 room	 temperature,	 then	 were	
centrifuged	(4500	rpm,	30	min	x	3	times).	Pellets	were	dispersed	in	the	original	
volume	 of	 10	 mM	 NaCl	 solution	 containing	 2%	 w/v	 anhydrous	 D-glucose	 as	
cryoprotective	agent,	then	were	freeze-dried.	
3.3.6 NPS	YIELD	
The	 yield	 of	 the	 process	 of	 preparation	 for	 both	 NPs	 was	 expressed	 as	 the	
weight	 percentage	of	 the	 final	 product	 after	 drying,	with	 respect	 to	 the	 initial	
total	amount	of	protein	and	other	materials	used	for	the	preparation.	
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3.3.7 CHARACTERIZATION	OF	NPS:	 SIZE,	 POLYDISPERSITY	 INDEX	 AND	ZETA	
POTENTIAL	
Particle	size	of	the	developed	NPs	was	measured	by	a	DLS,	Zetasizer	Nano	series	
ZS90	(Malvern	Instruments,	Malvern,	UK)	equipped	with	a	JDS	Uniphase	22	mW	
He-Ne	 laser	 operating	 at	 632.8	mm,	 an	 optical	 fiber-based	 detector,	 a	 digital	
LV/LSE-5003	correlator	and	a	temperature	controller	(Julabo	water-bath)	set	at	
25°C.	 Time	 correlation	 functions	 were	 analysed	 to	 obtain	 the	 Zh	 and	 the	 PDI	
using	 the	 ALV-60X0	 software	 V.3.X	 provided	 by	 Malvern.	 Autocorrelation	
functions	were	analysed	by	the	Cumulants	method,	 fitting	a	single	exponential	
to	 the	 correlation	 function	 to	 obtain	 particle	 size	 distribution.	 Scattering	 was	
measured	in	an	optical	quality	4	ml	borosilicate	cell	at	a	90°	angle,	diluting	the	
samples	in	10	nM	NaCl	solution.	ζ-potentials	of	the	NPs	were	measured	using	a	
Malvern	Instruments	Zetasizer	Nano	series	ZS90.	For	all	samples,	an	average	of	
three	measurements	 at	 stationary	 level	was	 taken.	 The	 temperature	was	 kept	
constant	 at	 25°C	 by	 a	 Haake	 temperature	 controller.	 The	 ζ-potential	 was	
calculated	 from	the	electrophoretic	mobility,	µE,	using	 the	Henry	correction	 to	
Smoluchowski’s	equation.	
3.3.8 MORPHOLOGICAL	CHARACTERIZATION		
NPs	 were	 analysed	 in	 terms	 of	 morphology,	 polydispersity,	 shape	 and	
dimensions	 by	 TEM.	 NPs	 dispersion	 diluted	 10-times	was	 applied	 to	 a	 carbon	
film-covered	copper	grid.	Most	of	the	dispersion	was	blotted	from	the	grid	with	
filter	 paper	 to	 form	 a	 thin	 film	 specimen,	 which	 was	 stained	 with	 a	
phosphotungstic	acid	solution	1%	w/v	 in	sterile	water.	The	samples	were	dried	
for	3	min	and	then	were	examined	under	a	JEOL	1010	electron	microscope	and	
photographed	at	an	accelerating	voltage	of	64	kV.	
3.3.9 PURIFICATION	OF	NPS		
NPs	were	purified	 from	 free	probe	by	ultracentrifugation	 for	 75	min	 at	 18000	
rpm,	4°C.The	amount	of	NAF	 loaded	 into	NPs	was	 calculated	using	an	 indirect	
method.		
3.3.10 HPLC-DAD-FLD	ANALYSES	
The	 HPLC	 system	 consisted	 of	 a	 HP	 1200	 L	 instrument	 with	 a	 Diode	 Array	
Detector	 and	 fluorimetric	 detector	 and	 managed	 by	 a	 HP	 9000	 workstation	
(Agilent	 Technologies,	 Palo	 Alto,	 CA,	 USA).	 The	 column	was	 a	 LiChrosorb	 C18,	
(100	 mm	 x	 4.6	 mm)	 with	 a	 5µm	 particle	 size	 (Agilent)	 maintained	 at	 27	 °C.	
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Eluents	were	H2O	at	pH	3.2	by	formic	acid	(B)	and	acetonitrile	(A)	at	a	flow	rate	
of	0.8	ml/min.	The	gradient	condition	was:	0-10	min,	87-85%	B;	10-23	min,	85-
75%	 B;	 23-28	min	 75-5%	 B;	 28-31	min,	 5-87%	 B,	 with	 a	 10	min	 equilibration	
time.	Injected	volume	of	the	samples	was	10	or	20	µl.	Chromatographic	profile	
of	NAF	was	registered	at	λex	=	460	nm	and	λem	=	515	nm.	
3.3.10.1 Quantification	of	NAF	Fluorescein	sodium	salt	HPLC	analysis	
After	 freeze-drying,	HSA	 fluorescent	NPs	were	 resuspended	 in	10	mM	NaCl	 at	
the	concentration	of	20	mg/ml.	The	amount	of	NAF	(Total	Probe)	loaded	in	1	ml	
of	NPs	(or	in	20	mg	of	NPs)	was	calculated	as	follow	[11]:	𝐍𝐀𝐅 𝐛𝐥: 𝐍𝐏𝐬 𝐛𝐥 = 𝐍𝐀𝐅 𝐬𝐥: 𝐍𝐏𝐬 𝐬𝐥	
	
where:	
• 𝐍𝐀𝐅 𝐛𝐥concentration	of	NAF	before	freeze-drying	
• 𝐍𝐏𝐬 𝐛𝐥	concentration	of	NPs	before	freeze-drying	
• 𝐍𝐀𝐅 𝐬𝐥concentration	of	NAF	subsequent	freeze-drying	(Total	Probe)	
• 𝐍𝐏𝐬 𝐬𝐥concentration	of	NPs	subsequent	freeze-drying	
Total	Probe	in	the	HSAC	is	2.63	mg	in	1	ml	of	NPs	or	2.63	mg	in	20	mg	of	NPs.	
Total	Probe	in	the	HSAT	is	2.47	mg	in	1	ml	of	NPs	or	2.47	mg	in	20	mg	of	NPs.	
	
The	evaluation	of	 EE%	and	 LC%	were	performed	using	 an	 indirect	method,	by	
detracting	the	mg	total	of	NAF	used	 in	the	preparation	of	NPs	(Total	Probe)	 to	
the	 amount	 of	 NAF	 free	 (Free	 Probe)	 quantified	 in	 the	 supernatant	 after	
purification	of	the	NPs	by	ultracentrifugation,	as	described	in	the	Section	3.3.9.	
Free	Probe	determined	by	HPLC/FLD	was:	0.0395	±	0.002	mg	in	the	case	of	HSAC	
NPs	and	0.0154	±	0.002	mg	in	the	case	of	HSAT	NPs.	
The	EE%	and	the	LC%	were	calculated	by	using	the	following	equations:	
	
	
	
3.3.11 	NAF	STABILITY	
The	stability	of	NAF	was	evaluated	with	in	vitro	release	test.	The	suspensions	of	
NPs	were	inserted	in	a	dialysis	bag	and	were	placed	in	a	PBS	solution	at	pH	7.4	
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to	 mime	 the	 sink-conditions.	 The	 volume	 of	 PBS	 was	 calculated	 according	 to	
[12].	The	bags	were	placed	 inside	a	thermostatic	bath	at	37	°C	±	0.5	°C,	under	
magnetic	stirring	at	200	rpm.	Test	time	was	set	to	3	hours,	according	to	time	of	
the	in	vivo	tests.	The	release	was	monitored	at	10,	20,	30,	60,	120,	180	minutes;	
aliquots	of	one	millilitre	were	withdraw	in	duplicate,	replaced	with	fresh	PBS	at	
pH	 7.4	 maintained	 at	 37	 °C	 ±	 0.5	 °C,	 and	 analysed	 by	 HPLC-FLD	 for	 the	
quantification	of	released	fluorescent	probe.	
3.3.12 IN	VIVO	EXPERIMENTS	
3.3.12.1 Animals	
One-month-old,	 180-200	 g,	 Wistar	 rats	 (Harlan,	 Milan,	 Italy)	 (n=3/group)	 and	
three-month-old,	15-25	g,	C57/Bl6	mice	(Harlan,	Milan,	Italy)	(n=8/group)	were	
used	(male	and	female	were	equally	divided	within	treatment	groups).	Animals	
were	housed	in	macrolon	cages	with	ad	libitum	food	and	water	and	maintained	
on	a	12-h	light/dark	cycle	at	23	°C.	All	experiments	were	carried	out	according	to	
the	EC	Directive	86/609/EEC	for	animal	experiments	and	National	guidelines	for	
animal	 care	 (Permit	 Number:	 152/2014-B).	 All	 efforts	were	made	 to	minimize	
the	number	of	animals	used	and	their	suffering.		
3.3.12.2 Brain	injections	of	fluorescent	HSAC	NPs	
One-microliter	of	HSAC	NPs	(10	mg/ml)	or	PBS	(control	group)	was	injected	into	
the	right	NBM	of	anesthetized	(chloral	hydrate,	400	mg/kg,	intraperitoneally	(ip)	
plus	 Carprofen,	 5	 mg/kg,	 subcutaneously)	 rats,	 at	 the	 following	 stereotactic	
coordinates:	 AP=-0.2;	 L=-2.8	 and	 H=6.8	 from	 Bregma	 [13]	 as	 previously	
described	[14].Twenty-four	hours,	seven	and	fourteen	days	after	 injection,	rats	
were	deeply	anesthetized	with	chloral	hydrate	(400	mg/kg,	ip,	plus	Carprofen,	5	
mg/kg,	subcutaneously)	and	sacrificed	by	decapitation.		
3.3.12.3 Systemic	 administration	 of	 fluorescent	 HSAC	 NPs	 and	
fluorescent	HSAT	NPs	
To	study	the	ability	of	NPs	to	cross	the	BBB	rats	were	acutely	dosed	with	HSAT	
NPs	(100	mg/kg)	or	vehicle	 (0.9%	NaCl)	by	 intravenous	(iv)	 injection	by	the	tail	
vein.	Three	hours	after	systemic	administration	rats	were	perfused	transcardially	
with	saline	solution	(0.9%)	and	then	with	4%	ice-cold	paraformaldehyde	in	0.1	M	
PBS,	 pH	 7.2,	 under	 deep	 anaesthesia	 (chloral	 hydrate,	 400	 mg/kg,	 ip,	 plus	
Carprofen,	5	mg/kg,	subcutaneously).		
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3.3.12.4 Animal	Tissue	Processing	
After	 sacrifice,	 brains	 were	 quickly	 extracted	 and	 fixed	 in	 phosphate-buffered	
4%	 paraformaldehyde	 (pH	 7.4)	 for	 48	h	 (after	 decapitation)	 or	 4	 h	 (after	
transcardial	 perfusion)	 at	 4	°C.	 Subsequently	 brains	 were	 rinsed	 with	 PBS,	
dehydrated	 using	 an	 automated	machine,	 and	 embedded	 in	 paraffin.	 Coronal	
sections	(5.0	μm)	were	cut	using	a	microtome	and	mounted	on	slides.	
3.3.12.5 Immunohistochemistry	
Sections	were	subjected	to	antigen	retrieval	by	microwave	incubation	in	10	mM	
Na-citrate	 buffer,	 pH	 6.0,	 and	 immunostained.	 Polyclonal	 ionized	 calcium	
binding	 adaptor	 molecule	 1	 (Iba1)	 (1:250	 dilution,	 Wako)	 antibody	 (Ab)	 was	
used	to	detect	resting	and	activated	microglia	and	anti	glial	fibrillary	acid	protein	
(GFAP)	(1:1000	dilution,	Dako	Cytomation)	Ab	was	used	to	visualize	astrocytes.	
Polyclonal	 anti-choline	 acetyltransferase	 (ChAT)	 Ab	 (1:200	 dilution,	 Millipore)	
was	 used	 to	 stain	 cholinergic	 neurons	 and	 monoclonal	 anti	 CD34	 Class	 II	 Ab	
(1:200	dilution,	Dako	Cytomation)	was	used	for	the	identification	of	vessels.	Co-
localization	 experiments	 were	 performed.	 Sections	 were	 coverslipped	 using	
ProLong	(Lyfe	Technologies,	New	York,	USA)	mounting	medium	with	or	without	
DAPI	 for	 nuclear	 staining.	 An	 Olympus	 BX63	microscope	 coupled	 to	 CellSense	
Dimension	 Software	 (Olympus,	 MI,	 Italy)	 was	 used	 to	 acquire	 representative	
images.			
3.3.12.6 In	 vivo	HSAC	NPs	 toxicity	and	behavioural	 studies	 in	C57/Bl6	
mice	
To	 reduce	 the	 amount	 of	 NPs	 to	 be	 employed,	 the	 in	 vivo	 toxicity	 was	
investigated	 in	 C57/Bl6	 mice	 daily	 dosed	 with	 either	 HSAC	 NPs	 solution	 (100	
mg/kg,	ip)	or	vehicle	for	2	weeks.	The	animals	were	weighed	once	a	day	and	the	
body	weight	 recorded.	At	 the	end	of	 the	 sub-chronic	 treatment,	C57/Bl6	mice	
treated	with	 HSAC	 NPs	 or	 vehicle	were	 behaviourally	 tested	 to	 evaluate	 their	
locomotor,	 explorative	 and	 cognitive	 functions	 by	 a	 widely	 used	 non	 spatial	
memory	task:	the	novel	ORT.	Briefly,	we	used	a	white	box	(60X50X25	cm)	with	a	
grid	floor	covered	by	white	filter	paper.	A	75-Watt	 lamp	was	suspended	50	cm	
above	the	box.	The	day	before	testing,	mice	were	allowed	to	explore	the	box	for	
5	min.	A	session	of	two	trials	(T1	and	T2)	at	60	min	interval	was	given	on	the	test	
day.	 In	 T1,	 the	 time	 spent	 by	 each	mouse	 exploring	 two	 identical	 8.0	 cm	 side	
grey	 cubes	 presented	 for	 10	 min	 in	 two	 opposite	 corners	 of	 the	 box	 was	
recorded.	 During	 T2,	 one	 of	 the	 cubes	 was	 replaced	 by	 a	 8.0	 cm	 side	 grey	
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cylinder,	 and	 the	mice	were	 left	 in	 the	 box	 for	 5	min.	 The	 time	 spent	 for	 the	
exploration	 of	 the	 familiar	 (F)	 and	 the	 new	 (N)	 object	 was	 recorded	 and	 a	
discrimination	score	(D=N/N+F)	was	calculated.	A	discrimination	score	above	0.5	
indicates	 the	 ability	 of	 mice	 to	 discriminate	 between	 the	 familiar	 and	 novel	
objects	while	a	score	below	or	equal	to	0.5,	reflecting	a	novel	object	exploration	
time	less	or	equal	to	the	half	of	the	total	time	spent	between	the	two	objects,	
indicates	 memory	 impairment	 in	 this	 task	 [15,16].	 Mouse	 behaviour	 was	
recorded	 by	 a	 video-tracking/computer-digitizing	 system	 (HVS	 Image,	 UK)	 and	
the	 path	 length	 crossed	 during	 T1	 exploration	 was	 recorded	 (HVS	 Image,	
Hampton,	UK)	and	analysed	as	a	measure	of	locomotor	activity.		
3.3.12.7 Statistical	analysis		
Differences	 in	 the	 body	 weight	 between	 vehicle	 and	 HSAC	 NPs	 treated	 mice	
were	analysed	by	two-way	ANOVA	plus	Bonferroni’s	post	comparison	test.	ORT	
data	were	evaluated	by	Student’s	t	test	(two-tailed	probability).	All	calculations	
were	performed	using	GraphPad	Prism	version	5.0	for	Windows,	with	statistical	
significance	 established	 at	 P	 <0.05.	 Data	 were	 expressed	 as	mean	 ±	 standard	
error	of	the	mean	(S.E.M).	
3.4 RESULTS	AND	DISCUSSION	
3.4.1 PREPARATION	OF	HSA	NPS	WITH	CHEMICAL	CROSS-LINKING	METHOD	
(HSAC)	
HSAC	 NPs	 were	 prepared	 with	 chemical	 cross-linking	 method	 by	 using	
glutaraldehyde	 as	 described	 in	 section	 3.3.2.	 The	 pre-formulative	 study	 was	
focused	 on	 the	 optimization	 of	 different	 parameters	 in	 order	 to	 improve	
technological	characteristics	of	NPs.	The	 following	steps	were	 investigated	and	
optimised:	 polymerization	 process	 parameters	 (time,	 temperature),	
concentration	 of	 reagents	 (principally	 glutaraldehyde),	 purification	 process	 of	
NPs,	 method	 for	 the	 optimization	 of	 size	 and	 homogeneity	 of	 the	 sample	
(ultrasonic	bath	or	ultrasonication	probe),	choice	of	the	type	and	concentration	
of	cryoprotectant	(2%	w/v	of	mannitol	or	3%	w/v	of	sucrose).	Accordingly,	best	
results	were	obtained	after	2	h	of	polymerization	at	 room	temperature	with	a	
glutaraldehyde	 concentration	 of	 5	 µg/mg	 HSA	 and	 no	 sonication	 or	
ultrasonication	 process	 were	 further	 used	 to	 optimize	 the	 sizes.	 Purification	
process	 was	 performed	 by	 centrifugation	 with	 three	 cycles	 of	 10	 minutes	 at	
4500	rpm.	
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Table	 8	 shows	 the	 final	 characterization	 of	 developed	 HSAC	 NPs.	 Results	 in	
terms	 of	 size	 and	 homogeneity	 are	 reproducible	 and	 derived	 from	 the	
acceptable	 autocorrelation	 curves,	 dimensions	 are	 suitable	 for	 systemic	
administration.	A	dilution	factor	(DF)	between	5	and	30	was	applied	in	the	DLS	
analysis.		
TABLE	 8:	 PHYSICAL	 CHARACTERIZATION	 OF	 HSAC	 AND	 HSAT	 NPS	 (DATA	 ARE	 MEAN	
VALUE	±SD,	N	=	3).	
NPs	 Size	(nm)	 PDI	 ζ	-Potential	(mV)	 Yield		(%)	
HSAC	 151.67±1.53	 0.28±0.01	 -15.7±0.20	 89.60±3.60	
HSAT	 143.80±0.56	 0.23±0.02	 -11.80±4.09	 81.40±0.41	
	
The	extension	of	the	polymerization	time	from	3	to	24	h	does	not	affected	PDI	
value,	but	a	significant	 increase	of	size	was	observed	(from	400	to	500	nm,	for	
each	time,	respectively).	
In	the	next	step,	the	concentration	of	the	cross-linking	agent	was	evaluated.	 In	
particular,	 a	 lower	 amount	 of	 cross-linking	 agent	 with	 respect	 to	 that	 used	
routinely	 in	 the	 literature	 was	 tested,	 also	 to	 reduce	 the	 employment	 of	
chemicals.	The	methods	reported	in	the	literature	employ	100	µl	of	solutions	of	
glutaraldehyde	 to	 8%	 or	 4%	 per	 ml	 of	 the	 HSA	 solution	 (concentration	 100	
mg/ml	 or	 5	 mg/ml,	 respectively)	 [1,4,17-19].	 In	 our	 study,	 the	 optimized	
formulation	was	obtained	with 60	µl	of	0.5%	of	glutaraldehyde	solution	per	ml	
of	 the	 HSA	 solution	 (concentration	 20	mg/ml).	 These	 experimental	 conditions	
(corresponding	to	5	µg	of	glutaraldehyde	per	mg	HAS)	produced	sizes	of	about	
150	nm	with	a	PDI=0.28.	NPs	show	mean	diameter	of	250	nm	and	PDI	>	0.3	with	
an	amount	still	lower	of	crosslinking	agent	(1.56	µg/mg	HAS)	and	using	a	single	
cycle	 of	 centrifugation	 for	 10	 minutes	 at	 4500	 rpm.	 The	 increase	 of	
polymerization	time	up	to	24	h	produced	larger	particles	(approximately	330	nm	
and	 PDI=0.1).	 The	 samples	 obtained	 with	 ultrasonication	 bath	 and	 probe	
sonication	resulted	highly	polydispersed	because	it	modifies	the	sample.	Table	9	
reports	 the	 results	 obtained	 with	 cycles	 of	 1	 or	 2	 minutes	 of	 ultrasonication	
probe	 (amplitude	max	 50%).	 The	 samples	 without	 sonication	 or	 at	 most	 only	
one	 cycle	 of	 2	 min	 resulted	 the	 best	 in	 terms	 of	 size,	 but	 they	 were	 not	
homogenous.	Ultrasonication	bath	(8	cycles	of	15	minutes)	reduced	diameter	up	
to	about	190	nm,	with	PD=0.34.
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TABLE	 9:	 SIZE	 AND	 PDI	 OF	 HSAC	 NPS	 BY	 USING	 1	 AND	 2	 MINUTE’S	 CYCLES	 OF	
ULTRASONICATION	PROBE		
(DATA	ARE	MEAN	VALUE	±SD,	N	=	3)	
	
The	 purification	 of	 NPs	was	 optimised	 by	 centrifugation.	 Different	 intervals	 of	
centrifugation	were	tested	(1	cycle	of	10	minutes	at	4500	rpm	or	3	cycles	of	10	
minutes	at	4500	rpm).	One	cycle	resulted	not	sufficient	to	reduce	PDI	of	NPs	to	
a	 value	 less	 than	 0.3.	 Finally,	 type	 and	 concentration	 of	 cryoprotectors	 were	
considered	 in	 order	 to	 obtain	 a	 stable	 and	 easy	 to	 re-suspend	 lyophilised	
sample.	Mannitol	 (2%	w/v)	 and	 sucrose	 (3%	w/v)	 were	 tested.	 Sucrose	 had	 a	
protective	 effect	 preventing	 NPs	 aggregation	 and	 NPs	 were	 easely	 re-
suspended:	 lyophilisation	 process	 didn’t	 affect	 the	 size	 and	 the	 PDI	 of	 the	
sample.	 In	 the	case	of	addition	of	2%	of	mannitol	 the	NPs	mean	diameter	was	
350	nm	and	PDI	was	0.3.	
In	 order	 to	 test	 NPs	 in	 vivo,	 they	 were	 loaded	 with	 NAF	 at	 two	 different	
gravimetric	 ratio,	 namely	 1:1	 and	 2:1	HSA:NAF	 (HSAC	NAF	NPs).	 NAF	 shows	 a	
very	 high	 aqueous	 solubility	 (500	 g/l	 at	 20	 °C)	 and	 it	 does	 not	 possess	 the	
characteristics	to	cross	the	BBB.	The	probe	was	added	to	the	solution	of	HSA	in	
NaCl	before	polymerization,	and	left	2	hours	under	magnetic	stirring	at	500	rpm.	
HSA:NAF	2:1	given	the	greatest	reproducibility,	with	smaller	particles	and	more	
homogeneous,	 as	 reported	 in	 the	 Table	 3.	 These	 particles	 showed	 an	 EE%	 of	
98.50	±	0.05	and	a	LC%	value	of	13.50	±	0.07.	For	DLS	analysis,	a	DF	as	20	has	
been	applied.	The	size	was	optimized	by	2	cycles	of	5	minutes	of	ultrasonication	
probe,	more	cycles	 contribute	 to	 the	 loss	of	 stability	of	 the	 system.	The	mean	
diameter	 of	 fluorescent	 NPs	 increases	 marginally	 in	 comparison	 with	 the	
diameter	 of	 the	 empty	 NPs,	 instead	 there	 are	 not	 changes	 regarding	 the	
homogeneity	 of	 the	 system,	 as	 reported	 in	 Table	 10.	 It	 is	 also	 notable	 that	 ζ-
potential	increases	in	the	absolute	value.	The	values	obtained	were	reproducible	
in	terms	of	size	and	homogeneity	and	suitable	for	systemic	administration.	
Number	of	cycles	of	
2	min	
	
SIZE	(nm)	
	
PDI	
Number	of	cycles	of	
1	min	
	
SIZE	(nm)	
	
PDI	
0	 250±2.34	 0.30±0.02	 0	 250±2.34	 0.30±0.02	
1	 175.50±42.71	 0.34±0.06	 1	 374.70±21.66	 0.43±0.03	
2	 377.87±20.19	 0.41±0.08	 2	 346.13±54.05	 0.53±0.11	
3	 449.70±98.71	 0.34±0.14	 3	 200.60±92.91	 0.66±0.38	
4	 594.30±80.57	 0.30±0.23	 4	 386.63±205.94	 0.39±0.06	
5	 535.77±129.55	 0.47±0.21	 5	 401.23±45.88	 0.34±0.04	
CHAPTER	3	
	
101	
TEM	 analyses	 confirmed	 the	 results	 obtained	 by	 DLS	 analysis:	 NPs	 showed	
spherical	shape,	with	a	regular	and	narrow	size	distribution	(Figure	20).	
	
TABLE	10:	TECHNOLOGICAL	CHARACTERIZATION	OF	HSAC	NAF	NPS	
	(DATA	ARE	MEAN	VALUE	±SD,	N	=	3)	
	
	
	
	
	
	
FIGURE	20:	TEM	MICROGRAPH	OF	HSAC-NAF	NPS	
3.4.2 PREPARATION	OF	HSA	NPS	WITH	THERMAL	CROSS-LINKING	METHOD	
(HSAT)	
In	 this	 work,	 thermal	 cross-linking	 was	 also	 investigated	 in	 order	 to	 find	 a	
suitable	synthetic	approach	with	the	criteria	of	green	chemistry	and	to	minimize	
the	 use	 of	 unsafe	 substances.	 In	 our	 study,	 the	 optimization	 of	 different	
preparation	 parameters	 were	 investigated:	 polymerization	 process	 (time	 and	
temperature),	 purification	 method	 (solvent	 evaporation	 or	 centrifugation	 at	
different	 times),	 process	of	 resuspension	of	 the	pellets	 (type	of	 the	dispersing	
medium	 and	 its	 volume),	 method	 of	 optimization	 of	 size	 and	 homogeneity	
(ultrasonication	bath	or	probe),	choice	of	the	type	of	cryoprotector	(2%	w/v	of	
mannitol	or	2%	w/v	of	anhydrous	glucose).		The	final	optimised	method	resulted	
to	be:	polymerization	performed	for	1h	at	90	°C;	purification	process	of	3	cycles	
of	30	minutes	of	centrifugation	at	4500	rpm;	medium	of	resuspension	was	10	ml	
HSA:NAF	 Size	
(nm)	
PDI	 ζ	-Potential	
(mV)	
Yield	
(%)	
1:1	 268.33±16.15	 0.30±0.01	 -17.40±0.50	 80.40±3.00	
2:1	 247.10±17.11	 0.29±0.01	 -18.20±0.40	 79.00±5.00	
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of	 10	 mM	 NaCl	 solution;	 concentration	 of	 cryoprotectant	 was	 2%	 of	 D-
anhydrous	glucose.	
Table	8	shows	the	complete	characterization	of	developed	and	optimised	HSAT	
NPs:	the	results	in	terms	of	size	and	homogeneity	are	reproducible	and	derived	
from	 the	 acceptable	 autocorrelation	 curves.	 For	 the	 analysis,	 a	 DF	 between	 0	
and	 20	 was	 applied.	 NPs	 have	 acceptable	 narrow	 size	 distribution,	 with	 PDI	
around	 0.2.	 The	mean	 diameter	 of	 HSAT	NPs	 resulted	 suitable	 for	 the	 in	 vivo	
systemic	 administration,	was	 less	 than	 150	 nm,	 and	 the	 process	 yields	 of	NPs	
was	≈80%.		
The	 first	 reaction	 of	 polycondensation	was	 conducted	 at	 75	 °C	 for	 1h.	 In	 this	
case,	size	and	PDI	decrease	to	192.9±1.10	nm	and	PDI	0.23±0.02.	
The	 influence	of	temperature	was	considered.	 In	particular,	the	polymerization	
at	 90°C	 for	 30	minutes	 or	 60	minutes	 was	 tested.	 The	 NPs	 obtained	 with	 60	
minutes	of	polymerization	are	the	smallest	and	homogeneous	(size	143.8±0.60	
nm;	 PDI	 0.23±0.02)	 with	 respect	 to	 30	min	 process	 (size	 187.2±3.90	 nm;	 PDI	
0.32±0.01).	Also	in	this	preparative	process	the	size	reduction	with	sonication	or	
ultrasonication	is	not	necessary	because	small	and	monodispersed	particles	are	
obtained	and	the	process	results	to	be	reproducible	(data	are	mean	value	±SD,	n	
=	3).		
The	 evaporation	 of	 the	 ethanol	 under	 vacuum	 at	 30	 °C	was	 also	 studied	 as	 a	
simple	and	easy	 to	perform	purification	method.	This	method	 involves	 serious	
problems	in	terms	of	stability,	compromising	the	yield	of	NPs	and	producing	risk	
of	 contamination.	 DLS	 analysis	 confirmed	 this	 hypothesis,	 by	 obtaining	 mean	
diameter	around	350	nm	with	PDI=0.45.	As	centrifugation	conditions,	3	cycles	of	
15	minutes	at	4500	rpm	and	3	cycles	of	30	minutes	at	4500	rpm	were	 tested.	
The	last	method	resulted	the	most	efficient.	
The	 process	 of	 resuspension	 of	 the	 pellets	 was	 considered	 and	 optimized	 in	
terms	 of	 type	 and	 volume	 of	 dispersing	 medium.	 The	 highest	 ability	 of	
dispersion	 of	 pellets	 requires	 10	 mM	 NaCl	 in	 equal	 volume	 as	 that	 used	 as	
desolating	agent.	
NPs	were	lyophilized	overnight	using	as	a	cryoprotectant	agent.	D-mannitol	(2%	
v/v)	 was	 tested	 and	 the	 considerable	 increasing	 of	 size	 was	 observed	 (mean	
diameter	 around	 300	 nm	 with	 PDI	 0.48).	 D-anhydrous	 glucose	 prevents	 the	
aggregation	 of	 NPs	 compared	 to	 other	 cryoprotectant	 agents,	 with	 a	 higher	
protective	effect.	
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The	 thermal	method	 resulted	 to	 be	 superior	 in	 term	of	 reduction	 of	 chemical	
substances	used	and	time	necessary	for	the	NPs	preparation:	the	polymerization	
time	was	1	hour,	compared	to	an	hour	and	a	half	of	chemical	method.	
After,	 fluorescent	 HSAT	 NPs	 were	 prepared	 by	 investigating	 two	 different	
gravimetric	 ratios	 HSA:NAF	 (1:1	 and	 1:2).	 The	 ratio	 HSA:NAF	 1:1	 gave	 smaller	
particles	and	more	homogeneous,	as	shown	in	Table	11.These	particles	had	an	
EE%	of	99.40	±	0.04	and	a	LC%	value	of	24.50	±	0.26.	A	DF	between	10	and	20	
has	been	applied	for	DLS	analysis.	The	size	was	reduced	by	3	cycles	of	5	minutes	
of	 ultrasonication	 probe;	more	 cycles	 contribute	 to	 the	 loss	 of	 stability	 of	 the	
system.	
TABLE	 11:	 TECHNOLOGICAL	 CHARACTERIZATION	 OF	 HSAT	NAF	NPS	 (DATA	 ARE	MEAN	
VALUE	±SD,	N	=	3)	
	
	
	
	
The	size	of	fluorescent	NPs	increases	marginally	in	comparison	with	empty	NPs,	
but	 no	 changes	 in	 homogeneity	 of	 the	 system	 are	 reported,	 proving	 that	 the	
probe	 does	 not	 alter	 the	 optimized	 formulation.	 It	 is	 also	 notable	 that	 ζ-
potential	increased,	indicating	greater	system	stability.		
TEM	 investigation	 provided	 details	 on	 the	morphology:	 NPs	 had	 a	 sphere-like	
shape	with	a	 regular	and	narrow	size	distribution,	which	was	comparable	with	
the	dimensional	distribution	results	obtained	from	DLS	analysis	(Figure	21).	
	
	
FIGURE	21:	TEM	MICROGRAPH	OF	HSAT	NPS	
HSA:NAF	 Size	
(nm)	
PDI	 ζ-Potential	
(mV)	
Yield	
(%)	
1:1	 145.60	±	13.7	 0.18	±	0.04	 -	11.7	±	2.66	 72.4	±	0.34	
2:1	 286.3	±	20.8	 0.55	±	0.10	 -	10.7	±	1.70	 70.4	±	0.54	
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The	results	in	terms	of	size	and	homogeneity	are	similar	to	those	obtained	with	
chemical	 polymerization,	 but	 HSAT	 NPS	 resulted	 to	 be	 greater	 in	 term	 of	
formulative	 parameters,	 such	 as	 saving	 reagents,	 reduction	 of	 costs	 and	 the	
time	necessary	for	the	NPs	preparation.	NPs	were	both	produced	with	very	good	
yields	(89.6%	for	HSAC	and	81.4%	for	HSAT).	The	mean	diameter	of	fluorescent	
NPs	was	247	nm	 (PDI=0.3)	 for	HSAC	NPs	 and	145	nm	 for	HSAT	NPs	 (PDI=0.2).	
NPs	showed	a	good	EE	(≈	98%)	and	LC	too	(≈	13	%	for	HSAC	NPs	and	≈	24%	for	
HSAT	NPs).	From	the	stability	study	on	fluorescent	NPs,	probe	was	stably	linked	
to	 both	 NPs	 for	 3	 hours.	 Both	 NPs	 are	 suitable	 for	 the	 in	 vivo	 systemic	
administration.	
3.4.3 	IN	VIVO	EXPERIMENTS	
3.4.3.1 Fluorescein-labelled	HSAC	NPs	injection	into	the	rat	NBM		
1µl	(10µg/µl)	of	HSAC	NAF	NPs	was	directly	injected	into	the	NBM	of	adult	rats	
to	follow	the	cellular	distribution	of	NPs	within	the	brain,	the	occurrence	of	local	
toxicity	as	well	as	NPs-induced	inflammatory	response	in	terms	of	glia	reaction.	
Histochemical	analysis	revealed,	at	the	injection	site	(asterisk),	a	large	amount	of	
fluorescent	 HSAC	 NPs	 (green)	 one	 and	 seven	 days	 after	 injection	 (Figure	 22).		
The	day	after	 surgery	some	NPs	were	detected	close/within	 the	cellular	nuclei	
(DAPI,	 blue)	 in	 the	 injection	 site	 surroundings	 (Figure	 22,	 arrows,	 and	 inset).		
Seven	 days	 after	 injection	 some	 NPs	 co-localized	 (yellow)	 with	 Iba-1	 positive	
microglial	cells	(red)	(Figure	3),	while	no	HSAC	NAF	NPs	were	either	found	within	
ChAT-positive	neurons	(red)	(Figure	3)	or	inside	GFAP-positive	astrocytes	(blue)	
(Figure	 3)	 in	 the	 ipsilateral	 injected	 hemisphere.	 	 Of	 relevance,	 fourteen	 days	
after	 injection,	HSAC	fluorescent	staining	was	strongly	reduced	at	the	 injection	
site	 (Figure	 22,	 asterisk);	 NPs	 uptake	mediated	 by	microglial	 cells	 could	 likely	
result	in	their	removal/phagocytosis	from	brain	tissue.	
No	NPs	were	almost	detected	in	the	contralateral	un-injected	hemisphere	(data	
not	shown).	Immunohistochemical	analysis	did	not	reveal	any	astrocytosis	either	
at	the	site	of	 injection	or	 in	 its	vicinity,	as	shown	by	the	resting	morphology	of	
GFAP-immunopositive	cells	(Figure	22,	blue)	in	PBS	and	NPs	injected	groups,	as	
exemplified	for	7	days	after	the	injection.	By	contrast,	1	and	7	days	after	surgery	
microglial	cells	 (red)	 increased	 in	number	with	time	at	the	 injection	site	and	 in	
its	 proximity	 as	 compared	 to	 PBS-injected	 controls	 Figure	 23).	 Overall,	 these	
data	indicate	that	in	situ	administration	of	NPs	was	well	tolerated,	didn’t	induce	
astrogliosis	 and	 favoured	 microglial	 cells	 migration	 to	 the	 injection	 site	 for	
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phagocytosis	 of	 NPs,	 ensuring	 their	 elimination	 from	 brain	 tissue	 and	 their	
biocompatibility.	
	
	
FIGURE	 22:	 INTRACEREBRAL	 INJECTION	OF	HSAC	NPS	 INTO	 THE	 RAT	 NUCLEUS	 BASALIS	
MAGNOCELULARIS	
REPRESENTATIVE	PHOTOMICROGRAPHS	SHOWING	NPS	(GREEN)	AT	THE	INJECTION	SITE	
(ASTERISK)	ONE,	SEVEN	AND	FOURTEEN	DAYS	AFTER	SURGERY.	NPS	WERE	DETECTED	
CLOSE/WITHIN	THE	CELLULAR	NUCLEI	(DAPI,	BLUE)	IN	THE	INJECTION	SITE	
SURROUNDINGS	(ARROWS,	AND	INSET)	ONE	DAY	AFTER	SURGERY.	NO	HSAC	NPS	
LABELLING	WAS	DETECTED	IN	THE	UN-INJECTED	HEMISPHERE.		SCALE	BARS:	100	µM	
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FIGURE	23: INTRACEREBRAL	INJECTION	OF	HSAC	NPS		
REPRESENTATIVE	PHOTOMICROGRAPHS	BETWEEN	HSAC	NPS	(GREEN)	LABELLING	AND	
GFAP	(BLUE),	IBA-1	(RED)	AND	CHAT	(RED)	ABS	PLUS	DAPI	(BLUE)	IN	INJECTED	RATS	
SEVEN	DAYS	AFTER	SURGERY.		IN	THE	NBM	INJECTED	WITH	HSAC	NPS	(GREEN)	
CLUSTERS	OF	IBA-1	POSITIVE	CELLS	(RED)	WERE	DETECTED,	LIKELY	INDICATING	A	
PHAGOCYTOSIS	BY	MICROGLIAL	CELLS	OF	NPS	AND	NO	HSAC	NPS	WERE	DETECTED	
WITHIN	GFAP	POSITIVE	ASTROCYTES	AND	CHAT	POSITIVE	NEURONSGFAP	AND	IBA	1	
IMMUNOPOSITIVE	CELLS	WITH	RESTING	MORPHOLOGY	WERE	DETECTED	IN	THE	NBM	OF	
RATS	INJECTED	WITH	PBS	
3.4.3.2 Systemic	administration	of	fluorescent	HSAC	and	HSAT	NPs	in	
rats	
The	ability	of	fluorescent	HSAC	and	HSAT	NPs	to	cross	the	BBB	was	evaluated	in	
rats	administered	acutely	with	500	µl	of	HSA	NPs	(20	mg/ml)	 loaded	with	NAF.	
Four	 hours	 after	 iv	 or	 ip	 administration	 of	 fluorescent	 HSAC	 NPs	 and	 iv	
administration	 of	 fluorescent	 HSAT	 NPs	 (Figure	 24),	 both	 HSA	 formulations	
(green,	 arrows)	 administered	 ip	 or	 iv,	were	 detected	 in	 the	 brain	 parenchyma	
outside	 the	 vascular	 bed	 (CD34,	 red)	 indicating	 the	 ability	 of	 these	 novel	
nanoformulations	 to	cross	 the	BBB	after	systemic	administration.	 Interestingly,	
as	 reported	 in	 Figure	 24	 the	 two	 different	 formulations	 had	 a	 very	 similar	
behaviour	in	crossing	BBB.	
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FIGURE	24:	BBB	CROSSING	OF	HSAT	AND	HSAC	NPS	IN	RATS 
THE	LACK	OF	COLOCALIZATION	BETWEEN	HSAC	AND	HSAT	NPS	(GREEN,	ARROWS)	AND	
CD34	(RED),	THE	BRAIN	VASCULAR	ENDOTHELIUM	MARKER,	INDICATES	THE	ABILITY	OF	
THE	TWO	NANOFORMULATIONS	TO	CROSS	THE	BBB	AFTER	AN	ACUTE	SYSTEMIC	
ADMINISTRATION	
3.4.3.3 	Systemic	administration	of	fluorescent	HSAC	NPs	in	mice		
To	exclude	potential	NPs	toxicity	and	behavioural	alterations,	fluorescent	HSAC	
NPs	 (100	mg/kg,	 ip)	 were	 daily	 administered	 to	 C57/Bl6	mice	 for	 two	 weeks.	
During	 this	 period,	 the	 nanoformulation	 was	 well	 tolerated,	 no	 evident	 side	
effects	were	 revealed,	 as	 also	 shown	by	 the	 body	weight	 trend	 graph	 of	NPs-
treated	mice	as	 compared	 to	 controls	 (Figure	25)	 and	no	animals	died.	At	 the	
end	 of	 the	 treatment,	 mice	 were	 behaviourally	 evaluated	 in	 the	 ORT	 test,	 to	
check	for	their	locomotor-exploratory	abilities	and	cognitive	functions.	As	shown	
in	 Figure	 25,	 no	 locomotors	 (path	 length)	 or	 cognitive	 impairments	
(discrimination	 score)	 were	 detected	 in	 NPs-treated	 mice	 as	 compared	 to	
controls	 (P>0.05).	 Overall,	 these	 data	 provide	 strong	 evidence	 on	 the	
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biocompatibility	 and	 potential	 delivery	 of	 molecules	 to	 the	 CNS	 of	 this	
nanoformulation.	
	
	
FIGURE	 25:	 BODY	 WEIGHT	 AND	 BEHAVIOURAL	 EVALUATIONS	 ON	 MICE	 CHRONICALLY	
ADMINISTERED	WITH	HSAC	NPS	FOR	TWO	WEEKS 
HSAC	NPS	DID	NOT	AFFECT	PONDERAL	 (A)	AND	ORT	 (B)	COGNITIVE	AND	LOCOMOTOR	
PARAMETERS	
3.4.4 CONCLUSION	
Albumin	NPs	are	widely	used	as	carrier	for	drug	delivery	to	a	variety	of	organs,	
but	 only	 a	 very	 few	 studies	 have	 been	 reported	 as	 vectors	 to	 brain	 delivery	
subsequent	to	different	modifications	of	the	NPs	surfaces.	In	this	study,	HSA	NPs	
using	 two	 cross-linking	methods	were	 developed	 and	 optimised	 to	 investigate	
their	in	vivo	behaviour	in	brain	tissues	targeting,	crossing	BBB,	brain	distribution	
and	fate.	A	first	set	of	studies	evaluated	in	vivo	distribution,	cellular	uptake	and	
fate	HAS	NPs	in	healthy	rats,	after	intracerebral	injection.	The	ability	of	HAS	NPs	
to	 cross	 the	 BBB	 was	 investigated	 both	 by	 intravenous	 and	 intraperitoneal	
administration	 in	 healthy	 rats,	 while	 the	 potential	 toxicity	 of	 the	 developed	
carriers	was	estimated	by	behavioural	tests.	HSA	NPs	were	produced	with	very	
good	yields,	with	a	 sphere-like	shape	and	 regular	and	narrow	size	distribution.	
Both	 fluorescent	 HSAC	 NPs	 and	 HSAT	 NPs	 resulted	 suitable	 for	 the	 in	 vivo	
systemic	administration.	In	the	chemical	polymerisation	NPs	were	optimized	by	
using	 a	 very	 low	 amount	 of	 cross-linking	 agent	 compared	 to	 the	 methods	
reported	 in	 the	 literature	 (0.5%	vs	4%).	Moreover,	 the	 thermal	polymerization	
method	 of	 HSA	 was	 also	 investigated	 and	 optimized,	 according	 to	 green	
chemistry	 criteria.	 These	 NPs	 result	 to	 be	 superior	 than	 those	 obtained	 via	
chemical	 method	 in	 term	 of	 formulative	 parameters,	 such	 as	 reduction	 of	
chemical	 substances	 used,	 reduction	 of	 costs	 and	 the	 time	 necessary	 for	 NPs	
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preparation.	The	 in	vivo	performance	of	both	HSA	nanoparticles	is	comparable:	
as	 assumed	 in	 the	 choice	 and	 design	 of	 formulation	 strategy,	 the	 fluorescent	
NPs	are	able	to	cross	the	BBB	by	adsorptive	transcytosis.		
Biodistribution	studies	showed	that	NPs	did	not	 induce	 inflammatory	response	
after	intracerebral	injection	and	they	were	able	to	cross	the	BBB	and	reach	brain	
tissue,	 while	 behavioural	 test	 demonstrated	 no	 locomotor,	 explorative	 and	
cognitive	 functions	 impairment	 induced	by	NPs.	All	 in	 vivo	 tests	 confirmed	 the	
excellent	 biocompatibility	 and	 biodegradability	 of	 NPs.	 The	 developed	
nanocarriers	represent	valuable	and	safe	vectors	for	brain	delivery.		
Since	the	developed	HSA	NPs	are	able	to	cross	the	BBB	and	are	larger	than	200	
nm,	this	opens	up	new	possibilities	for	all	types	of	drugs	even	up	to	the	size	of	
nucleotides	and	genes	and	 including	enzymes	 for	 replacement	 therapy.	At	 the	
moment,	 it	 appears	 that	 any	 drug	 or	 larger	 biologically	 active	 compound	 or	
complex	can	be	transported	across	the	BBB	if	it	can	be	efficiently	bound	to	the	
BBB-transcytosable	 NPs	 and	 is	 released	 within	 the	 brain	 in	 a	 therapeutically	
relevant	concentration	and	time	profile.	Further	studies	will	be	oriented	to	the	
investigation	of	 the	BBB	 crossing	properties	of	 the	developed	HSA	NPs	 loaded	
with	different	drugs.			
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4.1 ABSTRACT		
AG	is	a	major	diterpenoid	of	Andrographis	paniculata	(Burm.	f.)	Nees	which	has	
been	 clinically	 demonstrated	 in	 the	 treatment	 of	 inflammation-related	
neurodegenerative	 disorders.	 Nevertheless,	 low	 bioavailability	 and	 poor	water	
solubility	 limit	 further	 developments	 of	 this	 compound.	 In	 order	 to	 overcome	
these	limitations,	we	loaded	AG	into	HSA	NPs	and	into	PECA	NPs.	HSA	NPs	were	
prepared	 by	 coacervation	 and	 both	 thermal	 cross-linking	 (HSAT	 AG	 NPs)	 and	
chemical	 cross-linking	 (HSAC	 AG	 NPs)	 were	 investigated.	 PECA	 AG	 NPs	 were	
produced	by	emulsion-polymerization.	Both	NPs	appeared	as	spherically	shaped	
under	 transmission	 electron	microscopy.	 After	 the	 study	 of	 release	 of	 AG	 and	
the	results	in	terms	of	size,	ζ-potential	and	polydispersity,	the	ability	of	free	AG	
and	AG-loaded	in	PECA	and	HSAT	NPs	to	cross	the	blood-brain	barrier	(BBB)	was	
assessed	 with	 an	 in	 vitro	 BBB	model	 based	 on	 human	 hCMEC/D3	 endothelial	
cells.	For	BBB	drug	permeability	assays,	a	quantitative	UPLC-MS/MS	method	for	
AG	 in	Ringer	HEPES	buffer	was	successfully	developed	and	validated	according	
to	 international	 regulatory	 guidelines	 for	 industry.	 Our	 results	 show	 that	 free	
form	of	AG	free	does	not	permeate	the	BBB,	HSA	NPs	improve	the	permeation	
of	AG	maintaining	the	integrity	of	cell	layer	while	PECA	NPs	permanently	disrupt	
the	BBB	integrity.	
4.2 INTRODUCTION		
The	BBB	is	composed	of	cerebral	endothelial	cells	with	tight	junctions	formed	by	
a	 complex	 of	 intramembranous	 proteins,	 such	 as	 claudin	 and	 peripheral	
membrane	 proteins	 like	 zonula	 occludens	 proteins.	 It	 restricts	 paracellular	
passage	 of	 small	molecules	 and	 aids	 in	 the	 transport	 of	 several	 nutrients	 and	
proteins	 into	 the	 brain.	 On	 the	 other	 hand,	 the	 BBB	 limits	 the	 delivery	 of	
neurotherapeutics	to	the	CNS.	Crossing	the	BBB	is	a	major	challenge	for	drugs,	
as	more	 than	98%	of	 small-molecules,	 and	almost	100%	of	 large	drugs	do	not	
cross	the	BBB[1].	Many	factors	influence	the	permeability	of	molecules,	such	as	
molecular	weight,	the	number	of	hydrogen	bonds,	pharmacokinetic	properties,	
and	the	presence	of	active	efflux	transporters[2].	The	BBB	prevents	the	delivery	
of	 neurotherapeutics	 to	 the	CNS	not	 only	 as	mechanical	 fence,	 but	 also	 like	 a	
dynamic	 biological	 barrier	 in	 which	 active	 metabolism	 and	 carrier	 mediated	
transport	 occur[3].	 The	 development	 of	 nanodrug	 delivery	 systems	 for	 the	
controlling	 of	 neurological	 diseases	 seems	 promising	 and	 is	 still	 awaited	 to	
provide	 sufficient	drug	permeability	 into	 the	brain.	 The	possibility	 for	drugs	 to	
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reach	 the	brain,	when	 loaded	 into	nanovectors,	 is	based	on	 the	 fact	 that	 their	
crossing	will	depend	completely	on	the	physiochemical	and	biomimetic	features	
of	 the	 carrier	 and	will	 not	 depend	 anymore	 on	 the	 chemical	 structure	 of	 the	
drug,	which	is	hindered	inside	the	NPs[3].		
In	our	study,	two	different	mechanisms	to	cross	the	BBB	were	investigated	with	
the	 employment	 of	 PECA	 and	 HSA	 NPs.	 In	 the	 first	 case,	 NPs	 were	 done	 by	
emulsion	 polymerization	 method,	 and	 coated	 with	 the	 non-ionic	 surfactant	
TW80.	Several	mechanisms	have	been	proposed	for	the	transport	of	these	NPs	
across	 the	 BBB:	the	 receptor-mediated	 transcytosis	 was	 supported	 by	 many	
studies[4–8].	 TW80	 acts	 as	 an	 anchor	 for	 the	 apolipoprotein-overcoated	 NPs	
thus	would	mimic	 lipoprotein	 particles	 and	 could	 interact	with	 their	 receptors	
and	then	be	taken	up	by	the	brain	capillary	endothelial	cells	[9].		
HSA	was	selected	as	ideal	material	to	fabricate	NPs	for	drug	delivery	because	it	
is	 non-toxic,	 non-immunogenic,	 biocompatible	 and	 biodegradable;	 therefore,	
have	 high	 binding	 capacity	 of	 various	 drugs	 and	 is	 well	 tolerated	without	 any	
serious	 side-effects[10].	 In	 this	 case,	 the	 rationale	 for	 the	 design	 of	 NPs	 was	
based	 on	 the	 observation	 that	 cationic	 proteins	 can	 bind	 the	 endothelial	 cell	
surface	and	 cross	 the	BBB	 through	adsorptive-mediated	 transcytosis	 (ATM)[3],	
this	 mechanism	 involves	 electrostatic	 interaction.	 HSA	 NPs	 were	 prepared	 by	
coacervation	and	both	chemical	and	thermal	cross-linkings	were	investigated.	
Developed	nanovectors	were	loaded	with	AG,	a	diterpene	of	the	labdane	family,	
responsible	of	most	of	the	biological	effects	of	Andrographis	paniculata	 (Burm.	
f.)	Nees	(Acanthaceae).	AG	is	used	in	clinics	in	China,	and	has	been	reported	to	
exhibit	a	wide	spectrum	of	biological	activities[11].	Recent	reports	suggest	that	
AG	 protects	 against	 damage	 induced	 by	 dopamine,	 with	 protective	 effects	
against	 inflammation-mediated	 neurodegeneration,	 against	 oxidative	 stress	 by	
nicotine	 in	 the	 brain,	 and	 against	 cerebral	 ischemia	 via	 inhibition	 of	 pathways	
related	to	inflammation	and	apoptosis,	including	NF-kB	and	MAPK	signaling	[12–
14].	 Recently,	 Serrano	 and	 coworkers[15]	 showed	 that	 AG	 protected	 against	
damage	 induced	 by	 amyloid-β	 oligomers	 in	 vitro,	 reduced	 α-β	 levels	 and	 tau	
phosphorylation	 in	 mice,	 modulated	 the	 formation	 of	 amyloid	 plaques,	 and	
recovered	spatial	memory	functions.		
By	 contrast,	 its	 poor	 water	 solubility	 and	 instability	 resulted	 in	 lower	
bioavailability	 and	 seriously	 limited	 its	 pharmacological	 function.	 AG	 is	 slightly	
soluble	 in	 water	 and	 chloroform	 with	 a	 solubility	 rancing	 from	 0.07	 to	
0.21mg/mL,	 respectively,	while	 the	 solubility	was	 relatively	higher	 in	methanol	
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(14.5	 mg/mL).	 It	 is	 stable	 under	 neutral	 and	 acidic	 conditions,	 but	 unstable	
under	 alkaline	 conditions.	 Furthermore,	 it	 is	 rapidly	 metabolized	 in	 the	
duodenum	and	jejunum	to	form	a	sulfate	conjugate	that	is	hydrophilic	and	likely	
to	be	impermeable.	The	formulation	of	nanodelivery	systems	could	improve	the	
pharmacokinetic	 characteristics	 of	 problematic	 drugs.	 Many	 researchers	 have	
designed	different	new	dosage	forms	for	AG	such	as	dropping	pills,	dispersible	
tablets,	 oral	 micro	 emulsion,	 cyclodextrin	 inclusion	 complex,	 liposomes	 and	
certain	 effects	 were	 obtained	 for	 improving	 the	 bioavailability	 but	 the	 clinical	
application	was	still	restricted	for	the	lower	drug-loading	rate,	entrapment	rate,	
and	 the	 poor	 stability	 of	 pharmaceutical	 dosage	 forms[11,16,17].	 Up	 to	 now,	
there	 is	 no	 evidence	 in	 literature	 that	 the	 BBB	 permeability	 of	 AG	 itself	 is	
sufficient	to	possibly	achieve	therapeutically	relevant	concentrations	in	the	CNS.	
We	evaluated	whether	loaded	NPs	could	be	used	to	potentially	deliver	AG	to	the	
human	 brain	 endothelium	 using	 hCMEC/D3	 cell	 line	 [18,19],	 a	 well-known	
established	human	 in	vitro	based	BBB	model,	which	expresses	LRP1,	and	 if	 the	
compound	in	the	free	form	is	BBB	permeable.	
For	 the	 permeability	 assays,	 we	 developed	 a	 quantitative	 ultra-performance	
liquid	 chromatography	 tandem	 mass	 spectrometry	 (UPLC-MS/MS)	 method	 in	
Ringer	 HEPES	 buffer	 (RHB)	 for	 AG	 and	 validated	 it	 in	 terms	 of	 selectivity,	
specificity,	precision,	accuracy,	and	reliability	according	to	the	US	FDA	and	EMA	
regulatory	guidelines	for	industry[20,21].	Our	results	demonstrated	that	free	AG	
did	 not	 cross	 the	 BBB	 at	 the	 concentration	 of	 5	 µM,	 HSA	 NPs	 improve	 the	
permeability	of	AG	maintaining	the	integrity	of	cell	layer,	while	PECA	NPs	coated	
with	1%	TW80	permanently	altered	cell	layer	integrity.	
4.3 EXPERIMENTAL	SECTION	
4.3.1 MATERIALS	
NAF,	 TW80,	 ECA,	HSA,	 bovine	 serum	albumin	 (BSA),	 glutaraldehyde	 25%,	 PBS,	
NaCl,	sodium	hydroxide,	hydrochloric	acid	37%,	sulfuric	acid	97%,	D-(+)-glucose	
anhydrous,	 sucrose	 and	 dextran	 70000	 were	 purchased	 from	 Sigma-Aldrich	
(Steinheim,	 Germany).	 Acetonitrile,	 methanol,	 formic	 acid	 (FA),	 trifluoroacetic	
acid	 (TFA),	 and	 ammonium	 formate	were	 all	 HPLC	 grade	 and	were	 purchased	
from	BioSolve	(Valkenswaard,	the	Netherlands).	Dimethyl	sulfoxide	(DMSO)	was	
purchased	 from	 Scharlau	 (Scharlab	 AG,	 Sentmenat,	 Spain).	 Analytical	 grade	
ethanol	 (EtOH)	 was	 from	 Riedel-de	 Haen	 (Seelze,	 Germany).	 Phosphotungstic	
acid	was	 obtained	 by	 Società	 Italiana	 Chimici	 (Rome,	 Italy).	 HPLC	 grade	water	
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was	obtained	by	a	Milli-Q	 integral	water	purification	system	(Millipore	Milford,	
USA).	 RHB	 (150	mM	NaCl,	 2.2	mM	 CaCl2,	 0.2	mM	MgCl2,	 5.2	mM	 KCl,	 2.8	mM	
glucose,	 5	mM	HEPES,	 6	mM	NaHCO3)	was	 prepared	 in-house,	 adjusted	 to	 pH	
7.4,	 filtered,	 and	 stored	 at	 4°C.	 24-Well	 plates	 and	 inserts	 (transparent	 PET	
membrane,	3.0	µm	pore	size,	0.6	×	106	pores/cm2)	were	obtained	from	Greiner	
Bio-one®	 (Frickenhausen,	 Germany).	 Immortalized	 hCMEC/D3	 cells	 were	
obtained	 from	 Prof.	 Pierre-Olivier	 Couraud	 (Institut	 Cochin,	 Université	 René	
Descartes,	Paris,	France),	Prof.	Babette	Weksler	 (Weill	Cornell	Medical	College,	
New	York,	NY,	USA)	and	Prof.	Ignacio	A	Romero	(Department	of	Life,	Health	and	
Chemical	Sciences,	Open	University,	Milton	Keynes,	U.K).	
4.3.2 DESIGN	AND	OPTIMIZATION	OF	NANOVECTORS	LOADED	WITH	AG	
4.3.2.1 Production	and	coating	of	PECA	AG	NPs		
PECA	 NPs	 were	 prepared	 by	 emulsion	 polymerization,	 as	 described	 by	
Kreuter[22],	with	some	modifications	 to	 the	original	method.	Briefly,	100	µl	of	
the	monomer	ECA	were	added	drop	by	drop	under	magnetic	stirring	(500	rpm)	
to	 10	 ml	 of	 acidic	 polymerization	 medium	 (60:40	 methanol:water	 pH	 2)	
containing	1%	of	dextran	70,000	and	0.1%	w/v	or	0.5%	w/v	of	AG.	The	monomer	
ECA	is	a	clear	liquid,	which	undergoes	polymerization	in	contact	with	water.	The	
mixture	 was	 stirred	 magnetically	 for	 4	 h	 to	 facilitate	 NPs	 formation.	 The	
resulting	 suspension	 was	 neutralized	 with	 NaCl	 0.1	 N	 and	 filtered	 through	 a	
sintered	glass	filter	(pore	size	10	µm)	to	remove	any	agglomerates.	 In	order	to	
eliminate	methanol,	the	suspension	was	centrifuged	for	10	minutes,	3	times	at	
4500	rpm	at	4	°C.	The	pellet	with	NPs	was	resuspended	with	the	same	volume	of	
RHB.	 Anhydrous	 glucose	 (0.1%	 w/v)	 was	 added	 as	 cryoprotector	 to	 improve	
redispersibility	 of	 the	 NPs	 after	 lyophilization.	 The	 NPs	 suspension	 was	
lyophilized	overnight	and	resuspended	in	RHB	at	a	concentration	of	5	mg/ml	by	
vortex.	The	non-ionic	surfactant	TW	80	was	added	to	a	final	concentration	of	1%	
v/v	and	the	mixture	was	incubated	for	30	min	at	500	rpm	and	finally	lyophilized.	
4.3.2.2 HSAC-AG	NPs	preparation	
HSA	 NPs	 were	 prepared	 modifying	 a	 previously	 proposed	 desolvation	
technique[23–25].	In	principle,	HSA	(2%	w/v)	was	dissolved	in	a	solution	of	NaCl	
10	 mM	 under	 magnetic	 stirring	 (500	 rpm,	 15	 minutes).	 The	 resulting	 HSA	
solution	 was	 transformed	 into	 NPs	 by	 the	 continuous	 addition	 of	 EtOH	 at	 a	
defined	rate	of	1	ml/min	(ratio	NaCl-	EtOH	1:2	v/v)	under	stirring	(500	rpm)	at	
room	 temperature.	 After	 the	 desolvation	 process	 glutaraldehyde	 (5	 μg/mg	
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protein)	was	added	to	 induce	particle	crosslinking.	The	process	was	performed	
under	 magnetic	 stirring	 for	 2	 hours	 at	 room	 temperature.	 The	 resulting	 NPs	
were	 centrifugated	 (4500	 rpm,	 10	 min	 x	 3	 times,	 4°C)	 to	 separate	 the	
supernatant,	containing	free	HSA	and	glutaraldehyde,	from	the	pellet	containing	
HSA	 NPs.	 The	 pellet	 was	 dispersed	 in	 the	 original	 volume	 of	 10	 mM	 NaCl	
solution	 containing	 3%	 w/v	 sucrose	 as	 cryoprotective	 agent	 and	 freeze-dried	
overnight.	HSAC	NPs	loaded	with	AG	were	obtained	using	the	same	method	and	
solubilized	AG	in	the	EtOH	(ratio	1:1	w/w	with	HSA)	with	one	hour	of	incubation.		
4.3.2.3 HSAT-AG	NPs	preparation		
HSA	 NPs	 were	 prepared	 modifying	 and	 optimizing	 thermal	 cross-linking	
method[26,27].	HSA	(0.5%	w/v)	was	dissolved	in	a	solution	of	NaCl	10	mM	under	
magnetic	stirring	(500	rpm,	15	min).	The	resulting	HSA	solution	was	transformed	
into	NPs	by	the	continuous	addition	of	the	desolvating	agent	EtOH	at	a	defined	
rate	of	1	ml/min	(ratio	NaCl-EtOH	1:1	v/v)	under	magnetic	stirring	(500	rpm)	at	
room	 temperature.	 Stirring	 was	 continued	 at	 90°C	 for	 1	 hour	 to	 obtain	 NPs	
thermal	 cross-linked.	 The	 suspension	 was	 centrifuged	 (4500	 rpm,	 30	 min	 x	 3	
times,	4°C)	and	the	pellet	contained	NPs	was	dispersed	in	the	original	volume	of	
NaCl	solution	10	mM	with	2%	w/v	anhydrous	D-glucose	as	cryoprotector,	 then	
was	freeze-dried	overnight.	NPs	loaded	with	AG	were	prepared	using	the	same	
method,	incubating	AG	(ratio	1:1	w/w	with	HSA)	in	EtOH	for	one	hour.	
4.3.2.4 NPs	yield	
The	 yield	 of	 the	 processes	 of	 preparation	 were	 determined	 as	 the	 weight	
percentage	 of	 the	 final	 product	 after	 drying,	 with	 respect	 to	 the	 initial	 total	
amount	materials	used	for	the	preparation[28].	
4.3.2.5 Characterization	of	NPs	 in	 terms	of	size,	polydispersity	 index	
and	ζ	potential	
Particle	size	of	the	developed	NPs	were	measured	by	a	DLS,	Ζsizer	Nano	series	
ZS90	(Malvern	Instruments,	Malvern,	UK)	equipped	with	a	JDS	Uniphase	22	mW	
He-Ne	 laser	 operating	 at	 632.8	mm,	 an	 optical	 fiber-based	 detector,	 a	 digital	
LV/LSE-5003	correlator	and	a	temperature	controller	(Julabo	water-bath)	set	at	
25°C.	Time	correlation	functions	were	analysed	to	obtain	the	Zh	and	the	particle	
size	 distribution	 using	 the	 ALV-60X0	 software	 V.3.X	 provided	 by	 Malvern.	
Autocorrelation	 functions	 were	 analysed	 by	 the	 Cumulants	 method,	 fitting	 a	
single	exponential	to	the	correlation	function	to	obtain	particle	size	distribution.	
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Scattering	 was	 measured	 in	 an	 optical	 quality	 4	 ml	 borosilicate	 cell	 at	 a	 90°	
angle,	diluting	the	samples	in	10nM	NaCl	solution	or	RHB	for	HSA	NPS	and	PBS	
or	RHB	 for	PECA	NPs.	 ζ	 potentials	were	measured	using	 the	 same	 instrument;	
for	all	samples,	an	average	of	three	measurements	at	stationary	level	was	taken.	
The	temperature	was	kept	constant	at	25°C	by	a	Haake	temperature	controller.	
ζ	 potential	 was	 calculated	 from	 the	 electrophoretic	 mobility,	 using	 the	 Henry	
correction	to	Smoluchowski’s	equation.	
4.3.2.6 Morphological	characterization		
NPs	 were	 analyzed	 in	 terms	 of	 morphology,	 polydispersity,	 shape	 and	
dimensions	by	TEM.	The	dispersions	diluted	10-times	were	applied	to	a	carbon	
film-covered	copper	grid.	Most	of	the	dispersion	was	blotted	from	the	grid	with	
filter	paper	to	form	a	thin	film,	which	was	stained	with	a	phosphotungstic	acid	
solution	 1%	w/v	 in	 sterile	water.	 The	 samples	were	 dried	 for	 3	min	 and	 then	
were	examined	under	a	JEOL	1010	electron	microscope	and	photographed	at	an	
accelerating	voltage	of	64	kV.	
4.3.2.7 Purification	 of	 NPs,	 Encapsulation	 Efficiency	 and	 Loading	
Capacity	
The	amount	of	AG	entrapped	into	nanocarriers	was	calculated	using	the	indirect	
method.	NPs	were	purified	 from	free	drug	by	ultracentrifugation	for	75	min	at	
18000	rpm	and	4°C.	EE%	and	the	LC%	of	NPs	were	calculated	by	the	difference	
between	the	total	amount	of	the	drug	loaded	and	the	amount	of	AG	determined	
in	 the	 supernatants	 obtained	 after	 the	 purification	 of	 the	 NPs,	 using	 the	
following	equations[29]:		
EE%=(Total	Drug-Free	Drug)/(Total	Drug)·100	
LC%=(Total	Drug-Free	Drug))/(Weight	of	NPs)·100	
4.3.2.8 In	vitro	release	of	AG		
The	 ability	 of	 NPs	 to	 provide	 a	 controlled	 or	 sustained	 release	 of	 AG	 was	
evaluated	using	the	dialysis	bag	method,	in	a	PBS	solution	at	pH	7.4	to	mimic	the	
sink	conditions.	The	volume	of	medium	of	 release	was	calculated	according	 to	
Yang	et	al	[11].The	systems	were	placed	in	a	thermostatic	bath	at	37	°C	±	0.5	°C,	
under	magnetic	 stirring	 at	 200	 rpm.	 The	 release	 was	measured	 for	 24	 hours.	
Aliquots	of	one	milliliter	were	withdraw	in	duplicate	at	the	following	time	point:	
20,	 40,	 60,	 120,	 240,	 360,	 480	end	1440	minutes	 and	 replaced	with	 the	 fresh	
PBS,	maintained	at	37	°C.	
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4.3.3 UPLC-	MS/MS	ASSAY	FOR	THE	QUANTIFICATION	OF	AG	
4.3.3.1 Stock	 solutions,	 calibration	 standards,	 and	 quality	 controls	
(QCs)	
Stock	 solutions	 (SS)	 of	 AG	 as	 analyte	 and	 forskolin	 as	 I.S.	 were	 prepared	
separately	 by	 dissolving	 at	 least	 2	 mg	 of	 compound	 in	 10	 mL	 of	 DMSO.	
Weightings	 were	 done	 on	 an	 analytical	 microbalance	 (Sartorius,	 Switzerland).	
Working	solutions	(WSs)	of	analyte	and	I.S.	at	concentrations	of	50	µg/mL	were	
prepared	 by	 further	 diluting	 the	 respective	 SSs.	 For	 analytes,	 calibration	
standards	 (calibrators)	 and	 quality	 controls	 (QCs)	 in	 RHB	 at	 low,	medium,	 and	
high	 concentrations	 (QCL,	QCM,	 and	QCH)	were	prepared	by	 serial	 dilution	of	
the	 respective	WSs	 (range	 10.0–2000	 ng/mL).	 The	 first	 concentration	 level	 of	
the	calibrators	was	defined	as	lower	limit	of	quantification	(LLOQ),	and	the	last	
level	as	upper	limit	of	quantification	(ULOQ).	Calibrators	and	QCs	were	aliquoted	
into	 polypropylene	 tubes	 and	 stored	 below	 -65°C	 until	 analysis.	 For	 the	 I.S.,	 a	
second	working	solution	(WS2)	was	freshly	prepared	on	the	day	of	the	analytical	
run	by	further	diluting	the	I.S.	WS1	at	the	concentration	of	2000	ng/mL.	
4.3.3.2 Sample	extraction	from	Ringer	HEPES	buffer		
Analytes	and	corresponding	I.S.	(Figure	26)	were	extracted	from	RHB	by	means	
of	protein	precipitation.		
	
FIGURE	26:	CHEMICAL	STRUCTURES	OF	(3E,4S)-4-HYDROXY-3-{2-
[(1R,4AS,5R,6R,8AS)-6-HYDROXY-5-(HYDROXYMETHYL)-5,8A-DIMETHYL-2-
METHYLENEDECAHYDRO-1-NAPHTHALENYL]ETHYLIDENE}DIHYDRO-2(3H)-FURANONE	
(ANDROGRAPHOLIDE)	(A)	AND	INTERNAL	STANDARD,	
(3R,4AR,5S,6S,6AS,10S,10AR,10BS)-6,10,10B-TRIHYDROXY-3,4A,7,7,10A-
PENTAMETHYL-1-OXO-3-VINYLDODECAHYDRO-1H-BENZO[F]CHROMEN-5-YL	ACETATE	
(FORSKOLIN)	(B).	
Sample	aliquots	 (200	µL)	were	spiked	with	a	 freshly	prepared	working	solution	
(WS2)	 of	 the	 I.S.	 (100	µL).	 Subsequently,	 samples	 were	 spiked	 with	 a	 BSA	
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solution	 (60g/L)	 (200	µL)	 and	 then	 subjected	 to	 protein	 precipitation	with	 ice-
cold	 acetonitrile	 (800	µL).	 The	 mixture	 was	 briefly	 vortexed,	 then	 stirred	 for	
10	min	at	1400	rpm	on	a	Eppendorf	Mixmate	(Vadaux-Eppendorf,	Schönenbuch,	
Switzerland),	 and	 subsequently	 centrifuged	 for	20	min	at	13200	rpm	 (MiniSpin	
plus,	 Vaudaux-Eppendorf,	 Schönenbuch,	 Switzerland).	 The	 supernatant	 (1100	
µL)	was	 transferred	 into	 a	 96-deep	well	 plate,	 dried	under	nitrogen	 (Evaporex	
EVX-96,	Apricot	Designs,	Monovia,	 CA,	USA)	 and	 thereafter	 reconstituted	with	
the	injection	solvent	(200	µL)	(Table	12).		
TABLE	12:	OPTIMIZED	UPLC	PARAMETER.	INJECTION	SOLVENT:	65%	A1	+	35%	B1;	A1:	
HIGH	PURITY	WATER	+	0.1%	FA	ACID;	B2:	ACETONITRILE	+	0.05%	FA		
	
Analyte	 Gradient	
Total	run	
time	
(min)	
Eluents	
Injection	
volume	(µL)	
Column	
Column	
temperature	
(˚C)	
Flow	rate	
(mL/min)	
AG	
	
10–100%	B1	
in	4	min	
100–10%	B1	
from	5.01	
min	
6.00	 A1+B1	 10.0	
Waters	
Acquity	CSH	TM	
Phenyl-hexyl	
75.0	 0.500	
	
For	optimal	reconstitution,	the	96-deep	well	plate	was	stirred	on	an	Eppendorf	
Mixmate	 (45	 min	 at	 1500	 rpm)	 and	 subsequently	 centrifuged	 for	 4	min	 at	
3000	rpm	(Megafuge,	Heraeus	Instruments	AG,	Switzerland).	Samples	were	then	
injected	into	the	UPLC-MS/MS	in	full	loop	mode	(injection	volumes	see	in	Table	
12).	
4.3.3.3 UPLC-MS/MS	settings	
Method	validation	was	performed	on	a	Waters	Acquity	UPLC	system	coupled	to	
a	 Waters	 Acquity	 triple	 quadrupole	 (Waters,	 Milford,	 MA,	 USA).	 The	 UPLC	
system	 included	a	binary	pump,	a	 cooling	autosampler	 (set	 at	10°C,	protected	
from	 light),	and	a	column	heater.	Separation	of	analytes	and	 I.S.	was	achieved	
with	an	Acquity	(Waters,	Milford,	MA,	USA)	UPLC	Phenyl-Hexyl	column	(C18;	2.1	
x	50	mm;	1.8	µm	particle	size)	stored	at	75°C.	Mobile	phase	A	was	0.1%	formic	
acid	 (FA)	 in	water,	 and	mobile	phase	B	was	0.1%	FA	 in	acetonitrile	 (Table	12).	
Total	 run	 time	 was	 6	 min;	 the	 flow	 rate	 of	 the	 mobile	 phase	 was	 set	 at	 0.5	
mL/min	(Table	12).	Gradients	for	all	analytes	are	listed	in	Table	12.	Weak	wash	
solution	was	 a	mixture	 of	 acetonitrile	 and	water	 (50/50,	 v/v)	 containing	 0.2%	
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TFA.	 Strong	 wash	 solution	 was	 a	 mixture	 of	 acetonitrile,	 isopronanol,	 and	
acetone	 (40/30/30,	 v/v/v)	 containing	 0.2%	 TFA.	 Seal	 wash	 solution	 was	 a	
mixture	 of	 acetonitrile	 and	 water	 (10/90,	 v/v).	 The	MS	 system	 was	 equipped	
with	an	ESI	interface,	and	measurements	were	performed	in	negative	ion	mode	
(ESI-)	 with	 multiple	 reaction	 monitoring	 (MRM).	 Nitrogen,	 provided	 by	 a	
nitrogen	generator	N2-Mistral	 (Schmidlin	AG,	Neuheim,	Switzerland),	was	used	
both	as	desolvation	gas	and	as	cone	gas.	Argon	was	used	as	collision	gas.	Source	
temperature	 was	 set	 at	 150°C.	 MS/MS	 transitions	 and	 parameters	 were	
generated	 using	 Waters	 IntelliStart	 software	 and	 subsequently	 optimized	
manually.	Transitions,	cone	voltage,	and	collision	energy	for	analytes	and	I.S.	are	
listed	 inTable	 13.	 Data	 were	 acquired	 with	 MassLynx	V4.1	 software	 and	
quantification	was	done	using	QuanLynx	software	(Waters,	Milford,	MA,	USA).	
TABLE	 13:	 OPTIMIZED	 MS/MS	 PARAMETERS	 (SRM	 TRANSITIONS,	 CONE	 VOLTAGE,	
COLLISION	 ENERGY	 AND	 DWELL	 TIME)	 IN	 ESI	 NEGATIVE	 MODE	 FOR	 ANDROGRAPHOLIDE	
AND	FORSKOLIN	(I.S.)	
Compounds	 SRM	transitions	 Cone	voltage	(V)	 Collision	energy	(eV)	 Dwell	time	(ms)	
AG	
	
I.S.	Forskolin	
Quant:	394.8	>	287.1	
Qual:	394.8	>	331.1	
409.0	>	349.0	
20	
20	
21	
18	
10	
9	
95	
95	
195	
	
4.3.3.4 Method	validation	
Method	validation	for	the	quantification	of	AG	by	UPLC-MS/MS	was	performed	
according	 to	 international	 regulatory	 guidelines[20,21].	 Imprecision	 in	 all	
validation	tests	was	expressed	by	CV%.	According	to	both	guidelines,	the	CV	%	
had	to	be	below	15%	of	the	nominal	values	at	all	concentration	levels	(exception	
below	20%	at	the	LLOQ	level).	Inaccuracy	in	all	validation	tests	was	expressed	by	
RE	 %,	 and	 had	 to	 be	 within	 ±	15	 %	 of	 the	 nominal	 value	 at	 all	 concentration	
levels	 (exception	 within	 ±	20	 %	 at	 the	 LLOQ	 level)	 according	 to	 both	
guidelines[20,21].		
Ø Calibration	curve	and	regression	parameters	
Seven	 calibrators	 were	 injected	 with	 increasing	 concentration	 after	 a	 blank	
sample	 (blank	 RHB)	 and	 a	 zero	 sample	 (RHB	 only	 spiked	 with	 I.S.).	 Each	
validation	run,	performed	on	different	days,	consisted	of	a	set	of	calibrators	at	
the	 beginning	 and	 at	 the	 end	 of	 the	 run.	 The	 calibration	 curve	 was	 validated	
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through	 six	 QCs	 (duplicates	 of	 QCL,	 QCM,	 and	 QCH),	 which	 were	 inserted	
randomly	 into	 the	 analytical	 run.	 The	weighting	 factor	was	 determined	during	
the	 first	 run	 to	 obtain	 a	 consistent	 dispersion	 of	 measure	 errors	 across	 the	
range.	 According	 to	 FDA	 guidance,	 a	 run	 was	 considered	 to	 be	 valid	 if	 the	
coefficient	of	determination	(R2)	was	higher	than	0.96	and	if	at	least	75	%	of	all	
calibrators	were	used	 to	generate	 the	calibration	curve.	For	 the	LLOQ	and	 the	
ULOQ,	at	 least	one	replicate	had	to	be	accepted.	For	 the	six	QCs,	at	 least	 four	
replicates	 in	 total	 and	 at	 least	 one	 replicate	 at	 each	 level	 had	 to	 be	
accepted[20].	
Ø Carry-over	
To	 assess	 the	 carry-over	 of	 both	 analyte	 and	 I.S.	 in	 each	 analytical	 run,	 blank	
samples	were	 injected	after	 the	ULOQ.	Peak	 areas	of	 analyte	 and	 I.S.	 in	 these	
blank	samples	were	then	compared	to	the	peak	areas	at	the	LLOQ.	Mean	carry-
over	 in	each	analytical	 run,	expressed	 in	%,	had	to	be	below	20	%	for	analytes	
and	below	5%	for	I.S.	[21]	
Ø Specificity	
A	total	of	six	blank	samples	(duplicates,	three	different	batches	of	RHB)	without	
the	 addition	 of	 analyte	 or	 I.S.	 were	 injected	 into	 the	 UPLC-MS/MS	 within	 an	
analytical	run.	Peak	areas	were	assessed	using	a	valid	calibration	curve,	and	they	
had	not	to	exceed	20	%	of	the	mean	peak	area	of	both	replicates	at	the	LLOQ.	
Ø Selectivity	
Six	 samples	 at	 the	 LLOQ	 (duplicates,	 three	different	 batches	 of	 RHB)	 were	
injected	 into	 the	 UPLC-MS/MS	 within	 a	 validation	 run.	 Concentrations	 were	
calculated	using	a	valid	calibration	curve.	Selectivity	 imprecision	 (CV	%)	had	 to	
be	below	20	%	and	 inaccuracy	 (RE	%)	had	 to	be	within	±	20	%	of	 the	nominal	
values.	
Ø Within-run	and	between-run	reproducibility	
Six	 replicates	 at	 five	concentration	 levels	 (LLOQ,	QCL,	 QCM,	 QCH,	and	 ULOQ)	
were	 injected	 into	 the	 UPLC-MS/MS	 within	 three	validation	 runs	 on	
three	different	 days.	 In	 each	 validation	 run,	 within-run	 imprecision	 (CV	 %)	 of	
each	QC	series	had	to	be	below	15	%	(below	20	%	at	the	LLOQ)	and	within-run	
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inaccuracy	 (RE	%)	had	 to	be	within	±	15	%	 (within	±	20	%	at	 the	 LLOQ)	of	 the	
nominal	 values.	 Between-run	 imprecision	 (CV	 %)	 and	 inaccuracy	 (RE	 %)	 were	
then	assessed	calculating	the	overall	means	and	standard	deviations	(S.D.).	The	
acceptance	criteria	for	imprecision	(CV	%)	and	inaccuracy	(RE	%)	were	the	same	
as	described	above.	
Ø Dilution	test	
To	 assess	 the	 reliability	 of	 the	 method	 at	 concentration	 levels	 outside	 the	
calibration	ranges,	a	dilution	test	was	performed.	From	the	WS	of	the	analytes,	a	
solution	 at	 a	 concentration	 5-fold	 higher	 than	 the	 ULOQ	 was	 prepared.	 This	
solution	 was	 first	 diluted	 to	 give	 a	 solution	 at	 a	 10-fold	 lower	 concentration,	
then	further	diluted	to	give	a	second	solution	at	100-fold	 lower	concentration.	
Six	replicates	of	both	levels	were	injected	into	the	UPLC-MS/MS	system.	For	all	
replicates	 of	 both	 QC	 series,	 the	 concentration	 was	 assessed	 using	 a	 valid	
calibration	 curve	 and	 subsequently	multiplied	 with	 the	 corresponding	 dilution	
factor.	 Resulting	 mean	 concentrations,	 imprecision,	 and	 inaccuracy	 were	
calculated.	According	to	FDA	guidance,	the	imprecision	(CV	%)	had	to	be	below	
15%	 and	 the	 inaccuracy	 (RE	 %)	 had	 to	 be	 within	 ±	15%	 of	 the	 nominal	
values[20].	
Ø Extraction	yield	(recovery)	
The	extraction	yield	of	 the	analytes	was	determined	using	six	 replicates	spiked	
with	analyte	at	three	different	concentration	levels	(QCL,	QCM,	and	QCH)	before	
extraction,	 and	 spiked	with	 I.S.	 after	 extraction,	 compared	 to	 six	 replicates	 of	
blank	 RHB	 samples	 spiked	 after	 extraction	 with	 analyte	 at	 three	 different	
concentration	levels	(QCL,	QCM,	and	QCH)	and	with	I.S.	The	extraction	yield	of	
I.S.	 was	 determined	 using	 six	 replicates	 spiked	with	 I.S.	 before	 extraction	 and	
with	 analyte	 at	 medium	 concentration	 after	 extraction,	 compared	 to	 six	
replicates	of	blank	RHB	spiked	after	extraction	with	I.S.	and	analyte	at	medium	
concentration.	According	to	FDA	guidance,	recovery	does	not	need	to	be	100%,	
but	the	extent	of	recovery	of	an	analyte	and	of	the	internal	standard	should	be	
consistent,	precise,	and	reproducible[20].	
Ø Freeze	and	thaw	(F/T)	stability	
Six	 replicates	 of	QCL	 and	QCH	were	 subjected	 to	 three	 freeze	 and	 thaw	 (F/T)	
cycles,	processed,	and	subsequently	analyzed	using	a	valid	calibration	curve.	At	
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both	concentration	levels,	the	imprecision	(CV	%)	had	to	be	below	15%	and	the	
inaccuracy	(RE	%)	had	to	be	within	±	15%	of	the	nominal	values.	
Ø Short-term	stability	on	benchtop	
Six	 replicates	 of	 QCL	 and	 QCH	 were	 stored	 for	 2	hours	 at	 room	 temperature	
(RT),	 processed,	 and	 quantified	 using	 a	 valid	 calibration	 curve.	 At	 both	
concentration	 levels,	 imprecision	 (CV	%)	 had	 to	 be	 below	15%	 and	 inaccuracy	
(RE	%)	had	to	be	within	±	15	%	of	the	nominal	values.	
Ø Processed	sample	stability	at	autosampler	conditions	
Six	 replicates	 of	 QCL	 and	 QCH	 were	 injected	 into	 the	 UPLC-MS/MS	 after	
processing	and	quantified	using	a	valid	calibration	curve.	All	QCs	were	stored	in	
the	 autosampler	 (set	 at	 10°C,	 protected	 from	 light)	 and	 after	 a	 defined	 time	
period	 reassessed	using	 a	 new	 calibration	 curve.	At	 both	 concentration	 levels,	
imprecision	(CV	%)	had	to	be	below	15	%	and	inaccuracy	(RE	%)	had	to	be	within	
±	15	%	of	the	nominal	values.	
Ø Long-term	stability	below	-65°C	
Three	replicates	of	QCL,	QCM,	and	QCH	were	quantified	using	a	valid	calibration	
curve	at	 time	zero	 (t=0),	and	three	replicates	at	 the	same	concentration	 levels	
(QCL,	QCM,	and	QCH)	were	stored	below	-65°C.	After	one	week	of	storage,	the	
samples	were	processed	and	quantified	using	a	valid	calibration	curve	generated	
by	 freshly	 prepared	 calibrators	 and	QCs.	 Results	 from	 samples	 stored	 below	 -
65°C	were	plotted	 in	 function	of	 results	 from	time	zero	 (t=0),	and	a	curve	was	
fitted	 by	 linear	 regression	 (forced	 through	 zero).	 Samples	were	 considered	 as	
stable	when	the	slope	was	within	1	±	0.15.	
Ø Stock	solution	stability		
Fresh	 stock	 solutions	 for	 analytes	 and	 I.S.	were	prepared	and	kept	at	RT	 for	2	
hours.	 Old	 stock	 solutions	 which	 were	 stored	 below	 -65°C	 for	 various	 time	
periods	 were	 thawed,	 and	 similarly	 kept	 at	 RT	 for	 2	 hours.	 Subsequently,	
working	 solutions	 for	 each	 compound	 at	 5.00	 µg/mL	 in	 the	 injection	 solvent	
were	 prepared	 in	 6	 replicates	 and	 injected	 into	 the	UPLC-MS/MS	 system,	 and	
peak	 areas	 from	 old	 and	 fresh	 stock	 solutions	 were	 compared.	 The	 eventual	
degradation	had	to	be	≤	5%.		
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4.3.4 IN	SILICO	PREDICTION	OF	BBB	PERMEABILITY	
Three-dimensional	 computer	 model	 of	 AG	 was	 built	 in	 Maestro	 modeling	
environment[30].		The	global	minimum	geometry	identified	in	a	conformational	
search	was	used	as	an	input	for	the	QikProp	[31]	application,	to	evaluate	various	
descriptors	 relevant	 for	compound	permeability	 through	the	BBB.	PSA	and	the	
logarithm	of	 partition	 coefficient	 (LogP)	 descriptors	were	 calculated	 also	using	
the	Calculator	plugin	of	Chemaxon	Marvin	application[32].	
4.3.5 BLOOD-BRAIN	BARRIER	DRUG	PERMEABILITY	ASSAYS	
4.3.5.1 Human	in	vitro	BBB	model		
The	human	mono-culture	 in	vitro	BBB	model	based	on	hCMEC/D3	cell	 line	was	
prepared	as	reported	previously[33].	As	culture	medium,	EBM-2	supplemented	
with	hydrocortisone,	ascorbic	acid,	heparin,	antibiotic-antimycotic	solution,	and	
5%	FBS	(heat	inactivated	at	56°C	for	30	min)	was	used	(Single-Quots).	After	5–7	
days	of	incubation	of	hCMEC/D3	monolayers	(at	a	maximal	TEER,	Table	14),	the	
permeability	assays	for	the	compounds	were	carried	out.		
TABLE	 14:	 APPARENT	 PERMEABILITY	 COEFFICIENTS	 APICAL	 TO	 BASOLATERAL	 (PAPP	 A>B)	
FOR	AG	AND	NAF	AS	BARRIER	INTEGRITY	CONTROL	(N	=	3)	
Assays	 Mean	Papp	AG	±	
SEM	 
(x	10-6	cm/s)	
Mean	NAF	Papp	±	
SEM	 
(x	10-6	cm/s)	
Time	of	withdrawal	
(min)	
Recovery	(%)	
for	AG	
Recovery	(%)	for	
NAF	
Free	form	of	
AG		
9.51±0.707	 7.85	±0.188	 60	 85.3	 90.7	
HSAT	AG	
NPs	
18.7±3.31	 9.34±0.611	 60	 96.2	 94.2	
PECA	AG	
NPs	
32.6±1.62	 29.9±4.38	 60	 102.8	 88.9	
	
Briefly,	the	tissue	culture	inserts	were	transferred	into	a	24-well	plate	containing	
1200	 μL	 of	 pre-warmed	 (37°C)	 RHB	 in	 each	 well	 (basolateral	 compartment).	
Medium	in	inserts	(apical	compartment)	was	subsequently	replaced	with	300	μL	
of	a	pre-warmed	(37°C)	working	solution	containing	the	test	compound	(5	μM)	
and	NAF	as	 integrity	 control	marker	 (10	μg/mL)	 in	RHB.	The	24-well	plate	was	
incubated	at	37°C	on	an	orbital	shaker	(ELMI	DTS-2,	Riga,	Latvia)	with	moderate	
speed	 (300	 rpm),	 and	 aliquots	 of	 270	 μL	 of	 both	 apical	 and	 basolateral	
compartments	were	collected	after	several	timepoints	(15,	30,	60,	and	120	min)	
(one	insert	per	timepoint)	and	stored	below	-65°C	until	analysis.	All	experiments	
were	 performed	 at	 least	 in	 triplicate.	 Quantification	 of	 NAF	 fluorescence	 was	
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carried	 out	 using	 a	 Chameleon	 microplate	 reader	 (Hidex,	 Turku,	 Finland).	
Quantification	 of	 AG	 was	 performed	 by	 means	 of	 the	 validated	 UPLC-MS/MS	
methods.		
4.3.5.2 Calculation	of	permeability	coefficients		
The	apparent	permeability	coefficient	(Papp)	 for	AG	and	NAF	was	calculated	in	
centimeters	per	second	(cm/s)	according	to	the	equation[34]:	
Papp	(cm/s)	=	VR/ACD0	×	(ΔCR/Δt)	
where:		
• VR	is	the	volume	in	the	receiver	compartment,	
• 	A	 is	 the	 surface	 area	 of	 the	 filter	 membrane	 (0.336	 cm2	 for	 24-well	
inserts),		
• CD0	is	the	initial	concentration	in	the	apical	compartment,		
• (ΔCR/Δt)	 is	 the	 change	 of	 concentration	 over	 time	 in	 the	 basolateral	
compartment.	
Recovery	for	AG	and	NAF	was	calculated	according	to	the	equation:	
Recovery	(%)	=	CDf	VD	+	CRf	VR	/	(CD0VD)	×	100	
where:	
• CDf	and	CRf	are	the	final	concentrations	of	 the	compound	 in	the	donor	
and	receiver	compartments,	respectively,		
• CD0	is	the	initial	concentration	in	the	donor	compartment,		
• VD	 and	 VR	 are	 the	 volumes	 in	 the	 donor	 and	 receiver	 compartments,	
respectively.		
All	 results	 are	 expressed	 as	means	 ±	 SD.	 To	 confirm	 that	AG	 and	NAF	did	 not	
attach	to	the	plastic	material	and	that	the	diffusion	barrier	was	only	provided	by	
the	 cells,	 control	 experiments	 were	 performed	 using	 collagen	 coated	 inserts	
without	cells.	
Endothelial	 permeability	 coefficients	 (Pe)	 for	 AG	 and	 NAF	 were	 calculated	 as	
follows.	 For	 each	 replicate	 (controls	 and	 samples),	 the	 cleared	 volume	 was	
calculated	according	to	the	following	equation[35,36]:	𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒	 𝜇𝐿 = 	𝐶V𝑉V𝐶W 	
where:		
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• CB	 and	 VB	 are	 the	 concentration	 and	 volume	 in	 the	 basolateral	
compartment,	respectively,		
• CA	is	the	concentration	in	the	apical	compartment.		
The	mean	 cleared	 volume	was	 plotted	 as	 a	 function	 of	 time	 (30,	 60,	 and	 120	
min),	 and	 the	 slope	was	 estimated	 by	 linear	 regression	 analysis.	 Permeability-
surface	area	product	(PS)	and	Pe	values	were	subsequently	calculated	according	
to	the	following	equations:	
	 1𝑃𝑆XYXZ[	 − 1𝑃𝑆\][X^_ 	= 	 1𝑃𝑆^ 	
	 𝑃𝑆^𝐴 	= 𝑃 	
where:	
• PStotal	 is	 the	 slope	 of	 the	 clearance	 curve	 of	 cell	monolayer	with	 filter	
inserts,		
• PSf	 is	 the	 slope	of	 the	clearance	curve	of	 control	 filter	 inserts	without	
cells,		
• PSe	 is	 the	 slope	 of	 the	 the	 clearance	 curve	 for	 the	 endothelial	
monolayer,	 and	 A	 is	 the	 surface	 area	 of	 the	 filter	 membrane	 (0.336	
cm2).	
Recovery	(mass	balance)	was	calculated	according	to	the	following	equation:	
	 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦	 % = 	𝐶W\𝑉W +	𝐶V\𝑉V𝐶Wc𝑉W ×100	
	
where:	
• CAf	and	CBf	are	the	final	concentrations	of	the	compounds	in	the	apical	
and	basolateral	compartments,	respectively,		
• CA0	is	the	initial	concentration	in	the	apical	compartment,		
• VA	and	VB	are	the	volumes	in	the	apical	and	basolateral	compartments,	
respectively.		
All	results	are	expressed	as	means	±	SD.		
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4.4 RESULTS	AND	DISCUSSION	
4.4.1 CHARACTERIZATION	OF	PECA	NPS		
The	results	obtained	in	term	of	dimensional	analysis,	PDI	and	ζ-potential	of	PECA	
NPs	are	reported	in	the	following	Table	15.	
TABLE	 15:	 CHARACTERIZATION	 OF	 PECA-BASED	 NPS	 IN	 TERMS	 OF	 MEAN	 DIAMETER,	
POLYDISPERSITY,	 Ζ	 –POTENTIAL,	 YIELD	 OF	 PREPARATIVE	 PROCESS,	 ENCAPSULATION	
EFFICIENCY	AND	LOADING	CAPACITY.	(MEAN±SD;	N=3)	
PECA	NPs	 Size	(nm)	 PDI	
ζ	-Potential	
(mV)	
Yield	(%)	
	
EE%	
	
LC%	
PECA	 288	±	7.00	
0.19	±	
0.01	
-2.85	±	1.18	 81.40±0.41	 -	 -	
PECA-TW80	 303	±	8.00	
0.36	±	
0.04	
-4.07	±	0.05	 81.40±0.41	 -	 -	
PECA	AG	
0.1%	
221.20±3.20	
0.20	±	
0.05	
-2.78	±	0.10	 	 96.04±0.21	 4.61±0.20	
PECA	AG	
0.1%	TW80	
242.85±4.10	
0.20	±	
0.05	
-5.22	±	0.10	 	 96.04±0.21	 4.61±0.20	
PECA-AG	
0.5%	
232.90±8.2	
0.22	±	
0.02	
-3.85	±	0.10	 86.95±3.50	 94.60±0.41	 13.20±0.36	
PECA-AG	
0.5%-	TW80	
255.40±8.9	
0.19	±	
0.02	
-4.77	±	0.18	 86.95±3.50	 94.60±0.41	 13.20±0.36	
	
The	 data	were	 obtained	 by	DLS	 analysis;	 a	 dilution	 factor	 between	 10	 and	 50	
was	applied	for	measurement.	The	sizes	were	not	affected	after	coating	with	1%	
TW	 80.	 PECA	 AG	 NPs	 done	 with	 a	 modified	 method	 of	 preparation	 have	
satisfactorily	narrow	 size	distribution,	with	PDI	 around	0.2.	 The	 yields	of	NPs’s	
preparation	were	 ≈90%	 for	 empty	 NPs	 and	 for	 PECA	 AG	 0.5%	 NPs	 too,	 while	
≈70%	 for	 PECA	 AG	 0.1%.	 TEM	 analyses	 provided	 important	 details	 on	 the	
morphology	and	the	dimension	of	the	NPs(Figure	27).	
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FIGURE	27: TEM	ANALYSIS	OF	PECA	AG	NPS	
PECA	AG	NPs	were	sphere-shaped,	with	a	good	size	distribution	comparable	to	
DLS	analysis,	 suitable	 for	systemic	administration.	Changing	 the	polymerization	
medium	 does	 not	 affect	 the	 properties	 of	 NPs.	 The	 suspension	 becomes	
opalescent	 after	 the	 addition	 of	 the	 monomer	 ECA	 as	 soon	 as	 started	 the	
process	of	polymerization.	After	freeze-drying,	NPs	were	suspended	with	RHB	at	
concentration	of	5	mg	/	ml	for	the	NPs	containing	0.1%	w	/v	of	AG	and	20	mg	/	
ml	for	the	NPs	containing	AG	at	0.5%	w	/	v	with	vortex.	The	size	and	the	PDI	did	
not	 change.	 The	 increase	 of	 concentration	 of	 AG	 loaded	 did	 not	 negatively	
impact	on	 the	 formulation.	 This	 indicates	 that	 the	 selected	molecule	does	not	
alter	the	optimized	nanocarriers.	The	value	obtained	in	term	of	EE%	are	too	high	
(≈	 95%)	 for	 both	 concentration	 of	 AG,	 NPs	 size	 increased	 when	 AG	
concentration	increased	with	lower	EE%.	
4.4.2 CHARACTERIZATION	OF	HSA	NPS	
At	 the	 beginning,	 HSA	 AG	 NPs	 were	 prepared	 using	 the	 method	 of	 chemical	
cross-linking,	trying	to	reduce	the	%	of	glutaraldehyde.	In	the	preparation	phase,	
was	observed	a	considerable	turbidity	of	the	HSA	solution	during	the	addition	of	
ethanol	 with	 subsequent	 formation	 of	 a	 coacervate	 of	 white	 colour,	 that	
became	 even	 more	 evident	 by	 the	 addition	 of	 glutaraldehyde	 which	 acts	 as	
cross-linker	 for	 the	 formation	 of	 NPs.	 The	 size,	 the	 homogeneity	 and	 the	 ζ	
potential	 of	 optimized	 HSAC	 NPs	 were	 determined	 by	 DLS.	 A	 dilution	 factor	
between	 5	 and	 30	was	 applied.	NPs	 have	 acceptable	 narrow	 size	 distribution,	
with	PDI	around	0.3;	 the	process	yields	of	NPs	were	≈90%.	The	Table	16shows	
the	final	characterization	of	HSAC	NPs.		
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TABLE	 16:	 CHARACTERIZATION	 OF	 HSAC	 NPS	 IN	 TERMS	 OF	 MEAN	 DIAMETER,	
POLYDISPERSITY,	 Ζ	 –POTENTIAL,	 YIELD	 OF	 PREPARATIVE	 PROCESS,	 ENCAPSULATION	
EFFICIENCY	AND	LOADING	CAPACITY.	(MEAN±SD;	N=3)	
HSAC	NPs	 Size	(nm)	 PDI	 ζ	–Potential	(mV)	 Yield	(%)	 EE%	 LC%	
HSAC	 151.67±1.53	 0.28±0.01	 15.7±0.20	 89.60±3.60	 -	 -	
HSAC-AG	2:1	 335.10±1.12	 0.06±0.05	 11.25±0.20	 77.33±0.01	 99.22±0.01	 7.76±0.01	
HSAC-AG	1:1	 225.20±3.10	 0.24±0.01	 12.30±0.10	 86.88±0.34	 98.50±0.01	 14.09±0.01	
	
The	size	of	the	NPs	loaded	with	AG,	does	not	change	respect	to	the	diameter	of	
the	empty	NPs.	In	particular,	increasing	the	concentration	of	AG,	the	formulative	
parameters	became	superior.	The	acceptable	values	obtained,	 in	terms	of	size,	
homogeneity	and	surface	charge	were	constantly	reproducible	and	suitable	for	
systemic	administration.	TEM	analyses	confirm	the	data	obtained	by	the	DLS,	in	
particular	show	the	spherical	shape	of	NPs	Figure	28.	
	
	
FIGURE	28:	TEM	ANALYSIS	OF	HSAC	AG	NPS	
In	 order	 to	 find	 a	 safe	method	 of	 preparation	 of	 NPs	 and	 according	with	 the	
criteria	 of	 green	 chemistry,	 thermal	 cross-linking	was	 investigated	 to	minimize	
the	use	and	the	generation	of	unsafe	substances	by	replacing	solvents	and	toxic	
elements	 with	 biocompatible	 and	 non-toxic	 ones.	 The	 chemical	 cross-linkers	
glutaraldehyde	was	substituted	by	 temperature.	 	The	size,	 the	homogeneity	of	
the	sample	and	the	ζ	potential	of	optimized	HSAT	AG	NPs	were	determined	by	
DLS.	 Tem	 analysis	 confirmed	 the	 results	 in	 term	of	 size	 and	 homogeneity	 and	
showed	the	spherical	shape	of	HSAT	AG	NPs	(Figure	29).		
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FIGURE	29:	TEM	ANALYSIS	OF	HSAT	AG	NPS	
For	 analysis	 a	dilution	 factor	between	20	and	50	was	 applied.	Table	17	 shows	
the	 final	 characterization	 of	 HSAT	 NPs:	 the	 results	 in	 terms	 of	 size	 and	
homogeneity	are	reproducible	and	derived	from	the	acceptable	autocorrelation	
curves.	NPs	have	good	size	distribution,	with	PDI	around	0.2;	the	process	yield	of	
NPs	was	≈95%.	The	data	obtained	in	term	of	EE%	and	LC%	are	very	satisfactory	
for	all	NPs	developed,	very	high	for	this	type	of	nanocarriers.		
TABLE	 17:	 CHARACTERIZATION	 OF	 HSAT	 NPS	 IN	 TERMS	 OF	 MEAN	 DIAMETER,	
POLYDISPERSITY,	 Ζ	 -POTENTIAL,	 YIELD	 OF	 PREPARATIVE	 PROCESS,	 ENCAPSULATION	
EFFICIENCY	AND	LOADING	CAPACITY.	(MEAN±SD;	N=3)	
HSAT	NPs	 Size	(nm)	 PDI	 ζ	–Potential	(mV)	 Yield	(%)	 EE%	 LC%	
HSAT	 143.80±0.56	 0.23±0.02	 11.80±4.09	 81.40±0.41	 -	 -	
HSAT-AG	2:1	 257.60±1.25	 0.17±0.01	 9.75±0.10	 96.25±0.01	 98.40±0.01	 5.53±0.01	
HSAT-AG	1:1	 202.15±6.15	 0.17±0.01	 10.20±0.15	 94.65±0.45	 98.21±0.01	 8.50%±0.01	
	
The	second	method	of	preparation	of	HSA	NPs	is	more	safe,	biocompatible	and	
obviously	 easy	 to	 scale	 up.	 The	 result	 in	 term	 of	 characterization	 by	 DLS	 and	
TEM	analysis	and,	of	 course,	as	EE%	and	LC%	show	comparable	value,	 for	 this	
reason,	to	screen	the	best	formulation	to	deliver	AG	in	the	brain,	were	selected	
the	non-toxic	HSAT	NPs	and	the	synthetic	PECA	AG	NPs.	
4.4.3 IN	VITRO	RELEASE	STUDY	
The	 test	 provides	 to	 comprehend	 the	 kinetics	 of	 release	 of	 the	 AG	 from	 the	
different	drug	delivery	systems,	during	24	hours.	To	calculate	the	percentage	of	
AG	released	 in	the	medium	at	pH	7.4	at	each	point	time	the	following	formula	
was	used:	
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%	AG	released	=	(mg	AGt	x	100)	/	mg	AG	tot	
where:	
• mg	AGt	=	mg	AG	released	for	each	timepoint	t,		
• mg	AG	tot	=	mg	of	AG	Total	loaded	in	NPs.		
NPs	loaded	with	the	higher	amount	of	AG	were	selected	for	the	test.	The	shows	
the	comparison	of	the	%	of	AG	released	to	the	time.		
	
	
FIGURE	30: RELEASE	OF	AG	FROM	NPS	IN	PBS,	PH	7.4.	DATA	DISPLAYED	AS	MEAN	±	
SD	(N=3)	
Controlled	end	sustained	release	of	AG	can	be	detected	when	the	compound	is	
entrapped	 into	 NPs,	 in	 this	 case	 is	 not	 be	 observed	 a	 burst	 effect	 at	 the	
beginning	 of	 test.	 PECA	 AG	 NPs	 releases	 the	 compound	 slowly	 in	 the	 first	 20	
minutes	and	then	a	plateau	can	be	observed.	The	highest	%	of	drug	released	is	
17.23%	±	0.01	corresponding	to	about	0.50	mg	of	AG.	 In	the	case	of	HSA	NPs,	
we	 can	 see	 a	modulate	 release	 of	 AG.	 A	 plateau	 of	 concentration	 40	minutes	
later	 in	 the	case	of	HSAC	NPs	and	60	minutes	 in	 the	case	of	HSAT	NPs	can	be	
observed.	 The	 maximum	 amount	 of	 drug	 released	 is	 the	 31.17%	 ±	 0.02,	
corresponding	to	0.55	mg	for	HSAT	NPs	and	the	21.29%	±	0.01	for	the	HSAC	NPs	
equal	 to	0.60	mg.	The	results	 indicate	 that	 the	systems	are	able	 to	 release	AG	
for	 prolonged	 times.	 The	 encapsulation	 of	 AG	 improves	 the	 solubility	 and	
consents	to	administer	higher	concentration	of	molecule.	
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4.4.4 METHOD	VALIDATION	
Ø Chromatographic	performance	
Calibration	curves	in	the	range	of	10.0–2000	ng/mL	were	fitted	by	least-squares	
quadratic	regression,	and	weighting	factors	of	1/X2	were	applied	(Table	18).	
TABLE	 18: CALIBRATORS	 AND	 CALIBRATION	 CURVE	 PARAMETERS	 FOR	 AG	 METHOD	 IN	
RHB	 (N=14).RESPONSE:	 A	 X	 CONC.2	 +	 B	 X	 CONC.	 +	 C,	 QUADRATIC	 REGRESSION,	
WEIGHTING	 FACTOR	 1/X2,	 ORIGINS:	 INCLUDED.	 *	 >15%	 ACCEPTANCE	 CRITERIA,	 NOT	
USED	FOR	CALCULATIONS	
Run	
number	
Nominal	concentration	(ng/mL)	 Regression	parameters	
	
10.0	 50.0	 100	 200	 500	 1000	 2000	 A	 B	 C	 R2	
	
1	
11.4	 *61.9	 *120	 229	 503	 942	 2038	
-0.000000911	 0.00532	 0.0182	 0.996	
	
8.88	 57.4	 *117	 228	 485	 918	 2108	
	
2	
10.4	 *58.7	 *115	 227	 501	 927	 2089	
-0.000000898	 0.00525	 0.0156	 0.997	
	
9.49	 55.9	 111	 216	 457	 *836	 2006	
	
3	
9.80	 *61.1	 114	 224	 484	 934	 *2376	
-0.00000121	 0.00640	 0.0212	 0.995	
	
9.50	 55.6	 110	 216	 451	 *820	 1866	
	
4	 10.3	 *60.1	 111	 227	 486	 974	 2285	 -0.00000884	 0.00512	 0.0154	 0.997	
	
10.0	 *61.7	 113	 209	 482	 929	 1879	
	
5	 10.4	 *59.8	 112	 223	 480	 963	 2109	 -0.00000759	 0.00491	 0.0178	 0.996	
	
9.6	 *60.0	 115	 226	 484	 915	 2013	
	
6	
9.55	 52.6	 104	 209	 492	 972	 2065	
-0.00000297	 0.00341	 0.00762	 0.999	
	
9.21	 56.1	 110	 211	 499	 950	 1984	
	
7	
10.6	 52.3	 105	 199	 511	 996	 2163	
-0.00000464	 0.00367	 0.00758	 0.998	
	
9.46	 53.9	 103	 205	 494	 949	 1884	
	
Mean	
S.D.	
9.90	 54.8	 110	 218	 486	 947	 2038	 -0.00000387	 0.00487	 0.0148	 0.997	
	0.660	 1.93	 3.98	 9.77	 16.6	 25.0	 120	 0.00000330	 0.00110	 -	 -	
	
CV%	
RE%	
6.66	 3.52	 3.62	 4.49	 3.41	 2.64	 5.89	
	-1.00	 9.70	 9.85	 8.90	 -2.72	 -5.26	 1.89	
		
Ø Carry-over	assessment	
Mean	carry-over	in	blank	RHB	samples	injected	after	the	ULOQ	was	0.0295	%	for	
andrographolide	and	0.00439	%	for	forskolin	as	I.S.	(Table	19,	for	the	carry-over	
of	 AG	 see	 Figure	 31).	 Acceptance	 criteria	 from	 the	 EMA	 guidance[21]	 were	
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hence	fulfilled	(below	20	%	for	analyte,	below	5	%	for	I.S.)	and	it	was	proved	that	
carry-over	did	not	affect	precision	and	accuracy	of	the	method[21].	
TABLE	19:	CARRY-OVER	EVALUATION	FOR	AG	AS	ANALYTE,	AND	FOR	 FORSKOLIN	AS	 I.S.	
(N=14)	
Run	number	 Replicate	 Peak	response	(counts)	 Carry-over	(%)	 Mean	Carry-over	(%)	
Blank	sample	 LLOQ	
Analyte	 IS	 Analyte	 IS	 Analyte	 IS	 Analyte	 IS	
1	 1	 0.00	 1.22	 629	 7996	 0.00	 0.0153	 0.00	 0.00764	
2	 0.00	 0.00	 518	 7913	 0.00	 0.00	
2	 1	 0.00	 0.00	 533	 7636	 0.00	 0.00	 0.00	 0.00	
2	 0.00	 0.00	 544	 8329	 0.00	 0.00	
3	 1	 0.00	 0.00	 535	 6386	 0.00	 0.00	 0.00	 0.00	
2	 0.00	 0.00	 590	 7205	 0.00	 0.00	
4	 1	 0.00	 0.00	 493	 7235	 0.00	 0.00	 0.00	 0.00	
2	 0.00	 0.00	 513	 7897	 0.00	 0.00	
5	 1	 0.00	 0.00	 571	 8279	 0.00	 0.00	 0.00	 0.00	
2	 0.00	 0.00	 495	 7646	 0.00	 0.00	
6	 1	 1.00	 2.79	 242	 6035	 0.412	 0.0462	 0.206	 0.0231	
2	 0.00	 0.00	 288	 7378	 0.00	 0.00	
7	 1	 0.00	 0.00	 311	 6692	 0.00	 0.00	 0.00	 0.00	
2	 0.00	 0.00	 346	 8187	 0.00	 0.00	
	 	 	 	 	 Mean	 0.0295	 0.00439	 	 	
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FIGURE	31:	TYPICAL	MRM	CHROMATOGRAMS	OF	RHB	SPIKED	WITH	2000	NG/ML	
(ULOQ)	OF	AG	(A),	AND	WITH	2000	NG/ML	OF	I.S.	FORSKOLIN	(B),	OF	BLANK	RHB	
INJECTED	DIRECTLY	AFTER	THE	ULOQ	AND	MONITORED	FOR	AG	(C)	AND	FOR	I.S.	
FORSKOLIN	(D),	OF	RHB	SPIKED	WITH	10.0	NG/ML	(LLOQ)	OF	AG	(E),	AND	WITH	2000	
NG/ML	OF	I.S.	FORSKOLIN	(F).	VALUES	DISPLAYED	ON	TOP	OF	PEAKS:	RETENTION	TIME	
(MIN)	AND	PEAK	AREA	(CPS)	
Ø Specificity	test	
Peak	areas	of	the	six	blank	samples	(duplicates,	three	different	batches	of	RHB)	
were	equal	 to	0.00%	of	 the	mean	peak	area	of	 the	duplicates	LLOQ	(Table	20)	
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fulfilling	the	acceptance	criteria	of	guidelines	of	 industry	(below	20%	of	LLOQ).	
Thus,	UPLC-MS/MS	method	was	proved	to	be	specific	for	AG.	
TABLE	 20: SPECIFICITY	 TEST	 FOR	 AG,	 BASED	 ON	 EXTRACTED	 BLANK	 SAMPLES	 FROM	
THREE	DIFFERENT	BATCHES	OF	RHB	(N=6)	
Run	number	
Matrix	
Number	
Peak	area	 LLOQ%	
1	
1	
0.00	 0.00	
0.00	 0.00	
2	
0.00	 0.00	
0.00	 0.00	
3	
0.00	 0.00	
0.00	 0.00	
	
LLOQ	1	 629	 		
	
LLOQ	2	 518	
	
	
Mean	 573	
	Ø Selectivity	test	
Selectivity	imprecision	(CV	%)	for	the	six	samples	at	the	LLOQ	(duplicates,	three	
different	 RHB	 batches)	 was	 6.76%	 (below	 20	 %),	 and	 inaccuracy	 (RE	 %)	 was	
4,15%	(within	±	20	%)	(Table	21).	Hence,	the	quantification	method	was	proved	
to	be	selective	for	AG.	
TABLE	 21: SELECTIVITY	 TEST	 AT	 THE	 LLOQ	 FOR	AG,	 BASED	ON	 THREE	DIFFERENT	RHB	
BATCHES	(N=6)	
Nominal	concentration	(ng/mL)	 10.0	
Run	number	 Matrix	Number	 Measured		
conc.	
4	
1	
10.4	
9.58	
2	
8.66	
9.61	
3	
8.80	
9.34	
Mean	 9.40	
S.D.	 0.636	
CV%	 6.76	
RE%	 4.15	
	
CHAPTER	4	
	
138	
Ø Intra-run	and	Inter-run	precision	assessment	
Intra-run	 imprecision	 (CV	%)	was	between	0.673	and	7.45%	 (below	15	%)	 and	
intra-run	inaccuracy	(RE	%)	was	between	-10.3	to	-0.776%	(within	±	15	%)	at	five	
QC	levels	(Table	22).	Inter-run	imprecision	(CV	%)	was	between	2.01	and	6.31%	
and	inter-run	inaccuracy	(RE	%)	was	between	-9.10	and	-1.97%	at	five	QC	levels	
(within	±	15	%)	(Table	22).	FDA/EMA	requirements	were	hence	fulfilled,	and	the	
quantification	 method	 was	 proved	 to	 be	 precise,	 accurate,	 repeatable	 and	
reproducible.	
TABLE	 22: INTRA-RUN	 (N=6)	 AND	 INTER-RUN	 (N=18)	 IMPRECISION	 (EXPRESSED	 AS	
CV%)	AND	INACCURACY	(EXPRESSED	AS	RE%)	OF	CALIBRATORS	AND	QC	SAMPLES	OF	AG	
IN	RHB,	BASED	ON	3	SERIES	OF	6	REPLICATES	FOR	EACH	LEVEL	
	
LLOQ	 QCL	 QCM	 QCH	 ULOQ	
Nominal	concentration	(ng/mL)	 10.0	 30.0	 1000	 1600	 2000	
Intra-run	Mean	 9.81	 29.8	 936	 1511	 1795	
Intra-run	S.D.	 0.731	 1.31	 6.30	 36.8	 63.7	
Intra-run	CV%	 7.45	 4.41	 0.673	 2.44	 3.55	
Intra-run	RE%	 -1.92	 -0.776	 -6.42	 -5.55	 -10.3	
Inter-run	Mean	 9.65	 27.8	 909	 1485	 1961	
Inter-run	S.D.	 0.608	 1.08	 19.9	 29.9	 94.4	
Inter-run	CV%	 6.31	 3.87	 2.19	 2.01	 4.81	
Inter-run	RE%	 -3.53	 -7.28	 -9.10	 -7.19	 -1.97	
	
Ø Dilution	integrity	test	
For	both	dilution	QCs	diluted	10	and	100	fold,	imprecision	(CV	%)	was	between	
1.51	and	1.70%	(below	15	%)	and	 inaccuracy	was	between	8.64	%	and	14.7	%	
(within	±	15	%)	(Table	23).	It	could	hence	be	proved	that	dilution	of	RHB	samples	
up	 to	 100-fold	 did	 not	 impact	 the	 precision	 and	 accuracy	 of	 the	 quantitative	
method.	
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TABLE	23:	DILUTION	INTEGRITY	TEST	FOR	AG	IN	RHB	AT	TWO	DILUTION	FACTORS:	10	X	
AND	100	X	(N	=	6).	*>15%	ACCEPTANCE	CRITERIA,	USED	FOR	CALCULATIONS	
Nominal	concentration	(ng/mL)	 10000		 10000		
Dilution	factor	 10x	 100x	
Run	number	 Measured	conc.	Measured	conc.	
7	
10594	 11522*	
10908	 11771*	
10692	 11280	
10982	 11333	
11085	 11451	
10921	 11443	
Mean	 10864	 11467	
S.D.	 185	 173	
CV%	 1.70	 1.51	
RE%	 8.64	 14.7	
	
Ø Extraction	yield	
Absolute	 recoveries	 were	 consistent	 along	 the	 quantitative	 range	 at	 all	 three	
levels	(QCL,	QCM,	and	QCH)	AG	and	these	recoveries	(between	89.8	and	98.7%)	
were	 comparable	 with	 the	 recovery	 (97.0%)	 of	 forskolin	 as	 I.S.	 (Table	 24	 and	
Table	25).	
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TABLE	24:	ABSOLUTE	EXTRACTION	YIELD	OF	AG	IN	RHB	METHOD	(N=6)	
	 	
Nominal	concentration	(ng/mL)	
	 	
30.0	 1000	 1600	
AG	
	
Peak	ratio	in	
processed	
samples	
Peak	ratio	in	
unprocessed	
samples	
Peak	ratio	in	
processed	
samples	
Peak	ratio	in	
unprocessed	
samples	
Peak	ratio	
in	
processed	
samples	
Peak	ratio	in	
unprocessed	
samples	
1	 0.123	 0.141	 3.52	 3.85	 4.85	 4.90	
2	 0.134	 0.146	 3.49	 3.89	 4.93	 5.00	
3	 0.127	 0.141	 3.65	 3.95	 4.89	 4.87	
4	 0.132	 0.140	 3.40	 3.86	 4.66	 5.09	
5	 0.135	 0.152	 3.52	 3.91	 5.18	 5.10	
6	 0.137	 0.144	 3.47	 4.00	 5.07	 5.01	
Mean	 0.131	 0.144	 3.51	 3.91	 4.93	 4.99	
SD	 0.00532	 0.00452	 0.0814	 0.0575	 0.181	 0.0942	
CV%	 4.05	 3.14	 2.32	 1.47	 3.67	 1.89	
Absolute	recovery	(%)	 91.2	
	
5.12	
	
4.67	
89.8	
	
2.75	
	
2.46	
98.7	
	
4.13	
	
4.07	
	
CV%	
SD	
	
TABLE	25: ABSOLUTE	EXTRACTION	YIELD	OF	FORSKOLIN	IN	RHB	METHOD	(N=6)	
	 	
Internal	standard	conc.	(ng/mL)	
	 	
846	
Forskolin	
	
Peak	ratio	in	processed	
samples	
Peak	ratio	in	
unprocessed	samples	
1	 3.86	 4.00	
2	 3.75	 3.92	
3	 3.76	 3.79	
4	 3.85	 3.87	
5	 3.86	 3.92	
6	 3.72	 4.00	
Mean	 3.80	 3.92	
SD	 0.0637	 0.0820	
CV	%	 1.68	 2.09	
Absolute	recovery	(%)	
97.0	
2.68	
2.60	
CV%	
SD	
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Ø Freeze	and	thaw	(F/T)	stability	test	
Imprecision	 (CV%)	 for	 the	 six	 replicates	of	QCL	and	of	QCH	subjected	 to	 three	
successive	 F/T	 cycles	 was	 between	 2.31	 and	 6.94	 %	 (below	 15	 %),	 and	
inaccuracy	 (RE	 %)	 was	 between	 -6.34	 and	 -4.99%	 (within	 ±	 15	 %)	 (Table	 26).	
Hence,	AG	was	proved	to	be	stable	in	RHB	after	three	F/T	cycles	below	-65°C.	
TABLE	 26:	 THREE	 SUCCESSIVE	 FREEZE	 (BELOW	 -65°C)	 AND	 THAW	 (ROOM	
TEMPERATURE)	CYCLES	STABILITY	TEST	IN	RHB	FOR	AG	(N	=	6)	
	 	
	Nominal	concentration	(ng/mL)	 30.0	 1600	
Run	number	 Measured	conc.	 Measured	conc.	
3	
28.5	 1415	
28.6	 1501	
28.4	 1519	
28.5	 1453	
27.0	 1719	
27.6	 1514	
Mean	 28.1	 1520	
S.D.	 0.649	 106	
CV%	 2.31	 6.94	
RE%	 -6.34	 -4.99	
	
Ø Benchtop	stability	test	at	room	temperature	
Imprecision	 (CV%)	 for	 the	 six	 replicates	 of	 QCL	 and	 QCH	 in	 RHB	 stored	 for	 2	
hours	at	RT	was	between	2.91	and	3.97	%	 (below	15%),	and	 inaccuracy	 (RE%)	
was	between	0.125	and	4.04%	(within	±	15%)	(Table	27).	Thus,	AG	proved	to	be	
stable	 in	 RHB	 when	 stored	 for	 2	 hours	 at	 RT	 before	 subjection	 to	 sample	
preparation.	AG	was	not	stable	in	RHB	after	4	hours	at	RT	(data	not	shown).	
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TABLE	 27:	 BENCHTOP	 STABILITY	 TEST	 OF	 AG	 IN	 RHB	 DURING	 2	 HOURS	 AT	 ROOM	
TEMPERATURE	(N	=	6)	
Nominal	concentration	(ng/mL)	 30.0	 1600	
Run	number	 Measured	conc.	 Measured	conc.	
2	
30.2	 1580	
31.0	 1675	
32.7	 1622	
29.9	 1550	
32.7	 1563	
30.7	 1622	
Mean	 31.2	 1602	
S.D.	 1.24	 46.6	
CV%	 3.97	 2.91	
RE%	 4.04	 0.125	
	
Ø Processed	sample	stability	at	autosampler	conditions	
Imprecision	 (CV	 %)	 for	 six	 replicates	 of	 QCL	 and	 QCH	 stored	 after	 extraction	
from	RHB	at	autosampler	conditions	(10°C,	protected	from	light)	for	4	days	was	
between	 2.93	 and	 3.07	%	 (below	 15	%),	 and	 inaccuracy	 (RE	%)	 was	 between	
0.802	and	6.89	%	(within	±	15	%).	Hence,	processed	RHB	samples	proved	to	be	
stable	for	4	days	at	10°C	and	protected	from	light	(Table	28).	
TABLE	28:	AUTOSAMPLER	STABILITY	TEST	OF	PROCESSED	RHB	SAMPLES	OF	AG	DURING	4	
DAYS	AT	10°C	AND	PROTECTED	FROM	LIGHT	(N	=	6)	
Nominal	concentration	(ng/mL)	 30.0	 1600	
Run	number	 Measured	conc.	 Measured	conc.	
5	
32.8	 1555	
32.9	 1650	
33.1	 1678	
31.0	 1613	
31.1	 1566	
31.5	 1615	
Mean	 32.1	 1613	
S.D.	 0.985	 47.3	
CV%	 3.07	 2.93	
RE%	 6.89	 0.802	
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Ø Long-term	stability	(LTS)	below	-65°C	
The	 slope	 of	 the	 calculated	 linear	 regression	 was	 0.9372	 (within	 1	 ±	 0.15).	
Hence,	 stability	 of	 samples	 in	 RHB	 could	 be	 confirmed	 for	 7	 days	 of	 storage	
below	-65°C	(Figure	32).	
	
	
FIGURE	32: LONG-TERM	STABILITY	OF	AG	IN		STORED	FOR	7	DAYS	BELOW	-65°C	
Ø Stock	solution	stability	
Stock	 solutions	 of	 AG	 and	 I.S.	 proved	 to	 be	 stable	 for	 various	 time	 periods	 in	
DMSO	(AG	for	109	days	and	forskolin	for	1355	days),	as	degradation	expressed	
by	 the	 difference	 percentage	 was	 -0.996	 %	 for	 AG	 and	 0.802	 %	 for	 forskolin	
(below	5	%)	(Table	29:	Stock	solution	stability	of	AG	in	DMSO	stored	below	-65°C	
for	109	days	and	2	hours	at	room	temperature	(n=6))	
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TABLE	29:	STOCK	SOLUTION	STABILITY	OF	AG	IN	DMSO	STORED	BELOW	-65°C	FOR	109	
DAYS	AND	2	HOURS	AT	ROOM	TEMPERATURE	(N=6)	
Stock	solutions	tested	 Replicates	 Peak	area	ratios	
t=109	days	 1	 3.10	
Old*SS	AG	 2	 3.07	
+	 3	 3.13	
New	SS	I.S	 4	 3.10	
	
5	 3.10	
	
6	 3.07	
Mean	 3.09	
S.D.	 0.0224	
CV%	 0.724	
t=0	 1	 3.24	
New	SS	analyte	 2	 3.11	
+	 3	 3.09	
New	SS	I.S.	 4	 3.00	
	
5	 3.02	
	
6	 2.91	
Mean	 3.06	
S.D.	 0.110	
CV%	 3.60	
Difference	%	 -0.996	
*	Stored	below	-65°C	for	109	days	
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TABLE	30:	STOCK	SOLUTION	STABILITY	OF	FORSKOLIN	 (I.S.)	 IN	DMSO	STORED	BELOW	-
65°C	FOR	1355	DAYS	AND	2	HOURS	AT	ROOM	TEMPERATURE	(N=6)	
Stock	solutions	tested	 Replicates	 Peak	area	ratios	
t=1355days	 1	 0.320	
Old*SS	I.S.	 2	 0.328	
+	 3	 0.326	
New	SS	AG	 4	 0.318	
	
5	 0.325	
	
6	 0.328	
Mean	 0.324	
S.D.	 0.00415	
CV%	 1.28	
t=0	 1	 0.309	
New	SS	I.S.	 2	 0.321	
+	 3	 0.324	
New	SS	AG	 4	 0.333	
	
5	 0.331	
	
6	 0.343	
Mean	 0.327	
S.D.	 0.0117	
CV%	 3.57	
Difference	%	 0.802	
*	Stored	below	-65°C	for	1355	days	
	
	 	
4.4.5 IN	SILICO	PREDICTION	OF	BLOOD-BRAIN	BARRIER	PERMEABILITY	
The	 analysis	 of	 descriptors	 relevant	 for	 the	 BBB	 permeation	 (Table	 31)	 shows	
that	 AG	 meets	 several	 criteria	 for	 BBB	 permeation:	 it	 is	 not	 too	 flexible	 (3	
rotatable	bonds),	has	a	low	molecular	weight	(MW	<	450	g/mol)	and	a	balanced	
lipophilicty	(logP)	falling	into	the	preferred	range	1.0	–	4.0	units.	 	However,	AG	
contains	as	much	as	 five	oxygen	atoms	 (ideally	 the	oxygen	atom	count	 should	
not	 exceed	 three	 form	 BBB+	 drugs)	 accounting	 for	 its	 rather	 high	 molecular	
polar	 surface	 area	 (above	 the	 threshold	 value	 of	 70	 Å2[37,38])	 clearly	
disfavoring	 BBB	 permeation.	 The	 QikProp	 model	 for	 brain/blood	 partitioning	
LogBB	predicts	 that	 only	 a	 low	proportion	would	be	distributed	 into	 the	brain	
and	AG	cell	permeability	predicted	using	the	QikProp	MDCK	model	is	rather	low,	
too.		
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TABLE	31:	IN	SILICO	CALCULATIONS	OF	BBB	PERMEATION	FOR	AG	
	 QikProp	descriptors	(3D	based)	
Marvin	
descriptors	
	
Compound	 MW	
Donor	
HBa	
accptHBb	
PSA	
(Å2)	
LogP		
(o/w)	
LogBBc	
QPPMDCKe	
(nm/s)	
PSA	
(Å2)	
LogP	
Rotatable	
bondsd	
AG	 350.5	 3	 8.1	 100.8	 1.44	 -1.33	 96.5	 87.0	 1.66	 3	
adonorHB:	donor	hydrogen	bonds;	bacceptor	hydrogen	bonds;	cLogBB:	Predicted	brain/blood	partition	coefficient	(for	
95%	of	known	drugs,	values	range	between	-3.0	and	1.2);	cQPPMDCK:	predicted	apparent	Madin-Darby	Canine	Kidney	
(MDCK)	cell	permeability	in	nm/s	(<	25	poor,	>	500	great);	dCounting	according	to	Veber	rule	
4.4.6 BLOOD-BRAIN	BARRIER	(BBB)	DRUG	PERMEABILITY	ASSAYS		
The	 first	BBB	drug	permeability	assay	was	done	with	 the	 free	 form	of	AG	at	5	
µM	with	a	co-incubation	with	a	 fluorescent	barrier	 integrity	marker	NAF	at	10	
µg/mL	 as	 negative	 control.	 The	 Papp	of	 AG	 in	 free	 form	 state	 for	 the	 apical	 to	
basolateral	transport	after	60	min	(Papp	A→B)	was	9.51±	0.707	x	10	-6	cm/s	(Figure	
33).	Compared	to	 the	Papp	A→B	of	 the	negative	control	NAF	 (7.85	±	0.188	x	10	 -6	
cm/s),	 the	 free	 form	 of	 AG	 did	 not	 permeate	 significantly	 the	 human	 BBB	
monolayer,	as	confirmed	by	 in	silico	predictions	 (Figure	33,Table	31).	The	%	of	
recovery	of	AG	was	85.3%	in	all	experiments,	suggesting	that	the	obtained	Papp	
value	was	reliable.	A	recovery	above	80%	is	required	for	an	acceptable	 in	vitro	
prediction	of	Papp	value[39].	After	each	permeability	assay,	TEER	values	and	CCL	
were	recorded.	 In	 the	case	of	 the	 free	 form	of	AG,	TEER	values	were	closer	 to	
the	maximum	TEER	values	reached,	indicating	that	the	free	form	of	AG	at	5µM	
did	not	impact	the	cell	layer	integrity	(Figure	33A).	
The	 data	 obtained	 with	 AG	 50	 µM	 loaded	 into	 HSA	 NPs	 in	 term	 of	 Papp	 are	
reported	 in	 the	 Figure	 33,	 while	 the	 TEER	 value	 and	 CCL	 after	 and	 before	 the	
screening	are	showed	 in	Figure	33	B.	The	Papp	A→B	of	AG	 loaded	 in	HSA	NPs	was	
18.7±	3.31	x	10	-6	cm/s	(Figure	33),	while	the	Papp	A→B	of	the	negative	control	NAF	
was	9.34	±0.611	x	10	 -6	 cm/s.	These	 results	 suggest	 that	HSA	NPs	AG	 improve	
the	 permeation	 of	 AG	 across	 the	 human	 BBB	monolayer.	 The	 integrity	 of	 the	
barrier	 was	 preserved	 during	 the	 experiments	 as	 shown	 in	 Figure	 33	 B	 and	
recoveries	for	both	AG	and	NAF	were	above	80	%.	
In	the	case	of	PECA	NPs	coated	with	1%	of	TW80	and	loaded	with	AG	at	50	µM,	
Papp	A→B	of	AG	was	32.6±	1.62	x	10	-6	cm/s	and	Papp	A→B	of	the	negative	control	NAF	
29.9	±4.38	x	10	-6	cm/s	(Table	6).	These	data	suggest	that	PECA	NPs	coated	with	
1%	of	 TW80	 induce	 a	 BBB	disruption	 since	 low	 TEER	 values	 (Figure	 33	 C)	 and	
high	 Papp	 value	 of	 the	 barrier	 integrity	 marker	 NAF	 were	 observed.	 After	 a	
second	exchange	of	 culture	medium	which	 improved	 the	 removal	of	 all	 TW80	
CHAPTER	4	
	
147	
traces,	TEER	values	reached	again	the	maximum	TEER	values	before	the	assays.	
This	 temporary	disturbance	of	 the	BBB	monolayer	 integrity	demonstrated	 that	
this	nanocarrier	appeared	to	be	non-suitable	for	in	vitro	studies.	Both	recoveries	
for	AG	and	NAF	were	above	80	%.	
	
*	Fresh	medium	exchange,	**AG	BBB	permeability	assays,	***	CellZscope	transferred	back	into	incubator	(37°C,	5%	CO2)	for	barrier	
integrity	control,	****	Fresh	medium	exchange	to	discard	all	traces	of	tween	80.	(A)	BBB	drug	permeability	assays	with	free	form	of	AG	
at	5	µM	and	NAF	at	10µg/mL,	(B)	BBB	drug	permeability	assays	with	HSA	NPs	loaded	with	AG	at	50	µM	and	and	NAF	at	10µg/mL,	(C)	BBB	
drug	permeability	assays	with	PECA	NPs	coated	with	1%	Tween	80	and	loaded	with	AG	at	50	µM	and	and	NAF	at	10µg/mL	
FIGURE	 33:	 MEAN	 TEER	 ±	 SD	 VALUES	 (BLACK	 CURVE)	 AND	 MEAN	 CELL	 LAYER	
CAPACITANCE	 (CCL)	 ±	 SD	 VALUES	 (BLUE	 CURVE)	 RECORDED	 IN	 REAL-TIME	 BY	 THE	
CELLZSCOPE	 SYSTEM	 OF	 HCMEC/D3	 CELL	 MONOLAYERS	 GROWN	 ON	 24-WELL	 TISSUE	
CULTURE	 INSERTS	 (N	=	14).	CCL	VALUES	 IN	 THE	RANGE	OF	0.5–5.0	µF/CM2	 INDICATE	
CELL	CONFLUENCY	AND	VALIDATE	TEER	VALUES.	
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4.5 CONCLUSION		
We	have	reported	the	optimization	of	formulative’s	parameters	in	term	of	size,	
polydispersity,	 surface	 charge,	 morphology	 and	 encapsulation	 efficacy	 for	
different	types	of	nanocarriers	able	to	encapsulate	the	neuroprotective	AG,	with	
excellent	 encapsulation	 efficiency.	 NPs	 are	 produced	with	 high	 yield;	 they	 are	
easy	to	prepare	with	good	reproducibility.	The	method	of	preparation	of	HSAT	
NPs	 is	 completely	 free	of	 toxic	 agent,	 according	with	 the	 recommendations	of	
green-chemistry.	The	release	of	AG	is	controlled	and	sustained	during	one	day.	
We	 developed	 a	 UPLC-MS/MS	 method	 for	 the	 analysis	 of	 AG	 in	 RHB	 and	
validated	 it	according	to	EMA	and	FDA	guidelines	for	 industry[20,21].	Forskolin	
was	selected	as	I.S.	All	the	validation	data	obtained	proved	that	the	method	was	
selective,	specific,	precise,	accurate	and	capable	of	reproducing	reliable	results.	
A	well-established	 immortalized	mono-culture	 human	 (hCMEC/D3)	 BBB	model	
was	 selected	 to	 test	 the	 permeability	 across	 the	 BBB	 of	 AG	 in	 free	 form	 and	
loaded	in	HSAT	NPs	and	PECA	NPs	coated	with	1%	of	TW80.	The	data	obtained	
showed	 that	 the	 free	 form	of	AG	did	not	permeate	 the	 in	 vitro	BBB	model,	as	
predicted	by	in	silico	predictions	of	BBB	penetration.	HSAT	NPs	increase	slightly	
the	 permeability	 of	 AG	 across	 the	 BBB.	 PECA	 NPs	 coated	 with	 1	 %	 of	 TW80	
disrupt	the	BBB	integrity,	thus,	further	investigations	are	needed	to	improve	the	
formulation	and	to	clarify	the	real	mechanism	of	passage	across	the	BBB.	HSAT	
AG	 NPs	 seem	 to	 represent	 a	 better	 candidate	 for	 the	 neurodegenerative	
diseases	 treatment.	 The	 validated	 UPLC-MS/MS	 will	 be	 used	 and	 adapted	 for	
future	 pharmacokinetic	 studies	 and	 to	 test	 the	 oral	 bioavailability	 of	HSAT	AG	
NPs.	
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In	 the	 last	 years,	 nanotechnology	 is	 offering	 novel	 chances	 to	 enhance	 the	
therapeutic	potential	of	poorly	BBB-permeable	drugs.		
	
At	 the	 beginning	 of	 my	 PhD	 investigation,	 ECA	 was	 selected	 as	 synthetic	
monomer	to	made	NPs,	because	it	is	less	investigated	then	butyl	cyanoacrylate,	
studied	 from	many	years	 for	 the	synthesis	of	NPs	 from	brain	delivery	of	active	
compounds.	 Developed	 nanocarriers	 were	 coated	 with	 non-ionic	 surfactant	
TW80	 and	 were	 produced	 with	 high	 yields,	 spherical	 shape	 and	 regular	 and	
narrow	 size	 distribution	 The	 in	 vivo	 study	 demonstrated	 the	 ability	 of	 NPs	 to	
cross	 the	 BBB,	 the	 biocompatibility	 and	 biodegradability	 of	 the	 selected	
monomer.	
PECA-SalB	NPs	 coated	with	 TW80	were	 successfully	 developed	 and	 they	were	
suitable	 for	 parental	 administration,	 with	 high	 encapsulation	 efficiency	 and	 a	
sustained	 release	 behaviour,	 thus,	 they	 were	 valuable	 for	 CNS	 clinical	
applications.	These	studies	represented	a	starting	point	for	future	investigations	
to	 understand	 the	 potential	 application	 in	 vivo	 of	 PECA-SalB	 NPs	 to	 treat	
neurodegenerative	disorders.	
	
HSA	 was	 selected	 as	 material	 for	 the	 development	 of	 news	 brain	 delivery	
systems.	 In	 literature	 there	 are	 only	 few	 studies	 that	 report	 HSA	NPs	without	
surfaces	modification	 for	 brain	 delivery.	 Different	methods	 of	 preparations	 of	
HSA	NPs,	using	two	cross-linking	methods,	were	developed	and	optimized.	HSA	
NPs	were	produced	with	very	good	yields,	with	a	sphere-like	shape	and	reliable	
size	 distribution,	 suitable	 for	 systemic	 administration.	 Firstly,	 NPs	 were	
optimized	 by	 using	 a	 very	 low	 amount	 of	 cross-linking	 agent,	 moreover,	 NPs	
made	by	thermal	polymerization	method,	according	to	green	chemistry	criteria,	
resulted	 to	 be	 superior	 than	 those	 obtained	 via	 chemical	 method	 in	 term	 of	
formulative	 parameters,	 safety,	 reduction	 of	 costs	 and	 the	 time	 necessary	 for	
NPs	 preparation.	 The	 in	 vivo	 performance	 of	 both	 HSA	 nanoparticles	 is	
comparable:	NPs	 crossed	BBB	and	biodistribution	 studies	 showed	 that	did	not	
induce	 inflammatory	 response.	 Further	 studies	 will	 be	 oriented	 to	 the	
investigation	of	the	BBB	crossing	properties	of	the	loaded	HSA	NPs.			
	
The	 neuroprotective	 AG	 was	 loaded	 into	 all	 optimized	 nanocarriers,	 with	
excellent	encapsulation	efficiency.	NPs	are	produced	with	high	yield,	 improving	
the	formulative’s	parameters	in	term	of	size,	polydispersity,	surface	charge	and	
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morphology.	The	release	profile	of	AG	showed	that	it	is	controlled	and	sustained	
during	 one	 day.	 For	 the	 qualitative	 and	 quantitative	 analysis	 of	 AG,	 a	 UPLC-
MS/MS	method	in	RHB	was	developed	and	validated	according	to	EMA	and	FDA	
guidelines,	 using	 Forskolin	 as	 internal	 standard.	 The	 method	 was	 selective,	
specific,	 precise,	 accurate	 and	 capable	 to	 reproduce	 reliable	 results.	 A	 well-
established	mono-culture	human	 (hCMEC/D3)	BBB	model	was	 selected	 to	 test	
the	permeability	across	the	BBB	of	AG	in	free	form	and	loaded	in	HSAT	NPs	and	
PECA	NPs	coated	with	1%	of	TW80.	AG	free	did	not	permeate	the	 in	vitro	BBB	
model,	as	expected	by	 in	silico	predictions	of	BBB	penetration,	while	HSAT	NPs	
increase	 the	permeability	of	AG	across	 the	BBB.	PECA	NPs	 coated	with	1	%	of	
TW80	 disrupt	 the	 BBB	 integrity,	 thus,	 further	 investigations	 are	 needed	 to	
improve	the	formulation.		
HSAT	AG	NPs	seem	to	represent	a	better	candidate	for	the	neurodegenerative	
diseases	treatment.	Future	pharmacokinetic	studies	and	bioavailability	tests	will	
be	done	adapting	the	validated	UPLC-MS/MS	method.	
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I.I ABSTRACT	
A	chromatographic	method	for	the	qualitative	and	quantitative	characterization	
of	 peel	 of	 different	 species	 of	Citrus	was	 developed	 in	 order	 to	 obtain	 a	 total	
evaluation	 of	 the	 phytocomplex	 and	 to	 verify	 the	 eventual	 content	 of	
protoalkaloids.	 Twenty-four	 constituents	 comprising	 flavones,	 flavanones,	
polymethoxyflavonoids	and	protoalkaloids	were	fully	identified.	Fourteen	major	
constituents	 were	 quantified	 using	 validated	 HPLC	 method	 with	 UV–vis.	 The	
samples	 were	 analysed	 by	 HPLC-DAD	 and	 HPLC-MS,	 HPLC-MS/MS.	 The	
identification	 of	 the	 components	 was	 performed	 by	 comparing	 the	 retention	
times,	 UV-Vis	 and	 MS	 spectra,	 with	 these	 of	 reference	 standards	 or	 for	
comparison	 with	 the	 literature	 data.	 Sweet	 orange,	 lemon,	 mandarin	 and	
grapefruit	are	the	analyzed	matrices.	Flavanones	(hesperidin,	naringin),	flavones	
(lucenin-2,	 vicenin-2,	 stellarin-2,	 lucenin-2,4'-methylether,	 luteolin-7-O-
rutinoside)	 and	 polymethoxyflavones	 (sinensetin,	 nobiletin,	 tangeretin,	
3,5.6,7,8.3',4'-	 hepta-methoxy	 flavone)	 have	 been	 identified	 as	 the	 main	
constituents.	 Synephrine	 resulted	 present	 in	 all	 samples,	 except	 in	 the	
grapefruit.	
I.II INTRODUCTION	
The	 genus	Citrus	 represents	 the	 largest	 sector	 of	 the	world’s	 fruit	 production,	
with	more	than	100	million	tons	produced	each	season,	among	which,	the	major	
commercially	 important	 orange	 fruit	 accounted	 for	 almost	 45	 million	 tons.	
Around	 34%	 of	 these	 products	 were	 used	 for	 juice	 production,	 yielding	 large	
amounts	 of	 peels	 (roughly	 half	 of	 the	 fruit	mass)	which	 represent	 a	 source	 of	
molasses,	pectin,	and	essential	oil.	The	waste	material	 is	usually	dried	and	sold	
as	cattle	feed,	mixed	with	dried	pulps	[1].	
Citrus	 peels	 have	 recently	 been	 considered	 also	 potential	 sources	 of	 other	
functional	 components,	 a	 rich	 source	 of	 polyphenols,	 in	 particular	
polymethoxyflavonoids	 and	 flavanones	 (mainly	 glycosides),	 having	potent	 anti-
oxidant,	 anti-inflammatory	 and	 antithrombogenic	 anti-atherogenic	 activities,	
and	 hypolipidemic/hypoglycaemic	 effects	 [2-12].	 In	 addition,	
polymethoxyflavonoids	 have	 an	 antiproliferative	 activity	 [13-17].	 Other	 health	
significant	 constituents	 of	 Citrus	 peels	 are	 phenolic	 acids	 and	 protoalkaloids,	
namely	 hydroxyphenethylamine	 alkaloids	 principally	 represented	 by	 p-
synephrine	 and	 p-octopamine	 which	 are	 weak	 adrenergic	 agonists,	 active	 on	
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both	α-	and	β-adrenoceptors,	but	generally	orders	of	magnitude	less	active	than	
norepinephrine	[18].	
Protoalkaloids	have	been	involved	in	the	last	decade	in	safety	issues,	i.e.	several	
reports	of	adverse	effects	due	to	the	use	of	bitter	orange,	as	a	replacement	for	
ephedra,	in	weight-loss	dietary	supplements.	Synephrine	and/or	octopamine	are	
speculated	 to	 play	 a	 role	 in	 the	 advent	 of	 such	 effects,	 mainly	 increasing	 of	
cardiac	output	and	blood	pressure	[19].	Consequently,	many	health	authorities	
of	 EU	 and	 non-EU	 countries	 has	 set	 a	 maximum	 limit	 for	 the	 daily	 intake	 of	
synephrine	from	food	supplements.	Therefore,	the	Germany’s	Federal	 Institute	
for	Risk	Assessment	has	set	a	maximum	limit	for	the	daily	 intake	of	synephrine	
from	food	supplements	of	6.7	mg.		
Accordingly,	mostly	of	analytical	methods	reported	in	the	literature	focus	on	the	
identification	of	 the	 constituents	 of	 bitter	 orange	 (Citrus	 aurantium	 L.).	 In	 this	
work	 other	 Citrus	 matrices,	 namely	 sweet	 orange,	 lemon,	 mandarin	 and	
grapefruit	have	been	investigated	because	of	their	important	economic	value	as	
food	and	feed,	as	a	source	of	extracts	or	single	constituents	with	medicinal	and	
health	properties.	
Hence,	in	many	regions	of	the	world,	Citrus	peel	is	traditionally	used	for	relieving	
stomach	 upset,	 some	 inflammatory	 syndromes	 and	 infections,	 and	 as	 a	
consequence	 there	 are	 official	 monographs	 of	 Citrus	 peels	 and	 their	
preparations	 (i.e.	 fluid	 extract,	 tincture,	 syrup).	 In	 the	 current	 European	
Pharmacopoeia,	the	oldest	monograph	is	“Bitter	orange	epicarp	and	mesocarp”	
from	Citrus	aurantium	L.	ssp.	aurantium	(syn.	C.	aurantium	L.	ssp.	amara	Engl.)	
and	 the	 tincture	produced	 from	one	part	 of	 the	 freshly	 powdered	drug	 and	5	
parts	of	alcohol	 (70	per	cent	V/V)	by	an	appropriate	procedure.	Quality	of	 this	
peel	 is	 only	 based	 on	 the	 volatile	 oil	 content	 (1.0-2.5	 %	 V/m)	 with	 a	 main	
constituent,	 limonene	 (up	 to	 90	%)	 [20].	 In	 addition,	 there	 is	 a	monograph	 of	
“Sweet	orange	oil”	defined	as	essential	oil	obtained	without	heating,	by	suitable	
mechanical	 treatment	 from	 the	 fresh	 peel	 of	 the	 fruit	 of	 Citrus	 sinensis	 (L.)	
Osbeck	 (Citrus	 aurantium	 L.	 var.	 dulcis	 L.)	 [21].	 Finally,	 there	 are	 two	
monographs	 of	 Mandarin.	 One	 is	 “Mandarin	 oil”	 defined	 as	 the	 essential	 oil	
obtained	without	 heating,	 by	 suitable	mechanical	 treatment,	 from	 the	 peel	 of	
the	 fresh	 fruit	 of	Citrus	 reticulata	 Blanco	 [22].	 The	other	 is	 “Mandarin	 epicarp	
and	mesocarp”	defined	as	 the	dried	epicarp	and	mesocarp	of	 the	 ripe	 fruit	 of	
Citrus	reticulata	Blanco	or	its	cultivars,	partly	free	from	the	white	spongy	tissue	
of	the	mesocarp	[23].	Only	this	Citrus	monograph	reports	on	the	quality	control	
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based	on	flavonoids,	on	the	content	of	a	flavanone	glycoside	(minimum	3.5	per	
cent	of	hesperidin)	[23].	
Despite	the	extensive	pharmacological	studies	on	the	Citrus	constituents,	there	
are	 no	 available	 analytical	 methods	 able	 to	 simultaneously	 analyse	 flavones,	
flavanones,	 polymethoxyflavonoids,	 hydroxycynnamic	 acids	 and	protoalkaloids.	
Up	 to	 now	 several	 analytical	 methods	 have	 been	 developed	 for	 the	
quantification	 of	 the	 content	 of	 phenethylamine	 alkaloids	 (e.g.	 synephrine,	
octopamine)	 in	citrus	peels	and	fruits,	extracts	and	food	supplements;	most	of	
them	 use	 chromatographic	 (HPLC,	 GC)	 and	 electrophoretic	 (CE)	 methods,	
including	 enantioselective	 analysis	 [24].	 Other	 methods	 have	 been	 developed	
for	 the	 simultaneous	 characterization	of	 protoalkaloids	 and	organic	 acids	 [25],	
flavanones	 and	 protoalkaloids	 [26],	 flavanones,	 hydroxycinnamic	 acids	 and	
protoalkaloids	 [27],	 both	 polymethoxyflavonoids	 and	 flavonones	 [28],	
hydroxycinnamates	and	polymethoxylated	flavones	[29].		
Aim	of	this	study	was	to	develop	a	simple	and	rapid	HPLC-DAD	and	HPLC-MS/MS	
method	 for	 qualitative	 and	 quantitative	 standardization	 of	 all	 flavonoids	 and	
protoalkaloids	 in	 Citrus	 peels.	 The	 samples	 were	 analyzes	 by	 using	 high	
performance	liquid	chromatography	(HPLC-DAD)	and	mass	spectrometry	(HPLC-
MS,	 HPLC-MS/MS).	 Flavones	 (lucenin-2,	 vicenin-2,	 stellarin-2,	 lucenin-2,4'-
methylether,	 luteolin-7-O-rutinoside),	 flavanones	 (hesperidin,	 naringin)	 and	
polymethoxyflavones	 (sinensetin,	 nobiletin,	 tangeretin,	 3,5.6,7,8.3',4'-	 hepta-
methoxyflavone)	 have	 been	 identified	 as	 the	 main	 constituents.	 Synephrine	
resulted	present	in	all	samples,	except	in	the	grapefruit.	
I.III MATERIALS	AND	METHODS	
I.III.I 	CHEMICALS		
The	 solvents,	 HPLC	 grade	 acetonitrile,	 formic	 acid,	 dimethyl	 sulfoxide	 and	
methanol	were	purchased	from	Sigma-Aldrich	(Steinheim,	Germany)	and	with	a	
purity	of	96%	 is	ethanol	of	HPLC	grade	 (Riedel-de-Haën	Rdh	Soherchemikalien	
Gmbh	&	 Co.	 KG	 Seelze,	 Germany).	 Deionized	water	 (18	MX)	was	 prepared	 by	
distilled	 water	 through	 a	 Milli-Q	 system	 (Millipore,	 Milford,	 MA,	 USA).	 Other	
reagents	and	chemicals	are	of	analytical	grade.		
I.III.II 	SAMPLES	OF	CITRUS	PEELS	
Sweet	orange,	Citrus	sinensis	(L.)	Osb.	(CD	16781),	lemon,	Citrus	limon	(L.)	Brum.	
fil.	 (R7146Z),	 grapefruit,	 Citrus	 paradise	 Macf	 (R7144Z),	 mandarin,	 Citrus	
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reticulata	 Blanco	 (R7145Z)	 peels	 were	 kindly	 offered	 by	 Amway	 GmbH,	
Puchheim,	Germany.	
I.III.III STANDARDS	
For	 the	 qualitative	 and	 quantitative	 analysis	 of	 the	 extracts	 the	 following	
standards	 were	 used:	naringin	 (naringenin-7-O-neohesperidose),	 hesperidin	
(hesperetin-7-O-rutinoside),	 sinensetin	 (3',4',5,6,7-pentamethoxyflavone),	
synephrine	 were	 purchased	 from	 Extrasynthèse	 (Genay,	 France),	 and	 their	
purity	was	higher	than	98%.		
I.III.IV HPLC/DAD/MS-MS/MS	QUALITATIVE	AND	QUANTITATIVE	ANALYSIS	
OF	PLANT	EXTRACTS	
I.III.IV.I Preparation	of	extracts	
From	each	peels	different	extract	was	prepared.	Methanol	extract	of	grapefruit	
peels	was	 prepared	 by	maceration	 of	 2g	 of	 herbal	 drug	with	 100ml	 of	MeOH	
100%	 (thrice).	 Hydroalcoholic	 extracts	 of	 lemon	 and	 mandarin	 peels	 were	
prepared	 by	maceration	 of	 2g	 of	 herbal	 drugs	 with	 100ml	 of	 EtOH:H20	 70:30	
(thrice),	whereas	hydroalcoholic	extracts	of	 sweet	orange	peels	by	maceration	
of	 2g	 of	 peels	 with	 100ml	 of	 EtOH:H20	 80:20	 (thrice).	 After	 three	 days,	 the	
extract	were	filtered	and	evaporated	to	dryness.	
I.III.IV.II Sample	Preparation	
Dry	 extract	were	 solubilized	 in	MeOH:DMSO	4:1,	 ultrasonicated	 for	 5	minutes	
and	centrifugated	for	4	min	at	14.000	rpm	prior	to	injection.	
I.III.IV.III HPLC-DAD	and	HPLC–MS/MS	analysis	instrumentations	
The	 HPLC	 system	 consisted	 of	 a	 HP	 1100	L	 instrument	 with	 a	 Diode	 Array	
Detector	 and	managed	 by	 a	 HP	 9000	 workstation	 (Agilent	 Technologies,	 Palo	
Alto,	CA,	USA).	The	column	was	a	Zorbax	Eclipse	XDB-C18,	 (150	mm	×	4,6	mm)	
with	a	5	μm	particle	size	 (Agilent)	maintained	at	27	°C.	Eluents	were	methanol	
(A),	 H2O	 at	 pH	 3.2	 by	 formic	 acid	 (B)	 and	 acetonitrile	 (C)	 at	 a	 flow	 rate	 of	
1	ml/min.	 The	 gradient	 condition	 was:	 0–10	min,	 100-85%	 B,	 0-15%	 C;	 10–
20	min,	85–80%	B,	15-10%	C;	20–25	min	80–70%	B,	10-20%	C;	25–35	min,	70–
10%	B,	20-75%	C;	35–40	min,	10%	B,	75-80%	C;	40–45	min,	10–100%	B	80-0%	C,	
with	a	10	min	equilibration	time.	Injected	volume	of	the	samples	was	10	μl.	The	
UV	spectra	were	recorded	between	200	and	600	nm.	Chromatographic	profiles	
were	registered	at	240,	280,	330	and	350	nm.	
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MS	and	MS/MS	experiments	were	conducted	using	an	HPLC	Surveyor	coupled	to	
a	 LTQ	 equipped	 with	 an	 ESI	 interface	 (Thermo	 Electron,	 San	 Jose,	 CA,	 USA).	
Mass	 spectrometry	and	electrospray	operating	parameters	were	optimised	 for	
negative	and	positive	polarity.	ESI	parameters	were	as	follow:	Sheath	Gas	Flow	
Rate	 (arb):	 30,	 Aux	Gas	 Flow	 Rate	 (arb):	 9,	 Sweep	Gas	 Rate	 (arb):	 5,	 Capillary	
Temp	 (°C):	 280.00,	 Capillary	 Voltage	 (V):	 11.00,	 Tube	 Lents	 (V):	 60.00,	
Normalised	Collision	Energy:	25,	20.	MS	spectra	were	acquired	from	m/z	240	to	
100	in	negative	and	in	positive	mode.		
I.III.IV.IV Identification	of	peaks		
Identification	 of	 marker	 constituents	 was	 performed	 by	 HPLC-UV,	 MS	 and	
MS/MS	 analysis	 by	 comparing	 the	 retention	 time,	 the	 UV,	 MS	 and	 MS/MS	
spectra	of	the	peaks	 in	the	samples	with	those	of	authentic	reference	samples	
or	literature	data.	
I.III.IV.V Preparation	of	standard	solutions		
Calibration	curve	solutions	were	freshly	prepared	by	dilution	of	stock	solutions	
CH3OH/DMSO	4:1	to	obtain	the	following	concentrations:	2.285,	3.427,11.426,	
13.7112	and22.852	μg/ml	for	hesperidin,	3.15,	1.89,1.26,	0.88,	0.25	sinensetin	
and	14.1,	8.46,	5.64,	3.95,	1.12	μg/ml	for	naringin		
I.III.IV.VI Quantitative	determination	of	constituents	
The	 method	 of	 external	 standard	 was	 applied	 to	 quantify	 each	 compound.	
Quantification	 of	 individual	 constituents	 was	 performed	 using	 a	 regression	
curve,	each	point	 in	 triplicate.	Measurements	were	performed	at	280	and	350	
nm	 which	 is	 the	 maximum	 absorbance	 for	 flavonoids	 and	
polymethoxyflavonoids	 respectively.	Results	were	expressed	as	 the	mean	±	SD	
of	3	separate	experiments.	
I.III.IV.VII 	Limit	of	detection	and	quantification	
Limits	 of	 detection	 (LOD)	 and	 limits	 of	 quantification	 (LOQ)	 were	 determined	
using	 the	 linear	 regression	 equation.	 The	 LOD	 was	 defined	 as	 the	 lowest	
concentration	 level	 resulting	 in	 a	 peak	 area	 of	 three	 times	 the	 baseline	 noise	
(S/N=3).	 The	 LOQ	was	defined	 as	 the	 lowest	 concentration	 level	 resulting	 in	 a	
peak	area	of	10	times	the	baseline	noise	(S/N=10).	
Synephrine,	 naringin,	 sinensetin	 and	 hesperidin	 were	 accurately	 weighed	 and	
dissolved	in	methanol.	Synephrine	LOD	2.46	ng;	LOQ	12.3	ng.	Naringin	LOD	1.0	
ANNEX	I	
	
165	
ng;	LOQ	7.67	ng.	Hesperidin	LOD	1.32	ng;	LOQ	9.86	ng.	Sinensetin	LOD	1.78	ng;	
LOQ	10.7	ng.	
I.IV RESULTS	AND	DISCUSSION	
The	analytical	study	aimed	to	identify	the	substances	present	in	the	commercial	
peels	of	sweet	orange,	lemon,	grapefruit,	mandarin.	Peels	were	extracted	using	
hydroalcoholic	 solution	 for	 sweet	 orange,	 lemon	 and	 grapefruit	 and	methanol	
for	mandarin.	The	yields	of	the	extraction	process	were	26.25%,	49.23%,	45.88%	
and	23.10%,	 respectively.	The	extracts	were	analyzed	by	HPLC-UV-DAD-MS	 for	
the	qualitative	and	quantitative	evaluation	of	the	compounds	of	interest.	
I.IV.I OPTIMIZATION	OF	CHROMATOGRAPHIC	CONDITIONS	
The	selection	of	the	chromatographic	conditions	was	guided	by	the	requirement	
for	obtaining	chromatograms	with	better	resolution	of	adjacent	peaks	within	a	
short	analysis	time.	Formic	acid	was	used	as	a	mobile	phase	modifier,	because	it	
significantly	 restrained	 the	 peak	 tailing	 of	 phenolic	 acids	 and	 alkaloids	 in	 our	
experiments.	 Moreover,	 considering	 the	 different	 degrees	 of	 polarity	 of	 the	
compounds	of	the	phytocomplexes,	the	gradient	elution	was	used	to	achieve	a	
better	separation.	
Under	the	optimum	gradient	conditions	reported	 in	the	experimental	part,	the	
baseline	separation	of	these	peaks	was	achieved.	As	stationary	phase,	we	tested	
two	reverse	phase	columns:	Zorbax®	Eclipse	XDB-C18	(4.6	x	150	mm,	5μm)	and	
Vydac®	 C18,	 (4.6x250	 mm,	 5μm).	 The	 first	 column	 has	 shown	 the	 best	
performance	(Fig.	1A-1D).	The	optimal	wavelengths	for	simultaneous	analysis	of	
flavones,	 flavanones,	 polymetoxyflavonoids,	 alkaloids	 and	 phenolic	 acids	 were	
set	at	240	nm,	280	nm	and	330	and	350	nm.		
The	 satisfying	MS	 response	 of	 flavones,	 flavanones	 and	 polymetoxyflavonoids,	
was	mainly	obtained	in	the	negative	mode,	and	that	of	alkaloids	was	obtained	in	
the	positive	mode.	
The	 selected	 ion	monitoring	 (SIM)	mode	was	 employed	 to	 identify	 the	 target	
components	 in	 our	 experiments.	 The	 retention	 time,	 UV	 spectra	 and	 MS	
information	 could	 help	 identify	 the	 compounds	 in	 the	 plant	 extracts	 by	
comparison	with	those	from	authentic	standards	or	with	literature	data.	
I.IV.II QUALITATIVE	ANALYSIS	OF	SWEET	ORANGE	PEELS	
Retention	 times,	 UV-vis	 absorption	 and	 fragmentation	 profiles	 of	 MS	 and	
MS/MS	 of	 all	 the	 compounds	 identified	 in	 the	 extract	 of	 sweet	 orange	 were	
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showed	 in	 Table	 32:	 altogether	 10	 compounds	 were	 identified	 (C1-C10)	
belonging	to	the	chemical	class	of	flavonoids.		
TABLE	32:	CONSTITUENTS	OF	SWEET	ORANGE	IDENTIFIED	BY	HPLC-DAD-MS	AND	
HPLC-	MS/MS	
	
Next	figures	show	the	chromatographic	profile	(Figure	34:	Chromatogram	at	350	
nm	 of	 Sweet	 orange	 )	 and	 TIC	 in	 positive	 and	 negative	 mode	 (Figure	 35)	 of	
hydroalcoholic	extract	of	sweet	orange.		
	
 
Peak Rt 
Positive ion 
mode 
Negative ion 
mode  MS/MS fragmentation UV (nm) Identification 
C1 13.0  593.4 [M-H]- 
593.2 [M-H]-  
575.2 [(M-H)-18]- 
503.1 [(M-H)-90]- 
473.1 [(M-H)-120)]- 
383.1 [(M-H)-210)]- 353.1 
[(M-H)-240)]- 
271, 335 Apigenin 6,8-di-C-
glucoside (Vicenin-2) 
C2 26.3  579.4 [M-H]- 
579.3 [M-H]-  
459.2 [(M-H)-120)]- 313.1 
[(M-H)-266)]- 271.0 [(M-
H)-308)]- 
214, 226 
284, 334 
Naringin isomer 
C3 27.5 611.1[M+H]+ 609.4 [M-H]-  228, 284, 
334 
Hesperetin 7-O-
rutinoside (Hesperidin) 
C4 29.3  593.4 [M-H]- 285 [(M-H)-308)]- 282, 330 
Isosakuranetin-7-O-
neohesperidoside 
(Poncirin) 
C5 30.0 728.6[M+H]+ 726.6 [M-H]-   Citrusin III 
C6 32.0 373.4[M+H]+   
214,239, 
269, 331 
5,6,7,3',4'-
Pentamethoxyflavone 
(Sinensetin) 
C7 32.4 403.3[M+H]+   270, 330 Nobiletin isomer 
C8 32.8 403.3[M+H]+  
388.4 [(M+H)-14]+  
373.3 [(M+H)-30]+  
355.4 [(M+H)-48]+  
313.5 [(M+H)-90]+  
151.2 [(M+H)-151]+ 
248, 270, 
330 
5,6,7,8,3',4'-
Examethoxyflavone 
(Nobiletin) 
C9 33.2 433.4[M+H]+  
418.4 [8M+H)-15]+  
403.3 [(M+H)-30]+  
165.2 [(M+H)-268]+ 
254, 343 
3,5,6,7,8,3',4'-
Eptamethoxyflavone 
C10 33.6 373.4[M+H]+  
358.3 [(M+H)-15]+  
343.3 [(M+H)-30]+  
325.3 [(M+H)-48]+  
283.3 [(M+H)-90]+  
151.3 [(M+H)-222]+ 
271,336 5,6,7,8,4'-Pentamethoxyflavone 
(Tangeretin) 
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FIGURE	34:	CHROMATOGRAM	AT	350	NM	OF	SWEET	ORANGE	SAMPLE	
	
FIGURE	35:	TOTAL	ION	CURRENT	(POSITIVE	TOP	AND	NEGATIVE	BOTTOM	IONIZATION)	OF	
SWEET	ORANGE	SAMPLE	
Vicenin-2	 (PM	 594)	 provides	 [M-H]-	 with	m/z	 593.4.	 For	 further	 confirmation,	
this	ion	was	subjected	to	MS/MS	investigation	to	produce	secondary	fragments	
(575	[(M-H)-18]-,	503	[(M-H)-90]-,	473	[(M-H)-120)]-,	383	[(M-H)-210)]-,	353	[(M-
H)-240)]-),	 which	 were	 in	 agreement	 with	 those	 previously	 reported	 in	 the	
literature	 [30-31].	 The	 compound	 C2,	 with	 Rt	 of	 26.3	 minutes,	 is	 a	 structural	
isomer	of	naringin	(Rt	=	27.3).	The	MS	spectrometry	generates	the	ion	with	m/z	
579.4	 characteristic	 of	 both.	 Finally,	 as	 a	 further	 confirmation,	 the	 MS/MS	
analysis	produces	 the	same	pattern	of	 fragmentation	that	naringin	579	 [M-H]-,	
459	 [(M-H)-120)]-,	 313	 [(M-H)-266)]-,	 271	 [(M-H)-308)]-	 [32].	 Among	 these	
fragments	 the	 most	 abundant	 resulted	 m/z	 271.0	 [M-H]-,	 probably	 due	 to	
structural	differences	between	the	isomers	that	make	this	bond	cleavage	more	
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probable	 that	 the	 fragment	 with	 m/z	 459.2,	 typical	 of	 naringin.	 The	 cleavage	
consists	 in	 the	 loss	 of	 the	 sugar	 (rutinose)	 with	 formation	 of	 a	 fragment	
corresponding	to	the	aglycone	naringenin.	The	peaks	at	27.5,	32.0	minutes	were	
identified	 as	 hesperidin	 (C3)	 and	 sinensetin	 (C6)	 for	 comparison	 with	 the	
standards.	The	next	compound	at	29.3	min	was	attributed	 to	poncirin	 (C4),	by	
comparison	with	UV	and	mass	spectra.	The	negative	ionization	generates	an	ion	
with	m/z	593.4	 [M-H]-.	 In	 fact,	 even	 if	 the	 vicenin-2,	 present	 in	 sweet	orange,	
has	 the	 same	molecular	weight	 and	 it	 can	 generate	 this	 ion,	 the	 confirmation	
comes	 from	 the	 comparison	 with	 the	 literature	 data	 [28]	 and	 from	 different	
time	 elution	 and	MS/MS	data.	 Poncirin	 generates	 essentially	 the	 ion	with	m/z	
285.2,	resulting	from	the	bond	cleavage	of	the	sugar	and	loss	of	neohesperidose	
(m/z	308),	leaving	the	aglycone	isosakuranetina	(m/z	285[(M-H)-308)]).	This	ion	
is	 not	 observed	 in	 the	 case	 of	 vicenin-2	 because,	 in	 this	 case	 the	 fragments	
characteristic	 are	due	 to	 the	 sugars	 ring	opening.	 The	peak	 at	 30.0	minutes	 is	
the	superposition	of	three	substances	with	m/z	726.6	[M-H]-,	696.6	[M-H]-	and	
711.2	[M-H]-.	Among	these,	the	only	possible	 identification	was	that	of	the	 ion	
with	 m/z	 726.6	 attributed	 to	 Citrusina	 III	 (C5),	 a	 cyclic	 peptide	 consisting	 of	
seven	 aminoacids:	 Gly-Ser-Pro-Leu-Leu-Pro-Tyr.	 The	 compount	 at	 32.0	 min	 is	
the	 sinensetin	 (C6),	 confirmed	 by	 comparison	with	 the	 standard.	 The	 peak	 at	
32.4	minutes	is	a	structural	isomer	of	nobiletin	(C7),	with	the	same	UV	spectrum	
and	 the	 same	 ions	 generates	 in	 positive	mode	 (m/z	 403.3	 [M+H]+;	m/z:	 388.4	
[(M+H)-14]+;	 373.3	 [(M+H)-30]+;	 355.4	 [(M+H)-48]+;	 313.5	 [(M+H)-90]+;	 151.2	
[(M+H)-151]+.	Nobiletin	was	identified	at	33.8	min.	(C8).	The	C9	peak	with	Rt	of	
33.2	min	corresponds	to	3,5,6,7,8,3',4'-eptametossiflavone	as	can	be	evidenced	
by	its	characteristic	UV	and	MS	spectrum	[33].		The	last	compound	identified	in	
sweet	orange	was	 the	 tangeretin	C10	 (Rt	 33.6	min).	 In	 fact,	 comparing	 its	UV,	
MS,	MS–MS	data	and	retention	time	to	that	already	described,	it	was	possible	to	
obtain	unambiguous	structural	assignment	[33].	
I.IV.III QUALITATIVE	ANALYSIS	OF	LEMON	PEELS	
In	 lemon	 matrix	 11	 compounds	 were	 identified	 (L1-L11)	 belonging	 to	 the	
chemical	 class	 of	 flavonoids,	 as	 reported	 in	 Table	 33:Constituents	 of	 Lemon	
identified	by	HPLC-DAD-MS	and	HPLC-MS/MS.		
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TABLE	 33:CONSTITUENTS	 OF	 LEMON	 IDENTIFIED	 BY	 HPLC-DAD-MS	 AND	 HPLC-
MS/MS	
	
Next	 figures	 show	 the	 chromatographic	 profile	 (Figure	 36)	 and	 TIC	 of	 positive	
and	negative	ionization	(Figure	37)of	hydroalcoholic	extract	of	Lemon.		
	
 
Peak Rt Positive mode 
Negative 
mode 
MS/MS 
fragmentation 
UV 
(nm) Identification 
L1 11.9  609.4 [M-H]-  270, 349 
Luteolin-6,8-di-C-glucoside 
(Lucenin-2) 
L2 13.0  593.2 [M-H]- 
593.2 [M-H]- 
575.2[(M-H)-18]- 
503.1[(M-H)-90]- 
473.1[(M-H)-120)]- 
383.1[(M-H)-210)]- 
353.1[(M-H)-240)]- 
271, 
335 
Apigenin 6,8-C-di-glucoside 
(Vicenin-2) 
L3 13.7  623.4 [M-H]- 
623.5[M-H]- 
605.4[(M-H)-18)]- 
533.4[(M-H)-90)]- 
503.3[(M-H)-120)]- 
413.4[(M-H)-210)]- 
383.3[(M-H)-240)]- 
271, 
348 
Diosmetin 6,8-di-C-glucoside 
(Lucenin-2,4'-methylether) 
L4 14.4  623.4 [M-H]- 
623.4[M-H]- 
605.4[(M-H)-18)]-
533.4[(M-H)-90)]- 
503.3[(M-H)-120)]- 
413.3[(M-H)-210)]- 
383.3[(M-H)-240)]- 
271, 
347 
Chrysoeriol 6,8-di-C-glucoside 
(Stellarin-2) 
L5 22.1  595.3 [M-H]-  283, 325 
Eriodictyol 7-O-
neohesperidoside 
(Neoriocitrin) 
L6 24.5  593.4 [M-H]-  
260, 
292, 
350 
Luteolin-7-O-rutinoside 
L7 26.3 581.0 [M+H]+ 579.4 [M-H]- 
579.3[M-H]- 
459.2[(M-H)-120)]- 
313.1[(M-H)-266)]- 
271.0[(M-H)-308)]- 
287, 
324 Naringin isomer 
L8 27.5 611.1 [M+H]+ 609.3 [M-H]-  284, 326 
Hesperetin 7-O-rutinoside 
(Hesperidin) 
L9 32.9 403.4 [M+H]+  
388.4[(M+H)-14]+ 
373.3[(M+H)-30]+ 
355.4[(M+H)-48]+ 
313.5[(M+H)-90]+ 
151.2[(M+H)-151]+ 
248, 
270, 
330 
5,6,7,8,3',4'-
pentamethoxyflavone 
(Nobiletin) 
L10 33.3 433.4 [M+H]+  
418.4[(M+H)-15]+ 
403.3[(M+H)-30]+ 
165.2[(M+H)-268]+ 
254, 
343 
3,5,6,7,8,3',4'-
eptamethoxyflavone 
L11 33.7 373.4 [M+H]+  
358.3[(M+H)-15]+ 
343.3[(M+H)-30]+ 
325.3[(M+H)-48]+ 
283.3[(M+H)-90]+ 
151.3[(M+H)-222]+ 
271, 
336 
5,6,7,8,4'-pentamethoxyflavone 
(Tangeretin) 
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FIGURE	36:	CHROMATOGRAM	AT	350	NM	OF	LEMON	SAMPLE	
	
	
FIGURE	 37:	 TOTAL	 ION	 CURRENT	 (POSITIVE	 AND	 NEGATIVE	 IONIZATION)	 OF	 LEMON	
SAMPLE	
The	 peaks	 at	 13.0,	 26.3,	 27.5,	 32.9,	 33.3,	 and	 33.7	 minutes	 correspond	 to	
compounds	 already	 identified	 in	 the	 sweet	orange	peels	 (Table	1).	New	peaks	
are	L1	and	L3	corresponding	to	lucenin-2	and	lucenin-2,4'-methylether.	Lucenin-
2	 showed	 a	 retention	 time	 of	 11.9	minutes,	 identified	with	 UV	 spectrum	 and	
with	 MS/MS	 analysis.	 Lucenin-2	 generates	 a	 m/z	 609.4	 [(M-H)-].	 Others	 the	
fragments	 identified	were:	591	 [(M-H)	 -18]-,	519	 [(M-H)-90]-,	489	 [(M-H)-120]-,	
399	[(M-H)-210]-,	369	[(M-H)]-240]-	[31].	The	next	compound	L3	is	the	Lucenin-
2,4'-methylether,	confirmed	by	the	characteristic	UV	spectrum	UV,	MS,	MS–MS	
data	 and	 retention	 time	 [30-31].	 The	 peak	 at	 14.4	 minutes	 corresponds	 to	
stellarin-2	 (chrysoeriol	 6,8-di-C-glucoside)	 (L4)	 as	 confirmed	 by	 UV	 spectrum	
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analysis	and	MS	results	 [32].	The	substance	L5	 (Rt:	22.1	min)	was	 identified	as	
the	neoeriocitrin.	From	the	MS/MS	data,	three	ions	were	present:	595.3	[M-H]-,	
287.2	 [(M-H)-308]–,	459	 [(M-H)-136]-.	The	main	signal	 is	 [M-H]-	with	m/z	equal	
to	 595.3	 and	 [(M-H)-308]-	 287.2.	 This	 compound	 is	 the	 aglyconeeriodictyol,	
resulting	 from	 the	 loss	of	 the	disaccharide	neoesperidose.	 Literature	data	 [31]	
report	that	the	neoeriocitrin	(a	neohesperidoside)	is	able	to	form	the	fragment	
m/z	 459	 [(M-H)-136]-	 which	 is	 not	 observed	 for	 another	 compound,	 named	
eriotricin	(a	rutinoside),	that	presents	same	molecular	weight	and	UV	spectrum.	
The	 loss	of	a	fragmentor	of	m/z	136	may	correspond	to	a	back-cyclization	that	
involves	the	aglycone.	The	following	peaks,	with	retention	time	of	24.5	and	27.5	
minutes,	 were	 attributed	 to	 luteolin	 7-O-rutinoside	 (L6)	 and	 hesperidin	 (L8),	
respectively.	
I.IV.IV QUALITATIVE	ANALYSIS	OF	GRAPEFRUIT	PEELS	
In	 the	 extract	 of	Grapefruit	 three	 peaks	 have	 identified,	 (G1-G3)	 belonging	 to	
the	chemical	class	of	flavonoids,	as	showed	in	the	Table	34.	
TABLE	 34:	 CONSTITUENTS	 OF	GRAPEFRUIT	 IDENTIFIED	 BY	HPLC-DAD-MS	 AND	HPLC-
MS/MS	
	
	
In	 Figure	 38	 and	 Figure	 39	 we	 can	 observe	 the	 chromatographic	 profile	 and	
mass	spectra	in	positive	and	negative	ionization	of	an	hydroalcoholic	extract.	G1,	
at	26.6	minutes,	 is	a	derivative	of	naringenin,	already	identified	in	the	previous	
matrices.	To	prove	that	the	molecule	was	an	isomer	of	naringin	was	performed	
a	standard	addition	of	to	hydroalcoholic	extract	of	Grapefruit;	naringenin	has	a	
retention	time	of	27.3	minutes.	
 
Peak Rt Negative mode MS/MS 
fragmentation 
UV (nm) Identification 
G1 26.6 579.4 [M-H]- 
579.3[M-H]- 
459.2[(M-H)-120)]- 
313.1[(M-H)-266)]- 
271.0[(M-H)-308)]- 
214, 226 
284, 334 
Naringin isomer 
 
G2 27.3 579.4 [M-H]- 
579.3[M-H]-
459.2[(M-H)-120)]- 
313.1[(M-H)-266)]- 
271.0[(M-H)-308)]- 
214, 226 
284, 334 
Naringenin 7-O-
neoesperidoside 
(Naringin) 
 
G3 29.5 593.4 [M-H]-  282, 330 
Isosakuranetin-O-
neohesperidoside 
(Poncirin) 
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The	 last	molecule	 identified,	with	a	 retention	 time	of	29.3	minutes,	 is	poncirin	
G3	(Rt	=	29.3).	
	
	
FIGURE	38:	CHROMATOGRAM	AT	350	NM	OF	GRAPEFRUIT	SAMPLE	
	
	
FIGURE	39:	TOTAL	 ION	CURRENT	(POSITIVE	AND	NEGATIVE	 IONIZATION)	OF	GRAPEFRUIT	
SAMPLE	
I.IV.V QUALITATIVE	ANALYSIS	OF	MANDARIN	PEELS	
In	Mandarin	peels,	 9	 flavonoids	 (M1-M9)	were	 identified,	 as	 reported	 in	Table	
35	.		
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TABLE	 35:CONSTITUENTS	 OF	 MANDARIN	 IDENTIFIED	 BY	 HPLC-DAD-MS	 AND	 HPLC-
MS/MS	
	
	
All	 compounds	 were	 also	 found	 in	 previous	 matrices	 and	 their	 structure	 has	
been	 identified	 as	 previously	 reported.	 In	 Figure	 40	 and	 Figure	 41	 we	 can	
observe	the	chromatographic	profile	and	mass	spectra	in	positive	and	negative	
mode	of	methanol	extract.	
Peak Rt Positive ion mode 
Negative ion 
mode 
MS/MS 
Fragmentation 
UV 
(nm) Identification 
M1 12.9  593.2[M-H]- 
593.2[M-H]- 
575.2[(M-H)-18]- 
503.1[(M-H)-90]- 
473.1[(M-H)-120)]-  
383.1[(M-H)-210)]- 
353.1[(M-H)-240)]- 
271, 
335 
Apigenin 6,8-di-C-
glucoside 
(Vicenin-2) 
M2 26.5  579.2[M-H]- 
579.3[M-H]- 
459.2[(M-H)-120)]- 
313.1[(M-H)-266)]- 
271.0[(M-H)-308)]- 
214, 
226 
284, 
334 
Naringin isomer 
 
M3 27.3 581.0[M+H]+ 579.2[M-H]- 
579.3 [M-H]-  
459.2 [(M-H)-120)]- 
313.1 [(M-H)-266)]- 
271.0 [(M-H)-308)]- 
214, 
226 
284, 
334 
Naringenin-7-o-
neohesperidoside 
(Naringin) 
 
M4 27.6  609.2[M-H]-  
228, 
284, 
334 
Hesperetin 7-O-
rutinoside 
(Hesperidin) 
M5 29.3 595.0[M+H]+ 593.2[M-H]-  282, 330 
Isosakuranetin-O-
neohesperidoside 
(Poncirin) 
M6 32.0 373.0[M+H]+   
214,23
9, 269, 
331 
5,6,7,3',4'-
pentamethoxyflavone 
(Sinensetin) 
M7 32.8 403.2[M+H]+  
388.4[(M+H)-14]+ 
373.3[(M+H)-30]+ 
355.4[(M+H)-48]+ 
313.5[(M+H)-90]+ 
151.2[(M+H)-151]+ 
248, 
270, 
330 
5,6,7,8,3',4'-
esamethoxyflavone 
(Nobiletin) 
M8 33.2 433.3[M+H]+  
418.4[8M+H)-15]+ 
403.3[(M+H)-30]+ 
165.2[(M+H)-268]+ 
 
254, 
343 
3,5,6,7,8,3',4'-
eptamethoxyflavone 
M9 33.6 373.2[M+H]+  
358.3 [(M+H)-15]+ 
343.3 [(M+H)-30]+ 
325.3 [(M+H)-48]+ 
283.3 [(M+H)-90]+ 
151.3 [(M+H)-222]+ 
271,33
6 
5,6,7,8,4'-
pentamethoxyflavone 
(Tangeretin) 
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FIGURE	40:	CHROMATOGRAM	AT	350	NM	OF	MANDARIN	SAMPLE	
	
FIGURE	41:	 TOTAL	 ION	 CURRENT	 (POSITIVE	 AND	NEGATIVE	 IONIZATION)	OF	MANDARIN	
SAMPLE	
I.IV.VI IDENTIFICATION	OF	SINEPHRINE	
Identification	of	alkaloid	synephrine	in	the	four	extracts	was	also	performed.	In	
Figure	 42	 the	 comparison	 of	 HPLC-MS	 chromatograms	 were	 reported.	 The	
HPLC-DAD	 analysis	 has	 not	made	 possible	 the	 identification	 of	 the	 compound	
because	 it	 resulted	 below	 the	 LOD.	 The	 identification	 of	 synephrine	 was	
obtained	 by	 comparing	 the	 retention	 times	 and	 by	 mass	 spectra	 of	 the	
reference	standard	([M+H]+	m/z	168).	The	molecule	was	present	in	mandarin,	in	
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sweet	 orange	 and	 lemon	 while	 it	 is	 absent	 in	 grapefruit,	 as	 reported	 in	 the	
literature	[34].	
	
FIGURE	42:	TOTAL	ION	CURRENT	(POSITIVE	IONIZATION)	OF	SYNEPHRINE	STANDARD	(A),	
MANDARIN	(B),	GRAPEFRUIT	(D),	SWEET	ORANGE	(E)	AND	LEMON	(F)	SAMPLES	
I.IV.VII QUANTITATIVE	ANALYSIS	OF	CONSTITUENTS	OF	PEELS’	MATRICES	
Grapefruit	extract	was	 the	matrix	with	 the	 highest	 content	 of	 total	 flavonoids	
(29.93%±3.25	 of	 flavonoids	 and	 1.36%±0.07	 of	 polymethoxyflavonoids),	 while	
mandarin	 extract	 was	 richer	 in	 polymethoxyflavonoids	 (15.85%±1.79	 of	
flavonoids	and	11.55%±1.32	of	polymethoxyflavonoids).	The	contents	 in	 lemon	
extract	 were	 10.12%±0.98	 and	 0.11%±0.02	 of	 flavonoids	 and	
polymethoxyflavonoids,	respectively.	Sweet	orange	 resulted	the	poorest	matrix	
(3.11%±0.75	of	flavonoids	and	2.10%±0.58	of	polymethoxyflavonoids).		
I.V CONCLUSIONS	
The	 presence	 of	 polyphenols	 in	 the	 pericarp	 of	 some	 species	 of	 Citrus,	 in	
particular	 of	 polymethoxyflavonoids	 and	 flavonoid	 glycosides,	 with	 different	
biological	 activities,	 i.e.	 anti-oxidant	 and	 anti-inflammatory,	 have	 made	
interesting	the	waste	from	the	processing	of	Citrus	fruits.	In	this	study,	analytical	
A	
B	
C	
D	
E	
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studies	on	different	species	of	Citrus	peels	were	performed	in	order	to	develop	a	
method	for	the	evaluation	of	the	total	phytocomplex.		
Peels	of	four	species	of	Citrus:	C.	sinensin,	C.	limon,	C.	paradisii	and	C.	reticulata	
were	 considered	 to	 evaluate	 in	 particular	 the	 profile	 of	 flavonoids	 and	 the	
absence	of	synephrine	and	any	other	compounds	could	be	related	to	safety.	
The	 developed	 analytical	method	 is	 suitable	 for	 the	 evaluation	 of	 all	 the	 non-
volatile	 constituents	 of	 the	 peel	 of	 Citrus.	 In	 all	 tested	 samples	 the	 main	
constituents	 were	 O-glycosilated	 flavanones	 (hesperidin,	 naringin,	
neoeriocitrin),	 flavones	 (lucenin-2,	 2-vicenin,	 stellarin-2,	 lucenin-2,4'-methyl,	
luteolin-7-O-rutinoside)	 and	 polymethoxyflavonoids	 (sinensetin,	 nobiletin,	
tangeretin,	3,5,6,7,8,3',	4'-eptametoxyflavone)	and	phenolic	acids,	while	amines	
such	as	synephrine	and	octapamin	were	absent	or	at	the	limit	of	detection.	The	
developed	 method	 is	 applicable	 to	 quality	 control	 of	 Citrus	 peels,	 or	 their	
extracts	or	their	commercial	preparations	to	support	also	their	safety.	
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II.I ABSTRACT	
Aucklandia	lappa	Decne.	is	a	perennial	plant	of	the	Asteraceae	family,	native	to	
East	Asia,	growing	in	the	Himalayas,	Burma,	China	and	India.	The	root	is	widely	
used	in	Asian	traditional	medicine	due	to	sesquiterpene	lactones.	The	aim	of	this	
study	was	 the	development	and	optimisation	of	 the	extraction	and	analysis	of	
sesquiterpene	 lactones.	 The	 current	 Chinese	 Pharmacopoeia	 reports	 a	
monograph	of	“Aucklandiae	Radix”,	but	the	extraction	method	is	very	long	and	
tedious	 including	 a	 maceration	 overnight	 and	 ultrasonications.	 Different	
extraction	 protocols	 were	 evaluated	 with	 the	 aim	 of	 optimising	 maceration	
period,	 solvent,	 shake	 and	 sonication	 time.	 The	 optimised	method	 consists	 of	
only	one	hour	of	 shake	plus	30	minutes	of	 sonication	using	100%	of	MeOH	as	
solvent.	 1H	NMR	was	 used	 as	 a	 complementary	 analytical	 tool	 to	monitor	 the	
residual	presence	of	sesquitepene	lactones	in	the	herbal	material.	A	suitable	LC-
DAD	method	was	set	up	to	quantify	 the	sesquiterpene	 lactones.	Recovery	was	
ca.	97%	but	a	very	high	instability	of	constituents	was	found	after	powdering	the	
herbal	drug.	A	 loss	of	about	20%	of	 total	 sesquiterpenes	after	15-20	days	was	
found;	as	a	consequence,	 it	 is	strongly	endorsed	to	use	fresh	powdered	herbal	
material	to	avoid	errors	in	the	quantification.	
II.II INTRODUCTION	
Aucklandia	 lappa	 Decne.	 (Family	 of	 Asteraceae)	 is	 a	 perennial	 plant,	 native	 to	
East	 Asia,	 growing	 in	 the	 Himalayas,	 Burma,	 China	 and	 India.	 The	 root	 (⽊⾹,	
Muxiang,	 also	 called	 Costus	 Root)	 is	widely	 used	 in	 Asian	 traditional	medicine	
due	to	sesquiterpene	lactones.	Different	commercial	names	can	be	found	on	the	
market,	 according	 to	 the	 origin,	 the	 root	 produced	 in	 Yunnan	 and	Guangxi	 of	
China	 is	called	“Yunmuxiang”,	while	that	produced	in	 India	and	Burma	is	called	
“Guangmuxiang”.	 “Chuanmuxiang”	 is	 mainly	 produced	 in	 Sichuan	 and	 Tibet.	
“Aucklandiae	 Radix”	 is	 one	 of	 the	 fifty	 fundamental	 herbs	 employed	 in	 the	
Traditional	 Chinese	 Medicine	 and	 a	 monograph	 is	 reported	 in	 the	 current	
Chinese	 Pharmacopoeia	 [1].	 It	 is	 mainly	 used	 for	 treatments	 of	 digestive	
ailments,	 including	 gastric	 and	 abdominal	 pain,	 loss	 of	 appetite,	 indigestion,	
diarrhoea,	anorexia,	nausea	and	vomiting	 [2].	The	plant	 is	also	utilized	to	treat	
asthma	 and	 cough	 [3,4],	 coronary	 heart	 disease	 [4],	 acute	 pancreatitis,	 acute	
cholecystitis	 and	 hepatitis	 [5,6].	 The	 sesquiterpene	 costunolide	 and	
dehydrocostuslactone	 (Figure	 43)	 are	 considered	 the	major	 active	 compounds	
[7–8]	 of	 “Aucklandia	 root”,	 and	 many	 pharmacological	 activities	 have	 been	
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attributed	 to	 their	 presence,	 such	 as	 anti-ulcer	 [9],	 anti-cancer	 [10–11],	
hepatoprotective	[12]	and	cytotoxic	properties	[8].	Furthermore,	they	also	have	
been	found	to	exhibit	antiangiogenic	[13],	anti-inflammatory	[14],	antimicrobial,	
fungicidal	[15,16]	and immunomodulatory	activities	[17].  
At	present	this	plant	has	a	vast	diffusion	in	the	European	market,	requiring	the	
need	of	a	simple	and	rapid	HPLC	method	for	the	evaluation	of	quality	control	of	
the	 herbal	 drug.	 The	 HPLC	 assay	 described	 in	 the	 Chinese	 Pharmacopoeia	
monograph	reports	the	quantification	of	the	two	major	sesquiterpene	lactones	
but	 the	extraction	method	 is	 very	 long	and	 tedious	and	 includes	a	maceration	
overnight	 and	 several	 steps	 of	 ultrasonication.	 The	main	 purpose	 of	 our	work	
was	the	optimization	of	the	extraction	method	of	the	sesquiterpene	lactones	in	
the	roots	and	the	consequent	quantitative	analysis	 in	real	commercial	samples	
of	“Aucklandia	root”. 
Extraction	method	reported	in	the	Chinese	Pharmacopoeia	was	used	as	staring	
point	to	optimise	the	maceration	period,	the	duration	of	mechanical	stirring,	the	
application	of	ultrasound	bath,	solvent	choice,	shake	and	sonication	time.	NMR	
was	used	as	an	integrative	analytical	method	to	evaluate	the	performance	of	the	
developed	extraction	method.	
	
	
FIGURE	43:	CHEMICAL	STRUCTURES	OF	COSTUNOLIDE	(A)	AND	DEHYDROCOSTUSLACTONE	
(B)	
II.III MATERIAL	AND	METHODS	
II.III.I APPARATUS		
Extractions	were	 performed	using	 an	 electronic	 Sonorex	 RH	100	 SH	ultrasonic	
bath	(Bandelin,	Berlin,	Germany)	and	a	Bandelin	electronic	Sonoplus,	using	the	
mechanical	shaker	HS	250	BASIC	(Ika	Labortechnik,	Staufen,	Germany).	A	mortar	
of	 porcelain	 with	 10	 cm	 of	 diameter	 (reference	 code	 1259,	 Galeno	 s.r.l.,	
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Carmignano,	 Italy)	 was	 used	 to	 powder	 the	 roots	 before	 the	 extraction.	 An	
Agilent	 1100	 HPLC	 system	 coupled	 with	 DAD	 detector	 was	 used	 for	 chemical	
profile	 and	 quantitative	 analysis.	 NMR	 spectra	 were	 recorded	 using	 a	 Bruker	
DRX	 (Koln,	 Germany)	 operating	 at	 400.13	 MHz	 and	 a	 Bruker	 Avance-600	
spectrometer	operating	at	600.13MH	(14.1T),	both	using	a	5mm	inverse	probe	
equipped	 with	 a	 z-shielded	 gradient.	 Data	 processing	 was	 achieved	 using	
TOPSPIN	software	package	1.3.		
II.III.II CHEMICAL	AND	REAGENTS	
Dimethylsulfoxide-d6	 (99.9%	 purity)	 and	 MeOH	 were	 HPLC	 grade	 from	 Sigma	
Aldrich	 (Seelze,	 Germany).	 Water	 was	 purified	 by	 a	 Milli-Qplus	 system	 from	
Millipore	(Milford,	MA,	USA).	The	HPLC	column	used	was	a	Zorbax®	Eclipse	XDB	
C18,	 150×4.6	mm,	 5μm	 (Agilent,	 Palo	 Alto,	 CA,	 USA).	 The	 following	 standards	
were	used:	Costunolide,	code	Y0001307	and	Dehydrocostulactone,	code	38384	
both	CRS	and	gived	by	EDQM	(Strasbourg,	France).	
II.III.III HERBAL	DRUG	SAMPLES		
Two	samples	(46393,	named	Auck1	and	31401,	named	Auck2)	were	commercial	
herbal	drugs	from	Shenyang,	China,	were	sent	by	EDQM.	A	commercial	Chinese	
sample,	 Auck3,	 was	 donated	 by	 Phytax	 (Schlieren,	 Switzerland)	 while	 five	
samples	 from	 China	 (Auck5=410079,	 Auck6=750079,	 Auck7=110079,	
Auck8=671375,	 Auck9=130079),	 one	 from	 Austria	 (Auck10=112014)	 and	 one	
from	India	(Auck11=	21657100)	were	provided	by	Plantasia	(Oberndorf,	Austria).	
II.III.IV PREPARATION	OF	EXTRACTS	
All	 the	 investigated	 samples	were	whole	 roots,	 firstly	were	cut	 into	 transverse	
slices	 and	 subsequently	 powdered	 with	 a	 porcelain	 mortar.	 The	 extracts	 of	
Aucklandia	lappa	Decne.	were	obtained	by	macerating	0.3	g	of	herbal	drug	with	
50	mL	of	MeOH,	under	mechanical	shake	for	one	hour.	Macerate	overnight,	the	
samples	 were	 than	 sonicated	 for	 30	 minutes	 using	 ultrasonic	 bath.	 The	 total	
weight	of	preparation	were	monitored	at	 the	beginning	and	at	 the	end	of	 the	
extraction	process	 (after	cooling	of	 the	sample)	and	MeOH	was	 replenished	 in	
case	 of	 the	 loss	 of	 weight.	 The	 obtained	 liquid	 extracts	 were	 mix	 well	 and	
filtered	 through	 a	 membrane	 filter	 (nominal	 pore	 size	 0.45	 μm)	 before	 the	
analysis.	
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II.III.V PREPARATION	OF	SAMPLES	FOR	HPLC-DAD	ANALYSIS	
The	extracts	of	Aucklandia	 lappa	Decne.	were	 sonicated	 for	10	minutes	 in	 the	
ultrasonic	 bath	 and	 then	 centrifuged	 for	 4	 minutes	 at	 14,000	 rpm,	 prior	 the	
injection.	 Subsequently,	 the	 standard	 solutions	 were	 sonicated	 for	 2	 minutes	
before	the	injection.	The	Reference	solutions	were	prepared	as	following:	
• Reference	solution	(a):	5.0	mg	of	Custunolide	CRS	were	dissolved	in	5	mL	
of	MeOH,	 shake	well	 and	diluted	 to	50	mL	with	 the	 same	 solvent	 and	
finally	mixed	well.	
• Reference	 solution	 (b):	 2.5	 mg	 of	 Dehydrocostus	 lactone	 CRS	 were	
dissolved	 in	 5	mL	of	MeOH,	 shake	well	 and	diluted	 to	25	mL	with	 the	
same	solvent	and	finally	mixed	well.	
II.III.VI PREPARATION	OF	SAMPLES	FOR	1H	NMR	ANALYSIS	
The	 herbal	 material	 before	 and	 after	 the	 extraction	 was	 freeze-dried	 for	 12	
hours	 in	 order	 to	 remove	 the	 residual	 water.	 50	 mg	 of	 the	 dried	 powdered	
herbal	 material	 was	 put	 in	 glass	 tubes	 and	 treated	 with	 0.6	 ml	 of	 DMSO-d6.	
Tubes	were	manually	shaken	and	finally	filtered	before	analysis.	
II.III.VII PROCESS	OF	SAMPLE	SONICATION	AND	ULTRASONICATION	
The	 sonication	 was	 performed	 using	 a	 bath	 and	 the	 temperature	 never	
exceeded	 25°C.	 The	 ultrasonication	 was	 performed	 by	 immersion	 of	 probe	
directly	into	the	sample	with	a	maximum	ampitudine	of	50%	and	a	frequency	of	
20kHz,	 at	 room	 temperature.	At	 the	end	of	process	 the	 samples	become	very	
hot;	the	extracts	were	in	direct	contact	with	the	air	with	a	possible	 increase	of	
the	oxidative	processes	and	an	evaporation	of	the	solvent.	
II.III.VIII QUALITATIVE	AND	QUANTITATIVE	HPLC–DAD	ANALYSIS	
The	analysis	was	performed	using	a	column	Zorbax®	Eclipse	XDB	C18,	4.6	x	150	
mm,	5	μm,	at	24	°C.	The	mobile	phase	was	composed	by	methanol	(solvent	A)	
and	water	at	pH	3.2		(solvent	B),	13:7	V/V.	The	flow	rate	was	1.0	mL/min	and	the	
detection	wavelength	was	set	at	225	nm.	The	 injection	volume	was	10	μL.	The	
identification	 of	 two	 main	 constituents	 was	 performed	 by	 comparison	 of	 the	
retention	 times	 and	 UV	 spectra	 of	 the	 reference	 standards	 and	 of	 the	 data	
reported	in	the	literature.		
The	quantitative	analysis	of	 the	constituents	was	performed	using	the	external	
standard.	 The	 references	 Costunolide	 and	 Dehydrocostulactone	 were	 used	 to	
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obtain	 the	 calibration	 curve	 in	 a	 range	 of	 0.220-2.200	μg/mL	 and	 0.407-4.070	
μg/mL,	 respectively.	 The	 standards	 were	 weighed	 accurately	 and	 dissolved	 in	
MeOH	to	obtain	Stock	Solutions,	which	were	 then	diluted.	The	 linearity	of	 the	
calibration	 curves	 were	 expressed	 by	 the	 values	 of	 R2	 (0.99992)	 for	 both	
standards.			
II.IV RESULTS	AND	DISCUSSION	
II.IV.I OPTIMIZATION	 OF	 EXTRACTION	 METHOD	 OF	 SESQUITERPENES	 FROM	
AUCKLANDIA	LAPPA	DECNE.	ROOT			
Different	extraction	methods	of	the	powdered	herbal	material	were	evaluated.	
They	were	all	 identified	with	a	number	(1,	2,	3,	4,	5)	and	a	letter	indicating	the	
type	 of	 extraction,	 namely	 “S”	 for	 sonication	 bath	 and	 “U”	 for	 ultrasonication	
probe.	In	parentheses	the	time	of	extraction	expressed	in	minutes	and/or	hours	
is	 reported.	 In	all	 the	experiments	0.30	g	of	powdered	roots	were	tested	after	
addition	of	50	ml	of	MeOH.	
The	following	methods	were	investigated:		
-Method	1S	(30):	24	h	of	maceration	under	shake	plus	30	minutes	of	sonication	
bath		
-Method	 1U	 (30):	 24	 h	 of	 maceration	 under	 shake	 plus	 30	 minutes	 of	
ultrasonication	probe		
-Method	2S	(30):	30	minutes	of	sonication	bath	
-Method	2U	(30):	30	minutes	of	ultrasonication	probe		
-Method	3S	(15+15):	15	minutes	of	sonication	plus	1	h	of	maceration	under	
shake	plus	15	minutes	of	sonication		
-Method	3S	(30):	1	h	of	maceration	under	shake	plus	30	minutes	of	sonication		
-Method	3U	(15+15):	15	minutes	of	ultrasonication	probe	plus	1	h	of	maceration	
under	shake	plus	15	minutes	of	ultrasonication	probe		
-Method	 3U	 (30):	 1	 h	 of	 maceration	 under	 shake	 plus	 30	 minutes	 of	
ultrasonication	 probe		
-Method	 4S	 (15+15):	 15	minutes	 of	 sonication	 plus	 16	 h	 of	maceration	 under	
shake	 plus	 15	 minutes	 of	 sonication		
-Method	 4U	 (30):	 16	 h	 of	 maceration	 under	 shake	 plus	 30	 minutes	 of	
ultrasonication	probe		
-Method	 5E-S:	 48	 h	 of	maceration	 under	 shake	 plus	 30	minutes	 of	 sonication	
bath		
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-Method	 5E-U:	 48	 h	 of	 maceration	 under	 shake	 plus	 30	 minutes	 of	
ultrasonication	probe		
The	first	set	of	experiments	was	started	with	the	Method	1U	(30),	which	is	that	
described	in	the	Pharmacopoeia	Chinese	monograph	"Aucklandiae	Radix”	(⽊⾹,	
MuXiang).	This	method	was	used	as	reference	for	a	preliminary	analysis	of	 the	
data.	Recovery	of	Costunolide	and	Dehydrocostulactone	found	with	this	method	
was	considered	100%.		
Subsequently,	 the	 possibility	 to	 reduce	 the	 time	 of	 extraction	 process	 was	
evaluated.	Samples	of	roots	were	extracted	using	different	intervals	of	time	and	
the	 efficiency	 of	 the	 sesquiterpene	 extraction	 was	 evaluated.	 Five	 different	
methods	 of	 macerations	 were	 tested	 using	 increasing	 times	 (0,	 1,	 16,	 24,	 48	
hours)	of	mechanical	 stirring	and	 followed	by	30	minutes	of	ultrasonication	as	
reported	 in	 the	 official	 monograph	 of	 the	 Chinese	 Pharmacopoeia.	 A	
considerable	 loss	 of	 MeOH	 due	 to	 evaporation	 was	 observed	 in	 all	 samples,	
consequently,	ultrasonication	was	replaced	by	sonication.		
Preliminary	 experiments	 gave	 contradictory	 results,	 probably	 because	
sesquiterpene	 lactones	 degraded	 very	 quickly	 after	 powdering	 the	 herbal	
material	due	to	the	atmospheric	oxygen.		
Consequently,	HPLC	analyses	 in	 triplicate	on	 the	 same	sample	during	different	
days	after	the	powdering	were	carried	out.	A	gradual	loss	of	the	content	of	main	
constituents	 was	 observed.	 After	 12	 days	 residual	 percentage	 of	 active	
ingredients	was	 ca.	 90%,	while	 after	 18	 days,	 the	 residual	 percentage	was	 ca.	
80%.	 The	 herbal	 material,	 therefore,	 when	 powdered	 undergoes	 to	 rapid	
degradation.	
Accordingly,	sample	Auck1	was	tested	immediately	after	the	pulverizing	process,	
using	the	 following	experiments:	Method	1S	 (30),	Method	1U	(30),	Method	2S	
(30),	Method	2U	(30),	Method	3S	 (15	+	15),	Method	3U	(15	+	15),	Method	4S	
(15	+	15),	Method	4U	(15	+15).		
Table	36	 reported	 the	 results	of	quantitative	analysis	performed	by	HPLC-DAD	
expressed	as	percentages	of	 the	active	constituents.	Accordingly,	 to	 the	above	
results:	
§ Sonication	 bath	 seems	 to	 be	 able	 to	 extract	 both	 Costunolide	 and	
Dehydrocostus	 lactone	 in	 the	 same	 way	 or	 even	 better	 than	
ultrasonication	probe.	
§ Sonication	or	ultrasonication	splitted	gave	the	same	quantitative	results	
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§ The	 best	 extraction	method	was	 3S	 (30),	with	 only	 one	 hour	 of	 shake	
followed	by	30	minutes	of	sonication	bath.	
TABLE	36:	QUANTITATIVE	RESULTS	OBTAINED	FROM	SAMPLE	AUCK1	AFTER	EXTRACTION	
ASSAYS	BASED	ON	DIFFERENT	TIMES	OF	MACERATION	COMBINED	WITH	CENTRIFUGATION	
OR	ULTRACENTRIFUGATION	
	
Sample	Auck1	
%	costunolide	
(g/100g)	
%	dehydrocostus	
lactone	
(g/100g)	
%	costunolide	plus	
%	dehydrocostus	
lactone	
(g/100g)	
Method	1S	(30)	 1.00±	0.05	 1.38±	0.09	 2.37±	0.07	
Method	2S	(30)	 0.98±	0.03	 1.34±	0.05	 2.32±	0.04	
Method	2U	(30)	 0.85±	0.07	 1.18±	0.08	 2.02±	0.08	
Method	3S	
(15+15)	
0.96±	0.09	 1.35±	0.07	 2.31±	0.08	
Method	3U	
(15+15)	
0.87±	0.02	 1.25±	0.04	 2.12±	0.03	
Method	3S	(30)	 1.01±	0.03	 1.44±	0.02	 2.45±	0.02	
Method	3U	(30)	 0.85±	0.08	 1.22±	0.05	 2.07±	0.06	
Method	4S	
(15+15)	
0.96±	0.05	 1.38±	0.07	 2.33±	0.06	
Method	4U	
(15+15)	
0.85±	0.03	 1.20±	0.03	 2.05±	0.03	
Method	4S	(30)	 0.86±	0.03	 1.27±	0.09	 2.13±	0.06	
Method	4U	(30)	 0.96±	0.04	 1.41±	0.06	 2.37±	0.05	
Method	1U	(30)	 0.90±	0.02	 1.20±	0.03	 2.10±	0.02	
	
To	 further	assess	 the	 influence	of	maceration	 time,	 the	extraction	methods	3S	
(30),	2	S	 (30),	1S	 (30)	were	 repeated	with	samples	Auck2	and	Auck3.	Data	are	
reported	 in	 Table	 37	 and	 Table	 38.	 The	 best	 extraction	 method	 for	 Auck3	
resulted	to	be	the	1S	(30)	corresponding	to	24	hour	of	maceration	under	shake	
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plus	30	minutes	of	sonication	bath.	For	Auck2	it	seems	that	method	3S(30)	is	the	
best	one.	Similar	results	were	obtained	with	Auck4	(Table	39).	
TABLE	37:	REPEATED	ASSAYS	WITH	SAMPLE	AUCK2	
	
Sample	Auck2	
%	costunolide	
(g/100g)	
%	dehydrocostus	
lactone	
(g/100g)	
%	costunolide	plus	
%	dehydrocostus	
lactone	
(g/100g)	
Method	2S	(30)	 0.91±	0.08	 1.36±	0.06	 2.27±	0.07	
Method	3S	(30)	 1.01±	0.06	 1.47±	0.04	 2.47±	0.05	
Method	1S	(30)	 0.83±	0.02	 1.18±	0.01	 2.01±	0.01	
	
TABLE	38:	REPEATED	ASSAYS	WITH	SAMPLE	AUCK3	
	
Sample	Auck3	
%	costunolide	
(g/100g)	
%	dehydrocostus	
lactone	
(g/100g)	
%	costunolide	plus	
%	dehydrocostus	
lactone	
(g/100g)	
Method	2S	(30)	 1.85±	0.07	 1.76±	0.08	 3.61±	0.05	
Method	3S	(30)	 1.78±	0.09	 1.68±	0.07	 3.46±	0.06	
Method	1S	(30)	 2.17±	0.03	 2.03±	0.02	 4.21±	0.02	
	
TABLE	39:	EXTRACTION	ASSAYS	WITH	SAMPLE	AUCK4	
Sample	
Auck4	
%	
costunolide	
(g/100g)	
%	dehydrocostus	
lactone	
(g/100g)	
%costunolide	plus	
%dehydrocostus	lactone	
(g/100g)	
Method	2S	
(30)	
0.82±	0.09	 1.31±	0.08	 2.13±	0.07	
Method	2U	
(30)	
0.82±	0.03	 1.28±	0.06	 2.09±	0.04	
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Method	1S	
(30)	
0.89±	0.05	 1.37±	0.04	 2.26±	0.05	
Method	1U	
(30)	
0.86±	0.08	 1.32±	0.07	 2.18±	0.04	
Method	3S	
(30)	
0.89±	0.02	 1.43±	0.01	 2.32±	0.01	
Method	3U	
(30)	
0.85±	0.02	 1.32±	0.04	 2.17±	0.04	
	
1HNMR	experiments	were	performed	directly	on	the	pulverized	herbal	drug,	to	
confirm	the	and	exhaustive	extraction	of	active	constituents.	Firstly,	the	proton	
NMR	 spectra	 of	 Costunolide	 and	 Dehydrocostuslactone	 were	 recorded.	 Then,	
the	exhausted	powdered	sample	Auck	was	treated	with	DMSO-d6	and	evaluated	
for	the	presence	of	the	characteristic	chemical	shifts	in	the	NMR	proton	spectra.	
In	all	the	investigated	samples	no		characteristic	signals	in	the	range	between	8	
and	 5.5	 ppm	were	 found	 after	 extraction	 of	 the	 sample	with	methods	 3S(30)	
(Figure	44).		
	
	
FIGURE	44:	1H	NMR	SPECTRA	OF	AUCKLANDIA	LAPPA	DECNE.	ROOTS	AFTER	
METHANOLIC	EXTRACTION	(A)	WITH	3S(30)	METHOD	AND	BEFORE	THE	EXTRACTION	(B)	
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In	 conclusion,	 the	 sonication	 is	 less	 invasive	 then	 ultrasonication	 and	 the	
extraction	method	3S(30)	 is	 the	best	one	 for	 the	extraction	of	 the	main	active	
constituents	of	Aucklandia	root.	The	optimised	method	 is	able	to	extract	more	
than	97%	of	the	total	of	the	active	principles.	
II.IV.II HPLC	ANALYSIS	OF	AUCKLANDIA	LAPPA	DECNE.	ROOTS	EXTRACT	
A	 simple	 and	 validated	 HPLC-DAD	 method	 was	 used	 for	 the	 evaluation	 of	
sesquiterpene	 lactones.	 Figure	 45	 shows	 the	 chromatographic	 profile	 of	 the	
methanol	 extract	 of	 Aucklandia	 lappa	 Decne.	 at	 225	 nm,	 obtained	 by	 the	
extractive	 method	 3S	 (30).	 Both	 Costunolide	 (Rt	 7.55	 minutes)	 and	
Dehydrocostuslactone	(Rt	8.83	minutes)	were	easily	identified	by	comparison	of	
their	retention	times	of	reference	standards.	
	
	
FIGURE	45:	COMPARISON	OF	CHROMATOGRAMS	AT	225	NM	OF	AUCKLANDIA	LAPPA	
DECNE.	ROOTS	EXTRACT,	COSTUNOLIDE	AND	DEHYDROCOSTUSLACTONE	STANDARDS	
II.IV.II.I Evaluation	 of	 sesquiterpene	 lactones	 in	 Aucklandia	 Lappa	
Decne.	roots	
Six	different	commercial	sample	of	Aucklandia	Lappa	Decne.	were	evaluated	for	
the	 content	 of	 the	 main	 active	 constituents.	 The	 Chinese	 monograph	
“Aucklandiae	 Radix”	 (⽊⾹,	 Muxiang)	 reports	 a	 minimum	 content	 of	 0.6%	 of	
costunolide	and	minimum	1.8%	for	 the	sum	of	costunolide	and	dehydrocostus	
lactone	with	respect	to	the	dried	herbal	drug.	
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Quantitative	analyses	were	performed	by	HPLC–DAD	and	the	optimized	method	
3S	(30)	was	used	for	the	extraction	of	the	roots.	All	results	are	reported	in	Table	
40.	Among	the	tested	samples,	only	the	samples	Auck5	and	Auck7	contain	 less	
than	1.8%	of	active	compounds.		
TABLE	40:	EXTRACTION	ASSAYS	WITH	FURTHER	SAMPLES	
Sample	 %	costunolide	
(g/100g)	
%	
dehydrocostus	
lactone	
(g/100g)	
%costunolide	
plus	%dehydrocostus	lactone	
(g/100g)	
Auck5	 0.65±	0.02	 0.95±	0.03	 1.61±	0.02	
Auck6	 1.06±	0.05	 1.30±	0.6	 2.36±	0.05	
Auck7	 0.81±	0.03	 0.68±	0.04	 1.49±	0.02	
Auck8	 0.02±	0.04	 2.15±	0.06	 2.17±	0.05	
Auck9	 1.31±	0.06	 1.35±	0.03	 2.66±	0.05	
Auck10	 1.53±	0.08	 1.46±	0.07	 2.99±	0.04	
Auck11	 1.78±	0.04	 1.56±	0.04	 3.33±	0.05	
	
II.V CONCLUDING	REMARKS		
HPLC-DAD	 and	 NMR	were	 used	 as	 integrative	 analytical	 tools	 to	 optimise	 the	
extraction	 method	 of	 sesquiterpene	 lactones	 from	 Aucklandia	 lappa	 Decne.	
root.		
A	very	high	instability	of	both	constituents	was	found	after	powdering	the	herbal	
drug	 with	 80%	 residual	 percentage	 of	 active	 constituents	 after	 15-20	 days.	
Accordingly,	 it	 is	 strongly	 recommended	 to	 use	 fresh	 powdered	 herbal	 drug	
material	 to	 avoid	 errors	 in	 the	 quantification	 of	 constituents.	 The	 optimised	
rapid	and	efficient	extraction	method	is	3S	(30),	namely	the	powdered	material	
is	macerated	 for	 1	 h	 under	 shake	 followed	 by	 30	minutes	 of	 sonication	 (total	
time	of	extraction	is	1	h	and	30	min).	
The	developed	extraction	methods	and	HPLC	analytical	method	were	adequate	
for	the	quality	control	of	Aucklandia	root	in	order	to	guarantee	the	integrity	and	
stability	of	the	products	and	assess	their	efficacy	and	safety.	 	
ANNEX	II	
	
193	
II.VI REFERENCES		
[1]	National	Commission	of	Chinese	Pharmacopoeia,	Pharmacopoeia	of	People’s	
Republic	 of	 China	 –	 The	 First	 Division.	 China	 Medical	 Science	 Press,	 Beijing,	
2010,	pp	57	
	
[2]	 Jiangsu	 New	 Medical	 College,	 Dictionary	 of	 Chinese	 Material	 Medica,	
Shanghai	Scientific	and	Technological	Press,	Shanghai,	1979,	pp	353	
	
[3]	Zhang,	Y.,	Xiao,	X.D.	China	Pharm.	2003,	12	(4),	75.	
	
[4]	Wang,	X.Y.,	Jia,	X.B.,	Chen,	Y.,	Chin,	J.	Med.	Mater.	2010,	33	(1),	153.	
	
[5]	Tian,	Y.,	Gao,	H.Y.,	Zhang,	Y.	Inform.	Tradit.	Chin.	Med.	2000,	2,	55.	
	
[6]	Wang,	R.H.J.	Chin.	Med.	2001,	16	(4),	44.	
	
[7]	Rao,	A.S.,.	Kelkar,	G.R.,	Bhattacharyya,	S.C.	Tetrahedron	1960,	9,	275.	
	
[8]	Sun,	C.M.,	Syu,	W.J.,	Don,	M.J.,	Lu,	J.J.,	Lee,	G.H.	J.	Nat.	Prod.	2003,	66,	1175.	
	
[9]	 Yamahara,	 J.,	 Kobayashi,	M.,	Miki,	 K.,	 Kozuka,	M.,	 Sawada,	 T.,	 Fujimura,	H.	
Chem.	Pharm.	Bull.	1985,	33,	1285.	
	
[10]	Kawamori,	T.,	Tanaka,	T.,	Hara,	J.,	Yamahara,	Mori,	A.	H.	Cancer	Res.	1995,	
55,	1277.	
	
[11]	 Matsuda,	 H.,	 Kageura,	 T.,	 Inoue,	 Y.,	 Morikawa,	 T.,	 Yoshikawa,	 M.	
Tetrahedron.	2000,	56,	7763.	
	
[12]	Chen,	H.C.,	Chou,	C.K.,	Lee,	S.D.,	Wang,	J.C.,	Yeh,	S.F.	Antivir.	Res.	1995,	27,	
99.	
	
[13]	 Jeong,	 S.J.,	 Itokawa,	 T.,	 Shibuya,	 M.,	 Kuwano,	 M.,	 Ono,	 M.,	 Higuchi,	 R.,	
Miyamoto,	T.	Cancer	Lett.	2002,	187,	129.	
	
[14]	Damre,	A.A.,	Damre,	A.S.,	Saraf,	M.N.	Phytother.	Res.	2003,	17,	722.	
ANNEX	II	
	
194	
	
[15]	Wedge,	D.E.,	Galindo,	J.C.G.,	Macias,	F.A.	Phytochemistry,	2000,	53,	747.	
	
[16]	Luna-Herrera,	J.,	Costa,	M.C.,	Gonzalez,	H.G.,	Rodrigues,	A.I.,	Castilho,	P.C.	J.	
Antimicrob.	Chemother.	2007,	59,	548.	
	
[17]	 Taniguchi,	 M.,	 Kataoka,	 T.,	 Suzuki,	 H.,	 Uramoto,	 M.,	 Ando,	 M.,	 Arao,	 K.,	
Magae,	J.,	Nishimura,	T.,	Otake,	N.,	Nagai,	K.	Biosci.	Biotechnol.	Biochem.	1995,	
59,	2064.	
	
		
195	
SCIENTIFIC	ACKNOWLEDGEMENTS	
	
Department	of	Chemistry,	University	of	Florence:	
Professor	Anna	Rita	Bilia,	 for	 the	possibility	 to	start	 this	adventure,	 to	work	on	
this	 very	 ambitious	 project	 and	 for	 her	 believing	 in	 my	 competences,	 her	
enthusiasm,	her	energy	and	all	her	precious	advises.		
	
Dr	Maria	Camilla	Bergonzi	
	
Dr	Benedetta	Isacchi	
	
Dr	Chiara	Righeschi	
	
Dr	Karioti	Anastasia	
	
My	master	 students	Vieri	Piazzini,	Andrea	Torracchi,	Giorgia	Ros	and	Gaia	Orsi	
Bertolini	for	their	help	and	collaboration	in	the	experimental	parts	of	my	thesis.		
	
	
All	co-workers	of	Phytolab,	University	of	Florence,	especially	Camilla	Giuliani	
and	 Stefano	 Mulas	 for	 each	 funny	 moment,	 for	 the	 support	 and	 the	
understanding.	
	
	
Department	 of	 Neuroscience,	 Pharmacology	 and	 Child’s	 Health,	
University	of	Florence:	
Professor	Casamenti	Fiorella,	for	her	precious	collaboration	in	the	establishment	
of	the	in	vivo	studies.	
	
Dr	Cristina	Grossi	
	
Dr	Ilaria	Luccarini	
	
	
	
		
196	
Department	of	Pharmaceutical	Science,	University	of	Basel:	
Professor	Matthias	Hamburger,	to	have	given	me	the	great	possibility	to	work	in	
his	special	research	group,	as	it	was	my	research	group.		
	
Dr	Mouhssin	Oufir,	for	his	immense	help	and	for	all	the	tricks	that	he	taught	
	to	me,	 for	his	 big	patience	 and	 for	his	 passion	 for	 science	 that	motivated	me	
during	all	my	stay	in	Basel.	
	
Volha	Zabela,	because	she	was	immediately	a	friend,	for	her	care	and	laughs	of	
everyday.	
	
Daniela	Elisabeth	Eigenmann,	for	her	explanation	in	laboratory,	her	contribution	
in	writing	my	PhD	thesis	and	for	all	chocolate.	
	
Evelyn	Andrea	Jähne,	for	her	support	during	my	first	experience	with	cell	lines.	
	
Orlando	Fertig,	for	his	excellent	technical	assistance.	
	
	
Profs.	 Pierre-Olivier	 Couraud	 (Institut	 Cochin,	 Université	 René	 Descartes,	
Paris,	France),	Babette	B.	Weksler	(Weill	Cornell	Medical	College,	New	York,	
NY,	USA)	and	Ignacio	A.	Romero	(Department	of	Life,	Health	and	Chemical	
Sciences,	 Open	 University,	 Milton	 Keynes,	 U.K)	 for	 kindly	 providing	 the	
hCMEC/D3	cell	line.		
	
